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Glucocorticoid hormones, such as hydrocortisone, are produced in the adrenal cortex and exert 
pleiotropic effects in peripheral tissues by regulating the expression of up to 10% of genes that are 
associated with broad spectrum of metabolic processes. In addition to the adrenal‐derived steroids, 
it is now recognised that peripheral tissues, such as the epidermis, may also act as steroidogenic 
organs. Recently has been shown that oral keratinocytes regulate the local concentration of active 
steroids as well as synthesize hydrocortisone de novo following stimulation with 
adrenocorticotropin hormone (ACTH). Synthetic corticosteroids are routinely administered during 
the treatment of several diseases, including pre-malignant and malignant conditions, particularly to 
alleviate side effects of chemotherapy. However, recent evidence suggests that corticosteroids may 
have tumour-promoting effects, particularly in epithelial neoplasms.  
The aim of this thesis was to assess the influence of the recently characterized tumor-associated 
glucocorticoid (GC) system on both cell proliferation and migration, and on the efficacy of 
chemotherapeutic agents in the treatment of oral squamous cell carcinoma (OSCC).  
The chemotherapeutic agents used in the present study were 5-fluorouracil (5-FU), an established 
drug for OSCC treatment and doxorubicin (DOXO), a potential candidate  for the treatment of 
OSCC.Five different human malignant oral keratinocyte cell lines were selected: H314 / H357 / 
H400 / BICR16 / BICR56. The cell lines were treated with 5µM DOXO, 5 µg/mL 5-FU, 0,5 µg/mL 
Hydrocortisone (HC), 10 nM Adrenocorticotropic hormone (ACTH),  10 µM 5-pregnen-3-beta-ol-
20-one-16-alfa-carbonitrile (PCN) (a Glucocorticoid Receptor antagonist), 25 µM Fasentin (a novel 
inhibitor of glucose uptake that interacts with GLUT1), and 10 µM WZB-117 (an inhibitor of basal 
glucose transport; specific GLUT1 inhibitor). The cell lines were tested with both high (4.5 g/L) 
and low (1g/L) glucose mediums. Moreover in vitro wound healing assays were performed using 
the H357 human carcinoma cell line to assess cell migration. 
The literature review performed showed, in contrast to previous thought, how increased levels of 
autocrine, paracrine, and exogenous cortisol are important to tumor progression, as well as the 
expression of enzymes regulating the levels of tumor-derived cortisol. In the experimental part of 
the project we have clearly demonstrated, for the first time, the importance of cortisol on oral cancer 
cells ability to survive, migrate, and interestingly combat the effectiveness of chemotherapeutic 
agents. This effect would appear to be glucose dependent. Finally, Doxorubicin shows promise for 
the treatment of oral cancer. 
In conclusion, glucocorticoids promote oral carcinoma cell proliferation and migration implying an 
increase in cell invasiveness. This has important implications on the pharmacological use of 
glucocorticoids, as topical and systemic preparations, for the treatment of a wide variety of oral 
conditions and in combination with chemotherapy. 
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1. INTRODUCTION  
1.1. Introduction and thesis motivation 
Glucocorticoid hormones, such as hydrocortisone, are produced in the zona fasciculate of the 
adrenal cortex and exert pleiotropic effects in peripheral tissues by regulating the expression of up 
to 10% of genes that are associated with broad spectrum of metabolic processes [1]. In addition to 
the adrenal!derived steroids, it is now recognised that peripheral tissues, such as the epidermis, may 
also act as steroidogenic organs [2]. Recently it has been shown that oral keratinocytes regulate the 
local concentration of active steroids as well as synthesize hydrocortisone de novo following 
stimulation with adrenocorticotropin hormone (ACTH) [3].  
Synthetic corticosteroids are routinely administered during the treatment of several diseases, 
including pre-malignant and malignant conditions, particularly to alleviate side effects of 
chemotherapy. However, recent evidence suggests that corticosteroids may have tumour-promoting 
effects, particularly in epithelial neoplasms [4,5]. Therefore, the role of glucocorticosteroids in oral 
cancer should be examined.  
Oral Squamous Cell Carcinoma (OSCC) is one of the most common forms of epithelial oral cancer 
in the head and neck area with over 300,000 new cases per year worldwide and its prognosis still 
remains poor [6-8]. Current treatment strategies of OSCC include surgery, radiation therapy, and 
coadjutant therapy such as chemotherapy with agents such as cisplatin, carboplatin,  5-fluorouracil, 
paclitaxel and docetaxel [9]. Among these 5-Fluorouracil and cisplatin are the most used however 
there are limitations with both of these compounds and as such, other possibilities are being 
explored. One drug of particular interest could be  doxorubicin (DOXO) in the treatment of some 
forms of OSCC. 
Doxorubicin, an anthracycline drug that was discovered in Streptomyces peucetius var. caesius, for 
decades has been an established chemotherapeutic agent to treat various cancers such as sarcoma, 
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lung, gastric, ovarian, breast, and thyroid cancers [10]. It has several mechanisms of action 
including intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair and the 
generation of free reactive oxygen species (ROS) that cause DNA damage, oxidative stress, lipid 
peroxidation hence membrane damage, and activate apoptotic pathways [10,11].  
Recently, it was shown to work through additional mechanisms, when delivered in combination 
with are chemicals, in aggressive tumours like Oral Squamous Cell Carcinoma (OSCC) cells, 
indicating potential for its use to treat OSCC in the near future [12]. Nevertheless, in vitro effects of 
DOXO on human malignant oral keratinocytes have not previously been explored, and more in 
general no informations about potential adverse effects of glucocorticosteroids on 
chemotherapeutics agents are available so far. 
Therefore, the aim of this thesis was to assess the influence of the recently characterized tumor-
associated glucocorticoid (GC) system on malignant cell survival, migration and also on the 
efficacy of chemotherapeutic agents in the treatment of oral squamous cell carcinoma (OSCC).  
The chemotherapeutic agents used in the present study were 5-fluorouracil (5-FU), an established 
drug for OSCC treatment and Doxorubicin (DOXO), a potential candidate  for the treatment of 
OSCC. 
Our results demonstrated, for the first time, the importance of cortisol on oral cancer cells ability to 
survive, migrate, and interestingly combat the effectiveness of chemotherapeutic agents. This effect 
would appear to be glucose dependent.  
Finally, Doxorubicin showed promise for the treatment of oral cancer, being effective in all the cell 
lines tested. 
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2. LIT REVIEW 
2.1 The Non-Conventional Effects of Glucocorticoids in Cancer 
Cortisol is an endogenous glucocorticoid (GC) hormone produced by the adrenal cortex in response 
to adrenocorticotropic hormone (ACTH), and it is released in response to various stress stimuli. 
ACTH secretion from the pituitary gland is a result of hypothalamus activation. GCs have long been 
regarded as drugs that promote apoptosis and inhibit cell proliferation and wound healing [13]. 
However, a body of evidence has mounted over the last 10 years that shows potentially harmful 
effects of GCs in cancer therapy.  
Data from laboratory, preclinical, and clinical studies suggest that glucocorticoids induce treatment 
resistance in solid tumors, including prostate, ovarian, and breast cancer [5]. Our data also support 
this view by demonstrating that cortisol significantly reduces the cytotoxic effects of 
chemotherapeutic agents in several cell lines from oral squamous cell carcinoma (OSCC).  
GCs also form the mainstay of the therapeutic armamentarium of a number of diseases with 
malignant potential, such as oral lichen planus (OLP). Therefore, the potential pro-tumorigenic 
activity of GCs can have vast clinical implications and warrants urgent attention.  
Recent research demonstrates that epithelial cells, including those lining the skin and oral mucosa, 
can metabolize glucocorticoids de novo from cholesterol or systemic steroid intermediates. It has 
been shown that there is an endogenous non-adrenal glucocorticoid system existing in human 
epidermal keratinocytes and they exhibit high levels of corticosteroid metabolizing activity [14]. 
Keratinocytes express major enzymes involved in the synthesis and metabolism of cortisol, 
including cytochrome P450 chain, 11bhydroxysteroid dehydrogenases (11b-HSD1/11b-HSD2), 
adrenocorticotropic hormone receptor (ACTHR/MC2R), and glucocorticoid receptor [3]. (Fig. 1) 
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Alteration of both the Hypothalamus-
Pituitary and Adrenal (HPA) axis and non-
adrenal tumor-associated glucocorticoid 
system has been linked to carcinoma 
progression as it results in altered cortisol 
levels [15, 16]. These data may have major 
implications for cancer pathophysiology and 
therapy, as GCs are routinely administered 
during cancer treatment.  
This chapter primarily aimed to review the current evidence supporting the traditional 
(conventional) and non-conventional role of GCs in normal and malignant cells. 
GCs are conventionally used to up-regulate anti-inflammatory factors and down regulate pro-
inflammatory factors. In oncology, GCs have been widely used in association with other treatment 
for cancer patients because they have potent proapoptotic properties in lymphoid cells, can reduce 
nausea and acute toxic effects in healthy tissue [5]. However, a number of secondary effects have 
been documented that influence a variety of functions such as cell migration, differentiation, 
apoptosis, and proliferation. 
 
 
 
 
 
 
Fig. 1: Non-adrenal steroideal system in human 
keratinocytes: local regulation and metabolic chain of 
cortisol. 
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2.1.1 Role in cell proliferation and apoptosis  
The anti-inflammatory and pro-apoptotic effects of GCs [17,18] are fundamental in their use as 
therapeutic agents. However, as showed on normal human epidermal keratinocytes, the cortisol can 
exerts both immunostimulatory and immunosuppressive activities depending on its concentration 
[19]. 
GCs are able to alter signaling in key survival pathways and this can result in reversible growth 
arrest or cell death in certain cell types, which may be particularly important in the arrest of tumor 
cell proliferation [13]. However, although GCs are conventionally used to treat cancer or as 
adjuvants in cancer treatment, it has been observed that they may in fact induce tumor growth and 
metastasis formation [20,21]. The underlying mechanism in which GCs induce tumor growth has 
been explored and it has been proposed that the hyper-secretion of GCs decreases peripheral blood 
lymphocytes (PBLs); cells which play a central role in killing tumor cells [21].  
Alternatively, studies have focused on the fact that GCs are inhibitory to the immune system and 
thus may inhibit certain molecules which are known to be tumoricidal [22]. While the phenomenon 
of glucocorticoid-induced apoptosis in hematological cells is well established [23], a growing body 
of evidence now suggests that glucocorticoids can act as anti-apoptotic agents in epithelial cells to 
promote cancer progression. It has been demonstrated that elevated levels of GCs during chronic 
restraint stress mediate an inhibitory effect on the tumor suppressing protein p53 thereby promoting 
tumorigenesis [24].  
Moreover, extraadrenal GCs produced by intestinal epithelium have been implicated in aiding the 
progression of colon carcinoma cells through an immune evading mechanism [17]. The colon 
carcinoma cells synthesize and release bioactive immunosuppressive GCs which in turn suppress T-
cell activation [17].  
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Guendisch et al. analyzed the role of glucocorticoids (GCs) in the survival and proliferation of 
tumor cells. The non-apoptotic actions of glucocorticoids on tumor cell lines, primary tumor cells, 
and an in vivo model along with molecular signaling studies were examined. The first important 
finding of this study was that dexamethasone, a commonly used glucocorticoid in cancer patients, 
enhances tumor cell proliferation in vitro and in vivo. Dexamethasone enhanced tumor cell 
proliferation in 9/17 cell lines from solid tumors from all three different germ layers [25]. It was 
found that these dexamethasone-induced proliferative changes were mediated by the glucocorticoid 
receptor. GCs lead to an activation of intracellular signaling molecules such as N3RC1, AKT, and 
p38-MAPK which all function in various ways to mediate dexamethasone-induced tumor cell 
proliferation. In terms of clinical relevance, the findings from this review suggest that the non-use 
of GCs might actually improve the prognosis of patients with cancer [25].  
Moreover, Dexamethasone showed to suppress antitumor immune responses and facilitate tumor 
progression by enhancing PD-1, a key cell-surface receptor of CD28 superfamily that can attenuate 
T-cell responses and promote T-cell tolerance, resulting in faster tumor growth and poor prognosis 
in the clinical setting of anti-cancer therapy [26].  
A reported well-known effect of GCs is their ability to inhibit cell proliferation [27-30]. However, it 
has also been shown that cortisol can increase cell proliferation at certain concentrations. Cortisol 
concentration modulates the level of Interleukin-6 (IL-6), a cytokine that stimulates the growth of 
cancer cells via an autocrine mechanism [31]. IL-6 has been associated with angiogenesis and 
tumor progression [32,33]. In head and neck SCC it can be correlated with recurrence, lymph node 
recruitment, and a poor prognostic survival [34,35]. At higher concentrations of cortisol (100 and 
1000 nM) there is a lower level of IL-6 mRNA expression and secretion in oral SCC. However, at 
cortisol concentrations that simulate physiological stress levels (10 nM) there is an increase in IL-6 
mRNA expression and secretion with a subsequent increase in cell proliferation [31].  
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There is also support for this increase in cell proliferation, as a result of cortisol treatment, in non-
malignant situations. This has been documented in foetal cardiomyocytes and Purkinje fibers [18]. 
Cell nuclei expressing Ki67, a marker for cell proliferation, were found in greater numbers in foetal 
heart tissue that were infused with cortisol. The myocyte proliferation due to exogenous GC 
treatment resulted in cardiac enlargement and hypertrophy leading to increased wall thickness. The 
proliferative effects of cortisol were blocked by the use of an antagonist to the mineralocorticoid 
receptor, which is a receptor of particular interest because it can be found in the epidermis of skin 
and interacts with the 11b-HSD enzyme [36]. In foetal hearts it was found that there was an increase 
in apoptosis in Purkinje fibers which was blocked through the use of a specific antagonist to the GR 
[18].  
In contrast, GR activation in cardiomyocytes has an anti-apoptotic effect, reflecting another 
nonconventional effect [37]. Studies on the transcriptional profiles of primary human keratinocytes 
revealed further evidence for the nonconventional anti-apoptotic effect. The treatment of 
keratinocytes with dexamethasone promoted anti-apoptotic gene expression and inhibited pro-
apoptotic expression. As a result, the treated keratinocytes did not undergo UV-induced apoptosis 
[38]. To explain the presence of both apoptotic and anti-apoptotic properties of GCs, it has been 
suggested that they are not mutually exclusive and these effects may occur at different stages, that 
is, GCs inhibit early stages of differentiation and promote later stages of differentiation [38]. 
Therefore, GCs can have different effects depending upon cell type, developmental age and cellular 
environment [18]. 
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2.1.2 Role in wound healing and anchorage independence  
Delayed wound healing is a well-known effect of the therapeutic use of GCs. It has been shown that 
overexpression of the GR in transgenic mice slows down the skin wound healing process. This 
delay is attributed to the inhibition of keratinocyte proliferation, motility, and migration. 
Furthermore, delayed wound healing is accompanied by a decrease in granulocyte and macrophage 
recruitment, as well as a reduction in ERK activity and the expression of TNF-a, IL-b, 
proangiogenic factor, and vascular endothelial growth factor [38,39].  
However, conflicting results have suggested that in fact GCs may have some repair potential. In one 
particular experiment, mucociliated human bronchial epithelial cell (HBEC) cultures were created 
to imitate an asthmatic environment and the effects of therapeutic agents such as dexamethasone 
were studied. As expected, it was found that dexamethasone delayed immediate wound repair of 
HBEC by lowering the proliferative rate of cells surrounding the injured site. However, this in turn 
reduced proliferative stress on epithelial stem cells and transit amplifying cells in the basal 
compartment of the bronchial epithelium during post-wound metaplasia. Hence, the functional 
lifespan of these replacement cells is enhanced leading to better long term repair potential [40].  
GCs have long been used as agents in the treatment and management of particular diseases. The 
effects of commonly used GC medications to treat pemphigus vulgaris (PV) were studied to 
demonstrate whether their supposed therapeutic properties in regenerating PV-like lesions could be 
demonstrated in vitro. Using methylprednisolone (MP) and pyridostigmine bromide (PBr) this 
study found that MP and PBr significantly improved the rate of keratinocyte wound regeneration 
associated with PV lesions. However, it was found that these drugs could not accelerate the rate of 
wound healing in monolayers cultured under no conditions. This suggests that MP and PBr function 
to specifically offset the effects of PV serum on wounded keratinocytes [41].  
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Other studies have explored the effects of both endogenous and exogenous corticosteroids on 
human keratinocyte survival and proliferation rates. The capacity of human keratinocytes to 
promote the formation of anchorage-independent multicellular aggregates (MCAs) in vitro was 
studied using endogenously produced and exogenously administered hydrocortisone. 
Benign/nontumorigenic (I-7/HaCaT) and malignant low metastatic/high metastatic (II-3/RT-3) 
keratinocytes were treated with ACTH and assessed for determine the levels of cortisol being 
synthesized. It was found that the malignant keratinocytes secreted higher levels of endogenous 
hydrocortisone in response to ACTH treatment compared to benign keratinocytes [42]. Overall, this 
study demonstrates the interaction between glucocorticoids and keratinocytes during cancer 
progression.  
These findings indicate that epidermal glucocorticoid systems are associated with tumor 
progression which is of clinical relevance as synthetic corticosteroids are so widely used for 
potentially malignant conditions. 
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2.2 Alteration of Cortisol and Related Enzymes in Malignancy: Possible Role of the Tumor-
Associated Glucocorticoid System 
Alteration of key molecules involved in the glucocorticoid pathway in cancer has been reported in 
previous literature. For instance, elevated cortisol levels have been found in cancer patients where it 
is believed it affects cancer prognosis by impairing the cellular and humoral immune response and 
by promoting tumor metastasis [15,16,43].  
11b-Hydroxysteroid dehydrogenase (11b-HSD) is the main enzyme that regulates the endogenous 
activity of GCs and is expressed in two isoforms, type 1 and type 2. These two enzymes are 
involved in activation and deactivation of GCs (11b-HSD1 and 11b-HSD2, respectively), thus 
controlling cell proliferation. Expression of 11b-HSD1 generally results in decrease in cell 
proliferation, whereas expression of 11b- HSD2 is involved in increase in cell proliferation.  
Studies have illustrated that expression of these enzymes is altered in tumors and may create a 
microenvironment favorable for tumor growth. For instance, an earlier study on murine and human 
epidermal cells observed the involvement of 11b-HSD1 in the natural skin ageing process [44]. It 
was found that 11b-HSD1 expression increases in ageing skin, resulting in local GC excess and 
adverse effects such as: altered skin integrity, thinning, and impaired wound healing. This is due to 
the changes in the extracellular matrix (ECM) including: collagen atrophy, collagen 
disorganization, shredded appearance of collagen structure, and large inter-fibril spaces. This 
disordered ECM microenvironment is vital for tumor metastasis. Hence the study suggested that the 
local increase in 11b-HSD1 in ageing skin may increase the risk of skin cancer.  
The GC receptor (GR) also plays a key role in the glucocorticoid pathway. It is a member of the 
nuclear hormone receptor family normally located within the cytoplasm of cells. Upon binding with 
cortisol it migrates to the nucleus and functions as a transcription activator or repressor that affects  
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Table 1: Dysregulation of serum cortisol, 11b-HSDs, and glucocorticoid receptor in different types of 
cancers 
STUDY  TYPE OF CANCER  DYSREGULATE
D MOLECULE  
SPECIFIC FINDINGS 
Bernabé et al. 
(2012) 
[16] 
 
Oral squamous cell 
carcinoma (SCC) 
Cortisol Elevated plasma and salivary cortisol levels in 
SCC and also higher levels in advanced stage 
compared to initial stage. 
Rasmuson et 
al. (2001) [15] 
Renal cell carcinoma 
(RCC) 
Cortisol Serum cortisol levels higher in RCC and 
positively correlated with tumor diameter and 
grade. Elevated cortisol levels also had worse 
prognosis. 
Sephton et al. 
(2000) 
[45] 
Metastatic breast 
cancer 
Cortisol Flat diurnal salivary cortisol circadian rhythm 
where elevated cortisol levels associated with 
early mortality. 
Sephton et al. 
(2013) [46] 
Lung cancer Cortisol Flattening of the diurnal cortisol rhythm 
associated with early death. 
Terao et al. 
(2013) [47] 
Skin SCC, basal cell 
carcinoma (BCC) and 
seborrheic keratosis 
(SK) 
11b-HSD1 and 11b-
HSD2 
enzyme 
Reduction in 11b-HSD1 expression with 
increased keratinocyte proliferation. 11b-HSD2 
expression increased in basal cell proliferating 
conditions such as BCC and SK. 
Parks et al. 
(1998) [48] 
DMS-79 cells (cell line 
derived from an 
ACTH-producing small 
cell lung cancer). 
11b-HSD2 enzyme 11b-HSD2 normally not found in healthy lung 
tissue, 
was expressed in cancerous lung tissue. 
Temkin et al. 
(2006) 
[49] 
Ovarian epithelial 
cancer 
11b-HSD2 enzyme 11b-HSD2 enzyme not found in normal 
postmenopausal 
ovarian tissue was increased in cancer cells. 
Bland et al. 
(1999) 
[50] 
Osteosarcoma 11b-HSD2 enzyme Overexpression of 11b-HSD2 enzyme in cancer, 
compared with predominant expression of 11b-
HSD1 enzyme in normal human osteoblast cells. 
Zbánková et 
al. (2004) 
[51] 
Colorectal cancer 11b-HSD2 and 11b-
HSD1 
enzyme 
Decrease in the abundance of 11b-HSD2 mRNA 
and enzyme activity in cancer tissue. Also 
demonstrated increase in 11b-HSD1 in some 
samples. 
Cirillo et al. 
(2012) 
[52] 
Oral squamous cell 
carcinoma (SCC) 
11b-HSD2 enzyme Decrease in 11b-HSD2 expression in cancer. 
Lu et al. (2011) 
[53] 
Breast cancer 11b-HSD1 enzyme Decrease in 11b-HSD1 expression in cancer. 
Budunova et 
al. (1997) 
[54] 
Mouse epidermal 
papillomas and SCC. 
Glucocorticoid 
receptor 
In early skin papilloma GR expression is 
reduced but in late papilloma and in SCC, GR 
levels are similar or higher than normal. 
Spiegelman et 
al. 
(1997) [27] 
Mouse epidermal 
papillomas and SCC. 
Glucocorticoid 
receptor 
No significant changes in GR gene structure and 
expression in cancer but resistance to 
glucocorticoid fluocinolone acetonid more likely 
due to alterations in receptor function. 
Waters et al. 
(2004) 
[55] 
Small cell lung 
carcinoma (SCLC) 
Glucocorticoid 
receptor 
Normal expression of GR, however its 
functionality altered by subtle changes in co-
factors such as Nuclear co-repressor which was 
overexpressed in cancer. 
Ray et al. 
(1996) [56] 
Small cell lung 
carcinoma (SCLC) 
Glucocorticoid 
receptor 
Mutations in GR gene structure lead to its 
impaired function. 
Parks et al. 
(1998) [57] 
Small cell lung 
carcinoma (SCLC) 
Glucocorticoid 
receptor 
Abnormal splicing of the GR transcript causes 
GR resistance to GC stimulation in cancer cells. 
Kay et al. 
(2011) [58] 
Small cell lung 
carcinoma (SCLC) 
Glucocorticoid 
receptor 
Increased DNA methylation of promoter c leads 
to decreased GR expression. 
Li et al. (1996) 
[59] 
Transformed A5 mouse 
lung cells 
Glucocorticoid 
receptor 
Transformed cells contain functional GR but 
express cjun which antagonizes glucocorticoids. 
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gene regulation to ultimately cause decreased cell proliferation [13,14]. Mutations in GR structure, 
aberrant processing of GR pre-mRNA and impaired functionality have been implicated in cancer 
progression. Table 1 lists studies that have demonstrated dysregulation of cortisol, 11b-HSD 
enzymes, and glucocorticoid receptor in different types of cancers. 
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2.3 Use of Corticosteroids in Malignancy and Premalignant Conditions 
GCs have a wide array of uses and effects in premalignant and malignant conditions. As strong anti-
inflammatory agents, they have the ability to regulate cell fate by inducing expression of anti-
apoptotic genes while suppressing apoptotic factors [60,61]. Additionally, GCs are used as 
analgesics and antiemetics by patients receiving cancer treatment [38].  
There are possible mechanism-based benefits in the use of GCs in pre-malignant conditions. An 
example of a potentially malignant condition that has potential for transformation is oral lichen 
planus. Progression to oral SCC can occur in up to 5.8% of cases [62,63]. Lichen planus is an 
autoimmune condition characterized by chronic inflammation [64]. It is postulated that chronic 
inflammation is a factor that may lead to the development of malignancy such as oral SCC. The 
powerful anti-inflammatory effects of GCs may, therefore, be a protective factor in this situation, 
and they are currently first-line treatment for this condition [65-67].  
Nevertheless, the recent finding that GCs may bear cancer-promoting effects warrants further 
consideration in this area. GCs are used as a monotherapy or in combination with other treatments 
to manage and treat many different forms of malignancy. GC monotherapy has been shown to have 
positive treatment outcomes in patients with breast and prostate cancer via proposed mechanisms of 
adrenocortical inhibition and adrenal androgen suppression, respectively [68].  
In a systematic review investigating the combination therapy of chemotherapy ± GCs, evidence 
supported such added treatment outcomes as decreased leukopenia, decreased thrombocytopenia, 
and an improved tolerance for increased chemotherapy dose in the group that received GCs as an 
adjunct to their chemotherapy compared to the group only receiving chemotherapy [68]. 
Corticosteroids are also prescribed for the treatment of hypercalcaemia associated with malignancy. 
Renal tubular resistance to endogenous calcitonin during treatment for hypercalcaemia in 
malignancy can be overcome by the addition of corticosteroids to the treatment [69].  
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Despite their benefits in cancer treatment, GCs have also paradoxically been implicated in cancer 
progression [17,70,71]. The postulated benefits of corticosteroids in preventing malignancy should 
therefore be balanced against the possible carcinogenic effects of immunosuppression warranting 
further research in this area.  
In a study of the primary adult brain tumor, glioblastoma, the use of GCs as part of the standard 
treatment protocol was examined. The standard treatment protocol for primary adult tumors 
included maximum surgical resection, radiation therapy, and chemotherapy with about 99% of the 
patients also receiving perioperative corticosteroids with some patients receiving continued doses 
throughout the course of care [72]. High dose GCs are generally prescribed for their anti-
inflammatory mechanism to help combat radiation therapy associated brain swelling and tumor 
oedema (a conventional use and effect). However, GCs such as Dexamethasone that are regularly 
prescribed have been shown to considerably increase blood glucose levels.  
The blood glucose is a fuel for glycolysis-dependent tumors and also facilitates production of 
glutamate, a neurotransmitter linked with causing excitotoxic damage to neurons [72]. Higher levels 
of blood glucose have been shown to accelerate brain tumor growth and lower treatment prognosis 
[72]. Glucocorticoid-induced resistance has been identified in cells of solid tumors when used with 
various anticancer drugs and with radiotherapy.  
Such observations were made in established carcinoma cell lines cultured in vitro, in xenografts on 
nude mice, and in primary cells that had been isolated from fresh surgical samples of solid tumors 
[73-75]. Tumors analyzed were derived from bladder, brain, breast, cervix, colon or rectum, liver, 
lung, kidney, ovary, pancreas, and prostate.  
The finding that the tumor-associated glucocorticoid system is active in all these tumors (Cirillo et 
al., manuscript in preparation) adds a further level of complexity and raises the possibility that a de-
regulated GC metabolism may serve as a tumor promoting mechanism in cancer (Fig. 2).  
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Overall, it can be ascertained from the wide array of research on this topic that the effects and uses 
of GCs in malignant conditions can be both beneficial and detrimental in terms of controlling tumor 
growth and progression.  
Conventional uses of GCs have been shown to help treat malignant conditions either alone or in 
combination with other treatment modalities. Yet the literature also supports the adverse effects of 
GCs in tumor progression and growth which are linked closely to the non-conventional effects of 
GCs in malignant conditions. 
"
Fig. 2: Schematic representation of cancer-promoting glucocorticoid effects 
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2.4 Conclusion  
Based on preliminary data and evidence obtained from this literature review it can be suggested that 
in contrast to previous thought, increased levels of autocrine, paracrine, and exogenous cortisol are 
important to tumor progression. Hence, it is possible that alterations in the expression of enzymes 
regulating the levels of tumor-derived cortisol take place in cancers.  
It will be important, therefore, to assess the levels of expression of steroidogenic molecules, 
steroids, and receptors among normal and malignant epithelial cells as well as the correlation of the 
expression levels of steroid-related molecules to the clinical-pathological parameters of cancer.  
In addition to shedding light on key patho-physiological mechanisms of SCC, characterization of 
the tumor-associated GC systems will have salient diagnostic, preventive, and therapeutic clinical 
implications. Changes in the expression levels of components of the epithelial GC pathway may aid 
in the selection of novel markers of cancer progression. Identification of the presence of alterations 
in the steroid pathway in malignant epithelial cells would open new avenues in the management of 
inflammatory pre-malignant conditions such as lichen planus and provide basis for a mechanism-
based approach to cancer treatment. 
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3. MATERIAL AND METHODS 
3.1. Cell lines 
Five different human malignant oral keratinocyte cell lines were selected for the study: H314, 
H357, H400, BICR16, BICR56.  The main cell line used in most of the experiments was H357. The 
other cell lines were used as confirmatory when significant results were obtained with H357. 
The H series OSCC adherent cell lines H314/H357/H400 were established  at Bristol Dental 
School, University of Bristol, UK by Prime et al [76], from primary explants of floor of the mouth, 
tongue and alveolar process squamous cell carcinoma respectively.  
The BICR16, BICR56 OSCC adherent cell lines  were established at Beatson Laboratories, 
Glasgow, UK by Parkinson et al [77], from recurrent squamous cell carcinomas of the tongue. 
All of the OSCCs were HPV negative. All of the cell lines/strains were derived prior to 2001 and 
therefore, were not subject to Ethical Committee approval in the UK. 
 
3.2. Culture conditions 
At the time of experimentation, all the above mentioned cell lines were cultured in 100-mm Petri 
plastic dishes (Corning® 430167, Corning, NY, USA) and grown to 60-80% confluence before 
being splitted.  
Cells were cultured using standard a standard medium composed by:   
• Dulbecco’s Modified Eagle’s Medium DMEM (D5796) - F12 (N6658) (1:1) (Sigma-
Aldrich, Castle Hill, NSW, Australia) supplemented with  
• 10% Fetal Bovine Serum (FBS) (SFBS-F, Bovogen, Keilor East, Vic, Australia),  
• 1% pen/strep (P4333, Sigma-Aldrich, Castle Hill, NSW, Australia) and  
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• 0.5 µg/ml (100nM) hydrocortisone (HC) (H6909, Sigma-Aldrich, Castle Hill, NSW, 
Australia)  
in a humidified atmosphere at standard conditions (5% CO2, 37°C).  
The epithelial cells at confluency were then detached using a pre-treatment of 10 mM EDTA for 10 
minutes, and subsequently 0.25% trypsin - 1 mM EDTA (T4049, Sigma-Aldrich, Castle Hill, NSW, 
Australia) for 5 minutes.  
The viability of the keratinocytes was confirmed by Trypan Blue exclusion (Trypan Blue Dye, 0.4% 
solution, 1450021, Biorad, UK). 
 
3.3. Glucocorticoid system and chemotherapy  
The cell lines were treated with: 5µM DOXO (44583, Sigma-Aldrich, Castle Hill, NSW, Australia), 
5 µg/mL 5-FU (F6627, Sigma-Aldrich, Castle Hill, NSW, Australia), 100 nM HC, 10 nM ACTH 
(A2227, Sigma-Aldrich, Castle Hill, NSW, Australia), 10 µM 5-pregnen-3-beta-ol-20-one-16-alfa-
carbonitrile (PCN) (a Glucocorticoid Receptor antagonist) (P0543, Sigma-Aldrich, Castle Hill, 
NSW, Australia), 25 µM Fasentin (a novel inhibitor of glucose uptake that interacts with GLUT1) 
(F5557, Sigma-Aldrich, Castle Hill, NSW, Australia), and 10 µM WZB-117 (an inhibitor of basal 
glucose transport; specific GLUT1 inhibitor) (SML0621, Sigma-Aldrich, Castle Hill, NSW, 
Australia).  
The cell lines were tested with both high (4.5 g/L) and low (1g/L) glucose mediums (DMEM 
D5796 and D6046).  
Cell number and viability were assessed at 0/24/48/72 hours (TC10™ Automated Cell Counter & 
Trypan Blue assay, Bio-Rad, UK).  
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3.4. Apoptosis assays 
Firstly, DNA morphology was evaluated with Hoechst 33342 fluorescence staining, (Sigma-
Aldrich) at fluorescence microscopy (EVOS™ FLoid™ Cell Imaging Station, Life technologies). 
Morphological changes leading to condensed or fragmented nuclei were considered as apoptotic 
cells. 
Annexin V-FITC assay (APOAF, Sigma, Saint Louis, Missouri, USA) was subsequently used to 
study the apoptotic process in detail. At 0/3/6/12/24/48/72 hours the H357 cells, untreated, treated 
with DOXO or with DOXO+HC were fixed with 500 µL of 100% ice-cold methanol for 10 min at 
r/t and stained with annexin V (at the concentration suggested by the supplier). The use of methanol 
caused the permeabilization of the cellular membranes allowing us to study apoptotic 
phosphatidylserine exposure and cytoplasmic vescicles trafficking overtime. 
The same experiment was also performed at 0/6/12/24 hours, but fixing the cells with 4% formalin 
and assessing the apoptosis rate with or without the use of  FBS in the experimental medium. 
Confirmatory experiments were performed on BICR16 and BICR56 cell lines in the same 
experimental conditions. 
 
3.5. Wound healing assay 
Cell migration assay to investigate the effect of corticosteroids on cell migration was examined by 
the in vitro scratch wound healing assay using the H357 cell line.  
Keratinocytes were plated on 12 well tissue culture plates (Corning® Costar® 3513, Corning, NY, 
USA) and allowed to reach 100% confluence. At this point a scratch was introduced into the 
monolayer using a sterile 1 ml Eppendorf® pipette tip. The cells were then washed in phosphate 
buffered saline (0.01M PBS, pH!=!7.4) to remove the debris before being incubate with either plain 
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fresh medium (DMEM-F12, 10% FBS, 1%P/S) (control samples), 100nM hydrocortisone, 10 nM 
ACTH, 5µM DOXO.  
Digital microscopy (EVOS™ FLoid™ Cell Imaging Station, Life technologies) was used to 
observe cell migration across the edges and to capture images of the wound at 0/4/8/24 hours.  
10 pictures at each timepoint at x460 magnification were taken to measure wound healing over 
time.  
The captured images were analysed using ImageJ Software (ImageJ v. 1.50i, Wayne Rasband, 
National institute of Health, USA). All the experiments were performed in triplicate. 
 
3.6. Statistical analysis 
The statistical significance of the data was evaluated by using unpaired Student’s t test and 
ANOVA. Data are reported as mean ± standard deviation and differences were considered to be 
significant when p was <0.05. 
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4. PRELIMINARY EXPERIMENTS 
At the beginning of this project a series of preliminary experiments was performed with the 
main aim to assess the best experimental conditions. Each cell line was tested with several types 
of culture medium, experimental medium, seeding densities (ranging from 50% up to 100%), 
concentrations of hormones, chemicals and drugs, including  different cell splitting procedures 
and timing.  
e.g. for the DOXO the different concentrations tested were 5 µM, 10 µM, 50 µM, while for  
5-FU were 0.5 µg/mL, 1 µg/mL. 
An example of some of the main protocols and findings from the preliminary experiments is 
reported below. 
 
4.1. Experiment 1: growth curve, 80% confluent cells 
 
Protocol: 
• Cell line: H357 
• Cell culture 12-well Plate 
• Seed cells (2.5 x 10^5 cells/ml in all the wells) in standard volume of 1 ml 
• Wait overnight (12h) 
• Change medium (without washing)  
• Add the chemotherapeutical agents all together 
! At each timepoint: 
o Remove medium and put it in eppendorf 
o Centrifuge it at 200g x 4 min at 4°C  
o Discharge supernatant  
o In each well wash X2 with PBS 500µL 
o Pretreatment with EDTA (10 mM) (5 min) 
o ADD 100 µL of Tripsin-EDTA (wait 10 min) 
o Add 900 µL of medium 
o Add the above to the previous eppendorf in a final standard volume of 1 ml 
o and mix gently. 
o Cell counting (x1) 
o Trypane blue assay (x1) 
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4.2. Experiment 2: growth curve, 100% confluent cells 
   
Protocol: 
• Cell line: H357 
• Cell culture 12-well Plate 
• 100% confluent cells in a standard volume OF 1 mL 
• Change medium (without washing)  
• Add the chemetherapeutical agents all together 
! At each timepoint: 
o Remove medium and put it in eppendorf 
o Centrifuge it at 800g x 4 min at 4°C 
o Discharge supernatant  
o In each well wash X2 with PBS 
o Pretreatment with µL 150 EDTA (10 mM) (8 min) 
o ADD 150 µL of tripsin-EDTA (wait 11 min) 
o Add 700 µL of medium 
o Add the above to the previous eppendorf in a final standard volume of 1 ml and mix 
gently. 
o Cell counting (x1) 
o Trypane blue assay (x1) 
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4.3. Experiment 5: growth curve, 50% confluent cells 
   
Protocol: 
• Cell line: H357 
• Cell culture 12-well Plate 
• 50% CONFLUENT H357 cells in a standard volume of 1 mL 
• Change medium (without washing)  
• Add the chemetherapeutical agents all together 
! At each timepoint: 
o Remove medium and put it in eppendorf 
o Centrifuge it at 200g x 4 min at 4°C 
o Discharge supernatant  
o In each well wash X2 with PBS 500µL 
o Pretreatment with µL 150 EDTA (10 mM) (8 min) 
o ADD 150 µL of Tripsin-EDTA (wait 11 min) 
o Add 700 µL of medium 
o Add the above to the previous eppendorf in a final standard volume of 1 ml and mix 
gently. 
o Cell counting (x1) 
o Trypane blue assay (x1) 
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4.4. Experiment 7: DOXO , hydrocortisone, and PCN 
 
Protocol: 
• Cell line: H357 
• Cell culture 12-well Plate 
o Culture Medium: DMEM  5796 :HAMS F12 (1:1) +  
• 10% FBS  
• 1% Pen/Strept  
• 0.5 µg/ml hydrocortisone  
o Sub-culture passage number = 7 
o 24 hours before the experiments switch the medium (without Hydrocortisone) 
o split the H357 cells and seed them in 12 well plates with a final density of: 2x105 cells/mL 
in a STANDARD VOLUME OF 1 mL 
o wait overnight 
o  T=0:  
• wash twice with 500µL PBS 
• add all together the chemotherapeutic agents already diluted in1mL of fresh medium 
 
o At each timepoint in each well: 
• Take picture  
• Remove medium 
• wash X2 with 500 µL of PBS 
• Pretreatment with 150 µL of 10mM EDTA for 5 min 
• Discharge EDTA 
• Add 150 µL of trypsin-EDTA  0.25% for 5 min 
• Add 700 µL of medium 
• Cell counting  with Trypane blue assay (x1) (10 readings each slide) 
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4.5. Experiment 8: 5-FU , hydrocortisone, and PCN 
 
Protocol: 
• Cell line: H357 
• Cell culture 12-well Plate 
o Culture Medium: DMEM  5796 :HAMS F12 (1:1) +  
• 10% FBS  
• 1% Pen/Strept  
• 0.5 µg/ml hydrocortisone  
o Sub-culture passage number = 7 
o 24 hours before the experiments switch the medium (without Hydrocortisone) 
o split the H357 cells and seed them in 12 well plates with a final density of: 2x105 cells/mL 
in a standard volume OF 1 mL 
o wait overnight 
o Concentrations: 
o 5-FU: 5 µg/mL  
o Hydrocortisone: 0,5 µg/mL 
o Pregnenolone-16a-carbonitrile (PCN): 10 µM 
o Replace medium and chemotherapeutic agents every 24 hours 
o T=0:  
• wash twice with 500µL PBS 
• add all together the chemotherapeutic agents already diluted in1ml of fresh medium 
o At each timepoint in each well: 
• Take picture  
• Remove medium 
• wash X2 with 500 µL of PBS 
• Pretreatment with 150 µL of 10mM EDTA for 5 min 
• Discharge EDTA 
• ADD 150 µL of TRYPSIN-EDTA  0.25% for 5 min 
• Add 700 µL of MEDIUM 
• Cell counting  with Trypane blue assay (x1) (10 readings each slide) 
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4.6. Experiment 9: 5-FU , hydrocortisone and 3 different experimental mediums 
 
5-FU, HYDROCORTISONE,   TRIPLICATE ON 10 READINGS  
 Medium A- DMEM F12 (1:1) + 1% Foetal Bovine Serum (FBS) +1% Pen/Strept  
 Medium B- DMEM F12 (1:1) + 10% Foetal Bovine Serum (FBS) +1% Pen/Strept  
 Medium C- DMEM F12 (3:1) + 10% Foetal Bovine Serum (FBS) +1% Pen/Strept  
 24 hours before switch the medium (without Hydrocortisone) 
 48 hours before the experiments switch the medium (1%FBS) (12 well n.1) 
 density: 1.5x105 cells/mL 
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4.7. Experiment 10: 5-FU , hydrocortisone and 3 different experimental mediums 
 
DOXO and 5-FU, HYDROCORTISONE,                           ON 10 READINGS  
 A- DMEM F12 (1:1) + 1% Foetal Bovine Serum (FBS)  
 B- ONLY DMEM  + 10% Foetal Bovine Serum (FBS)  
 C- DMEM F12 (3:1) + 10% Foetal Bovine Serum (FBS)  
 24 hours before switch the medium (DMEM/F12 1:1, 1% FBS, NO HYDROCORTISONE, NO 
ANTIBIOTIC)  
 density: 1.5x105 cells/mL 
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5. THE EFFECTS OF GLUCOCORTICOID SYSTEM ON CANCER ENERGY 
METABOLISM AND RESPONSE TO CHEMOTHERAPY  
5.1. DOXO and 5-FU induce apoptosis in malignant oral keratinocytes.  
5.1.1. Material methods 
All the cell lines were grown in standard medium (see section 3.2). The cells at 60-80% confluency 
were then detached using a pre-treatment of 10 mM EDTA for 10 minutes, and subsequently 0.25% 
trypsin - 1 mM EDTA (T4049, Sigma-Aldrich, Castle Hill, NSW, Australia) for 5 minutes. The 
cells were then plated on 12 well tissue culture plates (Corning® Costar® 3513, Corning, NY, 
USA) and grown in standard conditions. After an overnight period, at T=0 the cells were washed 
twice with 500 µL of PBS and were grown in either experimental medium, or experimental medium 
with DOXO 5 µM or 5-FU 5 µg/mL. At each time point the medium was removed in each well and 
after two washing with 500 µL of PBS the cells that remain attached were considered as strongly 
adherent cells hence live.  The cells were then splitted and cell number and viability were assessed 
at each timepoint (TC10™ Automated Cell Counter & Trypan Blue assay, Bio-Rad, UK).  
DNA morphology was evaluated with Hoechst 33342 fluorescence staining, (Sigma-Aldrich) at 
fluorescence microscopy (EVOS™ FLoid™ Cell Imaging Station, Life technologies). 
Morphological changes leading to condensed or fragmented nuclei were considered as apoptotic 
cells. 
 
5.1.2. Results  
Both DOXO and 5-FU induced cytotoxic effects in all the cell lines tested as early as 24h after 
treatment, and peaked at 48h (Fig.3a). For this reason 48 hours was selected as the main time point 
for the further experiments.  
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Morphological changes, condensed and fragmented dna pattern at fluorescence microscopy 
confirmed that oscc cells underwent apoptosis (Fig.3b, Fig.4).  
"
Fig. 3: a) Effectiveness of chemotherapeutics agents on H357 cell line overtime; b) Hoechst  fluorescence 
staining observed at microscopy at 48 hrs timepoint confirmed the induction of apoptosis in both Doxo and 
5-FU groups. Statistical significance is given as follows: *p < 0.05; **p < 0.005. 
"
Fig. 4: Fluorescence microscopy showing fragmented and shrinked DNA pattern induced by DOXO at 48 
hrs on H357 cell line. (460X magnification) 
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5.2. Hydrocortisone reduce the apoptosis induced by chemotherapeutic agents  
Annexin V-FITC assay (APOAF, Sigma, Saint Louis, Missouri, USA) was subsequently used to 
study the apoptotic process in detail and to assess the effect of HC administration on the apoptotic 
process.  
Firstly, at 0/3/6/12/24/48/72 hours the H357 cells, untreated, treated with DOXO or with 
DOXO+HC were fixed with 500 µL of 100% ice-cold methanol for 10 min at r/t and stained with 
annexin V (at the concentration suggested by the supplier). The use of methanol caused the 
permeabilization of the cellular membranes allowing us to study apoptotic phosphatidylserine 
exposure and cytoplasmic vescicles trafficking overtime. 
The same experiment was also performed with DOXO and 5-FU at 0/6/12/24 hours, but fixing the 
cells with 4% formalin and assessing the apoptosis rate with or without the use of FBS in the 
experimental medium. Confirmatory experiments were performed on BICR16 and BICR56 cell 
lines in the same experimental conditions. 
 
5.2.1. Material and methods 
Culture Medium: 
• DMEM 5796 : F12 (1:1)  
• 10% FBS 
• 1% p/s 
• Hydrocortisone 100 nM 
Experimental medium : 
• DMEM 5796 : F12 (3:1)  
• 10% FBS 
• 1% p/s 
Experimental serum free medium (SFM): 
• DMEM 5796 : F12 (3:1)  
• 1% p/s 
 
Concentrations: DOXO: 5 µM , 5-FU: 5 µg/mL, HC: 100nM 
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Protocol: 
Cells were grown in complete culture medium and seeded into 12-well plates at a density of 
ranging from 1.5 to 2 *105 cells/mL in a standard volume of 1 mL (again culture medium). 
After overnight, the wells were washed twice with 500 µL of PBS. 1 mL of experimental 
medium or experimental SFM was placed in each well and the treatments were performed. 
At each time point the supernatant was remove, re-suspended in a 1.8 mL eppendorf and the 
cells counted. Then the cells were fixed with 500 µL of 100% ice-cold methanol or with 4% 
formalin for 10 min at R/T. Each well was washed 3 times with 500 µL of PBS. 500 µL of PBS 
were left in the fixed wells to avoid drying. 
Annexin Kit preparation:  
• 0.5 mL of the Binding Buffer was diluted in 4.5 mL of ultrapure distilled water (10977-
015, Invitrogen, Life technologies) in a 5 mL falcon tube. 100 µL of Annexin V FITC 
conjugate was added to 5 ml of the above buffer. 
At the end of all the timepoints, 200 µL of annexin diluted were added to each well and 
incubated for 30 mins at 4°C protected from light. The staining was then removed, the wells 
were washed 3 times with 500 µL of PBS and observed with fluorescence microscopy. The 
results were obtained by the analysis of 5 fields from each well. The apoptotic ratio was 
calculated as a ratio between the average number of positive cells (granular, strongly positive 
stained cells) divided by the average of the total number of cells found. 
1 mM hydroxide peroxide for 1 hr was used as positive control at 0/12/24/48 hours timepoints. 
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5.2.2. Results 
The results were consistent with the previous section. After being treated with doxorubicin or 5-FU 
up to 24 h, cells were stained with FITC–Annexin V. The strong green fluorescence signal was 
identified on the treated cells but not on the untreated cells, allowing us to calculate the respective 
apoptotic ratio. 
All the cell lines tested showed to be sensitive to doxorubicin as early as 12 hours after treatment 
(Fig. 5, Fig . 6, Fig. 7).  
In all the experiments the administration of 100nM HC was able to reduce the effectiveness of the 
chemotherapeutics tested when compared to the groups treated with the chemotherapeutics agents 
alone. This effect was demonstrated with statistical significance in the biological  triplicate (H357, 
BICR16, BICR56) with DOXO (Fig. 10). 
 
 
 
 
 
Conversely, an inverted trend has been found in H357 cells when the experimental medium was  
deprived of the serum (SFM). In this case in fact the effectiveness of DOXO was even enhanced by 
the addition of HC (Fig. 8). 
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Fig. 5: Annexin apoptosis assay 
on H357 cell line with DOXO, 
and DOXO+HC at 0/6/12/24 
hours 
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5-FU also effectively showed to exert citotoxic effects on H357 cells. Also in this case the HC 
administration was able to reduce the number of apoptotic cells, hence the effectiveness of the drug 
(Fig. 9).  
 
Fig. 6: Annexin apoptosis assay on BICR56 cell line with DOXO, and DOXO+HC at 0/6/12/24 hours 
"
 
Fig. 7: Annexin apoptosis assay on BICR16 cell line with DOXO, and DOXO+HC at 0/6/12/24 hours 
"
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Fig. 8: Annexin apoptosis assay on H357 cell line with DOXO, and DOXO+HC at 0/6/12/24 hours with 
serum free medium (SFM) 
 
 
 
Fig. 9: Annexin apoptosis assay on H357 cell line with 5-FU, and 5-FU+HC at 0/6/12/24 hours 
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Fig. 10: Annexin apoptosis assay. The results showed were calculated as the average (biological 
triplicate) of the results obtained with the single cell lines: H357, BICR16, BICR56. Statistical 
significance is given as follows: *p < 0.05; **p < 0.005 
!
 Hydrogen peroxide is a well known inducer of apoptosis in vitro. The positve control was then 
performed with 1 mM hydroxgen peroxide at 0/6/12/24 hours. The results showed that 50% of the 
cells underwent apoptosis as early as 12 hours after H2O2 exposure, and after 24 hours the apoptotic 
cells were more than 90% of the total  (Fig. 11, Fig. 12). 
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Fig. 11:  Positive control of Annexin apoptosis assay with 1 mM hydroxgen peroxide at 0/6/12/24 hours. The 
apoptotic cells showed strong green fluorescence signal increasing overtime at fluorescence microscopy. 
 
 
Fig. 12:  Positive control of Annexin apoptosis assay with 1 mM hydroxgen peroxide at 0/6/12/24 hours.  
 
It is well-known that apoptosis is a dynamic process. In fact, as the cell undergoes apoptosis, there 
are a number of steps in the process that may be investigated using very different imaging 
modalities [78].  
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Among them, phosphatidylserine (PS) exposure occurs very early in the apoptotic chain of events, 
preceding such hallmark events as nuclear condensation and DNA laddering.  
Moreover, PS exposure is a near-universal event in apoptosis, and it presents a very abundant target 
(millions of binding sites per cell) that is readily accessible on the extracellular face of the plasma 
membrane [79].  
Annexin V, an endogenous human protein with molecular weight of 36 kDa, has a high affinity 
(kd=7 nM) for PS binding [80]. Due to the high affinity for apoptotic cells, no immunogenicity, and 
lack of in vivo toxicity, Annexin V is the dominant probe to detect and image apoptosis. 
In our first apoptosis experiment we decided to use 100% methanol as fixative agent, to 
permeabilize the cellular membranes and to study apoptotic phosphatidylserine exposure and 
trafficking overtime.  
While at 6 hours the fluorescence was mainly detected with a weak, diffuse cytoplasmic pattern, at 
12 hours after the exposure to DOXO a strong green fluorescence signal with a linear pattern was 
identified on the cell membranes of the treated cells but not on the untreated cells indicating the 
presence of early apoptosis processes (Fig. 13).  
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Fig. 13: Phosphatidylserine exposure and trafficking overtime in the annexin apoptosis assay. The early 
apoptotic events were studied at 0/3/6/12/24/48 hours"performing the cells fixation with 100% methanol 
inducing the permeabilization of the cell membranes. 
"
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5.3. Glucocorticoids reduce chemotherapeutic effectiveness on OSCC cells via glucose-
dependent mechanisms  
In this series of expriments the cell lines were grown in standard conditions and treated with the two 
chemotherapeutic agents DOXO and 5-FU overtime.  
We tested the effects of the drugs alone or the effects of the administration of the cemotherapeutic 
agents in combination with exogenous and endogenous corticosteroids. In particular HC was used 
as an exogenous corticosteroid, while the study of endogenous corticosteroids was obtained through 
the stimulation of the cells with  ACTH to induce cellular cortisol production [3,52]. 
Besides the normal controls, 5-pregnen-3-beta-ol-20-one-16-alfa-carbonitrile (PCN), a 
Glucocorticoid Receptor antagonist, was also used to furtherly assess the coherency of the 
glucocorticoids effects.  
The results suggested us a high correlation between the glucocorticoids effects and the cell culture 
metabolic conditions. For this reason, the cell lines were also tested with two different metabolic 
conditions using both high (4.5 g/L) and low (1g/L) glucose grow medium. In this case the results 
were confirmed with the use of Fasentin and WZB-117, two inhibitors of glucose uptake. 
 
5.3.1. Material and methods 
All the cell lines were grown in standard medium (see section 3.2).  
24 hours before the experiments the medium was switched with a standard medium deprived of 
Hydrocortisone. The cells at 60-80% confluency were then detached using a pre-treatment of 10 
mM EDTA for 10 minutes, and subsequently 0.25% trypsin - 1 mM EDTA (T4049, Sigma-Aldrich, 
Castle Hill, NSW, Australia) for 5 minutes. The cells were then plated on 12 well tissue culture 
plates (Corning® Costar® 3513, Corning, NY, USA) and grown in standard conditions. After an 
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overnight period, at T=0 the cells were washed twice with 500 µL of PBS and were grown overtime  
in either experimental medium, or experimental medium supplemented with:  
• 5µM DOXO (44583, Sigma-Aldrich, Castle Hill, NSW, Australia),  
• 5 µg/mL 5-FU (F6627, Sigma-Aldrich, Castle Hill, NSW, Australia),  
• 100 nM HC, (H6909, Sigma-Aldrich, Castle Hill, NSW, Australia), 
• 10 nM ACTH (A2227, Sigma-Aldrich, Castle Hill, NSW, Australia),  
• 10 µM 5-pregnen-3-beta-ol-20-one-16-alfa-carbonitrile (PCN) (a Glucocorticoid Receptor 
antagonist) (P0543, Sigma-Aldrich, Castle Hill, NSW, Australia),  
• 25 µM Fasentin (a novel inhibitor of glucose uptake that interacts with GLUT1) (F5557, 
Sigma-Aldrich, Castle Hill, NSW, Australia), and  
• 10 µM WZB-117 (an inhibitor of basal glucose transport; specific GLUT1 inhibitor) 
(SML0621, Sigma-Aldrich, Castle Hill, NSW, Australia).  
 
During all the experiments, the medium and all the above treatments were replaced every 24 hours. 
The cell lines were tested with both high (4.5 g/L) and low (1g/L) glucose mediums (DMEM 
D5796 and D6046).  
At each time point the medium was removed in each well and after two washing with 500 µL of 
PBS the cells that remain attached were considered as strongly adherent cells hence live.  The cells 
were then splitted  (see section 3.2) and cell number and viability were assessed at each timepoint 
(TC10™ Automated Cell Counter & Trypan Blue assay, Bio-Rad, UK). 
 
5.3.2.  Results  
DOXO, a potential candidate  for the treatment of OSCC, was effective on all the 5 lines tested 
(Fig. 14, Fig. 15). 5-FU was slightly more effective than DOXO in three of cell lines tested.  
On H357 cell line both endogenous and exogenous corticosteroids significantly reduced the 
effectiveness of DOXO (Fig. 14a).  
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Fig. 14: The effect of glucocorticoid system on the effectiveness of DOXO on H357 cell line (a). The cell line 
was also tested with the GR inhibitor PCN, glucose uptake inhibitors, and different glucose dosages. !
Statistical significance is given as follows: *p < 0.05; **p < 0.005 
"
Overall, HC administration (100nM) reduced the effectiveness of DOXO and 5-FU in 3 (H314, 
H357, H400) and 2 (H314, BICR56) of the 5 cell lines tested, respectively.  
The increased production of cortisol through ACTH administration instead  reduced the 
effectiveness of DOXO in 2 cell lines (H357, BICR56).  
The use of the GR inhibitor PCN drastically deleted these corticosteroids effects, confirming our 
hypotesis (Fig. 14b). 
Fasentin and WZB, novel inhibitors of glucose uptake, were able to partially block the increased 
resistance to the cytotoxic drugs induced by HC in H357 cell line (Fig. 14b). 
Switching the growth medium to a lower glucose dosage (1 g/L), this effect was still present, but 
only with exogenous HC (Fig. 14b). 
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Fig. 15: The effect of glucocorticoid system on the effectiveness of DOXO and 5-FU at 48 hours on 
BICR56 (a), BICR16 (b), H314 (c), and H400 (d) cell lines. Statistical significance is given as follows: 
*p < 0.05; **p < 0.005 
 
On BICR56 cell line endogenous corticosteroids significantly reduced the effectiveness of 
doxorubicin while exogenous reduced the effectiveness of 5-FU. Also in this case the use of the GR 
inhibitor PCN drastically deleted corticosteroids effects (Fig. 15a). 
The use of low glucose medium deleted and even inverted the Hydrocortisone effects. 
In fact also in BICR56 and H314 cell lines the results showed that while in high glucose metabolic 
conditions the corticosteroids were able to reduce the effectiveness of both DOXO and 5-FU, the 
switch to a lower glucose dosage deleted and even inverted this trend, highlighting the key role that 
glucose transport may play in these effects (Fig. 15b, Fig. 15c).  
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Paradoxically, in one of the cell line tested, the H400 we found that the use of corticosteroids 
increased the effectivness of both the chemotherapeutic tested (Fig. 15d). Interestingly the H400 
cell line was primarily isolated from a  moderately differentiated, node negative tumour and is the 
only cell line among those tested to be non-tumourigenic on subcutaneous injection into athymic 
nude mice. 
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6. THE EFFECT OF GLUCOCORTICOIDS ON THE INVASIVE BEHAVIOUR OF 
SQUAMOUS CARCINOMA CELLS 
6.1. Exogenous glucocorticoids promote oral carcinoma cell migration implying an increase 
in cell invasiveness 
To assess the effect of glucocorticoids on cell migration in vitro, wound healing assays were 
performed using the H357 cell line. The scratch assay is a simple and reproducible method to 
measure cell migration in vitro (Fig.16).  
"
Fig. 16: Schematic representation of wound healing assay: the grey areas represent the initial cell fronts 
(T=0). The blue (T=4hr) and yellow (T=8hr) areas represent the change in the size of the wound, as the cell 
fronts close. At T=24hr the wound is completely closed because of the cell migration. 
 
The Cells were grown to 100% confluency, before being scratched and incubated with either plain 
medium, hydrocortisone, ACTH or 18-β glycyrrhetinic acid.  
Digital microscopy was then used to capture images of the wound at 0/4/8/24 hours.  
Precisely, 10 pictures at each timepoint at x460 magnification were taken to measure wound healing 
over time and the captured images were subsequently analysed using ImageJ Software 
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6.1.1. Material and methods 
Keratinocytes were plated on 12 well tissue culture plates (Corning® Costar® 3513, Corning, NY, 
USA) and allowed to reach 100% confluence (Fig. 17). At this point a scratch was introduced into 
the monolayer using a sterile 1 ml Eppendorf® pipette tip. The cells were then washed in 
phosphate buffered saline (0.01M PBS, 
pH!=!7.4) to remove the debris before being 
incubate with either plain fresh medium 
(DMEM-F12, 10% FBS, 1% P/S) (control 
samples), 100nM hydrocortisone (Exogenous 
glucocorticoids), 10 nM ACTH (for increasing 
the levels of endogenous glucocorticoids), 
0.02% w/v 18β-Glycyrrhetinic acid (Inhibitor 
of 11β-HSD2, which inactivates cortisol). 
Digital microscopy (EVOS™ FLoid™ Cell Imaging Station, Life technologies) was used to 
observe cell migration across the edges and to capture images of the wound at 0/4/8/24/48 hours. 
10 pictures at each timepoint at x460 magnification were taken to measure wound healing over 
time. Total of 840 pictures were taken and measured. The captured images were analysed using 
ImageJ Software (ImageJ v. 1.50i, Wayne Rasband, National institute of Health, USA).  
All the images were firstly adjusted with ImageJ software enhancing the contrast to better identify 
the edges of the wound. Subsequently “Area selection” tool was used to draw the area between the 
two healing fronts for each image, and the area was then measured in arbitrary units for each image 
(Fig. 18)."All the experiments were performed in triplicate.  
 
Fig. 17: Aspect of the H357 cells at 100% confluency 
before being scratched for the wound healing assay 
(x460 magnification) 
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Fig. 18: Example of image processing. a) aspect of the original picture (wound at T=0); b)the same image 
with enhanced contrast; c) the wound edges are detected and the wound area can be correctly measured. 
x460 magnification  
 
6.1.2. Results 
Closure of the wound generally occurred between 8 and 24 hours.  The wells incubated with 
hydrocortisone displayed the greatest degree of wound closure (Fig. 19). A statistically significant 
difference (*, Fig. 20) (one-way ANOVA) was found between different treatment groups (F(3,8) = 
7.35, p = 0.011). Tukey post-hoc tests revealed that wound closure % was statistically significantly 
higher in the hydrocortisone group (27.1% ± 5.31%, p= 0.15) compared to that of the control group 
Fig. 20: Wound closure percentage at 4 and 8 hours in the 
4 study groups 
Fig. 19: Aspect of the control and  hydrocortisone 
groups wounds at 0/4/8/24 hours  
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(14.2% ± 1.86%). There were no statistically significant differences between the control, ACTH 
and 18-Beta-glycyrrhetinic-acid groups. "
Overall, the results show that Hydrocortisone increase the migration of H357 cells (Fig. 20), while 
the addition of ACTH and 18-beta glycyrrhetinic acid had minimal effect.  
ACTH receptor (MC2R), is a G protein-coupled receptor. Ligand-bound G protein-coupled receptor 
would then undergo conformational change and subsequent downstream transduction cascade that 
ultimately leads to the increased production of endogenous glucocorticoids. Similarly for 18ß-GA 
we think that there was lack of an incubation period in our experimental design. Future 
investigations should take into account an incubation period to allow time for ACTH and 18ß-GA 
to exert their effects of clinical significance. 
 
 
"
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7. DISCUSSION AND CONCLUSIONS 
At the beginning of this thesis our attention was dedicated to understand through the literature 
review which was the current evidence supporting the roles of GCs in normal and malignant cells. 
The aim was supported by the need to discover which was the current knowledge about less known 
secondary effects of GCs. In fact, have been documented that GCs can influence a variety of 
functions such as cell migration, differentiation, apoptosis, and proliferation and may have tumour-
promoting effects, particularly in epithelial neoplasms. 
Synthetic corticosteroids are widely used nowadays mainly as anti-inflammatory drugs during the 
treatment of several diseases including potentially malignant disorders. Furthermore they are used  
in oncology in association with other treatment for cancer patients because of their potent 
proapoptotic properties in lymphoid cells, or to reduce side effects of chemotherapy.  
Therefore, the hypothesis of a possible GCs role in promoting cancer cells survival, proliferation or 
in reducing the effectiveness of chemotherapy leads to a warring scenario. 
The literature review performed showed, in contrast to previous thought, how increased levels of 
autocrine, paracrine, and exogenous cortisol are important to tumor progression, as well as the 
expression of enzymes regulating the levels of tumor-derived cortisol. The results also confirmed 
that a gap exists in the literature of exploration of the role of GCs in the oral cancer field. 
Therefore, after the completition of the literature review phase, a 2 years period of in vitro research 
was carried out, with the attempt to reveal the effects of both endogenous and exogenous 
glucocorticoids on the behavior of oral squamous carcinoma cells, including the effects of these 
hormones on the efficacy of two chemotherapeutic agents: 5-fluorouracil, a well established 
chemotherapeutic agents used for the treatment of head and neck cancer and doxorubicin, a 
potential candidate for the treatment of OSCC. 
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Both DOXO and 5-FU induced cytotoxic effects in all the cell lines tested as early as 24h after 
treatment, and peaked at 48h. firstly, apoptosis was evaluated with Hoechst stain, and subsequently 
using the Annexin V-FITC assay at fluorescence microscopy. The experiments performed showed 
that the citotoxicity of 5-FU in 5 different malignant cell lines was comparable with the efficacy of 
DOXO in inducing OSCC cells apoptosis. The DOXO has been recently indicated by Abbasi et al. 
for its potential use to treat OSCC [12],  but nevertheless in vitro effects of DOXO on OSCC cells 
have not previously been explored. This is then the first piece of work demonstrating in vitro the 
efficacy of DOXO, and its potential use in oral cancer trestment. 
The chapter 5 also clearly established the role of exogenous corticosteroids in reducing the 
citotoxicity of the chemotherapeutics tested, confirming our alarming starting hypothesis. These 
results open new avenues in the future treatment decisions for our patients. On one side, we can 
already clearly state that the concomitant use of glucocorticoids and chemotherapy for oral cancer 
treatment should be carefully revised. On the other side there is the stimulus to open an urgent field 
of research to assess the effects of GCs administration in all those potentially malignant disorders, 
e.g. oral lichen planus or lupus erythematosus, to elucidate if GCs can actually promote malignant 
transformation. If that will be the case, we can speculate that it is time to perform a critical 
revaluation of the pharmacological management of several dangerous conditions not limited to the 
oral cavity. 
In chapter 5 we have also demonstrated the effect of HC administration in reducing the 
effectiveness of DOXO and 5-FU in 3 (H314, H357, H400) and 2 (H314, BICR56) of the 5 cell 
lines tested, respectively. An increased endogenous cortisol production, obtained through ACTH 
administration, also showed to reduced the effectiveness of 5-FU on 2 cell lines tested (H357 and 
BICR56). Furthermore, through additional experiments in different metabolic conditions, and with 
the use of fasentin and WZB, novel inhibitors of glucose uptake, we have shown that GCs effects 
would appear to be glucose dependent.  
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In chapter 6 we dedicated our attention in the understanding of the effect of glucocorticoids on the 
invasive behaviour of squamous carcinoma cells. Increased migration, increasing the depth of 
invasion and influencing the prior chance on nodal metastasis, is one of the features that is 
enhanced in cancer cells and metastasis, and should be then taken in consideration. Hence in this 
study the effect of GCs on malignant cells migration was examined by in vitro scratch wound 
healing assay using the H357 cell line. Statistically significantly faster wound closure rate was 
found in exogenously administered GC group compared to control. Exogenous glucocorticoids 
promote oral carcinoma cell proliferation and migration implying an increase in cell invasiveness. 
This has important implication on the widespread pharmacological usage of glucocorticoids as 
topical and systemic preparations for the treatment of a wide variety of oral conditions and as a 
primary combination chemotherapy . 
ACTH and 18β-GA groups did not show significance. We believe that ACTH failed to show 
significance due to the lack of incubation period in the experimental medium, and consequently, 
18β-GA failed to show significance due to low baseline endogenous cortisol. Nevertheless, we have 
demonstrated the ability, at least for exogenous corticosteroids, to increase malignant cell 
migration. 
In conclusion, we have clearly demonstrated, for the first time, the importance of Cortisol on oral 
cancer cells ability to survive, migrate, and interestingly combat the effectiveness of 
chemotherapeutic agents. This effect would appear to be glucose dependent. Finally, Doxorubicin 
shows promise for the treatment of oral cancer. 
Furthermore, in the near future it will be important, therefore, to assess the levels of expression of 
steroidogenic molecules, steroids, and receptors among normal and malignant epithelial cells as 
well as the correlation of the expression levels of steroid-related molecules to the clinical-
pathological parameters of cancer. The characterization of the tumor-associated GC systems will 
have salient diagnostic, preventive, and therapeutic clinical implications. Changes in the expression 
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levels of components of the epithelial GC pathway may aid in the selection of novel markers of 
cancer progression. Identification of the presence of alterations in the steroid pathway in malignant 
epithelial cells would open new avenues in the management of inflammatory pre-malignant 
conditions such as lichen planus and provide basis for a mechanism-based approach to cancer 
treatment. 
Obiviously, this study is not free from limitations. What we have demonstrated with one synthetic 
steroid (hydrocortisone) cannot be assumed as a general rule. For example in other solid tumors 
(e.g. bladder cancer) has been shown that different steroids can induce different effects on cancer 
cell viability and invasion. Then, a list of urgent questions is waiting for answers, opening new 
avenues in the understanding of Head and Neck cancer and creating translational research 
opportunities on different levels. 
In the field of clinical research, retrospective/prospective cohort studies (single or multicenter 
based) should be performed to assess if there is any possible correlation between malignant 
transformation of OPMDs, outcome/prognosis of cancer patients and use of glucocorticoids. 
In the field of translational research, given the variety of synthetic glucocorticoids commercially 
available and different chemotherapeutics [81,82], remains to clarify the different effects induced 
by different steroids on cancer cell proliferation, invasion, migration and to asses which is able to 
reduce/increase chemotherapy effectiveness. 
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Abstract 
Background: Although the exact incidence of pediatric oral lichen planus (OLP) is unknown, 
the oral mucosa seems to be less commonly involved and the clinical presentation is often 
atypical. The aim of the study is to present a case series of oral lichen planus in childhood. 
Methods: From our database, we retrospectively selected and analyzed the clinical data of 
oral lichen planus patients aged under 18 where the diagnosis had been confirmed by 
histopathological analysis.  
Results: The case series from our database shows eight patients, four males and four females.  
The mean (± SD) age at the time of diagnosis of the disease was 13.5 (±2.73) years, ranging 
in age from 9 to 17. Clinically, a reticular pattern was present in six patients (75%) and the 
tongue was the most commonly involved oral site (6 cases, 75%). We also report the first case 
of OLP in a 9 year-old girl affected by autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED). 
Conclusions: We report the largest case series of pediatric OLP so far published in literature. 
Differences in the disease between adults and pediatric patients  have been detected but 
further investigation and a larger case series are needed to establish any detailed differences in 
clinical outcomes. 
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Introduction 
Lichen planus (LP) is a common chronic inflammatory disorder that affects the skin, mucous 
membranes, nails, and scalp; the etiology of this condition is still unknown although an 
immune-mediated pathogenesis has been hypothesized.1 The age at onset is usually between 
the third and sixth decade of life and it is predominantly seen in females.2 
Although the exact incidence of LP is unknown, it  seems to vary between 0.1% to 1.2%. 
Children represent only 1% to 4% of patients with LP and the clinical presentation is often 
atypical.3 
Clinically, cutaneous LP is characterized by purple, polygonal, pruritic papules frequently 
covered by a lacy network of white scales on their surface, known as Wickham striae. The 
flat-topped papules are often located on the flexor surface of the wrist, the shins, the trunk, 
and the medial thighs, subdivided into one of the following variants: linear, hypertrophic, 
annular, follicular, actinic, vesciculobullous and pemphigoid-like. The disease often resolves 
within 8 to 12 months of treatment and it is not believed to be capable of malignant 
transformation.4,5 
Any nail involvement may appear as a thinning of the nail plate, longitudinal fissuring, or 
distal splitting. Any hair follicle involvement is called lichen planopilaris and if untreated can 
lead to scarring alopecia. Any involvement of the mucous membranes can affect the oral 
mucosa, conjunctivae, larynx, esophagus, tonsils, bladder, vaginal vault, vulva, and anus.5 
In contrast to skin LP, oral lichen planus (OLP) demonstrates a clinical variability6 and  the 
oral manifestation in adults is more frequently resistant and persistent than the cutaneous 
type.7 
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The oral lesions are categorized as reticular, papular, plaque-like, atrophic, erosive, or 
bullous.8 
The hyperkeratotic variants are commonly asymptomatic while the atrophic/erythematous 
variant, the erosive/ulcerative variant  and the bullous type often have persistent symptoms of 
pain or stinging aggravated during eating and drinking.9,10 
The clinical differential diagnosis depends on the age of the patient, the clinical form of OLP,  
and the severity and persistence of the lesions and  includes: lichenoid drug reaction, 
leukoplakia, lupus erythematosus,  candidiasis, graft-versus-host disease (GVHD), frictional 
keratosis, autoimmune bullous diseases, erythema multiforme, allergic gingivostomatitis, and 
gluten sensitivity enteropathy.10–12 
In challenging cases more sensitive diagnostic techniques could be useful to achieve diagnosis 
such as direct and indirect immunofluorescence. 13  
The aim of this study is to provide an update of the oral involvement of the disease in children 
through the report of a retrospective analysis of pediatric patients referred to our Department 
during the last four years for whom lichen planus has presented in the oral cavity as the single 
or as an additional site of involvement. We also conducted a literature review of the topic in 
order to highlight the similarities and differences between our data and the previously 
published clinical cases.  
 
Subjects and Methods 
From our database, we retrospectively selected and analyzed the clinical data of pediatric OLP 
patients in the outpatient clinic of the Department of Neurosciences, Reproductive and 
Page 4 of 21International Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Odontostomatological Sciences, Federico II University of Naples. The selection was based on 
the following inclusion criteria: 
- age <18 years old at the time of diagnosis 
- a clinical and histological diagnosis of OLP 
 
The exclusion criteria were 
- GVHD lichenoid lesions 
-  the lack of a confirmatory histology 
- oral lichenoid drug reaction 
- the lack of any results of  routine hematological testing including tests for hepatic and 
kidney functionality, markers of hepatitis A, B and C viruses, and a red and white blood cell 
count and platelet count.  
From our database we collected the following data: age at time of diagnosis, sex, preexisting 
medical conditions, presence of a positive family history of immunological disorders, 
concomitant or previous assumption of drugs, concomitant oral predisposing or iatrogenic 
factors, confirmatory histology, clinical pattern, oral sites involved, oral symptoms reported, 
extra-oral sites involved, and the treatment and resolution of oral lesions.   
Literature review 
A PubMed search was carried out of articles published between 1966 and 2015 using the 
keywords “lichen” OR “lichenoid” alternatively matched with “oral” OR “lip” AND 
“juvenile” OR “child*” OR “familial” OR “pediatric”. 
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The selection of the studies was based on the following inclusion criteria: 
- the English language 
- a case series or case reports 
- age <18 years old at the time of diagnosis 
- clinical and histological diagnosis of OLP 
- an accurate description of the oral sites and clinical features 
The exclusion criteria were 
- lack of clarity in reporting data about the clinical form(s) of OLP and/or the oral site(s) 
involved 
- GVHD lichenoid lesions 
-  lack of confirmatory histology 
- oral lichenoid drug reaction 
The study was approved by the Ethics Committee of the University of Naples “Federico II” in 
July 2014 and it conforms to the provisions of the Declaration of Helsinki (as revised in 
Tokyo 2004).  
 
Results 
The case series from our database shows eight patients, four males and four females. The 
mean (± SD) age at the time of diagnosis of the disease was 13.5 (±2.73) years, the patients 
ranging in age from 9 to 17. 
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A positive familial history of immunological disorders was found in seven cases (87.5%). 
Seven patients had been submitted to hepatitis B virus (HBV) vaccination and three (37.5%)  
patients presented concomitant oral factors. Findings and/or a history of an immune disorder 
were present in seven patients (87.5%). 
For each patient a confirmatory histology was obtained and in no case was dysplasia reported. 
A reticular pattern was the one most frequently reported, present in six (75%) patients, 
followed by the atrophic (50%), plaque-like (37.5%), erosive (12.5%) and bullous (12.5%) 
patterns; no patient showed a papular pattern. A simultaneous multiple clinical pattern was 
observed in six cases (75%) and in one patient a mucosal pigmentation was detected. 
The tongue was the most commonly involved oral site (6 cases, 75%), followed by the buccal 
mucosa (4 cases, 50%), gingiva (3 cases, 37.5%), retromolar fossae (1 case, 12.5%), palate (1 
case, 12.5%) and lip (1 case, 12.5%). No patient showed any floor of the mouth or extra-oral 
involvement. Four patients (50%) were symptomatic. 
The most commonly used drugs were topical antifungal medications prescribed  in order to 
avoid overlapping fungal overgrowth. Topical steroids were also associated in three cases. 
Two patients (25%) showed a complete disappearance of the oral lesions. 
The analysis of the literature yielded 344 articles published between 1966 and 2015. After the 
application of the inclusion criteria, 12 articles were included in our study. We also searched 
among the references of the aforementioned articles and found a further six articles making a 
total of 18 articles that fulfilled our inclusion criteria, which described a total of 26 patients. 
The flow chart is reported in Table 1.  
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Data from our cases concerning the epidemiology, predisposing factors, clinical features, 
diagnosis and treatment are recorded in Table2. 
Data from the PubMed search concerning the epidemiology, predisposing factors, clinical 
features, diagnosis and treatment are recorded in Table 3.  
A comparison between our cases and the review of literature is provided in Table 4. 
Discussion 
Many previous studies have reported that in LP among pediatric patients the oral mucosa 
seems to be less commonly involved with a prevalence of approximately 0.03%17 compared 
with 1% to 2% of the general population.2  
The present case series confirms the epidemiological data previously collected concerning the 
pediatric LP population with a balanced M:F ratio25 and a greater prevalence for familial LP 
in children (25%) than in adults. In fact, although LP is usually a sporadic disorder, there is a 
rare familial form more prevalent in the pediatric population ranging from 1% to 4.3%, with 
childhood familial LP considered to occur at an earlier age and with a greater severity.3 An 
autosomal dominant mode of inheritance with a variable penetration has been suggested and a 
linkage of familial LP with HLA-B7 and HLA-BR10 has been observed.3 
 
The exact etiology of LP is unknown but it appears to be complex and multifactorial. Possible 
cofactors of OLP, such as a hypersensitivity to dental restorative materials (e.g. amalgam and 
gold), local trauma (the Koebner phenomenon) and several kinds of infections (plaque-
causing microorganisms and hepatitis B or C virus infection) have been reported.10,25    
Furthermore childhood LP has been documented as a complication of hepatitis B virus (HBV) 
vaccination, where the recombinant proteins of the HBV vaccine – specifically the viral S 
epitope – may trigger a cell-mediated autoimmune response targeted at the keratinocytes.11   
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For these reasons, in Tables 2 and 3 we have recorded the presence of any concomitant 
systemic and oral factors that could have had a role in the OLP pathogenesis or in its 
exacerbation; however to date these associations are still unclear. 7 
The medical histories collected from our cases confirm the presence of an increased 
association between OLP and auto-immune diseases1,3,7,10,11,22  with seven of our cases 
showing associated immunological disorders. Among our patients we also report the first case 
of an oral lichenoid lesion related to autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED) also known as polyglandular autoimmune syndrome (PGA) type I, in a 
9 year-old girl. Until now there has been only one other case in literature of  OLP associated 
autoimmune polyendocrine syndrome type II26  in a 42 year- old woman, reinforcing the 
suggestion of a common  immune-mediated pathogenesis between OLP and PGA. (Fig. 1) 
From the reported data in our case series the reticular pattern appears to be the most common 
in childhood followed by the erosive one, in accordance with the literature. Interestingly, we 
instead recorded a clear difference, when comparing our eight cases to the literature (Table 4), 
concerning the oral site predilection with 75% of our eight pediatric patients showing lesions 
on the tongue. Previous studies have reported the buccal mucosa as the most commonly 
involved oral site in pediatric OLP with the next most common location being the tongue.25 
Finally, confirming the hypothesis of a less common oral involvement in pediatric patients 
with LP25 previously reported  at a rate of 12.6%27, none of our eight cases showed any extra-
oral involvement.  
The histology of OLP has revealed that parakeratosis is the most frequent type of keratosis 
while the erosive variety has involved the acanthotic epithelium in more than 50% of cases; 
the rete pegs are predominantly of a wavy pattern while basal cell degeneration and band-like 
subepithelial lymphocytic infiltration seem to be present in all cases. Our data are consistent 
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with the previous literature with basal cell degeneration and band-like subepithelial 
lymphocytic infiltration present in all of our eight cases.25 
The treatment of juvenile OLP does not differ significantly from the treatment of adult OLP 
and is often unnecessary in asymptomatic patients. Oral symptoms are relatively frequent 
when the erosive and/or atrophic pattern occurs; although patients with a keratotic form can 
report a roughness, treatment is rarely necessary. In the present paper we have considered 
prescribing topical antifungal medications to all patients in order to avoid overlapping fungal 
overgrowth in patients undergoing contemporary topical steroidal therapy. The analysis of 
previously published studies confirms that topical corticosteroid therapy is the most 
commonly used treatment in symptomatic OLP, reported in connection with 12 of the 18 
symptomatic pediatric patients (66.6%), even if the chronic use of topical steroids can lead to 
oral candidiasis; an association with retinoid therapy and a plaque control regimen in children 
have shown favorable responses.11 Systemic steroid therapy and dapsone are typically 
reserved for refractory and recurrent cases; extreme caution is employed because significant 
long-term effects are of concern in this young patient population. Of note, tacrolimus 
ointment, topical tretinoin and topical cyclosporine have also been used with success in some 
cases6 but the safety of any long term continuous use of some of these drugs in pediatric 
patients has not been adequately evaluated.25 The effect of the treatment of OLP in children 
seems to be more favorable than in adults for whom the symptoms usually persist for many 
years in spite of intensive treatment and a thorough investigation of any associated factors.17 
Considering our case series and the previously reported papers, a complete resolution of oral 
lesions has been observed in 38.2% of cases (Table 4).  
In Table 5 we show a summary of the most important similarities and differences in OLP 
between children and adults so far reported in literature. 
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In conclusion, our case series mostly mirrors previous epidemiological, clinical and 
therapeutic knowledge about pediatric OLP but a larger case series is needed to confirm the 
possibility of a different oral site predilection between adults and children as suggested by our 
findings. Clinicians must be aware that OLP in childhood may also have a simultaneous or 
future involvement of the skin and other mucosal sites6 and, due to a more frequent positive 
familial history of LP in childhood, close relatives should be examined. Although there have 
been no OLP-related malignancies described to date in the pediatric population, most 
previous studies suggest that the schedule of follow-up of pediatric OLP should be of at least 
one or two examinations per year as long as the OLP persists25 even if the prognosis seems to 
be more favorable. 19 
 
What is new:  
- the present paper represents the largest case series so far published  
- we report the first case of an oral lichenoid lesion related to APECED in a 9 year-old girl 
- our cases suggest a different site predilection in OLP between children and adults 
- the accurately tabulated review of the literature relating to pediatric OLP may facilitate 
further studies on the topic    
Limitations of the study: 
even if the present paper represents the largest case series so far published, further studies are 
needed to establish the epidemiological and clinical features in this population of patients. 
The review of the literature conducted may be conditioned by previous biases in reporting  
exceptional cases on PUBMED and therefore the results of the present comparison with 
previous studies should be considered critically.  
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Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+ 
344 articles found through searching the pubmed  database 
• 36 not humans 
• 51 not English language 
• 22 graft versus host disease 
• 79 title out of topic 
• 5 unviable  
• 7  not accurate clinical design of the study 
• 15 no mention of clinical cases 
• 7 reported absence of oral lesions 
• 4 reported absence of pediatric patients 
• 12 out of topic 
235 articles er research filters application  
156 analyzed abstracts 
106 full text analysis 
• 35 unviable  
• 3 no case reports 
• 2 out of topic 
• 32 lack of clearness in reporting clinical data 
• 14 no pediatric patients 
• 3 no oral involvement  
• 2 lack of histopathological analysis 
• 3 drug induced lichenoid lesions suspicion 
12 articles selected 
6 additional articles found among references of aforementioned articles 
18 articles fulfilling our inclusion criteria 
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Table 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CASE SERIES 
(n=8) 
REVIEW CASES  
(n=26) 
         TOTAL 
        (n=34) 
AGE    
overall age range (years) 9 - 17  6 – 17     6 – 17 
mean (± sd)age 13.5 (± 2.73) 10.41 (± 3.24) 11.18 (± 3.40) 
GENDER       
males 4 (50%) 11 (42.3%) 15 (46.8%) 
females 4 (50%) 15    (57.7%) 19 (55.8%) 
FAMILIAL OLP   3     (37.5%) 1     (3.8%) 4 (11.7%) 
SYSTEMIC CONDITIONS       
PREEXISTING MEDICAL CONDITIONS 7 (87.5%) 9  (34.6%) 16 (47%) 
IMMUNOLOGICAL DISORDERS 7 (87.5%) 5    (19.2%) 12 (35.2%) 
CONFIRMATORY HISTOLOGY   8     (100%) 26   (100%) 34 (100%) 
CONCOMITANT ORAL FACTORS   3     (37.5%) 8 (30.7%) 11 (32.3%) 
OLP CLINICAL PATTERN       
reticular   5     (62.5%) 19 (79.1%) 24 (70.5%) 
papular      0 3     (11.5%) 3 (8.8%) 
plaque-like  3     (37.5%) 3     (11.5 %) 6 (17.6%) 
atrophic  3     (37.5%) 5   (19.2%) 8 (23.5%) 
erosive  1     (12.5%) 10  (38.4%) 11 (32.3%) 
bullous  1     (12.5%) 1      (3.8%) 2 (5.8%) 
mixed  5     (62.5%) 10    (38.4%) 15 (44.1%) 
OLP SITE INVOLVEMENT       
tongue  6       (75%) 13    (50%) 19 (55.8%) 
buccal mucosae  4       (50%) 19   (73%) 23 (76.4%) 
gingiva  3     (37.5%) 3     (11.5%) 6 (17.6%) 
retromolar fossae  1     (12.5%) 2       (7.6%) 3 (8.8%) 
lips  1     (12.5%) 4    (15.4%) 5 (14.7%) 
palate  1     (12.5%) 1      (3.8%) 2 (5.8%) 
floor of mouth      0 3     (11.5%) 3 (8.8%) 
EXTRA-ORAL INVOLVEMENT      0 5    (19.2%) 5 (14.7%) 
SYMPTOMS REFERRAL 4 (50%) 18    (69.2%) 22 (64.7%) 
COMPLETE RESOLUTION OF ORAL LESIONS 2      (25%) 11   (42.3%) 13 (38.2%) 
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Table 5 
topic childhood adulthood 
OLP frequency 0.03% 17   1-2% 2 
familial OLP 1-4% 3 1.5% 
21 
most common clinical pattern reticular  
erosive  
reticular (83.5%) 2 
erosive (15-39%) 2,6 
most common oral sites involved buccal mucosae and tongue 25 buccal mucosae (88%)  
tongue and gingiva (18.7%). 2 
involvement of both skin and oral 
mucosae 
12.6% 27 20-34%2 
histology no dysplasia, basal cell degeneration 
and band-like subepithelial 
lymphocytic infiltration 25 
no dysplasia, basal cell degeneration 
and band-like subepithelial 
lymphocytic infiltration 13 
treatment symptomatic6 symptomatic 28 
resolution more frequent than in adults17 2-5% 29,30 
malignant transformation of OLP never reported10 0.4-5.3% 2 
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Table legends 
Table 1: Flow chart 
Table 2: Data on the 8 patients from our case series: epidemiology, predisposing factors, 
clinical features, diagnosis and treatment. 
†:non-steroidal anti-inflammatory drugs ‡:hemotoxylin eosin §:hemoglobin  
¶:Immunoglobulin G versus epstein-barr virus ††:autoimmune-polyendocrinopathy-
candidiasis-ectodermal dystrophy ‡‡:not available 
Table 3: Data on the 24 patients from the PUBMED search: epidemiology, predisposing 
factors, clinical features, diagnosis and treatment.                                                              
‡:hemotoxylin eosin §:hemoglobin ‡‡:not available §§:direct immunofluorescence †:non-
steroidal anti-inflammatory drugs ¶¶:calcineurin inhibitors †††: antinuclear antibodies 
¶¶¶:Immunoglobulin A‡‡‡:basal membrane zone §§§:lichen planus pemphigoides 
Table 4: Comparison between our case series and the cases from the PUBMED search 
Table 5: Comparison between OLP in childhood and adulthood 
 
Figure legends 
Fig 1 Case No.9 a 9-year-old patient affected by APECED.(a)bullous lesions involving the 
dorsum and margins of the tongue bilaterally and  interlaced by reticular keratotic,   
erythematous and atrophic aspects of the epithelium;(b)bullous lesion involving the left 
 margin of the tongue surrounded by reticular keratotic, erythematous and atrophic aspects of  
the epithelium;(c)bullous lesion involving the left buccal mucosa surrounded by reticular  
keratotic, erythematous and atrophic aspects of the epithelium;(d)reticular keratotic lesions of  
the upper and lower gingiva 
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Case No.9 a 9-year-old patient affected by APECED.(a)bullous lesions involving the dorsum and margins of 
the tongue bilaterally and  interlaced by reticular keratotic, erythematous and atrophic aspects of the 
epithelium;(b)bullous lesion involving the left margin of the tongue surrounded by reticular keratotic, 
erythematous and atrophic aspects of the epithelium;(c)bullous lesion involving the left buccal mucosa 
surrounded by reticular keratotic, erythematous and atrophic aspects of the epithelium;(d)reticular keratotic 
lesions of the upper and lower gingiva in a 9-year-old patient affected by APECED.  
Fig. 1  
129x86mm (300 x 300 DPI)  
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Case Study
Delayed Diagnosis of a Nasal Type Lymphoma
Misdiagnosed as Persistent Sinusitis
Antonio Celentano, DDS,1,2 Massimo Mascolo, MD, PhD,3 Nicola Cirillo, DMD, PhD,2
Gaetano De Rosa, MD,3 and Michele Davide Mignogna, MD, DMD1
Nasal Type T/natural killer (NK)-cell lymphomas are rare clinical entities, highly aggressive with a very poor
prognosis. We present a case of a 37-year-old immunocompetent man presenting with deep palatal ulceration
and a 3-month history of symptoms, which appear to have been misdiagnosed by physicians. The final diagnosis
was achieved by a 15-day diagnostic algorithm, during which time the clinical status of the patient worsened
severely. In this article, we also provide a succinct update on the clinical and histopathological findings of
Peripheral T/NK-cell lymphomas and propose that symptoms that are consistent with these clinical entities
should be considered from the early stages to inform a suitable diagnostic pathway Because of their highly
aggressive behavior, we suggest that early therapy of T/NK-cell lymphomas may be started before completing
the specific diagnostic investigations.
Keywords: nasal type lymphoma, lymphoma, NHL
Introduction
Lymphoma, or lymphatic cancer, is a broad term en-compassing a variety of cancers of the lymphatic system.
Lymphomas in humans are generally classified in two main
groups: theHodgkin lymphomas (HL), also known asHodgkin
disease, and the non-Hodgkin lymphomas (NHL). NHL are
divided into B- and T-cell neoplasms and natural killer (NK)-
cell lymphomas.1,2
NK cells are a third lymphocyte lineage, in addition to B-
and T-cells, that mediate cytotoxicity without prior sensiti-
zation. NK cells also have phenotypic and genotypic char-
acteristics; they express the NK-related antigen CD56 and T-
cell markers such as CD2 and CD3 epsilon, but their T-cell
receptor locus is not rearranged.1
Included in the NHL group are the Peripheral T-cell
and NK-cell lymphomas (PTNKCLs), a wide family of
lymphomas with different clinicopathologic features,
which represent only 10%–20% of all NHLs in the Western
world.2
PTNKCLs are defined as angiocentric lymphomas in the
revised EuropeanAmerican Lymphoma (REAL) classification
and include the ‘‘nasal’’ and the ‘‘nasal type’’ varieties, which
are very rare clinical entities in the United States and Europe,
but more common in Asia and Central America.3 Nasal T/NK
cell lymphoma is a distinct clinicopathologic entity that is
highly associated with Epstein-Barr virus (EBV), with a very
poor response to treatment and prognosis (5-year overall sur-
vival rate of 25%).3–6
Generally, a variety of cells ranging from small or medium-
sized cells to large transformed cells can characterize the broad
cytologic spectrum of this entity. Tissue damage is a common
morphological feature of this form, due to both cytotoxicity of
the T/NK lymphoma cells and angiocentricity.4,5,7
The characteristic immunophenotype of Nasal T/NK cell
lymphoma is distinguished by a CD2 and CD56 positivity,
but usually a negativity for surface CD3.
The presence of EBV in early diagnosis can be effectively
evaluated by in situ hybridization.
The differential diagnosis includes lymphomatoid granulo-
matosis, blastic ormonomorphicNKcell lymphoma/leukemia,
CD56-positive peripheral T-cell lymphoma, and enteropathy-
associated T-cell lymphoma.4
Extranodal sites such as the skin, the subcutis, and the gas-
trointestinal tract can be affected by tumors with an identical
phenotype and genotype. These extranodal forms should be
referred to as nasal-type T/NK cell lymphomas.4
Here, we present a rare case of a 37-year-old Caucasian man
affected by nasal-type T/NK-cell lymphoma, referred to our
unit 3 months after the development of the first symptoms.
The purpose of this study is to update data on the clinical and
histopathological findings of this rare disease, pointing out
how misdiagnoses are responsible for therapeutic delays and,
consequently, of a worse prognosis for these aggressive forms.
1Department of Neuroscience, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy.
2The University of Melbourne, Melbourne Dental School and Oral Health CRC, Melbourne, Australia.
3Pathology Section, Department of Advanced Biomedical Sciences, University Federico II of Naples, Naples, Italy.
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Case Report
A 37-year-old Caucasian man was referred to our Oral
Medicine Unit, Department of Head and Neck Diseases,
Federico II University of Naples, in September 2014 with the
main complaint of a wide symptomatic ulcerative lesion of
the hard palate.
His family history encompasses three uncles who had died
of different forms of cancer in recent years (two of lung cancer,
and one of bowel cancer). The patient’s medical history was
negative, and hewas in apparent good health except for a weak
hypercholesterolemia.
His first referred symptomswere a moderate submandibular
lymphadenopathy and weak fever starting more than 2 months
earlier, for which reason he consulted the family doctor who
requested hematological tests with the main suspicion of an
EBV/CMV infection. The results of all the tests performed
were negative and for 1 month the patient received symptom-
atic therapy. With no sign of improvement, 4 weeks later the
patient started complaining of a sense of nasal obstruction,with
breathing difficulty for which he consulted an otorhinolaryn-
gologist who performed an endoscopic examination of the
nasal cavities, finding suppurative exudate and inflammation of
the nasal floor and lateral/medial walls. It was diagnosed as
severe maxillary sinusitis and therapy with corticosteroids
through an aerosol, and antibiotics were prescribed. After 1
month, without any improvement of the symptoms, the patient
started complaining of the first oral symptom, pain due to
swelling, and an ulcerated area in the median area of the hard
palate. For this reason, he consulted his dentist who advised
him to undergo an oral medicine consultation at our hospital.
Our first examinationwas performed soonafter, accordingly 10
weeks after the onset of the first symptoms, and the patient was
presented with the clinical condition shown in Figure 1A.
The patient, after providing his written informed consent,
was hospitalized and examined by routine hematological tests,
which revealed a glucose level of 120mg/dL (normal range,
60–110), a total cholesterol level of 200mg/dL (normal value
up to 190), a triglyceride level of 218mg/dL (normal value up
to 180), and an iron level of 49lg/dL (normal range, 55–160).
The physical examination showed a widespread ulcerative
andproliferative lesion involving thehardpalate, andmarginally
the soft palate and the left maxillary alveolar process (Fig. 1A).
The lesion measured about 4 cm at its maximum diameter and
showed a central zone of deep and extensive necrosis, with a
surrounding area of weakly brown-colored hyperplastic tissue.
Two incisional biopsies of the lesion were performed.
After 2 weeks, while the patient was undergoing a diag-
nostic pathway, the lesion presented with a considerably
worse clinical evolution, as shown in Figure 1B.
At histology, scanning magnification revealed a dense and
diffuse proliferation of pleomorphic small and medium-sized
lymphocytes within the entire chorion, with overlying exten-
sive squamous epithelium ulceration. An angiocentric pattern
of infiltration was evident. The predominant cell type was
lymphocyte with round nuclei, one or more nucleoli, and a
scant cytoplasm. Numerous mitotic figures were seen, and ar-
eas of necrosis were also present (Fig. 2A–C).
The neoplastic cells expressed CD2 and CD3; a weak ex-
pression of CD56 and granzyme B was observed (Fig. 2D).
CD8 and CD30 were consistently negative. The tumor had a
proliferative fraction (Ki-67/MIB1) approaching*70%–75%.
The analysis of the presence of EBV was performed with the
FISH (fluorescent in situ hybridization) technique (Dako
FIG. 1. Intraoral clinical aspect at initial presentation in Oral Medicine. The hard palate and the alveolar process presented
with an ulcerative and destructive lesion with an extensive zone of necrosis (A = 10 weeks, B = 12 weeks, C = 14 weeks).
Progressive disintegration of the bony support with development of a wide oronasal fistula during chemotherapy (D= 4
months, E = 5 months, F = 6 months). Clinical aspect of the fistula at 10 months during the radiotherapy (G), at 1 year (H), at
18 months (I) and at 2 years (K). Examples of palatal obturator prostheses used at 1 year (J), and 2 years (L).
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PNA ISH EBERER PNA Probe) and revealed a widespread
positivity for EBV.
A diagnosis of extranodal NK/T-cell lymphoma, nasal
type was made.
The patient was immediately referred to the Hematoncol-
ogy Department to complete the staging and start treatment of
the disease. A head/neck and chest computed tomography
(CT) scan and a total body positron emission tomography
(PET) scan were negative except for the oral and left nasal
cavity involvement. Chemotherapy following the SMILE
protocol (Methotrexate 2 g/m2 IV, Dexamethasone 40mg IV+
leucovorin 15mg· 4 doses/day IV + ifosfamide 1500mg/m2
IV + etoposide 100mg/m2 IV, and l-asparaginase 6000U/m2
IV, repeated every 21 days for 3 cycles) was started in early
November 2014, 4months after the onset of symptoms. During
chemotherapy treatment, the deep necrosis of the palatal soft
tissue evolved into an oronasal fistula, as documented in
Figure 1C–F. Four months after chemotherapy, the patient
received radiotherapy (at a dose of 56Gy) for 52 days. From
this period until October 2016, the oronasal fistula remained
fairly stable (Fig. 1G–I,K), and it was managed with the use of
a palatal obturator prosthesis (Fig. 1J,L). Bimonthly follow up
in our department occurred. The palatal obturator was changed
every 15 days due to a continuous remodeling of the soft tissue
and consequent passage of food into the nasal cavity. The
management of the fistula included use of chlorhexidine top-
ical gel. Oncology follow up continued every 6 months, and it
included a head/neck CT scan and a total body PET. The
patient was still alive at the time of writing this article and was
about to commence the preparation phase for the bone marrow
transplantation.
The study was approved by the Ethics Committee of the
University ‘‘Federico II’’ of Naples. Appropriate written in-
formed consent was obtained from the patient included in the
study.
Discussion
The head and neck is a common site of extranodal
NHL. PTNKCLs are rare and heterogeneous forms of NHL
that are usually characterized by a very poor clinical out-
come. Furthermore, many subtypes are currently present
in the World Health Organization (WHO) classification of
PTCL.8
Sequential chemotherapy and radiotherapy is the gold
standard treatment for extranodal lymphomas at early stages
(I–II), proved to be more effective in terms of 5-year overall
survival and progression-free survival than chemotherapy or
radiotherapy alone. For stage III/IV instead, chemotherapy is
the mainstay of treatment. Conventional anthracycline-based
regimens are ineffective. Since the advent of l-asparaginase-
based regimen, the outcome of extranodal lymphomas was
clearly improved. Radiotherapy plays an important role in
the treatment of low-grade lymphomas, with curative or
palliative intent. In the case of high-grade lymphomas, its
combination with chemotherapy is debated. The role of
radiotherapy remains, however, undeniable for two specific
entities: NK/T-cell lymphoma NK/T nasal type, and primary
central nervous system lymphomas.9–11 Nevertheless, the
outcome of advanced-stage diseases is still not satisfactory.
As confirmed by this present case, the diagnosis of these
forms is difficult for the general practitioner as well as for
medical specialists, a difficulty compounded by the frequent
underestimation/misdiagnosis of the first symptoms that are
often non-specific and can mimic an inflammatory process.
Each failure in a diagnostic step is usually followed by a
delay of several weeks for the patient to achieve the correct
diagnosis and to undergo the specific therapy. Given that the
specific treatment strategy and related prognosis for a patient
with NHL strictly depend on disease stage, this diagnostic
delay can seriously impact patients’ lives.
FIG. 2. ExtranodalNK/T-cell lym-
phoma, nasal type. (A) Low magnifi-
cation showing a dense and diffuse
infiltrate of pleomorphic lymphocytes
within the entire chorion with an
angiocentric pattern of infiltration
(hematoxylin and eosin,·25); (B)
prominent tumor necrosis (hema-
toxylin and eosin, · 100); (C)
medium-sized pleomorphic lympho-
cytes predominate (hematoxylin and
eosin,·200); and (D) most cells
strongly express CD2 (CD2,·25).
NK, natural killer.
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Because of the relative rarity of this condition, achieving
the correct diagnosis can be a challenge, even for patholo-
gists. In a recent study conducted before the most recent
WHO classification, the overall diagnostic accuracy among
experts was found to be *81%, with a value ranging from
67% to 95% depending on the specific subtype.12
In our case, prompt biopsies and histopathological exami-
nation led us to a diagnosis in only 2 weeks, but unfortunately
the patient had already undergone a 3 month delay since the
first medical examination. We speculate that such extended
delays could jeopardize a patient’s life, and can surely con-
tribute to the extensive damage to the nasal floor and sur-
rounding structures, with a consequent permanent wound that
is hard to manage and impacts the patients’ quality of life.
The head and neck healthcare specialists may be consid-
ered the main actors in the diagnostic pathway of these rare
diseases. Lack of response to first treatments must induce
physicians to increase level of suspicion and to refer their
patients for further examination as appropriate. The first ob-
servation/waiting periodmust be not longer than 2weeks, and
it should be followed by a histopathological examination in all
uncertain cases.
In this case, the patient had been treated symptomatically for
a persistent unspecified peripheral lymphadenopathy for the
first 4 weeks without any improvement, and without perform-
ing any further investigations. Next, management of the patient
by the ENT specialist for a further 4 weeks for an alleged
sinusitis was even bordering on negligence. In such a patient,
after the first 3–4weeks of observation, lymph node biopsywas
already required. It should be highlighted that imaging, for
example, a simple head and neck ultrasound, could have been
useful to identify node characteristics more accurately than the
physical examination only. It is well established that a change
in the long: short axis ratio of a node is a significant sign of
lymphoma and metastatic cancer. Furthermore, fine needle
aspiration cytology (FNAC) is a simple and safe procedure and
is proved tobe accurate in the diagnosis of reactive hyperplasia,
infections, granulomatous lymphadenopathies, lymphomas,
and metastatic malignancies. The accuracy of image-guided
lymph nodes biopsy by FNAC in diagnosing lymphoma and
metastatic cancer has been reported to be in the range of
76%–100% and 82%–96%, respectively.13 Further examina-
tions such as maxillofacial CT scan could have been useful to
have initial staging of the disease since the first visits.
Based on this experience, it is arguably undesirable to wait
even three days in respect of these forms of lymphomas in
which the cytotoxicity and angiocentricity can produce such
a fast and deep necrosis. The grievous impairment of the
surrounding anatomical structures is the main complication
that contributes to the already very poor prognosis.
Furthermore, in these highly aggressive forms, the possi-
bility of starting a therapy before completing the diagnostic
pathway should be evaluated. Starting an earlier therapy
could make a significant difference in improving such poor
survival rates.
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Abstract 
Lichen planus (LP) is a chronic T-cell-mediated mucocutaneous inflammatory disease 
that targets the stratified epithelia, including those lining the oral cavity. The intraoral 
variant of LP (OLP) is known to be associated with production of IFN-γ by the 
infiltrating T lymphocytes, however the role of epithelial cells in the etiopathogenesis 
of the disease is not completely understood. There is however a growing body of 
evidence about the involvement of a number of epithelial-derived cytokines, immune 
receptors as well as co-stimulatory molecules in the pathobiological processes that 
promote and sustain OLP. In the present study, we first used RT-PCR to assess 
whether CD40, a receptor found mainly on antigen presenting cells, and the co-
stimulatory molecule CD86, w re expressed in oral keratinocytes (three strains of 
primary normal oral keratinocytes and the H357 cell line) in the presence or absence 
of IFN-γ. To further characterize the involvement of CD40 in OLP, expression and 
distribution of both receptor and ligand (CD40/CD154) were evaluated by 
immunohistochemistry in tissues from OLP. The results showed, for the first time, 
that both CD40 and CD86 are constitutively expressed at low levels in oral 
keratinocytes and that their expression can be enhanced by IFN-γ stimulation. Strong 
intensity of CD40 staining was found in OLP tissues. Taken together, the results 
strongly suggest that CD40/CD86 play a role in the pathophysiology of oral 
inflammatory diseases such as OLP.  
 
 
Keywords: CD40; CD86; oral lichen planus; oral inflammation; Regulatory T Cells; 
mucosa 
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Introduction 
Lichen planus (LP) is a chronic T-cell-mediated mucocutaneous inflammatory disease 
whose aetiology and pathogenesis are not completely understood. To further clarify 
some of the pathological regulatory mechanisms associated with the disease, we 
investigated the expression of CD40 and CD86 in oral keratinocytes and their role in 
inflammatory disease of the oral cavity. 
CD40 is a 45–50 kDa phosphorylated type I integral membrane glycoprotein that 
belongs to the tumor necrosis factor (TNF) receptor superfamily which is expressed 
on a number of different haematopoietic and non-haematopoietic cells (1-11). It has 
been shown to be involved in several biological functions, such as cell mediated 
immunity and cell growth regulation. The ligand for CD40 is CD154, also known as 
CD40 ligand (CD40L), a cell surface molecule mainly expressed by activated T cells. 
Through interaction with its receptor, CD154 plays a pivotal role in T cell-dependent 
humoral response as well as cell-mediated immunity and inflammation. Thus, it 
represents a key element in the pathogenic proc ss of chronic inflammatory diseases, 
autoimmune disorders and has additional implication in many pathogenic steps of 
tumorigenesis (1,12,13). 
Interferon-gamma (IFN-γ) can cause an increase of CD40 expression in a number of 
different epithelial cell lines, including buccal oral epithelium (8,11). Due to the 
increase in CD40 expression after pro-inflammatory cytokine treatment, it is not 
surprising that CD40 epithelium expression is enhanced in some inflammatory 
conditions (4).  
Focusing on oral epithelium, CD40 has been demonstrated to be involved in many 
aspects of cell homeostasis, by being constitutively expressed by oral keratinocytes 
and able to stimulate T lymphocytes by reacting farther with several costimulatory 
Page 3 of 38
Japan Science and Technology Information Aggregator, Electronic (J-STAGE)
innovative, web-based, database-driven peer review and online submission workflow solution
For Peer Review
 4
molecules, including B7.2 (or CD86), one of the most important B7 molecules family 
member (14). CD86 can bind to the ligands CD28 or to the cytotoxic T-lymphocyte 
associated molecule-4 (CTLA-4), located on resting and activated T cells, thus 
determining respective upregulation of T cell stimulation and clonal expansion via 
multiple cytokines stimulation, or downregulation of this process (15,16). 
There is increasing evidence that the expression of CD40 on epithelium plays a role in 
immune response, stimulating the production of a number of cytokines and 
chemokines. Previous studies have shown that these chemokines are upregulated in 
oral lichen planus (OLP) and that this condition is characterised by large numbers of 
activated T cells present localised near the epithelium or infiltrating the basal 
epithelium (9,11). 
The aim of this study was to investigate the effect of IFN-γ treatment on CD40 
mRNA expression in oral epithelial cells. Antigen presentation by keratinocytes is 
proposed to have role in the pathogenesis of OLP, and the data on CD86 expression 
remains conflicting (8,17-24).  Thus, we investigated CD86 mRNA expression in oral 
epithelial cells due to its crucial role in this process.  The results showed, for the first 
time, that both CD40 and the co-stimulatory molecule CD86 are constitutively 
expressed at low levels in oral keratinocytes and that their expression can be enhanced 
by IFN-γ stimulation. 
CD40/CD154 were additionally evaluated by immunohistochemistry in OLP tissue 
with the intention to further characterize the CD40-CD154 cell-expression and 
distribution. 
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Materials & Methods 
 
Patients 
All OLP tissue (n = 12) was collected from patients that were attending the Oral 
Medicine Clinic, Eastman Dental Institute and the Royal dental Hospital of 
Melbourne. The condition in each case was confirmed as OLP by a pathologist, and 
only patients without any other systemic diseases were enrolled. All normal oral 
mucosa was obtained from patients attending the Oral Surgery Clinic, Eastman Dental 
Institute for routine third molar extraction. The internal Ethical Committee of the 
UCL Eastman Dental Institute approved the study protocol, which was performed in 
accordance with the tenets of the Declaration of Helsinki. All patients provided 
written informed consent. 
 
Cell culture techniques 
Normal Human Oral keratinocytes (NHOK) cell culture.   
Normal oral mucosal tissue was obtained for this study from healthy patients. Three  
different NHOK strains (NHOK1, NHOK2, NHOK3) were isolated from the excised 
normal tissue by separating the connective tissue. The samples were cut into 
approximately 1mm3 pieces and culturing at 37oC /5% CO2 in keratinocyte basal 
medium-2 containing the recommended growth supplements (Biowittaker, 
Wokingham, UK). The epithelial cells were then detached using 0.25% trypsin-1mM 
EDTA. The viability of the keratinocytes was confirmed by trypan blue exclusion. 
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H357 cell culture 
The oral squamous cell carcinoma cell line, H357, was established by Prime et al. 
(25), from a primary explant of a tongue squamous cell carcinoma. This cell line was 
grown in the same medium as described for the NHOK. 
 
CD40 / CD86 RT-PCR 
mRNA derived from H357 cells and primary oral epithelial cells treated with 
1000U/ml IFN-γ for 48 hours was investigated. Primers specific for human CD40 
mRNA and CD86 mRNA were generated for this reaction;  
CD40 forward 5’ - CTGGGCTAGCGATACAGGAG -3’, reverse 5’- GGAATTTCTG 
TTGGCCAAATCCA -3’ and  
CD86 forward 5’ –AGACGCGGCTTTTATCTTCA -3’, reverse 5’- 
AACTCCAGCTCTGCTCCGTA -3’ (Genosys-Sigma, Poole, UK) and RT-PCR carried out. 
Magnesium concentration was optimised for each primer as follows; 1µl of cDNA 
was added to 4µl dNTP (2.5mM), 5µl 10x buffer, 0.225µl AmpliTaq (5.0U/µl) 
(Perkin Elmer,), 4µl of each specific primer (5µM), 1.5mM, 3.0mM or 4.5mM MgCl 
in each reaction and dH2O added to give a final volume of 50µl. The thermocycler 
(Techne Genius; Cambridge, UK) parameters used also vary depending upon the 
primers utilised, the annealing temperature of the reaction was dependant upon the 
different guanidine-cytosine content of the primers. The general parameters used 
were: 94oC for 45secs; annealing temperature (57oC-60oC) for 45secs; 72oC for 
45secs; Repeated for 35 cycles. 
The products were separated on a 2% agarose (GibcoBRL Life Technologies, Paisley, 
UK) gel and visualised by staining with ethidium bromide (Sigma, Poole, UK), 
specific bands were visualised by ultra-violet trans-illumination in a MultiImage Light 
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Cabinet (AlphaInnotech Corp., Cannock, UK) and digital images acquired and stored 
using AlphaImager Software (AlphaInnotech Corp., Cannock, UK). The primers 
utilised for the study of housekeeping expression encoded a region of 18S ribosomal 
RNA (5’- tttcggaactgaggccatga-3’, 5’- gcatgccagagtctcgttcg -3’).   
 
IFN-γ cell treatment assay 
In a modification of the method utilised by Altenburg et al [26], the primary oral 
epithelial cells and the H357 cell line (at 2nd or 3rd passage) were seeded at 8x104cells/ 
well in a Falcon 6 well plate (Becton Dickinson, Oxford, UK) with 3mls of KBM-2 
medium containing no hydrocortisone. The cells were incubated for at least 3-5 days 
until cell culture was 60-80% confluent. We set up the optimal experimental 
conditions in preliminary experiments with dose-response curves. Medium containing 
1000U/ml IFN-γ was added to 3 wells and control cell culture medium only was 
added to the remaining 3 wells. The cells were incubated for 48hrs or, in the case of 
the H357 time course, for the following time-points: 3hrs, 6hrs, 9hrs, 24hrs, 48hrs and 
72hrs. The supernatant was extracted, centrifuged and stored at –70oC. The adherent 
cells were washed with PBS (Gibco Life Technologies, Paisley, UK) before 0.5ml of 
Trireagent (Sigma, Poole, UK) were added.  The suspension was then removed and 
stored at –70oC. 
 
Immunohistochemical methods 
Paraffin section preparation 
Archivial paraffin-embedded formalin-fixed (PEFF) oral lichen planus tissue was 
used. Normal non-diseased skin (leg) sections and oral mucosa (tonsil) sections were 
also utilised as positive and negative control samples. The paraffin blocks were cut to 
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a 4 µm thickness using a microtome, and mounted onto Superfrost Plus  slides 
(Thermo Scientific).   
Antigen retrieval methods 
Sections were de-waxed using a xylene wash (BDH, Poole, England) followed by 
ethanol washes; the sections for CD154 were boiled in citric acid on hot plate for 20 
minutes and cooled at room temperature for 20 minutes; for CD40, the sections were 
boiled in citric acid on hot plate for 10 minutes and cooled at room temperature for 20 
minutes. Then the sections were washed in PBS, and the endogenous peroxidase was 
quenched with 3% H2O2 in methanol for 5 minutes. 
 
Antibodies for immunohistochemistry 
- Primary antibodies: Purified anti-human CD154 (C-20) antibody (sc-978, rabbit 
polyclonal IgG, Santa Cruz Biotechnology Inc., Dallas, Texas; diluted 1:50 in 
PBS), purified anti-human CD40TNFRSF5 antibody (PA5-32325, rabbit 
polyclonal IgG, Thermo Fisher, diluted 1:50 in PBS).  
- Secondary antibody: Biotinylated Universal (PK-6200, anti-mouse IgG/rabbit 
IgG) antibody (Vectastain® Universal, Elite, ABC kit, Vector laboratories, Inc, 
Burlingam, California, USA). 
 
3’, 3’-diaminobenzide (DAB) staining and image acquisition  
The study slides containing OLP sections and positive control were incubated with the 
primary antibody for 30 minutes at room temperature. The negative control was 
incubated with no primary antibody (only PBS) for the same time at room 
temperature. The slides were then washed in PBS 3 times and incubated with the 
secondary antibody for 30 minutes at room temperature. The slides were then 
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incubated with Avidin DH/ Horse biotinylated HRP solution (Vectastain® Universal, 
Elite, ABC kit, Vector laboratories, Inc, Burlingam, California, USA). The slides 
were washed 3 times with PBS and DAB (Dako Australia Pty. Ltd, North Sydney, 
NSW, Australia) was applied for 5 minutes. After this, the slides were washed with 
PBS, counterstained in Mayer’s Haemotoxylin (Amber scientific, Midvale WA, 
Australia), and mounted. Consecutive sections of the same samples were also stained 
with Haemotoxylin and Eosin without Immunohistochemistry. Pictures were taken 
using Aperio CS2 Digital Pathology Slide Scanner (Leica Biosystems).  
 
Statistical analysis 
Statistical significance was evaluated using unpaired t-tests. 
 
Results  
Time course study of CD40/CD86 expression in H357 cells treated with IFN-γ. 
The production of CD40/CD86 in oral mucosal keratinocytes was first assessed over 
time in preliminary experiments using the keratinocyte cell line H357 (Figure 1). 
After three hours of IFN-γ treatment, very low levels of both CD40/CD86 mRNA 
were detectable in H357 cells. After 6 hours both CD40/CD86 mRNA were slightly 
higher in the IFN- γ compared to the control cells. Interestingly, both CD40 and CD86 
mRNA levels at 9 hours was virtually undetectable in the control cells. The IFN- γ  
treated cells showed CD86 mRNA levels up to 72 hours, whereas CD86 mRNA 
transcripts were present up to 48 hours in the control cells.  
Taken together, the data show that expression of CD40 and CD86 in H357 cells can 
be enhanced by IFN-γ stimulation.  
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Co-stimulatory molecule expression in oral epithelium in vitro 
CD40 is expressed constitutively in three different primary oral epithelial cell lines. 
but can be increased after treatment with IFN-γ treatment in vitro (Figure 2a-2b). The 
statistical analysis revealed that mRNA expression, was statistically significantly 
higher (P < 0.001) in the IFN-γ group (0.853 ± 0.025) compared to that of the control 
group (0.419 ± 0.0134) (Figure 2c). Furthermore, a similar pattern was witnessed for 
the co-stimulatory molecule CD86 on the same cell lines. Its expression was very low 
constitutively, but was increased after IFN-γ treatment although this effect was not 
statistical significant (Figure 2c). 
 
CD40 / CD154 expression in OLP tissue 
In sections of OLP lesional tissue, concentrated staining of CD40 is associated with 
cells within the infiltrate of OLP, although staining of individual cells in proximity to 
the epithelium are also visible as well as a moderate epithelial staining (Figure 3). 
Staining was particularly intense within the band-like inflammatory infiltrate (Figure 
4). Cells in the basal area appear to express relatively high expression, although 
positive cells are also present in the supra-basal area. Certain focal areas of the basal 
epithelium have particularly high expression levels. CD154 is expressed upon 
infiltrating cells in OLP lesions, but not within the epithelial layers (Figure 5). 
Positive cells appear to be preferentially located near areas of epithelial cells at the 
epithelial-connective tissue junction, especially in focal areas of cell damage.  
 
Discussion  
Page 10 of 38
Japan Science and Technology Information Aggregator, Electronic (J-STAGE)
innovative, web-based, database-driven peer review and online submission workflow solution
For Peer Review
 11
There was a strong intensity of CD40 staining in OLP, particularly on cells within the 
infiltrate and which may represent CD40-positive Langerhans’ cells. CD40 expression 
was also witnessed in association with oral epithelial cells. CD40 has been reported in 
other epithelial cell types in vivo, and appears to increase during other inflammatory 
disorders.  Furthermore, it was demonstrated that CD40 expression is increased on 
primary oral keratinocytes after IFN-gamma incubation, consistent with other studies 
(8), implicating this cytokine in the stimulation and inflammation of oral epithelium. 
Furthermore, CD86 mRNA could be enhanced after IFN-gamma treatment of oral 
keratinocytes and the implications of this expression in oral inflammatory disease 
could be paramount, as discussed below. 
In the light of current knowledge, our findings lead us to conjecture a possible 
involvement of CD40/ CD86 ligation in inflammatory enhancement. 
T cells in OLP appear to be in an activated state and would thus be expected to 
express CD154 (27), the ligand for CD40. The proximity of infiltrating T cells and 
epithelium in OLP, which, in some cases, can extend to interactions between T cells 
and the epithelium would suggest that ligation of CD40 and CD154 occurs in this 
disease. This ligation has been shown to induce / enhance a number of effects in 
epithelial cells, including an increase in the production of pro-inflammatory cytokines 
(3,28) and chemokines (3,29-31). It is likely that an increased production of these 
molecules from the epithelial area in OLP would increase the inflammation that 
occurs. Specifically, the increased expression of the CXC ELR- chemokines 
witnessed in OLP may be partially due to the ligation of CD40 on oral epithelial cells, 
as was  shown previously in cervical carcinoma cells (26). Furthermore, the increased 
production of RANTES witnessed from keratinocytes in OLP (32) could also be 
influenced by CD40 ligation (31, 33).  
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Interferon-gamma may also play an important contributory role in inflammation of 
oral epithelium as it can increase the expression of CD40 on epithelial cells, as well as 
induce the expression of chemokines such as CXCL10 (Marshall et al, manuscript in 
preparation).  These presumably promote migration of activated T cells into the area, 
which may interact with epithelial cells and bind CD40.   In turn, this would synergise 
to produce more chemokines and cause an increase in the inflammatory status of 
conditions such as OLP (34-36).  
It can be shown that the induction of B7 molecules on keratinocytes can cause an 
increased immunogenecity to a number of different antigenic stimulants, causing a 
large influx of stimulated T-cells. This increase in the delayed-type hypersensitivity 
(DTH) response to reencountered antigens witnessed in B7 transgenic mice displays 
many similarities to the pathogenic mechanisms visible in OLP, including the large T-
cell influx visible in oral lichen planus and the chronic nature of the disease. The fact 
that CD86 can be upregulated on oral epithelium in vitro by interferon-gamma and 
that there are many features suggestive of IFN-gamma stimulation on keratinocytes in 
OLP suggests that this molecule is likely expressed on these cells involved in the 
increased immunogenicity to antigens, including common oral commensals, such as 
Candida. Furthermore, the expression of CD86 on oral epithelium may also be 
relevant to cell migration, as CD28 ligation of CD4+ cells can alter chemokine 
receptor expression (37). 
Although we have shown that CD86 is induced in vitro on oral epithelium, its  
expression in OLP is unknown. Simon et al (38), investigated the expression of CD28 
and B7 in cutaneous lichen planus lesions and discovered that the B7-1 molecule was 
focally expressed on keratinocytes within the lesion. However, it was found that the 
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antibody for B7-1 also detected the MHC molecule (39) and it was likely that it was 
this molecule that was detected in lichen planus.  
Furthermore, the role of CTLA-4 and CD28 binding is known to affect Th1/ Th2 
differentiation, but this would appear to have a larger effect on naïve cells than  
memory cell interactions (40) which  occur in OLP. 
Due to the increase in co-stimulatory molecules in epithelium after inflammatory 
signals, including oral epithelial cells as shown in this study, it has been proposed that 
they may act as non-professional antigen presenting cells in OLP (41). However, 
despite keratinocytes possessing the genes necessary for antigen presentation (42), 
presumably if oral keratinocytes were capable of antigen presentation, it would have 
to be immunogenic antigen presentation in OLP to cause the reaction witnessed. 
However, it has proved difficult to assess the factors that provide even professional 
antigen presenting cells with either tolerogenic or activating signals to T cells in the 
periphery (43).   
Like bronchial and intestinal epithelium, oral epithelium is also capable of antigen 
presentation, although by other mechanisms (5,44-46).  Particularly, an increase in the 
expression of co-stimulatory molecules, such as in times of inflammation, is required 
for oral epithelial antigen presentation. 
It is tempting to suggest that those antigens that would be presented at high doses, 
thus more likely to elicit an effective T cell response (16), would be those at 
constantly localised high levels in the oral mucosa, such as betel nut antigens in 
persistent users and amalgam antigens of patients with these fittings. If these antigens 
were combined with inflammatory signals they may produce active antigen 
presentation of these antigens, which may produce an immunogenic opposed to 
tolergenic response.   
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The proposed activation / tolerance theories in dendritic cells that stimulatory function 
is either enhanced by toll-like receptors (TLR) on dendritic cells recognising 
microbial products and upregulating co-stimulatory molecules (47) or that damage in 
other cells, and the production of molecules, such as heat shock proteins, act as 
‘danger signals’ (48) to activate dendritic cells, may also be the case in epithelial cells 
(49-52,). 
Furthermore, the induction of co-stimulatory molecules upon the epithelium does not 
necessarily provide T cell activation, as these molecules may actually bind to CTLA-
4, which is thought to be an important molecule in providing tolerance (53). In fact, 
dysregulation of CTLA-4 in OLP patients may be responsible for a breakdown in 
tolerance for oral keratinocyte antigens (54).  However, in cutaneous lichen planus 
tissue there is a clear expression of CTLA-4 cells in most samples, whereas there is no 
expression in a variety of other skin inflammatory disorders (55). The implications of 
this expression are unclear, however, the findings that many infiltrating T cells in 
lichen planus express CD28 (38), suggests that these cells could interact with CD86-
expressing keratinocytes leading to specific clonal activation of these cells (56).  
A subset of CD4+ T cells that express CD25 represent regulatory T cells that are 
proposed to be involved in the suppression of autoimmunity (57-59). Interestingly, 
CD25+ cells are upregulated in OLP (58). However, these cells are also thought to 
involved in a role of the persistence of infection, perhaps in order to permit long-term 
immunity (59). Therefore, it could be proposed that these cells are involved in causing 
the chronicity of diseases, with a low-level (and perhaps non-detectable level) of 
infection occurring. The chronic nature and presence of CD25+ cells in OLP may 
therefore be related. 
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Presumably, if oral keratinocytes are capable of antigen presentation it would be ‘non-
professional’ antigen presentation i.e. these cells would not be able migrate to the 
lymph nodes to stimulate naïve T cells. This would suggest that predominately only 
memory cells could be activated in this manner, in fact, memory T cells are activated 
by a range of different APC and have less requirement of co-stimulatory function than 
naïve cells (60). It is interesting to note that memory T cells constitute the majority of 
infiltrating cells in OLP lesions. Furthermore, the possible increase in chemokine 
production by T cell ligation of keratinocytes in OLP would presumably promote the 
migration of further memory cells into this area. This suggests that Langerhans’ cells 
have an important role in initiating naïve T cell responses, whereas in the secondary 
response keratinocytes may play a role in re-activating memory T cell responses. 
However, resident tissue APCs are implicated in presenting self-antigen to Th1 cells 
during auto-immune conditions (61), and thus keratinocytes may also play a role in 
initiating the presentation process to Th1 cells. 
The reaction against oral keratinocytes in OLP suggests that may be a break-down in 
tolerance to self-antigens of oral epithelial cells. There may be many mechanisms 
influencing potential breakdown of self-tolerance in the oral mucosa such as the 
process known as molecular mimicry (62), or the epitope spreading theory (63).  
Due to the number of agents associated with the onset of OLP and the chronicity of 
the disease, which may be caused by different shift of epitopes detected in the disease, 
epitope spreading appears a possible candidate for the pathogenesis of this disease. 
Furthermore, CD80/86 blockade (64) or CD40-CD154 blockade (65) can inhibit 
epitope spreading and ease ongoing autoimmunity in animal models. The fact that 
CTLA-4+ve cells are a positive factor in easing epitope spreading (54), suggests that 
the CD25+ cells witnessed in OLP may cause a down-regulation in the immune 
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reaction, however, perhaps further epitope changes promote a wave of inflammatory 
T cells.  As epitope spreading is implicated in chronic diseases like multiple sclerosis, 
where there is relapses and remission this suggests this pathogenic pattern could occur 
in OLP. 
However, in OLP despite the large number of CD4+ cells present in the lesions, it 
appears that it is CD8+ cells that are in the proximity to the epithelial area. This 
suggests that it is actually MHC-class I restricted presentation that is occurring within 
lesions. However, it may be that prior class II presentation by keratinocytes assist in 
initiating a CTL reaction. Interestingly, CD40 ligation of antigen presenting cells play 
an important role in the generation of CTL cells (66,67). Therefore, maybe if 
keratinocytes are presenting antigen through the MHC-Class II pathway, the ligation 
of CD40, which is classically associated with antibody-mediated reactions, not only 
amplifies the inflammation of the area, but may be also involved in the generation of 
specific CTL.   
However, there are a group of CD8+ effector memory cells that are preferentially 
located in non-lymphoid tissue, that rapidly expand after activation (68), thus may not 
require further T helper cells. Furthermore, CD8+ memory cells also have a limited 
requirement for B7 co-stimulatory signals. However, as autoreactive CD4+ and CD8+ 
T cells often have a weaker affinity to antigen, they may actually require B7-
stimulation (40) thus the expression on oral epithelium may still be relevant. 
The process of cross-tolerance (69) is thought to be important in the gaining self-
tolerance to apoptotic cells. In fact, there is a subset of intestinal dendritic cells that 
have been shown to transport apoptotic epithelial cells to the lymph nodes (70), in a 
process thought to provide exposure and induction of tolerance to ‘self’ antigen. 
Furthermore, Langerhans’ cells have been shown to be capable of phagocytosis of 
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vaginal apoptotic epithelial cells (71). These findings are of particular interest as it is 
thought that there are apoptotic keratinocytes in OLP (9), and it may be that the 
process of transport of antigen from these cells to the lymph nodes may in fact induce 
an immunogenic response to these antigens instead of the tolerising effect (72)  
It could be speculated that this process produces auto-reactive T cells to keratinocytes. 
Additionally, ligation of CD40 on epithelial cells causes growth inhibition and 
increased apoptosis of cells in ovarian carcinoma cell lines (3), which is of interest 
due to the increased apoptosis of this cell type in OLP (in conjunction with associated 
CD40 expression). This may induce the transport of apoptotic cells to the lymph 
nodes for cross-presentation, a process that was found to be age-related  (73). 
Also, molecular mimicry and epitope spreading is thought to occur in Class I 
restricted antigens as well as Class II antigens, so it may an effect of direct MHC-
Class I presentation that may cause the cytotoxic effect in OLP.   
There is increasing evidence from the presence of molecules on epithelial cells that 
they may in some circumstances be capable of antigen presentation. Whether this 
antigen presentation produces a tolerogenic or immunogenic response remains to be 
seen, although the presence of MHC-II, CD40 and the potential of CD86 expression 
on oral epithelial cells, and CD28 in the T cell infiltrate of OLP suggests that 
‘activating’ antigen presentation could occur. The antigen presentation may take the 
form of ‘sampling’ antigens on the oral mucosa, such as bacterial antigens. The 
implications for antigen presentation may be very important in conditions such as 
OLP as there appears to be a breakdown in the tolerance for ‘self’ keratinocyte 
antigens. This breakdown could occur by a number of mechanisms, including 
molecular mimicry or epitope spreading. However, CD8+ cells appear to be acting 
cytotoxically in OLP, therefore, perhaps the Class I pathway is more important in the 
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disease process. Perhaps the presence of inflammatory signals present during cross-
presentation of apoptotic keratinocytes causes normal tolergenic CD8+ cells to 
become auto-reactive for these cells. Interestingly, ligation of CD40 on keratinocytes 
(which is expressed in OLP) is thought to cause apoptosis of this cell type.  
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Figure legends 
 
Figure 1: CD40 / CD86 mRNA expression in H357 (timecourse). 
  
Figure 2: a) The expression of 18S, CD40 and CD86 mRNA in 3 different normal 
human oral keratinocytes (NHOK) (indicated as 1, 2 and 3) either after IFN-gamma 
treatment (IFN-γ 1-3) for 48 hours or non-treated (CON 1-3) or the negative control (-
-). b) The values were normalized against 18S mRNA expression used as house 
keeping. c) Triplicate average with standard deviation and statistical significance 
(*=Significant .01 < p ≤ .05, **= Highly Significant p ≤ .01). 
 
Figure 3: CD40 localisation in OLP tissue using peroxidase staining. Intense staining 
was associated with subepithelial band-like infiltrate. Epithelial cells within OLP 
lesions also appeared to demonstrate mild to moderate staining. Magnification x4 and 
x20. Negative control sections demonstrated no staining. Normal Control and typical 
H&E staining of OLP are reported in Supplementary Figure 1.  
 
Figure 4: CD40 localisation associated with inflammatory infiltrate in OLP tissue. 
Staining was mostly present within the dense inflammatory infiltrate and also upon 
single cells in proximity and infiltrating the epithelial layer. Magnification x40. 
 
Figure 5: CD154 expression in oral lichen planus tissue. Magnification x10 and x40. 
Infiltrating cells in proximity to the basal epithelium are associated with anti-CD154 
positive staining, however epithelium shows faint or no staining.    
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Supplementary Figure 1 
IHC staining of CD40 (A) and CD154 (B) of non-diseased controls. Haematoxylin-
eosin staining of typical OLP tissue (C) and normal control (D).  
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Abstract
The interrelationship between malignant epithelium and the underlying stroma is of fundamental importance in tumour 
development and progression. In the present study, we used cancer-associated fibroblasts (CAFs) derived from genetically 
unstable oral squamous cell carcinomas (GU-OSCC), tumours that are characterized by the loss of genes such as TP53 and 
p16INK4A and with extensive loss of heterozygosity, together with CAFs from their more genetically stable (GS) counterparts 
that have wild-type TP53 and p16INK4A and minimal loss of heterozygosity (GS-OSCC). Using a systems biology approach 
to interpret the genome-wide transcriptional profile of the CAFs, we show that transforming growth factor-β (TGF-β) family 
members not only had biological relevance in silico but also distinguished GU-OSCC-derived CAFs from GS-OSCC CAFs and 
fibroblasts from normal oral mucosa. In view of the close association between TGF-β family members, we examined the 
expression of TGF-β1 and TGF-β2 in the different fibroblast subtypes and showed increased levels of active TGF-β1 and TGF-
β2 in CAFs from GU-OSCC. CAFs from GU-OSCC, but not GS-OSCC or normal fibroblasts, induced epithelial–mesenchymal 
transition and down-regulated a broad spectrum of cell adhesion molecules resulting in epithelial dis-cohesion and 
invasion of target keratinocytes in vitro in a TGF-β-dependent manner. The results demonstrate that the TGF-β family of 
cytokines secreted by CAFs derived from genotype-specific oral cancer (GU-OSCC) promote, at least in part, the malignant 
phenotype by weakening intercellular epithelial adhesion.
Introduction
Intercellular adhesion plays a major structural role in epithelial 
integrity and is altered in malignancy. Specifically, impairment 
of cohesion between cells and altered expression of adhesion 
molecules in epithelial cancers determine an invasive behaviour 
and are associated with poor prognosis, respectively (1,2). This 
suggests that the weakening of cell–cell adhesion strength is a 
feature associated with tumour progression.
Our current understanding of the molecular biology of 
head and neck cancer, including oral squamous cell carcinoma 
(OSCC), relates almost exclusively to tumour epithelium. 
Malignant keratinocytes, however, are heterogeneous. In colo-
rectal cancer, for example, subtypes with microsatellite or chro-
mosomal instability, or neither, have been reported (3). In OSCC, 
genetically stable (GS-OSCC) and genetically unstable (GU-OSCC) 
variants have been identified and characterized in cell culture 
(4). In contrast to the stable variants (GS-OSCC), malignant 
keratinocytes from GU-OSCC are characterized by TP53 and 
CDKN2A/p16INK4A dysfunction, telomerase activation, frequent 
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inactivation of the NOTCH1 canonical pathway and extensive 
loss of heterozygosity (4). Furthermore, there is evidence to 
show that the GS-OSCC and GU-OSCC genotypes have biologi-
cal relevance in vivo, because the GU-OSCC tumour group have 
a worst prognosis than GS-OSCC (5). Further, CDKN2A/p16INK4A 
deletions are detectable in vivo using in situ techniques (6). 
With respect to GS-OSCC keratinocytes, it is possible that they 
are normal contaminants of the tumour tissue, but these cells 
have an altered transcriptional profile (5) and are resistant to 
suspension-induced terminal differentiation (5). If the GS-OSCC 
and GU-OSCC variants have biological relevance, therefore, they 
may be important with regard to clinical diagnosis, behaviour, 
treatment and prognosis in OSCC.
It is now recognised that solid tumours are not simply clonally 
evolved epithelial cells that have accumulated a critical number of 
mutations but rather act as dysfunctional tissues where the mes-
enchymal component plays a critical role in tumour pathogenesis 
(3). The non-malignant cells, together with the extracellular matrix, 
constitute the tumour stroma and pre-eminent in the stroma are 
cancer-associated fibroblasts (CAFs). Cancers metastasize by a 
series of distinct steps that include invasion, intravasation, extrava-
sation and, ultimately, colonization. Epithelial–mesenchymal 
transition (EMT), a process in which epithelial integrity is lost 
and mesenchymal attributes are acquired (7), is thought to play 
a fundamental role in tumour progression. Although the role of 
EMT has been questioned recently, the fact remains that there 
is convincing morphological evidence that EMT is present at the 
invasive front of human tumours. Furthermore, EMT is dynamic, 
which suggests that the tumour stroma may be pivotal in its regu-
lation, a proposal that requires verification. It is important, there-
fore, to confirm that CAFs regulate EMT and also to understand 
the mechanisms by which this occurs.
Recently, we isolated CAFs from GS-OSCC and GU-OSCC 
and demonstrated that they had distinct transcriptional pro-
files (8). In GU-OSCC, but not GS-OSCC, malignant keratino-
cytes induced high levels of senescence in CAFs, which, in turn, 
induced target keratinocytes to invade collagen gels in vitro (9). 
This suggests that the epithelial–mesenchymal crosstalk occur-
ring in GU-OSCC involves paracrine signals in the microenvi-
ronment. CAFs are known to secrete numerous growth factors, 
chemokines and cytokines as well as modulating the extracel-
lular matrix through protease activity. Senescent fibroblasts, 
for example, produce a characteristic secretome termed the 
senescence-associated seceretory phenotype (10) that consists 
of both soluble and insoluble factors that have the capacity to 
promote the invasion of transformed cells (11). The key mol-
ecules that are secreted by CAFs from GU-OSCC and that are 
instrumental in inducing epithelial invasion have yet to be 
identified.
In the present study, we used a systems biology approach to 
interpret a genome-wide transcriptional profile of CAFs derived 
from OSCC. We show that members of the TGF-β family of 
cytokines distinguish CAFs from GU-OSCC and GS-OSCC and 
from normal oral fibroblasts. We show that CAFs from GU-OSCC 
overexpress TGF-β1 and TGF-β2 and induce EMT; in addition, they 
promote a widespread reduction in the expression of cell–cell 
adhesion molecules and disrupt epithelial cohesion and initiate 
keratinocyte invasion in vitro in a TGF-β-dependent manner.
Materials and methods
Cell lines and strains
The cells used for this study were collected and isolated at Bristol Dental 
School, University of Bristol, UK (H series) and Beatson Laboratories, Glasgow, 
UK (BICR series). All of the cell lines/strains were derived prior to 2001 and 
therefore were not subject to Ethical Committee approval in the UK. All of 
the OSCCs were human papillomavirus negative. Keratinocytes were derived 
from OSCC (H357, H103), SCC (HaCaT-II3), and normal skin (HaCaT). The fibro-
blasts used in this study were derived from normal oral mucosa (NHOF-1, 
NHOF-2, NHOF-4, NHOF-5, NHOF-6, NHOF-7), GS-OSCC (BICR-30F, BICR-59F, 
BICR-66F, BICR-69F, BICR-70F, BICR-71F, BICR-73F, BICR-80F) and GU-OSCC 
(H314F, H357F, H413F, BICR-3F, BICR-18F, BICR-31F, BICR-63F, BICR-68F, BICR-
78F, BICR-82F). The mesenchymal origin of the fibroblast strains was con-
firmed by positive and negative labelling with vimentin and pan-cytokeratin/
keratin 14 antibodies, respectively. In contrast, the origin of the keratinocyte 
lines was confirmed by positive and negative labelling with pan-cytokeratin/
keratin 14 antibodies and vimentin, respectively (8,9). We are confident that 
the fibroblasts are normal because preliminary data from genome-wide 
copy number analysis have shown that all of the strains have a normal gene 
copy number (N.Thakker and E.K.Parkinson, unpublished observations). 
Furthermore, in the many studies where OSCC have been examined in vivo, 
we have never seen elevated levels of p53 indicative of p53 mutations.
Culture conditions
Details of the keratinocyte cell lines and fibroblast strains have been doc-
umented previously (8,9). Fibroblasts were cultured in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% (v/v) fetal bovine serum and 
2 mM l-glutamine and grown in a humidified atmosphere of 5% carbon 
dioxide/95% air; cells were examined at passages <12. Keratinocytes were 
cultured in Dulbecco’s modified Eagle’s medium-F12 supplemented with 
10% (v/v) fetal bovine serum and 0.5  μg/ml hydrocortisone; cells were 
grown under the same standard conditions (5% carbon dioxide, 37°C).
In certain experiments, 1 × 104 normal fibroblasts (NHOF1) were seeded 
into 60 mm culture dishes, grown until 60% confluent and then treated 
with 600 μM hydrogen peroxide (H2O2; BDH) for 2 h each day for 5 days. The 
cells were recovered in fresh culture media for 5 days before use. Previous 
studies demonstrated induction of fibroblast senescence using this pro-
tocol (9), and therefore, the cells were used as positive controls for the 
non-proliferative, senescent GU-OSCC CAFs.
Collection of conditioned media
Cells were grown in 75 cm flasks until they were 70–90% confluent, washed 
with serum-free media (×3) and phosphate-buffered saline (PBS; ×3) and 
then incubated in serum-free media for a further 48 h. The conditioned 
media (CM) was centrifuged at 800g for 5 min to remove dead cells. The 
viable attached cells were trypsinised and counted; the CM was normal-
ized for 0.5 × 106 fibroblasts. CM was stored at −20°C.
Neutralization of TGF-β in fibroblast CM
To neutralize TGF-β in fibroblast CM, monoclonal antibodies to TGF-β1, -β2 
and -β3 (R&D Systems, cat no. MAB1835), TGF-β1 (R&D systems, cat no.AB-
101-NA) or TGF-β2 (R&D systems, cat no. AB-12-NA) were added to CM at 
concentrations of 5, 0.5 and 1μg/ml, respectively, and incubated for 30 min 
at 37°C. CM was used immediately.
Abbreviations 
BSA  bovine serum albumin
CAFs cancer-associated fibroblasts
CM  conditioned media
DTG  differentially transcribed genes
EMT  epithelial–mesenchymal transition
FC  fold change
GU-OSCC  genetically unstable oral squamous cell carcinomas
GS-OSCC  genetically stable oral squamous cell carcinomas
H2O2  hydrogen peroxide
huSM  highly up-regulated secretory molecule
muSM  mildly up-regulated secretory molecules
OSCC  oral squamous cell carcinoma
PPI  protein–protein interaction
TGF-β  transforming growth factor-β
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Network construction and analysis
The transcriptome of OSCC CAFs (9) was interrogated using a systems 
biology approach, as described by ourselves and others (12–15).
Briefly, in order to prepare a protein interaction map of genes differen-
tially expressed in CAFs, protein–protein interaction (PPI) networks were 
examined through functional protein association network (STRING) and 
confirmed by literature searches (PubMed). Only PPI with the highest con-
fidence (0.9 and above) were included. To identify which genes in the data-
bases corresponded to the genes listed in the microarray data, we used 
either the gene symbol or the SwissProt entry name shown in the protein 
databases. Proteins and their PPIs were combined to form networks and 
subnets using Cytoscape 3.4. The resulting network was visualized as a 
series of graphs in which each node (N) represented a protein and the 
interactions between proteins were shown by edges (E) in the graph.
We used the differentially transcribed genes (DTG) from our gene 
expression profile data (8) to build two PPI networks: in the first one, nodes 
were represented by DTG corresponding to putative secreted molecules 
with the highest fold change (FC), i.e. logarithmic FC > 3; these nodes were 
named highly up-regulated secretory molecules (huSM). The second net-
work, of the same size as the first, was made of DTG corresponding to 
putative secreted molecules with the lowest significant FC, i.e. logarithmic 
2 < FC < 3; these nodes were termed mildly up-regulated secretory mol-
ecules (muSM). The average number of connections for each group of DTG 
was used to describe the degree of connectivity (k). The average connectiv-
ity (k) of a whole network was calculated as k = 2E/N, corresponding to the 
average number of interactive partners for each protein.
Western blotting
Protein extraction and western blotting were undertaken using stand-
ard protocols. A  list of primary antibodies, concentrations and suppliers 
is shown in Table  1. Selected proteins were detected using Amersham 
enhanced chemiluminescence Western Blotting Detection Reagent 
(Amersham Biosciences, UK) and exposed to radiographic film (Kodak, UK).
In-cell western blotting (In-cell enzyme-linked 
immunosorbent assay)
In-cell western blotting was performed as described previously (16). First, 
2.5 × 104 cells were seeded into each well of 96 well plates, fixed in cold 
(−20°C) methanol for 20 min, washed with PBS (3×) and permeabilized with 
0.1% Triton for 10–15 min. After washing with PBS (3×), a blocking solution 
consisting of 3% bovine serum albumin (BSA) in PBS was added for 1 h. 
The samples were incubated with the appropriate primary antibody (1:100 
in 2% BSA/PBS) for 3 h, washed in 3% BSA/PBS and then exposed to specific 
secondary antibodies (1:10 000 in 2% BSA/PBS) conjugated to horseradish 
peroxidase for 1 h. After washing with PBS (3×), the enhanced chemilu-
minescence mixture was added for 5 min in a dark room and the protein 
expression was quantified at 415 nm using the ELx808 microplate reader 
(BioTek Instruments). Negative controls included omission of primary 
antibody. The readings of protein expression in each well were normal-
ized according to the readings of the negative control.
Enzyme-linked immunosorbent assay
CM from fibroblasts were collected as described previously. The produc-
tion of TGF-β1 and TGF-β2 was assessed with a TGF-β Parameter Assay 
kits (R&D Systems, Minneapolis, MN) and quantified at 415 nm with the 
EL×808 microplate reader (BioTek Instruments, Winooski, VT) according to 
the manufacturer’s instructions.
Immunofluorescence microscopy
Immunofluorescence microscopy was performed as reported by us previ-
ously (17), with minor modifications. Briefly, the cells were cultured onto 
four-well plates (Nunc™ Cell-Culture Treated Multidishes, Thermo Fisher 
Scientific) in standard conditions and at 60% of confluency were treated 
as reported in the text. Cells were fixed with 100% ice-cold methanol for 
10 min at 4°C and then incubated with 0.5 μg/ml of Hoetstch staining 
(H6024, Sigma–Aldrich) for 30 min at 4°C and then blocked with 5% BSA-
PBS solution at 4°C for 60 min. The samples were then incubated overnight 
at +4°C with E-cadherin/CDH1 antibody (FITC conjugate, A15757, Thermo 
Fisher Scientific) at a 1/100 dilution in 2% BSA-PBS, and with anti-vimentin 
antibody (Ab154207, Abcam’s RabMAb®) at a 1/1000 dilution in 2% BSA-
PBS. All intermediate washing steps were performed with PBS. Images 
were taken with a fluorescence microscope (EVOS™ FLoid™ Cell Imaging 
Station, Life technologies).
Epithelial adhesion
Desmosomal adhesion is crucial for epithelial cells (18) and intercel-
lular adhesion can be specifically measured using the dispase dissocia-
tion assay (16). First, 1 × 104 keratinocytes were cultured in six-well plates 
under standard conditions until ~95% confluent. The culture media were 
decanted, the cells washed with PBS (3×) and then incubated with 4 ml 
fibroblast CM for 48 h. The fibroblast CM was decanted from the keratino-
cyte cultures, and the cells were washed with PBS (2×). Then, the keratino-
cytes were incubated with 2 ml 0.5% Dispase II (Sigma–Aldrich) at 37°C 
for 15–20 min such that they were separated from the base of the culture 
dish as a single sheet. The dispase was carefully decanted, and the cell 
sheet was gently washed with 3 ml PBS prior to transferring to univer-
sal tubes containing 4 ml PBS. The tubes were then sealed and shaken 
by hand up and down (×20). The content of each tube was returned back 
to the six-well plates where 10μl crystal violet was added and the total 
number of detached fragments was counted. The number of detached 
fragments (>3 mm), determined by placing the six-well plate over a grid 
on a white paper, was taken as a measure of intercellular keratinocyte 
adhesive strength.
Epithelial invasion
Epithelial invasion was examined as described in detail previously (8).
Statistics
Unless otherwise indicated, the experiments were repeated 3×; the values 
cited were the mean of the repeats ± SD. Data were analysed using the 
one-way analysis of variance with Tukey`s multiple comparison test being 
used as a post-test. P < 0.05 was considered statistically significant.
Results
Interactome-transcriptome analysis of the putative 
secreted molecules
Of the 132 genes differentially expressed in CAFs versus normal 
fibroblasts, 61 were up-regulated and of these, 16 (~26%) were 
Table 1. Primary antibodies used for Western blotting, concentrations and suppliers
Primary antibody Origin Concentration Supplier Cat. no
Alpha-tubulin Mouse monoclonal 1:10 000 Sigma T5168
Beta-catenin Rabbit polyclonal 1:250 Santa Cruz Sc-7199
Desmoplakin (I/II) Rabbit polyclonal 1:200 Santa Cruz Sc-33555
DSC3 Rabbit polyclonal 1:200 Santa Cruz Sc-48750
DSG1 Rabbit polyclonal 1:250 Santa Cruz Sc-20114
DSG3 Rabbit polyclonal 1:200 Santa Cruz Sc-20116
E-Cadherin Rabbit polyclonal 1:200 Santa Cruz Sc-7870
Vimentin Mouse monoclonal 1:200 Santa Cruz Sc-73259
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putative ligands/secreted molecules (Supplementary Table  1, 
available at Carcinogenesis Online), which may interact with 
OSCC cells. In order to select key secreted molecules for further 
investigation, we undertook network analysis of interactomes 
from huSM and muSM. Of the 16 up-regulated molecules, 4 
had a logarithmic FC > 3 and therefore were included into the 
huSM network (INHBA, TGFB2, IGFBP3, IGFBP7). We first built an 
interactome formed by the 4 huSM plus their first neighbours 
(Figure 1); the resulting network (Supplementary Table 2, avail-
able at Carcinogenesis Online) constituted 87 nodes and 648 inter-
actions, with an average connectivity of k = 14.9 edges per node. 
An interactome formed by four nodes representing putative 
secreted molecules with low FC (muSM) was also built, which 
included STC2, CTGF, SPOCK1 and SERPINE2 (Supplementary 
Table 2, available at Carcinogenesis Online). As control networks, 
we used interactomes of comparable size (14), random interac-
tomes from databases (19) and an interactome formed by four 
random nodes that were up-regulated in CAFs (Supplementary 
Table  2, available at Carcinogenesis Online). When compared 
with structured networks such as a cell–cell adhesion interac-
tome (59 nodes, k = 4.39), the connectivity of huSM was 4-fold 
higher. The connectivity of huSM interactome greatly exceeds 
the k value of publicly available PPI databases: on average, each 
component has 14.9 direct interactions in the huSM network, 
compared with 5.54 in BIND, 7.23 in HPRD, 5.14 in PPID, 4.03 in 
IntAct, 3.53 in MINT and 2.46 in DIP (19).
When compared with an interactome formed by four nodes 
selected randomly in the CAF up-regulated genes, the huSM 
interactome displayed a larger size (87 versus 60) but still higher 
connectivity (14.9 versus 10.07). We then investigated whether 
the huSM nodes formed a network with different properties 
than those displayed by the putatively secreted molecules 
with low FC (muSM). muSM failed to form a single network 
(Supplementary Figure 1, available at Carcinogenesis Online) as 
the four nodes either did not interact among each other (STC2, 
SPOCK1, SERPINE2) or did not have binding partners within the 
set confidence parameters (CTGF). Overall, this analysis sug-
gests that the most up-regulated secreted molecules in CAFs 
form a network that is highly interconnected and, therefore, 
likely to have biological relevance (14).
CAFs secrete TGF-β1 and TGF-β2
As huSM nodes were TGF-beta family members, we investigated 
whether TGF-beta isoforms were secreted by CAFs, as predicted 
by gene expression data. To do so, we determined TGF-β1 and 
TGF-β2 protein levels in CM from CAFs derived from GS-OSCC 
and GU-OSCC, fibroblasts from normal oral mucosa (NHOF) and 
malignant keratinocyte cell lines; H2O2-treated normal fibro-
blasts were used as a positive control of GU-OSCC CAFs (8). We 
show that both TGF-β1 and TGF-β2 were overexpressed by CAFs 
derived from GU-OSCC relative to GS-OSCC, normal fibroblasts 
and keratinocyte lines (Figure 2A and B).
CAFs from GU-OSCC induce EMT
TGF-β is a well-known inducer of EMT. To examine the capac-
ity of CAFs to induce EMT, we treated a partially transformed 
keratinocyte cell line (H357) with CM from senescent and non-
senescent fibroblasts. We show that CM from GU-OSCC CAFs 
Figure 1. Interactome formed by four huSM and their first neighbours. (A) First-degree connections and binding interactions, i.e. edges (non-directional) are repre-
sented in light grey, whereas the four main nodes (huSM) are depicted in dark grey. The four individual subnetworks are shown in the small panel, namely INHBA (B), 
IGFBP3 (C), IGFBP7 (D) and TGFB2 (E).
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(H357F), but not GS-OSCC CAFs (BICR66F), caused depletion 
of E-cadherin and up-regulation of vimentin (Figure  3A). The 
molecular alterations were associated with typical morphologi-
cal changes such that the keratinocytes assumed a fibroblast-
like appearance (Figure 3B). H2O2-treated NHOF1 and untreated 
NHOF1 served as positive and negative controls, respectively, 
for the senescent CAFs derived from GU-OSCC. Induction of 
EMT was then confirmed by immunofluorescence using dif-
ferent CAF strains (Figure 4 and Supplementary Figure 2, avail-
able at Carcinogenesis Online). Control cells showed classical 
intercellular staining of E-cadherin with no or little expression 
of vimentin (Figure  4A–F). Incubation with CM from BICR31F 
(GU-OSCC) drastically reduced E-cadherin staining together 
with a dramatic increase of vimentin (Figure  4G–I). Similar 
results were obtained with BICR3F (GU-OSCC), however such 
changes were milder when cells were incubated with CM 
from BICR66F (GS-OSCC; Supplementary Figure 2, available at 
Carcinogenesis Online).
Taken together, these data showed that GU-OSCC CAFs 
induce EMT in target cancer cells.
CAFs from GU-OSCC inhibit keratinocyte adhesion
To determine whether CAFs inhibited the expression of adhe-
sion molecules other than E-cadherin, we used an in-cell 
enzyme-linked immunosorbent assay to show that CM from 
GU-OSCC CAFs (H357F), but not GS-OSCC CAFs (BICR66F), 
caused decreased expression of E-cadherin, Desmoglein 1 and 
3 (DSG1 and DGS3), Desmoplakin (DSP) and Desmocollin (DSC) 
in H357 (Figure 5A). Similar findings were noted with H103 and 
HaCaT-II-3 malignant keratinocytes (Supplementary Figure  3, 
available at Carcinogenesis Online), but the effect was more 
pronounced in H357. The results were confirmed by canonical 
Western blot analysis, which showed a major decrease in the 
expression of cadherins and DSP (Figure 5B).
The consequences of CAF-induced down-regulation of 
keratinocyte adhesion molecules were examined in a well-
established functional assay of intercellular adhesion strength 
(16). We show that CM from GU-OSCC CAFs (H357F), but not 
GS-OSCC CAFs (BICR66F) or normal fibroblasts, reduced the 
cohesive strength of malignant keratinocytes (H357) as shown 
by the increase in the number of small fragments (Figure 5C and 
D). Similar effects were noted using different target keratinocyte 
lines (H103, HaCaT-II3) treated with CM from H357F and BICR66F 
(Supplementary Figure 3, available at Carcinogenesis Online).
In view of the close association between intercellular epi-
thelial adhesion and the invasive phenotype, we examined 
the invasion of the partially transformed non-tumourigenic 
keratinocyte cell line H357 into collagen gels. We confirm our 
previous observations (9) using alternative fibroblast strains, 
which show that CM from GU-OSCC CAFs (H357F; BICR18F), but 
not GS-OSCC CAFs (BICR66F; BICR73F), stimulated the invasion 
of H357 keratinocytes in vitro (Supplementary Figure 4, available 
at Carcinogenesis Online).
The data demonstrate that CAFs derived from GU-OSCC 
induce a pro-invasive phenotype in malignant keratinocytes by 
the induction of EMT and a reduction in intercellular adhesion.
TGF-β mediates the effect of CAFs on keratinocyte 
adhesion and invasion
Since our in silico data indicated that TGF-β2 was an important 
secretory molecule of CAFs and both TGF-β1 and TGF-β2 were 
overexpressed by CAFs, we wanted to examine whether TGF-β 
Figure 2. TGF-β1 (A) and TGF-β2 (B) protein expression in CM from fibroblasts 
derived from GS-OSCC and GU-OSCC, together with fibroblasts from normal oral 
mucosa and malignant keratinocyte cell lines. Cells were grown to 70% conflu-
ence, rinsed in serum-free medium and incubated in serum-free medium for 
48 h. The medium was centrifuged and activated prior to the assay. TGF-β was 
quantified using Quantikine TGF-β1 or TGF-β2 enzyme-linked immunosorbent 
assay (R & D Systems, USA). Each point on the graph represented the mean of >3 
repetitions of each fibroblast strain or keratinocyte cell line.
Figure 3. Senescent CAFs induce EMT. (A) Western blot analysis showing CM 
from GU-OSCC CAFs (H357F), but not GS-OSCC CAFs (BICR66F), caused depletion 
of E-cadherin and up-regulation of vimentin in OSCC keratinocytes (H357). H2O2-
treated NHOF1 and untreated NHOF1 were used as positive and negative con-
trols. (B) Treatment of H357 keratinocytes with CM from GU-OSCC CAFs (H357F), 
but not NHOF1, caused cells to adopt a spindle cell morphology indicative of 
EMT.
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isoforms acted as intermediaries in CAF-induced EMT, inhibition 
of epithelial dis-cohesion and induction of keratinocyte inva-
sion in vitro. With regard to EMT, we demonstrate that anti-TGF-β 
antibodies inhibited EMT as demonstrated by the attenuation 
of E-cadherin and vimentin expression following the treatment 
of H357 keratinocytes with CM from H357F; the effect was most 
marked using a pan anti-TGF-β antibody and an anti-TGF-β2 
antibody (Figure 6A). With respect to CAF-induced epithelial dis-
cohesion (Figure 6B), we show that a pan anti-TGF-β antibody 
attenuated the dys-cohesive effects of GU-OSCC CAFs (H357F; 
BICR82F; BICR 18F), where H357 keratinocytes was used as tar-
get cells and when small epithelial fragments were counted 
(Figure  6B); similarly, anti-TGF-β1 and anti-TGF-β2 antibodies 
attenuated the induction of epithelial discohesion by GU-OSCC 
CAFs (H357F; Figure 6C). With regard to CAF-induced epithelial 
invasion in vitro, a pan anti-TGF-β antibody inhibited the inva-
sion H357 keratinocytes into collagen gels following stimulation 
by GU-OSCC CAFs (H357F; BICR82F; BICR18F; Figure  6D), and 
the effect was also achieved using anti-TGF-β1 and anti-TGF-β2 
antibodies (Figure 6E).
Taken together, the data demonstrate that CAFs derived 
from GU-OSCC induce EMT and, in addition, weaken epithelial 
cell–cell adhesion and promote invasion of malignant keratino-
cytes via TGF-β-dependent pathways.
Discussion
In the present study, we identified key molecules secreted by 
CAFs in oral cancer. Using a network analysis approach we show 
that the network formed by INHBA, TGFB2, IGFBP3 and IGFBP7 
had high connectivity, thereby implying biological relevance. 
Previous studies have shown that insulin-like growth factor 
-binding proteins are expressed at high levels by both activated 
and senescent fibroblasts (10), but the present study is the first 
to highlight a potential role for INHBA. INHBA is a subunit of 
both activin and inhibin, two closely related glycoproteins with 
opposing biological effects that belong to the TGF-β superfamily 
and that function through the Smad 2/3 canonical signal trans-
duction pathway (20). Recent data have shown that INHBA is 
an important constituent of the senescence-associated secere-
tory phenotype and induces paracrine senescence in normal 
cells both in vitro and in vivo (21). INHBA is also significantly up-
regulated in a broad spectrum of malignant tumours (22–25), 
including those of the head and neck (26,27). The present report, 
however, is the first to show that INHBA is up-regulated in CAFs 
and has biophysical significance. Our unpublished data also 
show that INHBA has prognostic significance in terms of patient 
outcome (N.Cirillo, unpublished observations). The up-regula-
tion of TGF-β2 was also particularly interesting because TGF-β2 
has been identified at the tumour–stroma interface (28), stro-
mal regulation of epithelial cell adhesion in the prostate gland 
occurs in a TGF-β2-dependent manner (29) and the ligand plays 
a key role in the pathogenesis of a variety of different tumours 
(30–32).
The role of TGF-β in tumour progression, however, is complex. 
In the early stages of epithelial tumorigenesis, TGF-β is thought 
to have a suppressor role by inducing cell cycle arrest and apop-
tosis whereas in the later stages, when the tumour cells become 
resistant to growth inhibition by TGF-β, the cytokine acts to pro-
mote tumour progression by stimulating invasion, angiogenesis 
Figure 4. Expression of E-cadherin and vimentin in malignant oral keratinocytes. Representative E-cadherin and vimentin immunofluorescent staining of H357 cells 
48 h with Dulbecco’s modified Eagle’s medium (serum-free medium, panels A, B, C), CM from normal human oral fibroblasts (NHOF, panels D, E, F) and CM from 
GU-OSCC CAFs (BICR31F) (G, H, I). Fluorescence indicates the presence of E-cadherin (A,D,G) and vimentin (B,E,H). In the merge column, Hoechst-stained nuclei are 
shown (C,F,I).
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and metastases, together with inhibiting immune surveillance 
(33). In the present study, network analysis identified TGF-β 
family members as having possible biological relevance to the 
behaviour of CAFs from OSCC. We extended these observations 
and showed that both TGF-β1 and TGF-β2 protein expression was 
up-regulated in CM from GU-OSCC CAFs relative to fibroblasts 
from GS-OSCC or normal oral fibroblasts. The results demon-
strate that overexpression of TGF-β in OSCC is not a ubiquitous 
characteristic of CAFs as once thought (34) but rather is a specific 
feature of CAFs in GU-OSCC. The magnitude of TGF-β overexpres-
sion could be even bigger in vivo, as suggested by the finding that 
three-dimensional co-culture of CAFs and cancer cells results 
in a considerably larger production of TGF-β compared with 2D 
cultures (35). Previous studies by our group have shown that the 
majority of human OSCC cell lines remain responsive to TGF-β1 
(36) and that overexpression of either TGF-β1 or TGF-β2 in TGF-
β-responsive human squamous cell carcinoma lines results in a 
more aggressive phenotype (37). The results of the present study, 
therefore, may have clinical implications; it is tempting to specu-
late that the use of TGF-β inhibitors may be of more therapeutic 
benefit in GU-OSCC than GS-OSCC.
It is now well established that senescent fibroblasts, generated 
as a result of replication, oncogenic stress or oxidative DNA dam-
age, induce EMT in breast cancer cell lines (10). In the present 
study, we show that CM from GU-OSCC CAFs, which are known to 
be senescent (8), induced EMT in partially transformed keratino-
cytes. EMT was not induced by the non-senescent GS-OSCC CAFs 
and was not induced in the immortal HaCaT cell line. The results 
are in keeping with the previous findings in different cell sys-
tems. Interestingly, cells that undergo EMT acquire stem cell-like 
Figure 5. CAFs induce epithelial discohesion in vitro. Treatment of H357 keratinocytes with CM from GU-OSCC CAFs (H357F) caused decreased expression of E-cadherin, 
DSG1 and 3, DSP, β-catenin and plakophilin, whereas CM from GS-OSCC CAFs (BICR66F) caused decreased expression of DSG3, DSP and DSG1 relative to treatment 
of keratinocytes with CM from NHOF1. Three independent experiments were undertaken, and the data points reflect the mean ± standard deviation (A). Canonical 
western blot analysis showing decreased expression the cadherins and DSP in H357 keratinocytes treated with CM from GU-OSCC CAFs (H357F); the lanes illustrated 
are from the same blot and CM from NHOF1 was used as a control (B). Treatment of H357 keratinocytes with CM from GU-OSCC CAFs (H357F), but not GS-OSCC CAFs 
(BICR66F) or normal fibroblasts (NHOF1), resulted in epithelial dis-cohesion, as demonstrated by the number of dissociated fragments in a dispase dissociation assay 
(C, D). Serum-free media and CM from normal fibroblasts (NHOF1 were used as controls. *P < 0.05; ** P < 0.01.
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properties such that they gain the capacity to self renew and form 
secondary tumours at distant sites (38) via TGF-β signalling (39). 
Taken together, the results suggest that cancer cell ‘stemness’ 
is regulated, albeit in part, by the tumour stroma. We believe 
that this observation raises important clinical issues. The con-
sequences of developing an activated/senescent stroma during 
healing of a biopsy wound may be the development of EMT and 
the induction of stem cell-like behaviour in the overlying epithe-
lium. It follows, therefore, that a partially transformed epithelium, 
as might be seen in a premalignant lesion, would be particularly 
susceptible to progression after a surgical biopsy. This reasoning 
argues strongly for the urgent need to develop non-invasive tech-
niques for the assessment of premalignancy.
Desmosome proteins, the main components of keratinocyte 
intercellular adhesion, are derived from the cadherin, plakin 
and armadillo gene families; the cadherins are subdivided into 
desmogleins (DSG1-4) and desmocollins (DSC1-3), the plakins 
include desmoplakin I/II and the armadillo proteins consist of 
plakoglobin (PG) and plakophilins (PKP1-4); armadillo proteins 
and desmoplakin link desmosomes to the underlying intermedi-
ate cytoskeleton. The role of these cell–cell adhesion molecules 
in cancer is unclear. Low transcript levels of DSG3, DSC2/3, DP, 
PG and PKP1, for example, have been reported in a large panel 
of immortal oral dysplasia and carcinoma cell lines (40), but 
DSG3 appears to be overexpressed in head and neck cancer (41) 
and is associated with cancer cell migration and invasion (42). 
Mutations of genes encoding cell adhesion molecules, however, 
are rare (43,44) suggesting that they may be regulated, at least 
in part, by the tumour stroma. The results of the present study 
are consistent with this view because we show that senescent 
fibroblasts from GU-OSCC down-regulate a broad spectrum of 
cell adhesion molecules resulting in keratinocyte dis-cohesion.
It is now recognized that there are multiple ways in which 
stromal fibroblasts influence the behaviour of cancer epithelial 
cells. CAFs are known to regulate epithelial proliferation (21), dis-
rupt epithelial differentiation (45), alter the metabolism of cancer 
cells and induce genomic instability (46) and induce EMT (10). 
In the present study, we show that CAFs from GU-OSCC, but not 
GS-OSCC, induced EMT in target epithelial cells. Further, we dem-
onstrate down-regulation of a broad spectrum of epithelial cell 
adhesion molecules in response to CAFs from GU-OSCC leading to 
epithelial dis-cohesion. There was some overlap in the capacity of 
TGF-β1 and TGF-β2 to mediate the stromal regulation of epithelial 
cell adhesion, but this most probably reflects the 70–80% homol-
ogy of their amino acid sequences (47). These data, combined with 
our observations that CAFs from GU-OSCC induce keratinocyte 
invasion in vitro, argue that a primary function of senescent CAFs 
is to regulate epithelial cell adhesion. The fact that the disruption 
of epithelial adhesion and promotion of epithelial invasion by 
CAFs from GU-OSCC occurred in a TGF-β-dependent manner in 
this study is consistent with previous observations (48,49). More 
important, the data also agree with the events in vivo, where TGF-
β signalling is low in the bulk of primary tumours but is greatest 
around the tumour margins and blood vessels where it switches 
cancer cells from a cohesive to single-cell motility (50).
The TGF-β-dependent disruption of epithelial adhesion 
mediated by CAFs involves the activation of MMPs, including 
MMP-2 (51). MMP family members are part of the desmosomal 
Figure 6. TGF-β acts as an intermediary in fibroblast–epithelial interactions. Western blot analysis demonstrating attenuation of EMT in H357 keratinocytes by GU-
OSCC CAFs (H357F) using pan-TGF-β (5 μg/ml), anti-TGF-β1 (0.05 μg/ml) and anti-TGF-β2 (1 μg/ml) antibodies (A). Loss of epithelial cohesion in H357 keratinocytes 
treated with CM from GU-OSCC CAFs (H357F; BICR82F; BICR18F) using a pan-TGF-β antibody (B); similar effects were demonstrated using anti-TGF-β1 and TGF-β2 
antibodies (C). Attenuation of epithelial invasion of H357 keratinocytes treated with CM from GU-OSCC CAFs (H357F; BICR82F; BICR18F) using a pan-TGF-β antibody (D); 
similar effects were demonstrated using anti-TGF-β1 and TGF-β2 antibodies (E).  by guest on January 13, 2017
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interactome (14) and have been reported to cleave desmo-
somal protein during apoptosis (52,53); hence, it is likely that 
MMP-2 weakens cell–cell adhesion by proteolytic targeting of 
desmosomes. It is also possible, however, that TGF-β signal-
ling down-regulates the expression of cell adhesion molecules 
via transcriptional or translational mechanisms. In addition 
to intercellular cohesion, matrix metalloproteinases can also 
modulate cell–extracellular matrix adhesion by degrading inte-
grins and components of the basement membrane. Therefore, 
the ability TGF-β members to work in concert with matrix met-
alloproteinases raises the possibility that these two classes of 
molecules operate synergistically to promote the disruption of 
the basement membrane and subsequent invasion of connec-
tive tissues by cancer cells. Further studies are needed to con-
firm this hypothesis.
In summary, the results of this study show that TGF-β fam-
ily members are secreted by CAFs from GU-OSCC and have 
biological relevance. TGF-β1 and TGF-β2 are overexpressed in 
non-proliferating, senescent CAFs from GU-OSCC, but not in 
proliferating, non-senescent CAFs from GS-OSCC or normal 
fibroblasts. CAFs from GU-OSCC induced EMT and down-reg-
ulated a broad spectrum of epithelial cell adhesion molecules 
resulting in epithelial discohesion and invasion in vitro in a TGF-
β dependent manner.
Supplementary material
Supplementary Tables 1 and 2 and Figures 1 to 4 can be found at 
http://carcin.oxfordjournals.org/
Funding
University of Bristol, UK grant no. CMM2010 (N.C.).
Acknowledgements
Y.H. was in receipt of a clinical Fellowship from the University of 
Jordan. N.C., A.C. and S.M. gratefully acknowledge the support of 
Melbourne Dental School, the University of Melbourne.
Conflict of Interest Statement: None declared.
References
 1. Tselepis, C. et al. (1998) Desmosomal adhesion inhibits invasive behav-
ior. Proc. Natl. Acad. Sci. USA, 95, 8064–8069.
 2. Fanjul-Fernández, M. et  al. (2013) Cell-cell adhesion genes CTNNA2 
and CTNNA3 are tumour suppressors frequently mutated in laryngeal 
carcinomas. Nat. Commun., 4, 2531.
 3. Tang, R. et  al. (2004) Colorectal cancer without high microsatellite 
instability and chromosomal instability—an alternative genetic path-
way to human colorectal cancer. Carcinogenesis, 25, 841–846.
 4. Edington, K.G. et  al. (1995) Cellular immortality: a late event in the 
progression of human squamous cell carcinoma of the head and neck 
associated with p53 alteration and a high frequency of allele loss. Mol. 
Carcinog., 13, 254–265.
 5. Hunter, K.D. et al. (2006) Divergent routes to oral cancer. Cancer Res., 
66, 7405–7413.
 6. Reed, A.L. et al. (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) 
inactivation in head and neck squamous cell carcinoma. Cancer Res., 
56, 3630–3633.
 7. Kalluri, R. et al. (2009) The basics of epithelial-mesenchymal transition. 
J. Clin. Invest., 119, 1420–1428.
 8. Lim, K.P. et al. (2011) Fibroblast gene expression profile reflects the stage 
of tumour progression in oral squamous cell carcinoma. J. Pathol., 223, 
459–469.
 9. Hassona, Y. et al. (2013) Progression of genotype-specific oral cancer 
leads to senescence of cancer-associated fibroblasts and is mediated 
by oxidative stress and TGF-β. Carcinogenesis, 34, 1286–1295.
 10. Coppé, J.P. et  al. (2008) Senescence-associated secretory phenotypes 
reveal cell-nonautonomous functions of oncogenic RAS and the p53 
tumor suppressor. PLoS Biol., 6, 2853–2868.
 11. Krtolica, A. et al. (2001) Senescent fibroblasts promote epithelial cell 
growth and tumorigenesis: a link between cancer and aging. Proc. Natl. 
Acad. Sci. USA, 98, 12072–12077.
 12. Shannon, P. et al. (2003) Cytoscape: a software environment for inte-
grated models of biomolecular interaction networks. Genome Res., 13, 
2498–2504.
 13. Pieroni, E. et al. (2008) Protein networking: insights into global func-
tional organization of proteomes. Proteomics, 8, 799–816.
 14. Cirillo, N. et al. (2009) Desmosomal interactome in keratinocytes: a sys-
tems biology approach leading to an understanding of the pathogen-
esis of skin disease. Cell. Mol. Life Sci., 66, 3517–3533.
 15. Thurlow, J.K. et al. (2010) Spectral clustering of microarray data elu-
cidates the roles of microenvironment remodeling and immune 
responses in survival of head and neck squamous cell carcinoma. J. 
Clin. Oncol., 28, 2881–2888.
 16. Cirillo, N. et al. (2010) Induction of hyper-adhesion attenuates auto-
immune-induced keratinocyte cell-cell detachment and processing of 
adhesion molecules via mechanisms that involve PKC. Exp. Cell Res., 
316, 580–592.
 17. Cirillo, N. et al. (2007) Pemphigus vulgaris immunoglobulin G can rec-
ognize a 130 000 MW antigen other than desmoglein 3 on peripheral 
blood mononuclear cell surface. Immunology, 121, 377–382.
 18. Celentano, A. et al (2016) Pathophysiology of the desmo-adhesome. J. 
Cell. Physiol, doi: 10.1002/jcp.25515
 19. Zaidel-Bar, R. et al. (2007) Functional atlas of the integrin adhesome. 
Nat. Cell Biol., 9, 858–867.
 20. Shi, Y. et al. (2003) Mechanisms of TGF-beta signaling from cell mem-
brane to the nucleus. Cell, 113, 685–700.
 21. Acosta, J.C. et al. (2013) A complex secretory program orchestrated by 
the inflammasome controls paracrine senescence. Nat. Cell Biol., 15, 
978–990.
 22. Seder, C.W. et al. (2009) Upregulated INHBA expression may promote 
cell proliferation and is associated with poor survival in lung adeno-
carcinoma. Neoplasia, 11, 388–396.
 23. Wang, Q. et al. (2012) Upregulated INHBA expression is associated with 
poor survival in gastric cancer. Med. Oncol., 29, 77–83.
 24. Okano, M. et  al. (2013) Significance of INHBA expression in human 
colorectal cancer. Oncol. Rep., 30, 2903–2908.
 25. Pesson, M. et al. (2014) A gene expression and pre-mRNA splicing sig-
nature that marks the adenoma-adenocarcinoma progression in colo-
rectal cancer. PLoS One, 9, e87761.
 26. Shimizu, S. et al. (2007) Identification of molecular targets in head and 
neck squamous cell carcinomas based on genome-wide gene expres-
sion profiling. Oncol. Rep., 18, 1489–1497.
 27. Ye, H. et al. (2008) Transcriptomic dissection of tongue squamous cell 
carcinoma. BMC Genomics, 9, 69.
 28. Gold, L.I. et al. (2000) TGF-beta isoforms are differentially expressed in 
increasing malignant grades of HaCaT keratinocytes, suggesting sepa-
rate roles in skin carcinogenesis. J. Pathol., 190, 579–588.
 29. Chambers, K.F. et al. (2011) Stroma regulates increased epithelial lat-
eral cell adhesion in 3D culture: a role for actin/cadherin dynamics. 
PLoS One, 6, e18796.
 30. Zhang, C. et al. (2009) Transforming growth factor-beta2 is a molecular 
determinant for site-specific melanoma metastasis in the brain. Can-
cer Res., 69, 828–835.
 31. Dieterich, L.C. et al. (2012) Transcriptional profiling of human glioblas-
toma vessels indicates a key role of VEGF-A and TGFβ2 in vascular 
abnormalization. J. Pathol., 228, 378–390.
 32. Fahey, M.S. et  al. (1996) Dysregulation of autocrine TGF-beta isoform 
production and ligand responses in human tumour-derived and Ha-ras-
transfected keratinocytes and fibroblasts. Br. J. Cancer, 74, 1074–1080.
 33. Jakowlew, S.B. (2006) Transforming growth factor-beta in cancer and 
metastasis. Cancer Metastasis Rev., 25, 435–457.
 34. Rosenthal, E. et al. (2004) Elevated expression of TGF-beta1 in head and 
neck cancer-associated fibroblasts. Mol. Carcinog., 40, 116–121.
 35. Kim, S.A. et al. (2015) Co-culture of 3D tumor spheroids with fibroblasts 
as a model for epithelial-mesenchymal transition in vitro. Exp. Cell 
Res., 335, 187–196.
 by guest on January 13, 2017
http://carcin.oxfordjournals.org/
Downloaded from 
N. Cirillo et al. | 85
 36. Prime, S.S. et  al. (1994) TGF-beta receptor regulation mediates the 
response to exogenous ligand but is independent of the degree of cel-
lular differentiation in human oral keratinocytes. Int. J.  Cancer, 56, 
406–412.
 37. Davies, M. et al. (2012) Transforming growth factor-β enhances inva-
sion and metastasis in Ras-transfected human malignant epidermal 
keratinocytes. Int. J. Exp. Pathol., 93, 148–156.
 38. Mani, S.A. et al. (2008) The epithelial-mesenchymal transition gener-
ates cells with properties of stem cells. Cell, 133, 704–715.
 39. Hasegawa, T. et al. (2014) Cancer-associated fibroblasts might sustain 
the stemness of scirrhous gastric cancer cells via transforming growth 
factor-β signaling. Int. J. Cancer, 134, 1785–1795.
 40. Teh, M.T. et al. (2011) A molecular study of desmosomes identifies a 
demoglein isoform switch in head and neck squamous cell carcinoma. 
J. Oral Pathol. Med, 40, 67–76.
 41. Chen, Y.J. et al. (2007) DSG3 is overexpressed in head neck cancer and 
is a potential molecular target for inhibition of oncogenesis. Oncogene, 
26, 467–476.
 42. Brown, L. et al. (2014) Desmoglein 3 promotes cancer cell migration 
and invasion by regulating activator protein 1 and protein kinase 
C-dependent-Ezrin activation. Oncogene, 33, 2363–2374.
 43. Agrawal, N. et al. (2011) Exome sequencing of head and neck squa-
mous cell carcinoma reveals inactivating mutations in NOTCH1. Sci-
ence, 333, 1154–1157.
 44. Stransky, N. et al. (2011) The mutational landscape of head and neck 
squamous cell carcinoma. Science, 333, 1157–1160.
 45. Parrinello, S. et al. (2005) Stromal-epithelial interactions in aging and 
cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell 
Sci., 118(Pt 3), 485–496.
 46. Martinez-Outschoorn, U.E. et al. (2010) Oxidative stress in cancer asso-
ciated fibroblasts drives tumor-stroma co-evolution: a new paradigm 
for understanding tumor metabolism, the field effect and genomic 
instability in cancer cells. Cell Cycle, 9, 3256–3276.
 47. Cheifetz, S. et al. (1987) The transforming growth factor-beta system, 
a complex pattern of cross-reactive ligands and receptors. Cell, 48, 
409–415.
 48. Yu, Y. et al. (2014) Cancer-associated fibroblasts induce epithelial-mes-
enchymal transition of breast cancer cells through paracrine TGF-β 
signalling. Br. J. Cancer, 110, 724–732.
 49. Pickup, M. et al. (2013) The roles of TGFβ in the tumour microenviron-
ment. Nat. Rev. Cancer, 13, 788–799.
 50. Giampieri, S. et al. (2009) Localized and reversible TGFbeta signalling 
switches breast cancer cells from cohesive to single cell motility. Nat. 
Cell Biol., 11, 1287–1296.
 51. Hassona, Y. et al. (2014) Senescent cancer-associated fibroblasts secrete 
active MMP-2 that promotes keratinocyte dis-cohesion and invasion. 
Br. J. Cancer, 111, 1230–1237.
 52. Dusek, R.L. et  al. (2006) The differentiation-dependent desmosomal 
cadherin desmoglein 1 is a novel caspase-3 target that regulates apop-
tosis in keratinocytes. J. Biol. Chem., 281, 3614–3624.
 53. Cirillo, N. et al. (2007) Metalloproteinase 9 is the outer executioner of 
desmoglein 3 in apoptotic keratinocytes. Oral Dis., 13, 341–345.
 by guest on January 13, 2017
http://carcin.oxfordjournals.org/
Downloaded from 
Pathophysiology of the
Desmo-Adhesome
ANTONIO CELENTANO,1,2* MICHELE DAVIDE MIGNOGNA,1 MICHAEL MCCULLOUGH,2,3
AND NICOLA CIRILLO2,3**
1Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy
2Melbourne Dental School, University of Melbourne, Carlton, Victoria, Australia
3Oral Health Cooperative Research Centre (CRC), University of Melbourne, Carlton, Victoria, Australia
Advances in our understanding of desmosomal diseases have provided a clear demonstration of the key role played by desmosomes in
tissue and organ physiology, highlighting the importance of their dynamic and ﬁnely regulated structure. In this context, non-desmosomal
regulatory molecules have acquired increasing relevance in the study of this organelle resulting in extending the desmosomal interactome,
named the “desmo-adhesome.” Spatiotemporal changes in the expression and regulation of the desmo-adhesome underlie a number of
genetic, infectious, autoimmune, and malignant conditions. The aim of the present article was to examine the structural and functional
relationship of the desmosome, by providing a comprehensive, yet focused overview of the constituents targeted in human disease. The
inclusion of the novel regulatory network in the desmo-adhesome pathophysiology opens new avenues to a deeper understanding of
desmosomal diseases, potentially unveiling pathogenic mechanisms waiting to be explored.
J. Cell. Physiol. 9999: 1–10, 2016. ! 2016 Wiley Periodicals, Inc.
Desmosomes are intercellular adhesive complexes that have a
well-established role in ensuring robust intercellular adhesion
in both embryonic and adult tissues subjected to mechanical
stress such as the skin and heart. Over 150 years of extensive
knowledge has accumulated on intercellular adhesion systems,
the desmosome, and its complex structure. The role of the
desmosome in human pathophysiology presents the main
stimulus for research in this ﬁeld. Recently more evidence is
emerging that desmosomal components are involved in the
regulation of cell signaling and the development of cancer
(Huber and Petersen, 2015). Therefore, impairment or lack of
expression at multiple levels of the desmosome components
can result in diseases of the epithelia, cardiac muscle, and
participate in cancer progression. Further, there is an
increasing in our understanding of the desmosome as a dense
multifunctional component network interacting with
regulatory proteins such as kinases (Cirillo and Prime, 2009).
This network directly interacts with cellular structural
components, and thus broadens the spectrum of targets that
may be affected in disease. Impairment or dysfunction of
desmosomal structural components directly relates to several
conditions, including infectious, autoimmune, genetic, and
neoplastic diseases. Table 1 provides a comprehensive
summary of these diseases. Exact molecular mechanisms that
lead to disease are not completely understood for the majority
of these conditions. Further, analysis of molecular networks
does not in itself provide enough information about the speciﬁc
context, such as biological processes and cellular
compartments, in which speciﬁc pathological processes occur.
Thewide list of conditions targeting the desmosomal functional
unit remains to be fully investigated. This review aims to
provide a comprehensive overview of our current
understanding of the role of the desmo-adhesome constituents
in human disease and associated pathophysiological pathways.
Desmosome Structure and Composition
Desmosomes represent the most prevalent type of adhesive
intercellular junction in vertebrate tissues (Marchiando et al.,
2010; Kowalczyk and Green, 2013; Khan and Asif, 2015) and
are distributed along the cellular membranes. Their integrity,
along with their peculiar structural and functional plasticity,
contribute to tissue integrity and homeostasis (Fig. 1). More
than 6400 papers published to date have deﬁned the major
components of the desmosome, although its speciﬁc
tridimensional architecture remains to be conﬁrmed. At an
ultrastructural level, desmosomes appear as multi-layered
symmetrical disc-shaped structures of 0.2–0.5mm in diameter
along the cellular membranes of adjacent cells (He et al., 2003).
The classical notion of desmosomes as static adhesive
barrier structures has more recently become obsolete.
Desmosomes are increasingly being recognized as highly
dynamic structures involved in all aspects of epidermal
pathophysiology, from tissue homeostasis and morphogenesis,
to aging and disease. Desmosomal assembly and disassembly by
differential expression and post-synthetic modiﬁcation of
desmosomal components exempliﬁes both its structural and
functional susceptibility. Precision remodeling requires time
dependent, bi-directional, signaling mechanisms that requires
cross talk with adherens junctions. This is exempliﬁed by the
formation of an hyper-adhesive state, that leads to increased
difﬁcultly in the dismantling of mature desmosomes compared
with thosemore recently formed. Hyper-adhesion functions to
maintain tissue integrity and plays an important role in
developmental processes, wound healing, as well as skin
diseases (Cirillo, 2016).
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Focusing on its composition, the structure of the
desmosome can be classiﬁed according to the location of its
main constituents into ﬁrstly extracellular and intracellular
compartments, as well as a desmosome-associated regulatory
network.
The extracellular compartment
The extracellular portion of the desmosome contains the
desmosomal cadherins desmoglein (Dsg) and desmocollin
(Dsc) that form strong extracellular homo/heterophilic
bonds and mediate adhesion (North et al., 1999; Al-Amoudi
et al., 2011). Desmosomal cadherins are transmembrane
molecules that adhere at their extracellular N-terminal
domains. They exist in at least four different isoforms of Dsg
(Dsg1–Dsg4) and three isoforms of Dsc’s (Dsc 1–3) (Dusek
et al., 2007; Amagai, 2010), and are expressed in a tissue-
speciﬁc and differentiation-dependent manner (Table 1)
(Collins et al., 1991; King et al., 1997; Bazzi et al., 2006). At
the intracellular level, their extremities interact with
plakoglobin (Pg) and plakophilins (Pkps) (Bass-Zubek et al.,
2009), which in turn bind to the desmoplakin (Dp) a plakin
TABLE 1. Comprehensive summary of the diseases that target desmosome components
Disease
Molecular target
Abbrev (molec. weight) Tissue distribution
Cancer type
(regulation) Autoimmune Infectious Genetic
Desmoglein 1 Dsg1
(160 kDa)
Restricted to stratified
squamous epithelia
SCC (down); PF SSSS SPPK
Pancreatic AC (down) PV BI SAM
PNP
IAP (i-e)
Desmoglein 2 Dsg2
(122 kDa)
All desmosome-
bearing epithelia
Familial and gastric
(down);
None known Respiratory and UT
infections (adenovirus
serotypes 3, 7, 11, and
14)
ARVD/C
Pancreatic AC (down);
Melanoma, Prostate,
SCC (up)
Desmoglein 3 Dsg3
(130 kDa)
Restricted to stratified
squamous epithelia
SCC (down); PV None known None known
Oral SCC (down); PNP
Head and neck (up) IAP (i-e)
Desmoglein 4 Dsg4
(114 kDa)
Highly differentiated
layers of the
epidermidis: Hair
follicle epithelia.
salivary gland, testis,
prostate, and skin
None known Cross- reactivity of anti-DSG1
IgG
None Localized autosomal
recessive
hypotrichosis;
Recessive monilethrix
Desmocollin 1 Dsc1
(100 kDa)
Stratified epithelia, hair
follicle epithelia
Anal SCC (down); IAP (s-c) None known None known
Lung (down) PV
PF (Brazilian endemic patients)
Desmocollin 2 Dsc2
(120 kDa)
Simple and stratified
epithelia,
myocardium
Pancreatic ductal AC
(down);
PV Giardiasis ARVD/C;
Oral SCC (down); PNP Wooly hair;
Lung (down) PF (Brazilian endemic pts) keratoderma
Desmocollin 3 Dsc3
(105 kDa)
Stratified epithelia Lung (down) PV Giardiasis None known
PNP
Plakoglobin Pg
(86 kDa)
All desmosome-
bearing epithelia,
myocardium
Oral SCC, Prostate
(down);
PNP Bacillus anthracis Naxos disease Lethal
congenital
epidermolysis bullosaSCC (abnormal)
Plakophilin 1 Pkp1
(75 kDa)
Suprabasal cells of the
epidermis
Prostate AC (down); PNP None known EDSFS,
Oral SCC (down) PPK
Plakophilin 2 Pkp2
(93–97 kDa)
Stratified epithelia Gastric (down) PNP None known ARVD/C, Brugada
syndrome
Plakophilin 3 Pkp3
(87 kDa)
Stratified epithelia Colorectal Ca (down); PNP None known None known
Lung, Prostate AC,
Breast (up)
P0071 Plakophilin 4
(Pkp4) (134 kDa)
Oropharynx SCC ARVD/C rare (Xu
et al., 2010;
Gandjbakhch et al.,
2013)
Desmoplakin 1 Dsp1
(250 kDa)
All desmosome-
bearing epithelia,
myocardium
Lung (down), PNP B. anthracis Carvajal syndrome
SAM Naxos-like
disease SPPK ARVD/C
LA-EB LDAC
Desmoplakin 2 Dsp2
(220 kDa)
SCC (abnormal) EM
SJS
Envoplakin EVP
(210 kDa)
Stratified epithelia and
myocardium
None known PNP None known None known
PF
Periplakin PPL
(195 kDa)
Stratified epithelia and
myocardium
Esophageal SCC
(down)
PNP None known None known
PF
Plectin (500 kDa) Basal surface of basal
keratinocytes
(hemidesmosomes);
None known PNP, None known None known
In striated muscle, (as a
component of the
z-line)
BP
AC, Adenocarcinoma; ARVD/C, Arrhythmogenic right ventricular dysplasia/cardiomyopathy; EDSFS, Ectodermal dysplasia–Skin fragility syndrome; EM, erythema multiforme; IAP (i-e), IgA
pemphigus (intra-epidermal neutrophilic dermatosis); IAP (s-c), IgA pemphigus (subcorneal pustular dermatosis); LA-EB Lethal acantholytic epidermolysis bullosa; LDAC left dominant
arrythmogenic cardiomyopathy MC, Mucocutaneous type; MD, Mucosal dominant type; PF, Pemphigus foliaceus; PG, Plakoglobin; PNP, paraneoplastic pemphigus; PPK, palmoplantar
keratoderma; PV, pemphigus vulgaris; SAM, Skin dermatitis multiple allergies and metabolic wasting syndrome; SCC, squamous cell carcinoma; SJS, Stevens-Johnson syndrome; SPPK, striate
palmoplantar keratoderma; SSSS, staphylococcal scalded skin syndrome.
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family protein, whose function is to anchor keratins and
stabilize desmosomes (Vasioukhin et al., 2001). The seven
genes for human desmosomal cadherins are clustered on
chromosome 18q12.1 (Nollet et al., 2000; Whittock and
Bower, 2003). Dsg’s and Dsc’s show highly homologous
structures with a strong similarity to the classical prototype
of cadherins, the E-cadherin. The processed extracellular
domain of desmosomal cadherins is composed of ﬁve
extracellular cadherin (EC1–5)-repeat domains with three
Ca2þ-binding sites in between these EC repeats. The ﬁfth
and more divergent membrane proximal repeat (EC5)
sometimes is also referred to as the extracellular anchor
domain.
The transmembrane sectionof the desmosome simply contains
a single transmembrane proteic domain that links the extracellular
domain with a cytoplasmic tail. This cytoplasmic tail connects a
speciﬁc set of desmosomal plaque proteins that provide
organization, association with IFs, and have a role in signaling.
The intracellular compartment
The major difference between Dsg’s and Dsc’s resides in their
cytoplasmic domains. A membrane proximal to the
intracellular anchor domain and an intracellular cadherin
segment (ICS) domain are common to both Dsg’s and Dsc’s
(except for the short Dscb splice variants). Dsg intracellular
domains are extended by an intracellular proline-rich linker
region, a repeated unit domain containing different numbers of
29" 1 amino acid repeats, and a glycine-rich Dsg-terminal
domain (DTD) at the C terminus.
The cytoplasmic portion is well recognizable in electron
microscopy as an electron-dense cytoplasmic plaque of
multiple proteins lining the membrane known as the
“desmosomal plaque.” This plaque is important for the
correct assembly and organization of desmosomes, for
association with intermediate ﬁlaments, and for cell signaling.
Besides the intracellular portion of the desmosomal
cadherins, the main proteins involved in the formation of the
desmosome plaque belong to two families, the armadillo-
repeat protein family and the plakin protein family. The
armadillo-repeat protein family include plakoglobin (Pg),
three plakophilin proteins (Pkp1–3), and a multifunctioning
protein known as either p0071 or Pkp4. The plakin protein
family consists of desmoplakin (Dsp), plectin, envoplakin
(EVP), and periplakin (PPL) (Coates, 2003; Hatzfeld, 2007;
Sonnenberg and Liem, 2007).
Plakoglobin, also found to be an important component of
the adherens junctions (AJs), is involved in the
tridimensional physical link of other plaque proteins and is
essential for cross talk between desmosomes and AJs in the
regulation of cell-to-cell adhesion (Cowin et al., 1986;
Bonn!e et al., 2003). The Pkp’s, instead, take part in the
lateral binding of Dsp and desmosomal cadherins
(Kowalczyk et al., 1999). Lastly, the members of the plakin
protein family such as Dsp, EVP, and PPL are cytolinker
multidomain proteins that complete the assembly between
cytoskeletal elements (intermediate ﬁlaments) and the
junctional complexes (desmosomal cadherine—Pg
complex) (Leung et al., 2002).
A schematic representation of desmosomal structure and
accessory components is outlined in Figure 2. Correct
desmosome assembly with its numerous components,
remodeling, and integrity of cross talk network, are essential
for tissue integrity.
Fig. 1. Desmosomes are particularly abundant in tissues subject to high mechanical stress such as stratified squamous epithelia (A).
Desmosomal molecules localise at the cell-cell border and their presence may be revealed by several techniques, including IF (B). Panel B
depicts the classical IF staining pattern of sera from patients with PV, which target desmosomal adhesion molecules. (C) Schematic
representation of a desmosome and its correspondent EM image (D) highlighting desmoglea and outer/inner dense plaques.
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Desmosome-associated regulatory network
The sophisticated construction of the desmosomal functional
unit requires a ﬁnely regulated network composed of intrinsic
nodes/proteins and accessory proteins such as kinases,
phosphatases, and caspases. These accessory proteins must
interact directly with the intrinsic nodes/proteins, without any
intermediary interactions, so as to be deﬁned as an integral
component of the desmosome-associated regulatory network
(Paris and Bazzoni, 2008). Regulatory molecules play key roles
in the homeostasis of cell adhesion structures, including
desmosomes. To fully elucidate the mechanisms that regulate
the dynamics of keratinocyte adhesion an understanding of
desmosomal structure and function is inadequate without
being augmented by a complete understanding of the
components of the regulatory network and their responses to
perturbations.
The molecular architecture, structure, and signaling of the
desmo-adhesome at multiple levels was previously outlined in
2009 by our group through a process of data-mining, database-
derived information as well as published studies (Cirillo and
Prime, 2009). At that time, we were able to deﬁne the
functional role and regulation of certain components of the
network, distinguishing between directional (either activating
or inhibiting binding interactions) and non-directional
interactions (Fig. 2) (binding interactions). The desmo-
adhesome was found to be formed by a total of 59 proteins
(30 intrinsic and 29 accessory components) linked by 128
direct interactions, including membrane and adaptor proteins,
enzymes, kinases, phosphatases, and caspases, to form the
regulatory subnets (Cirillo, 2014).
Many of these molecules, such as PKC, Src, MAPK,
epidermal growth factor receptor (EGFR), and caspase 2/3, are
now known to be involved in the assembly and disassembly of
desmosomes (North et al., 1999; Green and Simpson, 2007;
Kowalczyk and Green, 2013; Kitajima, 2014). It is interesting to
note that Pg, one of themain organizers of the desmosome that
is crucial for adhesiveness, was highly connected to both
protein kinases (n¼ 5) and phosphatases (n¼ 4), and this
provided an in silico demonstration that the dynamic regulation
of the desmosome may be orchestrated by this protein (Cirillo
and Prime, 2009). Furthermore, now that the existence of
molecular cross talk between adherens junctions and
desmosome has been demonstrated, the desmosome-
associated regulatory network should be regarded as a
constituent part of the desmosome.
Desmosome Diseases
It is rare for single components of the different desmosomal
compartments to be involved in one disease process.
Conditions typically affect either the extracellular portion
(essentially the desmosomal cadherins), the desmosomal
Fig. 2. Schematic representation of desmosome and its components, including accessory components of the desmo-adhesome.
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plaque proteins or accessory proteins that arrange the
regulatory network. We present description of the diseases
categorized by compartmental target.
Diseases targeting the extracellular portion
Autoimmune. Of diseases targeting the extracellular
portion, subtypes of the Pemphigus family, particularly the
more common Pemphigus Vulgaris, present primary examples.
This family of autoimmune conditions is characterized by
circulating autoantibodies that target desmosomal
components impairing keratinocytes adhesion resulting in
acantholysis (Amagai, 2010; Kneisel and Hertl, 2011a). The
autoantibodies detected in pemphigus patients may be
directed against Dsg1 and/or Dsg3, and can include a wide
variety of desmosomal, non-desmosomal, and non-epithelial
IgGs (Eyre and Stanley, 1988; Nguyen et al., 2000; Cirillo
et al., 2007). These diseases are considered relatively rare
with an overall incidence of 1–16 new cases per million
people per year (Ruocco et al., 2013; Kitajima, 2014). The age
of onset is usually in the ﬁfth or sixth decade of life, although
a younger age has been observed in endemic variants of the
disease (Rocha-Alvarez et al., 2007; Joly and Litrowski, 2011).
Despite the precise pathomechanisms of pemphigus
remaining elusive, recent studies have indicated that
desmosome disassembly involves not only direct inhibition of
desmosome formation by IgGs, but also desmosome
remodeling. Additionally, several intracellular signaling
pathways are possibly triggered by non-desmosomal
molecules (Green and Simpson, 2007). The signaling-related
events include apoptosis as well as modulation of Pg,
p38MAPK, heat shock protein 27, cdk2, Src, RhoA, and
others (Cirillo, 2016).
The subtypes of pemphigus can be classiﬁed in several way,
either by the location of acantholysis (i.e., suprabasilar or
superﬁcial) or by Ig class and autoantibody targets. Aside from
the main subtypes, speciﬁc clinical, microscopic, and
immunopathological features of less common variants including
IgG/IgA pemphigus and pemphigus herpetiformis have been
described.
The main pemphigus subtypes affecting the extracellular
compartment of the desmosome are pemphigus vulgaris (PV),
and IgA pemphigus (IAP). PV is the most common subtype
attributing for 70% of cases and found mainly in middle-aged
and elderly patients, with a female predisposition. Familial
cases are rare although a higher incidence has been found in
Ashkenazi Jewish and Japanese populations (Joly and Litrowski,
2011). Histologically, PV is characterized by an intra-epidermal
cleft between the basal and spinous layers (suprabasal
acantholysis) that correspond clinically to painful mucosal
lesions and skin blister formation. Autoantibodies primarily
target Dsg3 results in a mucosal dominant (MD) variant of PV
that is limited to the oral cavity, whereas, when these target
both Dsg1 and Dsg3 this leads to the mucocutaneous form
(MC), characterized by skin blisters in addition to oral erosions
(Sharma et al., 2007; Amagai, 2010). In addition, autoantibodies
in PV target Dsc1, Dsc2 (Dmochowski et al., 1993; Hashimoto
et al., 1995), and Dsc3 (Spindler et al., 2009; Mao et al., 2010;
Rafei et al., 2011).
IgA pemphigus is a further subtype characterized by the
presence of circulating IgA autoantibodies that can target
desmosomal and non-desmosomal keratinocyte cell surface
components. IAP in turn is divided into two subtypes:
subcorneal pustular dermatosis (s-c) in which Dsc1 is the
target antigen; and intra-epidermal neutrophilic dermatosis
(i-e) in which the targets are Dsg1 and Dsg3 (Kneisel and
Hertl, 2011b). Recently, a comparative clinicopathological
study described an IgG/IgA pemphigus that is a further
overlapping variant between classic IgG pemphigus and IAP,
and may be best regarded as a variant of IgG pemphigus as it
is distinct from IgA pemphigus (Toosi et al., 2016).
Histologically, IAP is characterized by acantholysis and
extensive neutrophilic inﬁltration within the epidermis
(Tsuruta et al., 2011). Reports of patients with IAP are
sparse, with only about 60 cases described. Prognosis of this
form is considered comparable to classic forms of
pemphigus.
Infectious. Several infectious can affect the extracellular
compartment of the desmosome:
– Bullous impetigo (BI) is a common, highly contagious
cutaneous infection that primarily affects children and is
caused by Staphylococcus aureus through the release of
exfoliative toxin (ET). ET is a serine protease that cleaves the
extracellular domain of Dsg1 with high speciﬁcity, and can be
sub-categorized into ETA, ETB, ETC, and ETD, the most
common form being ETA (Wiley and Rogolsky, 1977; Sato
et al., 1994; Yamaguchi et al., 2002). Dsg1 cleavage by ET
results in intra-epidermal cleavage similar to granular layer
blistering caused by IgG in Pemphigus Foliaceus (PF) (Amagai
et al., 2000).
– Staphylococcal scalded skin syndrome (SSSS), also known as
Ritter disease, is a cutaneous infectious disease that
commonly affects children under the age of six, particularly
neonates, although it may also affect immunocompromised
adults (Cribier et al., 1994; Amagai, 2010). SSSS is considered
to be a more generalized and severe form of BI
(Mockenhaupt et al., 2005). Presentation may range from
blisters and severe localized exfoliation at the site of the
infection, to involvement of over 90% of body surface area.
The latter presentation is due to systemic ETs present in the
circulation that cleave desmosomal cadherins, speciﬁcally
Dsg1, in superﬁcial epidermal sites (Ladhani and Evans, 1998;
Handler and Schwartz, 2014). Mucous membranes, including
those of the oral cavity and pharynx, are rarely involved. The
lips may be involved, especially in the later stages of
secondary desquamation, and are characteristically ﬂaky and
ﬁssured (Ossoff and Giunta, 1975). Commonly, therapy for
both BI and SSSS is based on the use of topically or orally
administered antibiotics, with the addition of symptomatic
treatment in severe SSSS cases (Bernard, 2008; Hartman-
Adams et al., 2014). Mortality rates in neonates and children
remain low, but may be over 60% in immunocompromised
adults (Patel, 2004).
– Respiratory and urinary tract infections caused by
adenovirusserotypes 3, 7, 11, and 14, may target Dsg2 (Amagai
and Stanley, 2012). Adenovirus 3, for example, can result in
disruption of intercellular junctions via interaction with Dsg2
(Wang et al., 2015).
– Giardiasis, is an infectious disease characterized by acute or
chronic diarrhoea, dehydration, abdominal discomfort, and
weight loss. It is caused by Giardia duodenalis, a ﬂagellated
unicellular eukaryotic protozoan that targets Dsc2 and/or
Dsc3. It disrupts the arrangement of tight, adherens, and
desmosomal junctions of intestinal cells (Adam, 2001;
Maia-Brigag~ao et al., 2012).
Genetic. There are genetic diseases that affect extracellular
desmosomal components:
– Localized autosomal recessive hypotrichosis is a disease that
affects the scalp, chest, arms, and legs and is caused by several
mutations in the Dsg4 gene (Moss et al., 2004). Histological
features of the scalp skin include thin and atrophic hair
follicles and hair shafts that often coil up within the skin
(Kljuic et al., 2003a).
– Recessive monilethrix, an autosomal dominant human hair
disorder, is caused by mutations in three type II hair cortex
keratins. When linked to Dsg4 mutations, there is overlap
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with localized autosomal recessive hypotrichosis
(Schaffer et al., 2006; Schweizer, 2006; Wang et al., 2015b).
– Woolly hair is a rare, autosomal recessive abnormality of
structure of scalp hair characterized by markedly coiled hair
in Caucasians. It has been associated with alterations of
Dsc2, but is also a clinical feature shared syndromically with
palmoplantar hyperkeratosis and heart anomalies by
diseases targeting intracellular components of the
desmosome.
Diseases targeting the desmosomal plaque
Autoimmune. Among this class fall two of the main
pemphigus subtypes, Pemphigus Foliaceus (PF) and Paraneoplastic
Pemphigus (PNP) that can target either extracellular portion of
the desmosomal cadherins or the desmosomal plaque
constituents.
– PF variant represents about 20–30% of pemphigus cases and
is characterized by superﬁcial epidermal blisters without
mucosal involvement. The blistering results from
autoantibodies
directed against Dsg1 and is restricted to the granular layer
of the epidermis. Further desmosomal targets, such as Dsc1,
Dsc2, Dsc3, Pg, Dsp, and Pkp3, have been described
(Korman et al., 1989; Dmochowski et al., 1993; Zhou et al.,
1997; Mimouni et al., 2004; Spindler et al., 2009). PF occurs
also in an endemic forms (known as “fogo selvagem”) in
some regions of Brazil, Columbia, and Tunisia (Joly and
Litrowski, 2011).
– PNP is a rare form of pemphigus that typically affects
patients diagnosed with malignancies such as non-
Hodgkin’s lymphoma and chronic lymphocytic leukaemia
(Allen and Camisa, 2000; Yong and Tey, 2013). This variant
is the most severe among pemphigus subtypes and shows a
distinctive set of clinical features that inclue a typically
polymorphous skin rash, severe mucosal involvement, life-
threatening bronchiolitis, and unusual histopathological
and immunological ﬁndings (Anhalt et al., 1990; Anhalt,
2004; Hata et al., 2013). Patients presenting with
immunological proﬁles suggestive of PNP and without
evidence of malignancy require close follow-up for the
possible subsequent development of cancer (Sprecher,
2015). Cell-mediated immunity plays a key role in PNP, as
demonstrated by the presence of keratinocyte necrosis
and inﬂammatory cells within the epidermis (Yong and Tey,
2013). The age of onset is usually 45–70 years, although
children and adolescents may be affected. The desmosome
proteins targeted by autoantibodies in PNP include Dsg’s
(particularly the Dsg3), Dsc’s, Dsp, and plakophilins
(Stahley and Kowalczyk, 2015), as well as EVP, PPL,
and a number of less well-speciﬁed antigens, such as
alpha-2-macroglobulin-like-1 (Schepens et al., 2010).
Clinically, PNP is characterized by extremely painful and
refractory oral lesions (Amagai, 2010), potentially followed
by full body cutaneous involvement. Unlike other
pemphigus subtypes, PNP can show the involvement of
palms and/or soles (Allen and Camisa, 2000), conjunctiva,
and simple squamous epithelia (Amagai, 2010). The
prognosis of PNP remains poor, with mortality rates
reaching 90% (Yong and Tey, 2013).
– Erythema multiforme (EM) and Stevens-Johnson syndrome
(SJS). EM and SJS are two acute immune-mediated
disorders that can be triggered by numerous factors
(Celentano et al., 2015). The skin and mucous membranes
can be affected through a type 4 cytotoxic reaction,
mediated by T lymphocytes and triggered by numerous
factors. Several reports described circulating
autoantibodies to Dsp1 and Dsp2 in EM patients
(Foedinger et al., 1995; Johnson et al., 1999; Fukiwake
et al., 2007; Cozzani et al., 2011; Ellis and Sidhu, 2014). So
far, the pathogenic signiﬁcance of the circulating Dsp
autoantibodies in EM and SJS has not been elucidated.
Whether there exists a subset of EM and SJS patients with
autoimmune disease or if instead these circulating anti-
Dsp antibodies are a manifestation of epitope spreading,
remains to be answered.
Infectious. Desmosomal plaque disruption and anomalies
have been linked to only one infectious agent, Bacillus anthracis.
Dsp and Pg of alveolar epithelial cells are targeted by B. anthracis
lethal toxin (BA-LT), with a consequent impaired desmosome
assembly (Langer et al., 2012).
Genetic. The desmosomal intracellular compartment has
shown to be targeted by a variety of genetic diseases.
– To date more than ten mutations in the Dsg1, Pkp1, and Dsp
genes are known to cause Palmoplantar Keratoderma in its
striated (SPPK) (MIM 148700) (Hunt et al., 2001; Kljuic et al.,
2003b; Barber et al., 2007; Sakiyama and Kubo, 2016) and
simple variants (PPK) (Milingou et al., 2006). It is an
autosomal dominant skin disease characterized by linear and
focal hyperkeratosis of the palms, hands, and soles of the
feet, probably due to haplo-insufﬁciency of Dsg1.
Histological and ultrastructural analyses show reduction in
the number of desmosomes, accompanied by widening of
intercellular spaces between suprabasal keratinocytes, and
retracted keratin intermediate ﬁlaments (KIF). In the simple
variant, the hyperkeratinisation affects sites exposed to
mechanical trauma, such as knees, ankles, and ﬁnger
knuckles. There may be mild nail dystrophy (Armstrong
et al., 1999; Whittock et al., 1999).
Another clinical entity recently identiﬁed through familial
studies, is
– Severe skin dermatitis, multiple allergies and metabolic wasting
(SAM) syndrome found to be linked to two homozygous
mutations in Dsg1 (Samuelov et al., 2013; Has et al., 2015;
Schlipf et al., 2016), a novel homozygous splicing mutation
(Cheng et al., 2016) and, in one case, to heterozygous
missense mutation in Dsp gene (McAleer et al., 2015). The
clinical features of this syndrome include recurrent
infections, severe metabolic wasting, severe PPK, severe
erythroderma, severe dermatitis, skin erosion and scaling,
ichthyosis, nail dystrophy, diffuse hypotrichosis,
macrocephaly, a widespread superﬁcial pustulosis,
development delay, nystagmus, multiple allergies, atopya,
persistent eosinophilia, increased IgE levels, hard and curly
hair. The severity of the symptoms is generally determined
by the position of mutation loci.
– Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is also considered a disease of the desmosome
with several mutations involving Dsg2, Dsc2, Pg, Dsp2, and
Pkp2 genes (Awad et al., 2006; Nagaoka et al., 2006; Syrris
et al., 2006). ARVD/C is an autosomal dominant primary
myocardial disorder characterized by myocardial atrophy
and ﬁbro-fatty replacement of cardiac myocytes, ventricular
arrhythmias, sudden cardiac death, and end-stage heart
failure, typically affecting the right ventricle. Dsg2 and Dsc2
are known to be expressed in cardiac myocytes and are the
main candidate genes for this disorder (Pilichou et al., 2006;
Syrris et al., 2007). ARVD/C was thought to primarily affect
the right ventricle, however, in some cases the disease can
affect the left ventricle (Left dominant arrythmogenic
cardiomyopathy) and truncating mutations in desmoplakin are
consistently associated with these aggressive phenotypes
(L!opez-Ayala et al., 2014).
– Woolly hair is a clinical feature shared syndromically with
palmoplantar hyperkeratosis and heart anomalies by
diseases such as:
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– Naxos disease, if Pg is targeted, which is an autosomal
recessive, inherited, cardiocutaneous disorder,
characterized by ARVC, woolly hair, and PPK.
– Carvajal syndrome, if Dp is targeted, which is characterized by
PPK, curly hair, dilated cardiomyopathy, especially on the left
ventricle side, and early morbidity.
– Ectodermal dysplasia–skin fragility syndrome (EDSFS) is an
autosomal recessive dermatosis that has been associated
with at least eleven different recessively inherited mutations
in the Pkp1 gene. It is characterized by skin fragility (with
trauma-induced erosions and blistering), non-cicatricial
alopecia, palmoplantar keratoderma (PPK),
onichodystrophy, and in some cases hypohidrosis (McGrath
et al., 1999; Hern!andez-Martín et al., 2013).
– Lethal acantholytic epidermolysis bullosa is a rare genetic
disease that has also been identiﬁed as the result of
heterozygosity of two loci containing the C terminus of Dsp
and leading to the formation of a truncated protein, thus
lacking the entire domain that binds the intermediate
ﬁlaments. Patients present with cardiomyopathy, severe
fragility of the skin and mucous membranes leading to severe
mucocutaneous erosions and marked ﬂuid loss, epidermal
dislodgment, complete alopecia, neonatal teeth, and nail loss.
The prognosis is poor with frequent early demise (Jonkman
et al., 2005).
– Lethal congenital epidermolysis bullosa is a recently
described phenotype of the epidermolysis bullosa diseases
group. It is caused by a homozygous nonsense Junction
Plakoglobin (JUP) mutation that leads to the lack of Pg.
Patients suffer from severe congenital skin fragility with
generalized epidermolysis and massive transcutaneous
ﬂuid loss, but no apparent cardiac dysfunction (Pigors
et al., 2011).
– Brugada syndrome is an inherited rare disease caused by
disturbed function of ion channel subunits or the proteins
that regulate them (channelopathies), and is associated
with sudden cardiac death at rest, mainly in men in the
third–fourth decade of life. This disease has been linked to
18 different gene mutations, with the gene encoding the
sodium voltage-gated channel alpha subunit 5, SCN5A
gene, represented in the majority. One of the most
recently identiﬁed genes was PKP2 encoding the protein
plakophilin-2. The absence and/or alteration of
plakophilin-2 structure in the cardiac desmosomes impair
myocyte interactions, inducing myocardium disruption,
particularly in response to mechanical stress (Campuzano
et al., 2016).
Diseases targeting the regulatory network
The desmosomal network of accessory proteins is
extensive and also populated by numerous protein–protein
interactions that play a functional, rather than just a
structural role (Cirillo and Prime, 2009). Unlike structural
desmosomal nodes, these regulatory proteins are
ubiquitous and are therefore associated with diseases of
virtually any human tissue. Nevertheless, several examples
exist of perturbations of functional nodes that result in
phenotypes similar to those seen in typical desmosomal
diseases.
The use of a mousemodel can be a valuable tool to approach
the study of accessory components targeted in disease and as
such, phenotypic effects of gene deletions in mice have been
reviewed.
Given the central role that desmosomal accessory proteins
play, a single deletion of any of speciﬁc genes has been
associated with marked phenotypic alterations. For example,
embryonic/perinatal lethality was found to be associated with
gene deletion of AKT1, MAPK1, and CASP2 (Bergeron et al.,
1998; Hatano et al., 2003); and postnatal lethality was
associated with FYN gene deletion (Yagi et al., 1993).
Gene deletion of Src, EGFR, PRKACA, ERBB2, CASP3
demonstrated both embryonic/perinatal and postnatal lethality.
Furthermore, phenotype alterations of the cardiovascular
systemwere associated with deletion of EGFR, PRKCA, ERBB2,
CASP3, and MAPK1; digestive/alimentary phenotype observed
with EGFR, ERBB2, CASP3, and MUC1 deletion; and skin, coat,
and nails altered in gene deletion of Src, EGFR, PRKACA, and
FYN (Soriano et al., 1991; Yagi et al., 1993; Lee et al., 1995;
Miettinen et al., 1995; Sibilia and Wagner, 1995; Spicer et al.,
1995; Threadgill et al., 1995; Kuida et al., 1996; Erickson et al.,
1997; Woo et al., 1998; Dietrich et al., 2000; Chan et al., 2002;
Crone et al., 2002; Leitges et al., 2002; Skålhegg et al., 2002;
Hatano et al., 2003; Braz et al., 2004; Nolan et al., 2004; Hara
et al., 2005; Natarajan et al., 2007).
Further, single perturbations in humans (e.g., deletion) of
one accessory protein of the network lead to severe clinical
ﬁndings.
AKT1 mutations have been associated with Proteus
syndrome, a very rare and non-inherited condition
characterized by progressive, segmental, or patchy overgrowth
of diverse tissues of all germ layers, most commonly affecting
the skeleton, skin, and adipose and central nervous systems.
This syndrome is known to be caused by a single, post-zygotic,
somatic mosaic mutation in AKT1 and it is hypothesized that a
non-somatic mosaic mutation would be lethal in early
development (Lindhurst et al., 2011). Moreover, Cowden
syndrome 6 has been shown to be caused by heterozygous
mutation in the AKT1 gene (164730) on chromosome 14q32.3
(Orloff et al., 2013).
Homozygosity from a missense mutation in the EGFR gene
has been found in neonatal inﬂammatory skin and bowel
disease-2. The clinical manifestations of this disease was ﬁrst
described by Campbell et al. (2014) and were numerous, from
widespread erosions affecting the trunk and limbs, to
development of papules and pustules, with frequent S. aureus
infections of the skin. Recurrent diarrhea, respiratory
difﬁculties, recurrent bronchiolitis, pulmonary infection,
developmental failure, trichomegaly, hypertension, and
bilateral renal enlargement were also observed.
Ventricular and atrial septal defects, hypertrophic
cardiomyopathy, hypsarrhythmia, severe developmental delay,
and more clinical features have been associated with speciﬁc
deletions in the YWHAG gene that encodes for 14-3-3 protein
gamma, an accessory protein of the desmosome-associated
regulatory network (Komoike et al., 2010; Ramocki et al., 2010;
R€othlisberger et al., 2010).
Choanal atresia is a rare congenital disorder where the
choana (posterior part of the nasal passage) is blocked during
development. This has been associated with lymphoedema due
to mutation in the protein-tyrosine phosphatase, non-
receptor-type, 14 gene (Au et al., 2010).
In summary, although the desmosomal regulatory proteins
are pleiotropic and their mutations affect virtually all tissues,
alteration of the regulatory network can lead to clinical
manifestations resembling desmosomal disease.
Desmosome and cancer
Perturbation of the complex integrated signaling network of the
desmosome has also been strongly linked to carcinogenesis. Late
in the last century, ﬁrst evidence of this linkwas shown of the role
of desmosomes in the suppression of tumour spread (Tselepis
et al., 1998). The loss of intercellular adhesion, dependent on
adhesive intercellular junctional integrity, could be directly related
to invasion. Subsequent data evaluating desmosomal components
expression in several forms of cancer have been far from easy to
interpret. For instance, expression of desmosomal cadherins was
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found to decrease in many tumours, such as skin (Chen et al.,
2012), head, and neck (Chen et al., 2007), lung (Cui et al., 2012),
breast (Klus et al., 2001; Oshiro et al., 2005), prostate (Barber
et al., 2014), cervix (Alazawi et al., 2003), etc. Paradoxically, the
expression of desmosomal cadherins has been reported to be
increased in the same cancer (Huber and Petersen, 2015).
Nevertheless, dysregulation of desmosomal components
frequently correlates with cancer aggression and poor prognosis.
Is this the case of renal cell carcinoma (Breault et al., 2005),
prostate cancer (Barber et al., 2014; Pan et al., 2014), endometrial
carcinoma (Nei et al., 1996), head and neck cancer (Chen et al.,
2007; Wong et al., 2008), lung cancer (Savci-Heijink et al., 2009;
Cui et al., 2012), gastric (Yashiro et al., 2006) and colon cancer
(Khan et al., 2006; Kn€osel et al., 2012; Sch€ule et al., 2014),
pancreatic ductal adenocarcinoma (Hamidov et al., 2011), SCC of
the sinonasal cavity (Huang et al., 2010), cutaneous SCC (Tada
et al., 2000; Kurzen et al., 2003), esophageal adenocarcinoma
(Wang et al., 2014), and not least OSSC (Xin et al., 2014).
Interestingly, cell cycle control and triggers for apoptosis can be
indirectly inﬂuencedby altered functional signalingbydesmosomal
cadherin (Cirillo, 2016). To date, several mechanisms by which
alterationofdesmosomal cadherinexpression canoccur in cancer
have been identiﬁed such as transcriptional regulation of
desmosomal cadherins, impaired transport, targeting, and
assembly into mature desmosomes, as well as, inactivation by
proteolytic cleavage.We refer to a several recent comprehensive
reviews on this topic (Huber and Petersen, 2015; Stahley and
Kowalczyk, 2015), and provide more detail in Table 1.
Concluding Remarks
The desmo-adhesome functional unit offers a valuable model of
how basic, translational, and clinical research merge to forward
our understanding of human disease. The study of desmosome
pathophysiology has salient clinical implications and resulted in
the development of novel diagnostic techniques and
therapeutic approaches to a number of autoimmune and
genetic conditions (Schmidt and Zillikens, 2010; Kalantari-
Dehaghi et al., 2013; Otten et al., 2014). This study has also
suggests that typical desmosomal disease analysis needs to be
extended to the regulatory network compartment that is likely
signiﬁcantly enhance the understanding of desmosomal
pathophysiology. The expectation is that an increasingly
supportive systems biology and experimental research model
will unveil novel disease mechanisms that will ultimately be
targeted for patients’ beneﬁt.
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INVITED CONCISE REVIEW
Desmosomes in disease: a guide for clinicians
A Celentano1,2, N Cirillo1
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The large number of diseases occurring when desmo-
some constituents are impaired provides striking evi-
dence for the key role of desmosomes in maintaining
tissue integrity. A detailed understanding of the molecu-
lar alterations causing desmosomal dysfunction has, in
turn, underpinned the development of novel diagnostic
tools. This has salient clinical implications for dentists
and oral medicine practitioners because the majority of
desmosomal diseases affect the oral cavity. In the pre-
sent article, we review the autoimmune, infectious,
genetic, and neoplastic diseases that target the desmo-
some, with particular emphasis on clinical manifesta-
tions, diagnostic pathways, and relevant laboratory
investigations.
Oral Diseases (2016) doi: 10.1111/odi.12527
Keywords: desmosome; pemphigus; blistering diseases
Giulio Bizzozero, an Italian pathologist, was the ﬁrst to
sketch and describe what would later be called ‘desmo-
some’ (Bizzozero, 1864). One hundred and ﬁfty years
later, vast knowledge has accumulated on the complex
biochemical structure and role of the desmosome in health
and disease. To date, approximately 30 different condi-
tions including infectious, autoimmune, genetic, and neo-
plastic diseases are known to involve desmosomal
dysfunction. This review presents an update on desmo-
some pathophysiology, particularly for clinicians involved
in the diagnosis of mucocutaneous diseases.
Molecular composition and ultrastructure of
the desmosome: the basics
Desmosomes, along with the adherens junctions (AJs),
gap junctions, and tight junctions (TJs), are the predomi-
nant type of adhesive intercellular junctions in vertebrate
tissues, particularly those requiring strength, extensibility,
and elasticity such as epithelium. It is now well
established that desmosomes are dynamic structures with
unique plasticity. Their ability to switch between hyperad-
hesive and unordered states is essential to maintain tissue
integrity and homeostasis.
At the ultrastructural level, desmosomes appear as mul-
tilayered symmetrical disk-shaped structures of 0.2–
0.5 lm in diameter found between cellular membranes of
adjacent cells. These organelles link keratin intermediate
ﬁlaments (KIFs) to the plasma membrane region and mor-
phologically consist of a central electron-dense midline
between two plasma membranes (desmoglea) and intracel-
lular dense plaques, that is, the outer and inner dense pla-
ques. The extracellular portion forming the desmoglea
contains desmosomal cadherins desmogleins (Dsg1-4) and
desmocollins (Dsc1-3). These calcium-dependent proteins
are expressed in a tissue-speciﬁc and differentiation-depen-
dent manner and mediate adhesion by forming strong
extracellular homo-/heterophilic bonds. At the intracellular
level, their extremities interact with plakoglobin (Pg) and
plakophilins (Pkps) (Bass-Zubek et al, 2009), thus form-
ing the outer dense plaque. These molecules bind to com-
ponents of the inner dense plaque, namely desmoplakin
(Dp), plectin, envoplakin (EVP), and periplakin (PPL),
whose function is to anchor KIFs and stabilize desmo-
somes (Vasioukhin et al, 2001). In addition to this struc-
tural role, components of desmosomal plaques are also
important for cell signaling and interaction with regulatory
molecules such as kinases and proteases. This ﬁnely regu-
lated network of intrinsic and accessory molecules consti-
tutes the desmosomal functional unit, or desmo-adhesome
(Cirillo and Prime, 2009).
To date, almost 30 different diseases (Table 1) in which
desmosomes are impaired have been identiﬁed. These can
be categorized into infectious, autoimmune, and inherited.
Additionally, recent evidence has shown that desmosomal
molecules are often dysregulated in cancer.
Autoimmune disease of the desmosome
Pemphigus disease
Among the acquired desmosomal diseases, a predomi-
nant role is surely represented by Pemphigus, a family
of autoimmune diseases characterized by circulating
autoantibodies that target desmosomal components as
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well as other epithelial antigens and impair keratinocytes
adhesion with subsequent acantholysis. The antidesmoso-
mal antibodies detected in pemphigus patients are direc-
ted against Dsg1 and/or Dsg3 (Cirillo et al, 2007).
These diseases are considered relatively rare with an
overall incidence of 1–16 new cases per million people/
year (Ruocco et al, 2013), and the age of onset is usu-
ally the ﬁfth or sixth decade of life. Although the
precise pathomechanisms of pemphigus have not yet
been fully elucidated, recent studies have shown that
desmosome disassembling involves not only the direct
inhibition of desmosome formation caused by IgGs, but
also desmosome remodeling. Additionally, several intra-
cellular signaling pathways possibly triggered by non-
desmosomal molecules. The signaling-related events
include apoptosis as well as modulation of Pg,
p38MAPK, heat-shock protein 27, cdk2, Src, RhoA, and
others (Kitajima, 2014; Cirillo, 2016).
The main subtypes of Pemphigus are pemphigus vul-
garis (PV), pemphigus foliaceus (PF), paraneoplastic pem-
phigus (PNP), and IgA pemphigus (IAP).
• PV is the most common subtype of pemphigus (~70%
of cases), found mainly in middle-aged and elderly
patients, with a female predisposition. Familial cases
are rare although a higher incidence was found in
Ashkenazi Jewish and Japanese populations (Joly and
Litrowski, 2011). Histologically, PV is characterized
by an intra-epidermal cleft between the basal and spi-
nous layers (suprabasal acantholysis), which manifests
clinically as painful mucosal lesions and skin blister
formation. Oral mucosal lesions appear early and asso-
ciate with the presence of anti-Dsg3, but not anti-
Dsg1, antibodies. Early diagnosis and treatment are
associated with a better prognosis (Mignogna et al,
2010) and may prevent the spreading of the disease to
skin tissues. The mucocutaneous type of PV is charac-
terized by skin blisters in addition to oral erosions and
associates with an autoantibody switch to both anti-
Dsg1 and anti-Dsg3 IgG (Amagai, 2010). In addition,
autoantibodies in PV can target Dsc1, Dsc2, and Dsc3
(Stahley and Kowalczyk, 2015).
• PF variants represent about 20–30% of pemphigus
cases and are characterized by superﬁcial epidermal
blisters without mucosal involvement. The blistering
results from autoantibodies directed against Dsg1 and
is restricted to the granular layer of the epidermis.
Further desmosomal targets such as Dsc1, Dsc2,
Dsc3, Pg, Dsp, and Pkp3 have been described in the
literature.
• PNP is a rare form of pemphigus that typically affects
patients diagnosed with malignancies such as non-
Hodgkin’s lymphoma and chronic lymphocytic leuke-
mia (Yong and Tey, 2013). This variant is the most
severe among pemphigus subtypes and shows a dis-
tinctive set of clinical features including a typically
polymorphous skin rash, severe mucosal involvement,
life-threatening bronchiolitis, and unusual histopatho-
logical and immunological ﬁndings (Hata et al, 2013).
The age of onset is usually 45–70 years, and intra-
orally, PNP is characterized by extremely painful and
refractory lesions potentially followed by full body
cutaneous involvement. Unlike other pemphigus sub-
types, PNP can show the involvement of palms and/or
soles, conjunctiva, and simple squamous epithelia.
The desmosome proteins targeted by autoantibodies in
PNP are several and include Dsgs (particularly the Dsg3),
Dscs, Dsp, and plakophilins (Stahley and Kowalczyk,
2015), as well as EVP, PPL, and a number of less well-
speciﬁed antigens such as alpha-2-macroglobulin-like-1
(Schepens et al, 2010). Patients presenting with immuno-
logical proﬁles suggestive of PNP and without evidence
of malignancy deserve strict follow-up for the possible
subsequent development of cancer. The prognosis of PNP
remains poor, with mortality rates reaching 90% (Yong
and Tey, 2013).
• IAP is a subtype characterized by the presence of cir-
culating IgA autoantibodies that can target desmoso-
mal and non-desmosomal keratinocyte cell surface
constituents. IAP in turn is divided into two subtypes:
the subcorneal pustular dermatosis (s-c), in which
Dsc1 is the target antigen, and the intra-epidermal
neutrophilic dermatosis (i-e) in which the targets are
Dsg1 and Dsg3. Recently, a comparative clinicopatho-
logic study has established that IgG/IgA pemphigus, a
further overlapping variant between classic IgG pem-
phigus and IAP, may best be regarded as a variant of
IgG pemphigus and distinct from IgA pemphigus
(Toosi et al, 2016). Histologically, IAP is character-
ized by acantholysis and extensive neutrophilic inﬁl-
tration within the upper layers or all layers of the
epidermis. Reports of patients with IAP are sparse,
with only about 60 cases described, although the prog-
nosis of this form was rated as comparable with the
classic forms of pemphigus.
Erythema multiforme (EM) and Stevens–Johnson
syndrome (SJS)
Besides the pemphigus group, desmosomes have shown to
be targeted in erythema multiforme (EM) and Stevens–
Johnson syndrome (SJS) cases. EM and SJS are two acute
immune-mediated disorders that can affect the skin and
mucous membranes through a type 4 cytotoxic reaction,
mediated by T lymphocytes and triggered by numerous
factors. Several reports described circulating autoantibod-
ies to Dsp1 and Dsp2 in EM patients (Johnson et al,
1999; Ellis and Sidhu, 2014). So far, the pathogenic sig-
niﬁcance of the circulating Dsp autoantibodies in EM and
SJS has not yet been elucidated. The unsolved question is
whether there is a subset of EM patients with autoimmune
disease or they are a manifestation of the phenomenon of
epitope spreading.
Infectious diseases of the desmosome
Disruption of desmosome integrity can be caused by
infective agents. Bullous impetigo (BI) and Staphylococcal
scalded skin syndrome (SSSS) are caused by Staphylococ-
cus aureus through the release of exfoliative toxin, a ser-
ine protease that speciﬁcally cleaves the extracellular
domain of Dsg1 (Amagai et al, 2000).
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Respiratory and urinary tract infections caused by aden-
ovirus serotypes (Ad) 3, 7, 11, and 14 can target Dsg2
(Amagai and Stanley, 2012).
Giardiasis (Gd) targets Dsc2/3 and disrupts tight, adhe-
rens and desmosomal junctions of intestinal cells (Adam,
2001). Lastly, Dsp and Pg of alveolar epithelial cells can
be targeted by Bacillus anthracis lethal toxin (BA-LT),
with a consequent impaired desmosome assembly (Langer
et al, 2012). These infectious diseases have limited oral
involvement and their discussion goes beyond the scope
of this review. More details can be found in Table 1. Des-
mosome disruption and anomalies have been also linked
to coxsackievirus B3 (CVB3) and infections of the oral
mucosa, although the speciﬁc targets remain unknown
(Stahley and Kowalczyk, 2015).
Genetic diseases of the desmosome
Diseases resulting from genetic alterations in desmosomal
components involve skin and heart tissues but have lim-
ited oral involvement. Details are reported in Table 1.
Striated palmoplantar keratoderma (SPPK) and Palmo-
plantar keratoderma (PPK) feature mutations in the Dsg1,
Pkp1, and Dsp genes (Cirillo, 2016). Severe skin dermati-
tis, multiple allergies, and metabolic wasting syndrome
(SAM) are linked to mutations in Dsg1 (Samuelov et al,
2013) and Dsp genes (McAleer et al, 2015). Localized
autosomal recessive hypotrichosis (LAH) is caused by sev-
eral mutations in the Dsg4 gene (Moss et al, 2004).
Recessive monilethrix may also be linked to Dsg4 muta-
tions. Ectodermal dysplasia–skin fragility syndrome
(EDFSF) is caused by mutations in the Pkp1 gene,
whereas Lethal congenital epidermolysis bullosa features
homozygous nonsense mutation, which leads to the lack
of Pg.
Desmosome-like structures are also present in cardiac
muscle cells, and mutations of desmosomal components
result in heart disease. Arrhythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C) and left dominant
arrythmogenic cardiomyopathy involve several mutations
in the Dsg2, Dsc2, Pg, Dsp2, and Pkp2 genes (Awad
et al, 2006; Nagaoka et al, 2006; Syrris et al, 2006).
Another variant of the disease named lethal acantholytic
epidermolysis bullosa has also been identiﬁed as the result
of heterozygosity of two loci containing the C terminus of
Dsp and leading to the formation of a truncated protein,
thus lacking the entire IF-binding domain. Brugada syn-
drome has been linked to 18 different gene mutations, one
being PKP2 (ENSG00000057294), which encodes for the
protein plakophilin-2 (PKP2).
In certain cases, both epidermis and heart can be
affected. Woolly hair, an autosomal recessive structural
abnormality of scalp hair, is a clinical feature shared syn-
dromically with palmoplantar hyperkeratosis and heart
anomalies by diseases targeting Dsc2, Pg (e.g., Naxos dis-
ease), and Dp (e.g., Carvajal syndrome).
Desmosome and cancer
David Garrod’s group ﬁrst proposed a mechanistic role of
desmosomes in cancer progression (Tselepis et al, 1998).
To date, at least three mechanisms through which alter-
ation in desmosomal cadherins occurs in cancer have been
identiﬁed, namely: (i) transcriptional regulation of desmo-
somal cadherins; (ii) impaired transport, targeting, and
assembly into mature desmosomes; and lastly, (iii) inacti-
vation by proteolytic cleavage. Furthermore, the control of
cell cycle as well as apoptosis can be indirectly affected
by desmosomal cadherin signaling function.
The idea that the loss of intercellular adhesion could be
directly related to cancer invasiveness is fairly predictable.
Surprisingly, analysis of the expression levels of desmoso-
mal components in cancer has yielded conﬂicting results.
Speciﬁcally, expression of desmosomal cadherins was
found to be decreased in many tumors such as skin, head
and neck, lung, breast, prostate, cervix but reported as
increased by others (Huber and Petersen, 2015).
There is, however, compelling clinical evidence that
correlates desmosomal deregulation with clinicopathologic
features of the tumor including staging and grading, and
consequently prognosis. This is the case of renal cell car-
cinoma, prostate cancer, endometrial carcinoma, head and
neck cancer, lung cancer, gastric and colon cancer, pancre-
atic ductal adenocarcinoma, SCC of the sinonasal cavity,
cutaneous SCC, esophageal adenocarcinoma, and not least
OSSC.
Thus, current evidence strongly suggests that desmoso-
mal proteins will soon assume a main role as cancer mark-
ers/prognostic factors, but also as potential molecular
targets for development of novel therapies.
We refer the reader to a couple of recent review articles
for a comprehensive discussion of this topic (Huber and
Petersen, 2015; Stahley and Kowalczyk, 2015).
Diagnostic pathway
The aim of this section is to provide guidance to dentists
and oral medicine specialists for the diagnosis of desmo-
some-related conditions, especially blistering diseases, and
to outline the rationale for the diagnostic investigations
required.
The diagnosis of blistering disease is reached from the
combination of clinical, histological, immunopathological,
and serological ﬁndings, the latter being a prerequisite for
the diagnosis of immunobullous disorders. Genetic disease
can be conﬁrmed by gene mutation analysis. Additional
tests may include immunoblotting, immunoprecipitation,
and electron microscopy.
Clinical evaluation
Diseases of the pemphigus group dominate the ﬁeld of
desmosome-related conditions with oral manifestations
and hence are more relevant to dental practitioners. Clini-
cal evaluation includes examination of the skin, mucous
membranes, and nails, and patients should be also ques-
tioned for symptoms suggestive of on extraoral mucosal
involvement. The patient’s medical history and medica-
tions should be thoroughly reviewed, as clinical and labo-
ratory studies may not discriminate between idiopathic
and drug-induced pemphigus. Despite some clinical ﬁnd-
ings being suggestive of speciﬁc immunobullous diseases,
for example, ﬂaccid blisters, and a positive Nikolsky sign
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for PV, laboratory-based detection of tissue-binding and
circulating autoantibodies is always required.
A standard laboratory work-up for these patients would
include the following:
• A lesional skin/mucosal biopsy for routine hema-
toxylin and eosin (H&E) staining
• A perilesional skin/mucosal biopsy for direct
immunoﬂuorescence (DIF), and/or
• Serum collection for indirect immunoﬂuorescence
(IIF) and enzyme-linked immunosorbent assay
(ELISA).
Sample collection
The biopsy for routine histopathology should ideally be
performed on an intact lesion, and a punch biopsy (4 mm)
is usually sufﬁcient. Clinicians may prefer to employ a
stab-and-roll technique using size 15 scalpel blade to
maintain the epithelial roof in the sample. The sample
should be placed immediately in 10% buffered formalin.
A tissue sample for DIF microscopy should be taken
from the perilesional area to contain both epithelium and
stroma. The sample should be placed this time in optimal
cutting temperature (OCT) compound and frozen immedi-
ately at !20°C and stored at !80°C until processing. If
OCT compound is not available, the tissue may alterna-
tively be placed in normal saline-soaked gauze and kept at
4°C, or in Michel’s medium that can preserve the sample
at room temperature for approximately 6 months (Vodegel
et al, 2004).
Biopsy for transmission electron microscopy (TEM) and
immunomapping are identical to that for routine
histopathology. The sample should be placed immediately
in an electron microscopy-speciﬁc medium, and in OCT,
respectively.
ELISA and IIF assays are used for serodiagnosis and
require the collection of a 5–10 ml blood sample without
anticoagulants. This is then centrifuged to separate plasma
(which contains the gamma globulins) from blood cells.
Histology
The characteristic histopathological ﬁndings in PV include
intra-epithelial cleavage with loss of keratinocytes adhe-
sion, known as acantholysis, localized primarily to the
suprabasal region. Retention of basal keratinocytes along
the basement membrane zone results in an appearance that
resembles a ‘row of tombstones’. There is additionally
sparse inﬂammatory inﬁltrate in the dermis with eosino-
phils. In the variant known as pemphigus vegetans, the
suprabasal cleavage is accompanied by hyperkeratosis,
papillomatosis, and prominent acanthosis with downward
proliferation of the rete ridges.
The characteristic histopathological ﬁndings of PF
include intra-epithelial acantholysis beneath the stratum
corneum or within the granular layer, occasional presence
of neutrophils within the blister cavity and mixed inﬂam-
matory inﬁltrate in the superﬁcial dermis with neutrophils
and eosinophils.
Typical histopathological ﬁndings of IAP include intra-
epidermal clefts and pustules located in a subcorneal loca-
tion (s-c) or in the entire or mid-epidermis (i-e), slight or
absent acantholysis and a mixed inﬂammatory inﬁltrate in
the dermis.
The most common histopathological ﬁndings in PNP
are suprabasal acantholysis, keratinocyte necrosis, and a
lichenoid interface dermatitis. However, in PNP the
histopathological ﬁndings are variable.
The istopathological features of all other desmosomal
diseases with limited involvement of the oral cavity are
reported in Table 1.
Direct immunoﬂuorescence microscopy (DIF)
DIF is a technique that aims to detect any in situ deposi-
tion of immunoreactants (typically immunoglobulins and/
or complement components) in patients’ epidermis or
mucous membranes. Detection of the immune deposits in
the sample allows conﬁrmation of presumed immunologi-
cal pathomechanism, and classiﬁcation of the disease
according to the exact location of the immune deposits.
The most common antibodies used for DIF comprise ﬂuo-
rescin-conjugated antibodies against IgG, IgM, IgA, C3,
and ﬁbrinogen. IF microscopy is still considered the diag-
nostic gold standard for pemphigus given that the tissue-
ﬁxed intercellular antibodies are present in about 90% of
the patients. In both PV and PF, an intercellular binding
of IgG and/or C3 is found in a typical ‘cobblestone’ or
‘ﬁshnet pattern’ in the epidermis/epithelium, while in
PNP, in addition to the above ﬁndings, an abnormal band-
like deposit of immunoglobulin/complement is detected in
the dermal—epidermal junction (Chiorean et al, 2014). In
IAP, the main ﬁnding is the deposition of IgA with an
intercellular pattern. Importantly, cryosections of perile-
sional biopsies are required for direct IF microscopy.
Indirect immunoﬂuorescence microscopy (IIF)
IIF aims to detect circulating autoantibodies in patients’
sera that target skin constituents. The procedure applies
patient serum to normal epithelial substrate in a two incu-
bation steps. One of the most used epithelial substrate is
the monkey esophagus. In general, is it well established
that the type of substrate used inﬂuences the sensitivity of
the test. More in detail, for PV and PF the best substrates
are monkey and guinea pig esophagus, respectively. For
PNP, rat or monkey bladder is used due to their high
expression of plakins. Interestingly, more than 80% of PV
and PF patients have detectable circulating autoantibodies
(Payne and Stanley, 2012), which makes IIF a reliable
technique for the diagnosis of these autoimmune blistering
diseases.
In IAP, the preferred substrate is monkey esophagus,
and binding of autoreactive IgA from patient’s sera to
epithelial cells with an intercellular pattern may be found.
Only recently a novel IF assay using desmocollin-
transfected COS-7 cells is available to characterize autore-
active IgA molecular speciﬁcity (Otten et al, 2014).
The staining patterns are similar to those described for
DIF.
ELISA
ELISA is a technique that measures speciﬁc autoantibod-
ies in serum. Test serum is incubated in microtiter plate
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wells that are coated with the antigen(s) of interest.
Matched autoantibodies will bind to the antigen and the
incubation with an enzyme conjugated secondary anti-IgG
antibody, resulting in proportional color change. In PV
and PF, serum levels of anti-Dsg1 and anti-Dsg3 antibod-
ies may be related to disease activity (Cirillo et al, 2012).
This test can also be useful to assess response to treatment
(Zone, 2009). In general, anti-Dsg1 levels better correlate
to disease course in PV and PF patients than anti-Dsg3
levels, which may remain high even in phases of remis-
sion (Abasq et al, 2009). ELISA kits are commercially
available for detection of serum IgG antibodies to Dsg1/
Dsg3. ELISA assay, with a sensitivity that exceeds 90 per-
cent, has been demonstrated to be more sensitive and
speciﬁc than IIF for the diagnosis of PV and PF (Payne
and Stanley, 2012).
In general, the following outcomes may be expected:
• In PV with exclusive mucosal involvement, anti-Dsg3
will be detected, whereas in mucocutaneous variant
both Dsg1 and Dsg3 autoantibodies can be found.
• PF is characterized by exclusive involvement of Dsg1
autoantibodies.
• In most cases of PNP, IgG autoantibodies against Dsg1
and Dsg3 are found but also against Dsc1/Dsc3/EVP/
PPL, followed by Dsp1/Dsp2/plectin, and BP230.
• IgA pemphigus is characterized by the detection of
IgA autoantibodies against Dsg1 and Dsg3 in the i-e
type and against Dsc1 in the s-c type. (Kneisel and
Hertl, 2011).
The ELISA system for detection of anti-envoplakin
antibodies is now commercially available. Conversely,
ELISA for detection of other molecules such as desmo-
collins, periplakin, while already available, has not yet
been released for routine clinical diagnostic use.
Additional test: immunoblotting and immunoprecipitation,
protein arrays, PCR, gene sequencing
Together with ELISA, immunoblotting (also referred to as
Western Blotting) and immunoprecipitation are highly sen-
sitive and speciﬁc detection techniques of autoantibodies
that use recombinant autoantigens or keratinocyte extracts
from healthy human skin. Recently, protein microarrays
have proven to be a powerful technique to detect large
number of autoantibodies in blistering disease (Kalantari-
Dehaghi et al, 2013).
Immunoprecipitation is more sensitive than
immunoblotting and in particular is used for immunosero-
logical follow-up and as deﬁnitive serological conﬁrma-
tory test. Remains, however, to consider that Western
blotting analysis is not necessarily useful in pemphigus
diagnosis given that most of the immunogenic epitopes on
Dsg1 and 3, are conformational. The increasing complex-
ity of autoantibody proﬁles in blistering diseases will
probably be addressed by protein arrays in future years.
Together with clinical and histological ﬁndings, the
diversity and heterogeneity of some genetic desmosomal
diseases make genetic testing indispensable for diagnosis,
assuming that the causative genes have been identiﬁed. In
general, single base pair mutations are identiﬁed by direct
sequencing, DNA hybridization, and/or restriction enzyme
digestion methods.
Concluding remarks
Alteration in desmosomal components leads to diseases
that feature skin, cardiac and oral involvement. The
desmosome offers a precious example of how basic, trans-
lational, and clinical research integrate and support each
other to gain insight into the understanding of human dis-
eases and, ultimately, to improve patient management.
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Synthetic corticosteroids are widely used for the treatment of a variety of diseases, including pre-malignant and malignant conditions. In
striking contrast, recent evidence suggests that corticosteroids can bear tumor-promoting effects in solid tumors of epithelial origin. We
have recently shown that epithelial tissues, including themucosa of the oral cavity and the skin, are able tomodulate the local concentration
of active corticosteroids and to produce steroids de novo. This has important clinical and physiopathological implications, because tissue-
speciﬁc regulation of glucocorticoids plays a key role in the overall effect of these molecules. In the present review of the current English
literature, performed using MEDLINE/PubMed/Ovid databases, we collected published evidence to demonstrate that corticosteroids
induce effects that aremore complex and controversial than previously acknowledged. Published studies clearly demonstrate that this class
of molecules inﬂuences pathophysiological processes that are strictly related to malignancy, providing the rationale for further
investigation.
J. Cell. Physiol. 231: 2368–2373, 2016. ! 2016 Wiley Periodicals, Inc.
Cortisol is an endogenous glucocorticoid (GC) hormone
produced by the adrenal cortex in response to
adrenocorticotropic hormone (ACTH), and it is released in
response to various stress stimuli. ACTH secretion from the
pituitary gland is a result of hypothalamus activation. GCs have
long been regarded as drugs that promote apoptosis and inhibit
cell proliferation and wound healing (Schlossmacher et al.,
2011). However, a body of evidence has mounted over the last
10 years that shows potentially harmful effects of GCs in cancer
therapy. Data from laboratory, preclinical, and clinical studies
suggest that glucocorticoids induce treatment resistance in
solid tumors, including prostate, ovarian, and breast cancer
(Herr and Pﬁtzenmaier, 2006). Our data also support this view
by demonstrating that cortisol signiﬁcantly reduces the
cytotoxic effects of chemotherapeutic agents in several cell
lines from oral squamous cell carcinoma (OSCC) (Celentano
et al, manuscript in preparation). GCs also form themainstay of
the therapeutic armamentarium of a number of diseases with
malignant potential, such as oral lichen planus (OLP).
Therefore, the potential pro-tumorigenic activity of GCs can
have vast clinical implications and warrants urgent attention.
Recent research demonstrates that epithelial cells, including
those lining the skin and oral mucosa, can metabolize
glucocorticoids de novo from cholesterol or systemic steroid
intermediates. It has been shown that there is an endogenous
non-adrenal glucocorticoid system existing in human epidermal
keratinocytes and they exhibit high levels of corticosteroid
metabolizing activity (Slominski et al., 2014). Keratinocytes
express major enzymes involved in the synthesis and
metabolism of cortisol, including cytochrome P450 chain, 11b-
hydroxysteroid dehydrogenases (11b-HSD1/11b-HSD2),
adrenocorticotropic hormone receptor (ACTHR/MC2R), and
glucocorticoid receptor (Cirillo and Prime, 2011). Alteration of
both the Hypothalamus-Pituitary and Adrenal (HPA) axis and
non-adrenal tumor-associated glucocorticoid system has been
linked to carcinoma progression as it results in altered cortisol
levels (Rasmuson et al., 2001; Bernab!e et al., 2012). These data
may have major implications for cancer pathophysiology and
therapy, as GCs are routinely administered during cancer
treatment.
This paper primarily aimed to review the current evidence
supporting the traditional (conventional) and non-conventional
role of GCs in normal and malignant cells.
Conventional and Non-Conventional Effects of GCs on
Epithelial Cells
GCs are conventionally used to up-regulate anti-inﬂammatory
factors and down regulate pro-inﬂammatory factors. In
oncology, GCs have been widely used in association with
other treatment for cancer patients because they have potent
proapoptotic properties in lymphoid cells, can reduce nausea
and acute toxic effects in healthy tissue (Herr and
Pﬁtzenmaier, 2006). However, a number of secondary effects
have been documented that inﬂuence a variety of functions
such as cell migration, differentiation, apoptosis, and
proliferation.
Role in cell proliferation and apoptosis
The anti-inﬂammatory and pro-apoptotic effects of GCs (Sidler
et al., 2011; Feng et al., 2013) are fundamental in their use as
therapeutic agents. However, as showed on normal human
epidermal keratinocytes, the cortisol can exerts both
immunostimulatory and immunosuppressive activities
depending on its concentration (Itoi et al., 2013).
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GCs are able to alter signaling in key survival pathways and
this can result in reversible growth arrest or cell death in
certain cell types, which may be particularly important in the
arrest of tumor cell proliferation (Schlossmacher et al., 2011).
However, although GCs are conventionally used to treat
cancer or as adjuvants in cancer treatment, it has been
observed that they may in fact induce tumor growth and
metastasis formation (Romero et al., 1992; Deguchi et al.,
1998). The underlying mechanism in which GCs induce tumor
growth has been explored and it has been proposed that the
hyper-secretion of GCs decreases peripheral blood
lymphocytes (PBLs); cells which play a central role in killing
tumor cells (Deguchi et al., 1998). Alternatively, studies have
focused on the fact that GCs are inhibitory to the immune
system and thusmay inhibit certain molecules which are known
to be tumoricidal (Hogan and Vogel, 1988).
While the phenomenon of glucocorticoid-induced apoptosis
in hematological cells is well established (Olnes et al., 2016), a
growing body of evidence now suggests that glucocorticoids
can act as anti-apoptotic agents in epithelial cells to promote
cancer progression. It has been demonstrated that elevated
levels of GCs during chronic restraint stress mediate an
inhibitory effect on the tumor suppressing protein p53 thereby
promoting tumorigenesis (Feng et al., 2012). Moreover, extra-
adrenal GCs produced by intestinal epithelium have been
implicated in aiding the progression of colon carcinoma cells
through an immune evading mechanism (Sidler et al., 2011).
The colon carcinoma cells synthesize and release bioactive
immunosuppressive GCs which in turn suppress T-cell
activation (Sidler et al., 2011).
Guendisch et al. analyzed the role of glucocorticoids (GCs)
in the survival and proliferation of tumor cells. The non-
apoptotic actions of glucocorticoids on tumor cell lines,
primary tumor cells, and an in vivo model along with molecular
signaling studies were examined. The ﬁrst important ﬁnding of
this study was that dexamethasone, a commonly used
glucocorticoid in cancer patients, enhances tumor cell
proliferation in vitro and in vivo. Dexamethasone enhanced
tumor cell proliferation in 9/17 cell lines from solid tumors
from all three different germ layers (Guendisch et al., 2012). It
was found that these dexamethasone-induced proliferative
changes were mediated by the glucocorticoid receptor. GCs
lead to an activation of intracellular signaling molecules such as
N3RC1, AKT, and p38-MAPK which all function in various
ways to mediate dexamethasone-induced tumor cell
proliferation. In terms of clinical relevance, the ﬁndings from
this paper suggest that the non-use of GCs might actually
improve the prognosis of patients with cancer (Guendisch
et al., 2012). Moreover, Dexamethasone showed to suppress
antitumor immune responses and facilitate tumor progression
by enhancing PD-1, a key cell-surface receptor of CD28
superfamily that can attenuate T-cell responses and promote
T-cell tolerance, resulting in faster tumor growth and poor
prognosis in the clinical setting of anti-cancer therapy (Xing
et al., 2015).
A reportedwell-known effect of GCs is their ability to inhibit
cell proliferation (Spiegelman et al., 1997; Newton, 2000;
Rabbitt et al., 2003; Yuan et al., 2016). However, it has also
been shown that cortisol can increase cell proliferation at
certain concentrations. Cortisol concentration modulates the
level of Interleukin-6 (IL-6), a cytokine that stimulates the
growth of cancer cells via an autocrine mechanism (Bernab!e
et al., 2011). IL-6 has been associated with angiogenesis and
tumor progression (Heikkil€a et al., 2008, Jobe et al., 2016). In
head and neck SCC it can be correlated with recurrence, lymph
node recruitment, and a poor prognostic survival (Duffy et al.,
2008; Nagata et al., 2003). At higher concentrations of cortisol
(100 and 1000 nM) there is a lower level of IL-6 mRNA
expression and secretion in oral SCC. However, at cortisol
concentrations that simulate physiological stress levels (10 nM)
there is an increase in IL-6 mRNA expression and secretion
with a subsequent increase in cell proliferation (Bernab!e et al.,
2011).
There is also support for this increase in cell proliferation, as
a result of cortisol treatment, in non-malignant situations. This
has been documented in foetal cardiomyocytes and Purkinje
ﬁbers (Feng et al., 2013). Cell nuclei expressing Ki67, a marker
for cell proliferation, were found in greater numbers in foetal
heart tissue that were infused with cortisol. The myocyte
proliferation due to exogenous GC treatment resulted in
cardiac enlargement and hypertrophy leading to increased wall
thickness. The proliferative effects of cortisol were blocked by
the use of an antagonist to the mineralocorticoid receptor,
which is a receptor of particular interest because it can be
found in the epidermis of skin and interacts with the 11b-HSD
enzyme (Kenouch et al., 1994). In foetal hearts it was found that
there was an increase in apoptosis in Purkinje ﬁbers which was
blocked through the use of a speciﬁc antagonist to the GR
(Feng et al., 2013). In contrast, GR activation in cardiomyocytes
has an anti-apoptotic effect, reﬂecting another non-
conventional effect (Ren et al., 2012).
Studies on the transcriptional proﬁles of primary human
keratinocytes revealed further evidence for the non-
conventional anti-apoptotic effect. The treatment of
keratinocytes with dexamethasone promoted anti-apoptotic
gene expression and inhibited pro-apoptotic expression. As a
result, the treated keratinocytes did not undergo UV-induced
apoptosis (Stojadinovic et al., 2007). To explain the presence of
both apoptotic and anti-apoptotic properties of GCs, it has
been suggested that they are not mutually exclusive and these
effects may occur at different stages, that is, GCs inhibit early
stages of differentiation and promote later stages of
differentiation. (Stojadinovic et al., 2007). Therefore, GCs can
have different effects depending upon cell type, developmental
age and cellular environment (Feng et al., 2013).
Role in wound healing and anchorage independence
Delayed wound healing is a well-known effect of the
therapeutic use of GCs. It has been shown that overexpression
of the GR in transgenic mice slows down the skin wound
healing process. This delay is attributed to the inhibition of
keratinocyte proliferation, motility, and migration.
Furthermore, delayed wound healing is accompanied by a
decrease in granulocyte and macrophage recruitment, as well
as a reduction in ERK activity and the expression of TNF-a,
IL-b, proangiogenic factor, and vascular endothelial growth
factor (Stojadinovic et al., 2007; Sanchis et al., 2012). However,
conﬂicting results have suggested that in fact GCs may have
some repair potential. In one particular experiment,
mucociliated human bronchial epithelial cell (HBEC) cultures
were created to imitate an asthmatic environment and the
effects of therapeutic agents such as dexamethasone were
studied. As expected, it was found that dexamethasone delayed
immediate wound repair of HBEC by lowering the proliferative
rate of cells surrounding the injured site. However, this in turn
reduced proliferative stress on epithelial stem cells and transit
amplifying cells in the basal compartment of the bronchial
epithelium during post-wound metaplasia. Hence, the
functional lifespan of these replacement cells is enhanced
leading to better long term repair potential (Wadsworth et al.,
2006).
GCs have long been used as agents in the treatment and
management of particular diseases. The effects of commonly
used GC medications to treat pemphigus vulgaris (PV) were
studied to demonstrate whether their supposed therapeutic
properties in regenerating PV-like lesions could be
demonstrated in vitro. Using methylprednisolone (MP) and
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pyridostigmine bromide (PBr) this study found that MP and PBr
signiﬁcantly improved the rate of keratinocyte wound
regeneration associated with PV lesions. However, it was
found that these drugs could not accelerate the rate of wound
healing in monolayers cultured under no conditions. This
suggests that MP and PBr function to speciﬁcally offset the
effects of PV serum on wounded keratinocytes (Lanza et al.,
2009). Other studies have explored the effects of both
endogenous and exogenous corticosteroids on human
keratinocyte survival and proliferation rates.
The capacity of human keratinocytes to promote the
formation of anchorage-independent multicellular aggregates
(MCAs) in vitro was studied using endogenously produced and
exogenously administered hydrocortisone. Benign/non-
tumorigenic (I-7/HaCaT) and malignant low metastatic/high
metastatic (II-3/RT-3) keratinocytes were treated with ACTH
and assessed for determine the levels of cortisol being
synthesized. It was found that the malignant keratinocytes
secreted higher levels of endogenous hydrocortisone in
response to ACTH treatment compared to benign
keratinocytes (Kennedy et al., 2015). Overall, this study
demonstrates the interaction between glucocorticoids and
keratinocytes during cancer progression. These ﬁndings
indicate that epidermal glucocorticoid systems are associated
with tumor progression which is of clinical relevance as
synthetic corticosteroids are so widely used for potentially
malignant conditions.
Alteration of Cortisol and Related Enzymes in
Malignancy: Possible Role of the Tumor-Associated
Glucocorticoid System
Alteration of key molecules involved in the glucocorticoid
pathway in cancer has been reported in previous literature. For
instance, elevated cortisol levels have been found in cancer
patients where it is believed it affects cancer prognosis by
impairing the cellular and humoral immune response and by
promoting tumor metastasis (Rasmuson et al., 2001;
Mazzoccoli et al., 2003; Bernab!e et al., 2012).
11b-Hydroxysteroid dehydrogenase (11b-HSD) is the main
enzyme that regulates the endogenous activity of GCs and is
expressed in two isoforms, type 1 and type 2. These two
enzymes are involved in activation and deactivation of GCs
(11b-HSD1 and 11b-HSD2, respectively), thus controlling cell
proliferation. Expression of 11b-HSD1 generally results in
decrease in cell proliferation, whereas expression of 11b-
HSD2 is involved in increase in cell proliferation. Studies have
illustrated that expression of these enzymes is altered in
tumors and may create a microenvironment favorable for
tumor growth. For instance, an earlier study on murine and
human epidermal cells observed the involvement of 11b-HSD1
in the natural skin ageing process (Tiganescu et al., 2013). It was
found that 11b-HSD1 expression increases in ageing skin,
resulting in local GC excess and adverse effects such as: altered
skin integrity, thinning, and impaired wound healing. This is due
to the changes in the extracellular matrix (ECM) including:
collagen atrophy, collagen disorganization, shredded
appearance of collagen structure, and large inter-ﬁbril spaces.
This disordered ECM microenvironment is vital for tumor
metastasis. Hence the study suggested that the local increase in
11b-HSD1 in ageing skin may increase the risk of skin cancer.
The GC receptor (GR) also plays a key role in the
glucocorticoid pathway. It is a member of the nuclear hormone
receptor family normally located within the cytoplasm of cells.
Upon binding with cortisol it migrates to the nucleus and
functions as a transcription activator or repressor that affects
gene regulation to ultimately cause decreased cell proliferation
(Schlossmacher et al., 2011; Slominski et al., 2014). Mutations in
GR structure, aberrant processing of GR pre-mRNA and
impaired functionality have been implicated in cancer
progression.
Table 1 lists studies that have demonstrated dysregulation of
cortisol, 11b-HSD enzymes, and glucocorticoid receptor in
different types of cancers.
Use of Corticosteroids in Malignancy and Premalignant
Conditions
GCs have a wide array of uses and effects in premalignant and
malignant conditions. As strong anti-inﬂammatory agents, they
have the ability to regulate cell fate by inducing expression of
anti-apoptotic genes while suppressing apoptotic factors (Sung
et al., 2009;Oakley and Cidlowski, 2011). Additionally, GCs are
used as analgesics and antiemetics by patients receiving cancer
treatment (Stojadinovic et al., 2007).
There are possible mechanism-based beneﬁts in the use of
GCs in pre-malignant conditions. An example of a potentially
malignant condition that has potential for transformation is oral
lichen planus. Progression to oral SCC can occur in up to 5.8%
of cases (Kesi!c et al., 2009; Kaplan et al., 2012). Lichen planus is
an autoimmune condition characterized by chronic
inﬂammation (Ismail et al., 2007). It is postulated that chronic
inﬂammation is a factor that may lead to the development of
malignancy such as oral SCC. The powerful anti-inﬂammatory
effects of GCs may, therefore, be a protective factor in this
situation, and they are currently ﬁrst-line treatment for this
condition (Scully et al., 2000; Usatine and Tinitigan, 2011; Lodi
et al., 2012). Nevertheless, the recent ﬁnding that GCs may
bear cancer-promoting effects warrants further consideration
in this area.
GCs are used as a monotherapy or in combination with
other treatments to manage and treat many different forms of
malignancy. GC monotherapy has been shown to have positive
treatment outcomes in patients with breast and prostate
cancer via proposed mechanisms of adrenocortical inhibition
and adrenal androgen suppression, respectively (Keith, 2008).
In a systematic review investigating the combination therapy of
chemotherapy!GCs, evidence supported such added
treatment outcomes as decreased leukopenia, decreased
thrombocytopenia, and an improved tolerance for increased
chemotherapy dose in the group that received GCs as an
adjunct to their chemotherapy compared to the group only
receiving chemotherapy (Keith, 2008). Corticosteroids are
also prescribed for the treatment of hypercalcaemia associated
with malignancy. Renal tubular resistance to endogenous
calcitonin during treatment for hypercalcaemia in malignancy
can be overcome by the addition of corticosteroids to the
treatment (Hosking et al., 1990). Despite their beneﬁts in
cancer treatment, GCs have also paradoxically been implicated
in cancer progression (Nakane et al., 1990; Zhang et al., 2006a;
Sidler et al., 2011). The postulated beneﬁts of corticosteroids
in preventing malignancy should therefore be balanced against
the possible carcinogenic effects of immunosuppression
warranting further research in this area.
In a study of the primary adult brain tumor, glioblastoma, the
use of GCs as part of the standard treatment protocol was
examined. The standard treatment protocol for primary adult
tumors included maximum surgical resection, radiation
therapy, and chemotherapy with about 99% of the patients also
receiving perioperative corticosteroids with some patients
receiving continued doses throughout the course of care
(Seyfried et al., 2010). High dose GCs are generally prescribed
for their anti-inﬂammatory mechanism to help combat
radiation therapy associated brain swelling and tumor oedema
(a conventional use and effect). However, GCs such as
Dexamethasone that are regularly prescribed have been shown
to considerably increase blood glucose levels. The blood
glucose is a fuel for glycolysis-dependent tumors and also
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facilitates production of glutamate, a neurotransmitter linked
with causing excitotoxic damage to neurons (Seyfried et al.,
2010). Higher levels of blood glucose have been shown to
accelerate brain tumor growth and lower treatment prognosis
(Seyfried et al., 2010).
Glucocorticoid-induced resistance has been identiﬁed in
cells of solid tumors when used with various anticancer drugs
and with radiotherapy. Such observations were made in
established carcinoma cell lines cultured in vitro, in xenografts
on nude mice, and in primary cells that had been isolated from
fresh surgical samples of solid tumors (Herr et al., 2003; Sui
et al., 2006; Zhang et al., 2006b). tumors analyzed were derived
from bladder, brain, breast, cervix, colon or rectum, liver, lung,
kidney, ovary, pancreas, and prostate. The ﬁnding that the
tumor-associated glucocorticoid system is active in all these
tumors (Cirillo et al., manuscript in preparation) adds a further
level of complexity and raises the possibility that a de-regulated
GCmetabolism may serve as a tumor promoting mechanism in
cancer (Fig. 1).
Overall, it can be ascertained from the wide array of
research on this topic that the effects and uses of GCs in
malignant conditions can be both beneﬁcial and detrimental in
terms of controlling tumor growth and progression.
Conventional uses of GCs have been shown to help treat
malignant conditions either alone or in combination with other
treatment modalities. Yet the literature also supports the
adverse effects of GCs in tumor progression and growth which
are linked closely to the non-conventional effects of GCs in
malignant conditions.
Conclusion
Based on preliminary data and evidence obtained from this
literature review it can be suggested that in contrast to
previous thought, increased levels of autocrine, paracrine, and
exogenous cortisol are important to tumor progression.
Hence, it is possible that alterations in the expression of
enzymes regulating the levels of tumor-derived cortisol take
place in cancers. It will be important, therefore, to assess the
levels of expression of steroidogenic molecules, steroids, and
receptors among normal andmalignant epithelial cells as well as
the correlation of the expression levels of steroid-related
molecules to the clinical-pathological parameters of cancer.
In addition to shedding light on key patho-physiological
mechanisms of SCC, characterization of the tumor-associated
GC systems will have salient diagnostic, preventive, and
TABLE 1. Dysregulation of serum cortisol, 11b-HSDs, and glucocorticoid receptor in different types of cancers
Study Type of cancer Dysregulated molecule Specific findings
Bernab!e et al. (2012) Oral squamous cell carcinoma (SCC) Cortisol Elevated plasma and salivary cortisol levels in SCC
and also higher levels in advanced stage compared
to initial stage.
Rasmuson et al. (2001) Renal cell carcinoma (RCC) Cortisol Serum cortisol levels higher in RCC and positively
correlated with tumor diameter and grade. Elevated
cortisol levels also had worse prognosis.
Sephton et al. (2000) Metastatic breast cancer Cortisol Flat diurnal salivary cortisol circadian rhythm where
elevated cortisol levels associated with early mortality.
Sephton et al. (2013) Lung cancer Cortisol Flattening of the diurnal cortisol rhythm associated
with early death.
Terao et al. (2013) Skin SCC, basal cell carcinoma (BCC)
and seborrheic keratosis (SK)
11b-HSD1 and 11b-HSD2
enzyme
Reduction in 11b-HSD1 expression with increased
keratinocyte proliferation. 11b-HSD2 expression
increased in basal cell proliferating conditions
such as BCC and SK.
Parks et al. (1998b) DMS-79 cells (cell line derived from an
ACTH-producing small cell lung
cancer).
11b-HSD2 enzyme 11b-HSD2 normally not found in healthy lung tissue,
was expressed in cancerous lung tissue.
Temkin et al. (2006) Ovarian epithelial cancer 11b-HSD2 enzyme 11b-HSD2 enzyme not found in normal post-
menopausal ovarian tissue was increased in cancer
cells.
Bland et al. (1999) Osteosarcoma 11b-HSD2 enzyme Overexpression of 11b-HSD2 enzyme in cancer,
compared with predominant expression of 11b-HSD1
enzyme in normal human osteoblast cells.
#Zb!ankov!a et al. (2004) Colorectal cancer 11b-HSD2 and 11b-HSD1
enzyme
Decrease in the abundance of 11b-HSD2 mRNA and
enzyme activity in cancer tissue. Also demonstrated
increase in 11b-HSD1 in some samples.
Cirillo et al. (2012) Oral squamous cell carcinoma (SCC) 11b-HSD2 enzyme Decrease in 11b-HSD2 expression in cancer.
Lu et al. (2011) Breast cancer 11b-HSD1 enzyme Decrease in 11b-HSD1 expression in cancer.
Budunova et al. (1997) Mouse epidermal papillomas and SCC. Glucocorticoid receptor In early skin papilloma GR expression is reduced but
in late papilloma and in SCC, GR levels are similar
or higher than normal.
Spiegelman et al.
(1997)
Mouse epidermal papillomas and SCC. Glucocorticoid receptor No significant changes in GR gene structure and
expression in cancer but resistance to glucocorticoid
fluocinolone acetonid more likely due to alterations
in receptor function.
Waters et al. (2004) Small cell lung carcinoma (SCLC) Glucocorticoid receptor Normal expression of GR, however its functionality
altered by subtle changes in co-factors such as
Nuclear co-repressor which was overexpressed
in cancer.
Ray et al. (1996) Small cell lung carcinoma (SCLC) Glucocorticoid receptor Mutations in GR gene structure lead to its
impaired function.
Parks et al. (1998a) Small cell lung carcinoma (SCLC) Glucocorticoid receptor Abnormal splicing of the GR transcript causes
GR resistance to GC stimulation in cancer cells.
Kay et al. (2011) Small cell lung carcinoma (SCLC) Glucocorticoid receptor Increased DNA methylation of promoter c
leads to decreased GR expression.
Li et al. (1996) Transformed A5 mouse lung cells Glucocorticoid receptor Transformed cells contain functional GR but express
cjun which antagonizes glucocorticoids.
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therapeutic clinical implications. Changes in the expression
levels of components of the epithelial GC pathway may aid in
the selection of novel markers of cancer progression.
Identiﬁcation of the presence of alterations in the steroid
pathway inmalignant epithelial cells would open new avenues in
the management of inﬂammatory pre-malignant conditions
such as lichen planus and provide basis for a mechanism-based
approach to cancer treatment.
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Antimicrobial activity and regulation of
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Chemokine (C-X-C motif) ligand (CXCL)9 and CXCL10 are dysregulated in oral
inflammatory conditions, and it is not known if these chemokines target microor-
ganisms that form oral biofilm. The aim of this study was to investigate the antimi-
crobial activity of CXCL9 and CXCL10 on oral microflora and their expression
profiles in oral keratinocytes following exposure to inflammatory and infectious
stimuli. Streptococcus sanguinis was used as a model and Escherichia coli as a posi-
tive control. The antimicrobial eﬀect of CXCL9/CXCL10 was tested using a radial
diﬀusion assay. mRNA transcripts were isolated from lipopolysaccharide (LPS)-
treated and untreated (control) oral keratinocyte cell lines at 2-, 4-, 6-, and 8-h
time-points of culture. The CXCL9/10 expression profile in the presence or absence
of interferon-c (IFN-c) was assessed using semiquantitative PCR. Although both
chemokines demonstrated antimicrobial activity, CXCL9 was the most eﬀective che-
mokine against both S. sanguinis and E coli. mRNA for CXCL10 was expressed in
control cells and its production was enhanced at all time-points following stimula-
tion with LPS. Conversely, CXCL9 mRNA was not expressed in control or LPS-
stimulated cells. Finally, stimulation with IFN-c enhanced basal expression of both
CXCL9 and CXCL10 in oral keratinocytes. Chemokines derived from oral epithe-
lium, particularly CXCL9, demonstrate antimicrobial properties. Bacterial and
inflammatory-stimulated up-regulation of CXCL9/10 could represent a key element
in oral bacterial colonization homeostasis and host-defense mechanisms.
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Bacteria colonize all surfaces of humans, but coloniza-
tion is particularly dense in the lower gastrointestinal
tract and in the oral cavity where streptococci represent
a large proportion of the resident microflora.
It has previously been shown that bacteria can
adhere to and invade host oral epithelial cells (1) and
also that there are bacterial receptors present in saliva
that can be absorbed onto oral mucosal surfaces (2).
Among them, the Toll-like receptors (TLRs), expres-
sed on host cells, are involved in the recognition of
conserved bacterial patterns such as lipopolysacchar-
ide (LPS), the cell-wall component of Gram-negative
bacteria (3).
Following bacterially mediated tissue damage, kerati-
nocytes produce a wide range of molecules, diﬀeren-
tially regulated to across epidermal layers, including
antimicrobial peptides (AMPs) and proinflammatory
cytokines (4).
The chemokines monokine, chemokine (C-X-C
motif) ligand (CXCL)9 and CXCL10, which are
induced by interferon-c (IFN-c) and IFN-c-induced
protein-10, respectively, are two chemokines belonging
to the CXC family, and both bind the same receptor,
namely chemokine (C-X-C motif) receptor (CXCR)3
(5). Chemokines play an important role in directing the
migration of specific immune-cell populations and, for
some, direct antibacterial and/or antifungal activities
have been demonstrated (6–8). As oral epithelial cells
are known to produce chemokines (9–11), these may
play a direct role in microbial defense.
It is known that CXC ELR-negative chemokines can
be induced by LPS in some cell types (12) and that
these chemokines are expressed during bacterial infec-
tions (13). It is also known that LPS is capable of
inducing a range of cytokines and chemokines from
epithelial cells predominately by signaling through
TLR-4 (14).
The induction of these chemokines may be triggered
in response to an alteration in the microbial flora, which
could, in turn, cause an ensuing immune-cell infiltration.
We recently found that CXCL9 and CXCL10 are dys-
regulated in oral inflammatory disease (A. MARSHALL,
A. CELENTANO, N. CIRILLO, M. MCCULLOUGH, S. POR-
TER, personal communication), but nothing is known
about their antibacterial activity. Furthermore, while
the induction of several diﬀerent types of cytokine has
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been demonstrated in oral epithelial cells after stimula-
tion with LPS (11, 14–17), the roles of CXCL9 and
CXCL10 in the infection and immunity of the oral cav-
ity have never been investigated.
Therefore, the aim of this paper was to investigate
the potential of CXC ELR-negative chemokines to
mediate microbicidal activity on the Gram-positive spe-
cies, Streptococcus sanguinis, one of the most prevalent
residents of the oral microflora, and on the expression
of chemokines in oral keratinocytes after exposure to
infectious and inflammatory stimuli.
The chemokine (C-C motif) receptor (CCR)10
ligands – chemokine (C-C motif) ligand (CCL)27
(CTACK) and CCL28 (MEC) – are two C-C chemoki-
nes that bind the CCR10 receptor found to exert potent
antimicrobial activity against Candida albicans, Gram-
negative bacteria, and Gram-positive bacteria (7). We
used these two chemokines as positive controls.
Material and methods
Cell-culture techniques
Cell culture of normal human oral keratinocytes: All
normal oral mucosa was obtained from healthy patients
attending the Oral Surgery Clinic, Eastman Dental Insti-
tute (London, UK) for routine third-molar extraction.
Three diﬀerent normal human oral keratinocyte (NHOK)
strains (NHOK1, NHOK2, and NHOK3) were isolated
from the excised normal tissue. The samples were cut into
pieces of approximately 1 mm3 and cultured at 37°C/5%
CO2 in keratinocyte basal medium-2 containing the recom-
mended growth supplements (Biowhittaker, Wokingham,
UK). The epithelial cells were then detached using 0.25%
trypsin/1 mM EDTA. The viability of the keratinocytes
was confirmed by Trypan Blue exclusion. All cell lines/
strains were derived before 2001 and therefore were not
subject to ethics committee approval in the UK (18). The
study was approved by the internal research committee at
the Eastman Dental Institute, University College London
(London, UK).
H357 cell culture: The oral squamous cell carcinoma cell
line, H357, was established by PRIME et al. (19). This cell
line was grown in the same medium as described for
NHOKs.
Bacterial cell culture and antimicrobial assessment
All bacterial stocks were maintained frozen at !70°C in
trypticase soy broth (TSB) (Becton Dickinson, Oxford
Science Park, Oxford, UK) supplemented with 0.6% yeast
extract (Oxoid, Basingstoke, UK) and 10% glycerol (BDH
Chemical, Dorset, UK). Cultures were checked weekly,
both visually and by Gram staining, for contamination
with other bacteria. Stocks of Escherichia coli NCTC JM22
and S. sanguinis NCTC 10904 (provided by Dr Rod
McNab at the Eastman Dental Institute, University College
London) were plated on agar plates containing 3% TSB.
They were grown for 48 h at 37°C/5% CO2 and maintained
by twice-weekly subculture onto TSB agar plates.
Each E. coli colony was collected and resuspended in
50 ml of 3% TSB. For the oral streptococcal species, three
streaks of each species on a culture plate were resuspended
in 10 ml of 3% TSB. The cultures were shaken, on an orbi-
tal shaker, at 250 rpm for 15–18 h at 37°C. Then, 50 ml of
the E. coli culture or 2 ml of the oral streptococcal species
culture was transferred into 50 ml or 10 ml of 3% TSB,
respectively. This was shaken, on an orbital shaker, at
250 rpm for 3.5 h at 37°C. At this point, the culture was
adjusted to an optical density (OD) of 1 at 620 nm.
To prepare the underlay, 50 ml of 100 mM sodium phos-
phate buﬀer, 5 g of agarose [low electroendosmosis (EEO);
Sigma, Poole, UK], and 5 ml of 3% TSB were added to 1 l
of distilled water. The pH was then adjusted to 7.4 and the
agarose was dissolved by heating the solution in the micro-
wave. The solution was dispensed into 50-ml aliquots and
autoclaved. The underlay aliquots were then stored at room
temperature until required for use in the radial diﬀusion
assays, at which point they were heated in a microwave until
fluid and then stored in a 60°C water bath.
Eight milliliters of E. coli or 16 ml of the streptococcal
species was added to 5 ml of molten underlay and dispensed
into a Petri dish, using a leveling tray. When the underlay
was set, 3-mm holes were punched in the gel, using 10-ml
pipettes (Sarstedt, Leicester, UK). Then, 5 ll of test solu-
tion diluted in 0.01% acetic acid was added to the wells.
For overlays, 10 g of agarose, low EEO (Sigma), was
added to 6% TSB, dispensed into 50-ml aliquots, and
autoclaved. The overlay aliquots were then stored at room
temperature before use in radial diﬀusion assays.
This plate was incubated for 3 h at 37°C, then 5 ml of
overlay was added to the plate and incubated at 37°C
overnight.
Radial diﬀusion assays were then performed, adding
5 ll of either recombinant human CXCL9/CXCL10/
CCL27/CCL28 (all Peprotech EC, London, UK) or 0.01%
acetic acid to the wells before incubating the plates. The
positive control for the assay was 100 lM tetracycline.
Images of the plates were taken using AlphaImager soft-
ware (AlphaInnotech, Cannock, UK) and the zones
around the cultures were measured from three diﬀerent
points from the end of the well.
IFN-c cell-treatment assay
In a modification of the method utilized by ALTENBURG
et al. (20), the H357 cells were seeded at 8 9 104 cells per
well in a Falcon 6-well plate (Becton Dickinson) in 3 ml
of KBM-2 medium containing no hydrocortisone. The
cells were incubated for at least 3–5 d until the cell culture
was 60–80% confluent. Medium containing 1,000 U ml!1
of IFN-c was added to three wells and control cell-culture
medium only was added to the remaining three wells. The
cells were incubated for 48 h. The supernatant was
extracted, centrifuged, and stored at !70°C. The adherent
cells were washed with PBS (Gibco Life Technologies,
Paisley, UK) before addition of 0.5 ml of TRI Reagent
(Sigma). The suspension was then removed and stored at
!70°C. The RNA was isolated as described below.
CXCL9 and CXCL10 mRNA transcripts in oral
epithelial cells in response to the presence of LPS
and IFN-c: mRNA isolation and semiquantitative
RT-PCR
mRNA transcripts for 18S, CXCL9, or CXCL10 were iso-
lated from H357 cells, exposed or not exposed (control) to
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LPS for 2, 4, 6, or 8 h. The RNA was extracted using
TRI Reagent (Sigma) and 2 ml of Pellet Paint Co-precipi-
tant (Novagen, Nottingham, UK) to visualize the RNA
pellet.
Single-strand cDNA synthesis was performed. Two
milliliters of RNA was added to 4 ml of deoxynucleotides
(dNTPs) (2.5 mM) (Sigma), 2 ml of random hexamers
(50 mm) (Ambion, Austin, TX, USA), and 9.5 ml of dis-
tilled H2O (dH2O). Then, 1 ml of RNAaseIN (Ambion),
2 ml of 109 MuLVRT buﬀer, and 0.5 ml of M-MuLVRT
(200 U ml!1) (Boehringer-Mannheim, Lewes, UK) was
added and the reaction mix was incubated at 42°C for
1 h.
RT-PCR for 18S, CXCL9, and CXCL10
The magnesium concentration was optimized for each pri-
mer as follows: 1 ml of cDNA was added to 4 ml of
dNTPs (2.5 mM), 5 ml of 109 buﬀer, 0.225 ml of Ampli-
Taq (5.0 U ml!1) (PerkinElmer, Waltham, MA, USA),
4 ml of each specific primer (5 mM), and 1.5, 3.0, or
4.5 mM MgCl in each reaction, and dH2O was added to
give a final volume of 50 ml. The products were separated
on a 2% agarose (GibcoBRL Life Technologies, Paisley,
UK) gel and visualized by staining with ethidium
bromide (Sigma). Specific bands were visualized by ultra-
violet transillumination in a MultiImage Light Cabinet
(AlphaInnotech, Cannock, UK), and digital images were
acquired and stored using AlphaImager software
(AlphaInnotech).
The CXCL9 (forward: 50-ccaacaccccacagaagtgc-30; reverse:
50-gccagcacctgctctgagac-30), CXCL10 (forward: 50-gccaatttt
gtccacgtgttg-30; reverse: 50-aaagaatttgggccccttgg-30), and 18S
ribosomal RNA (forward: 50-tttcggaactgaggccatga-30;
reverse: 50-gcatgccagagtctcgttcg-30) primers were generated
for use in this study (Genosys-Sigma, Poole, UK). The
thermocycler (Techne Genius, Cambridge, UK) parameters
utilized were 94°C for 45 s, 57°C for 45 s, and 72°C for 45 s.
For each primer the linear range was determined by
repeating the above reaction with optimized magnesium
concentration for each primer and stopping the reaction at
15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 cycles. The
mid-point of each linear range was determined by using
intensity analysis of the bands with AlphaImager software
(AlphaInnotech), and this cycle length was utilized for
each primer in subsequent reactions. 18S primer and 18S
Competitor primers (Ambion) were combined at ratios of
1:9, 2:8, and 3:7, respectively. For each of the primers
CXCL9 and CXCL10, 4 ml of the 18S primer/competitor
mix was added to the RT-PCR reaction. The band inten-
sity of the 18S and specific primers was quantified for each
primer in each sample using Phoretix 1D software (Phore-
tix, Newcastle, UK).
Unless specified otherwise, all experiments were per-
formed at least in triplicate.
Results
Production of CXCL9 and CXCL10 mRNA transcripts
in an oral epithelial cell line in response to IFN-c
The production of CXCL9 and CXCL10 in oral mucosal
keratinocytes was first assessed over time in preliminary
experiments using the keratinocyte cell lineH357 (Fig. S1).
The expression of CXCL10 mRNA was detected in H357
cellsasearlyas3 haftertreatmentwithIFN-candappeared
to peak at 24 h. In contrast, the control cells showed virtu-
allyundetectablelevelsofmRNAoverthesametimeperiod.
The patterns shownbyCXCL9 andCXCL10mRNAtran-
scriptswere similar, beingbiphasicpatterns that showedan
initial rapid induction ofmRNA in the stimulated cells fol-
lowed by a second peak at 24/48 h. Thus, the expression of
CXCL9/CXCL10 in H357 cells can be significantly
enhanced by IFN-c in a time-dependent manner, with a
peakafter48 h(Fig. 1).Similarresultswereobtainedinpri-
mary NHOKs (Fig. 2). These data were confirmed at the
proteinlevelbyELISA(datanotshown).Theseresults indi-
cate that the expression of CXCL9 and CXCL10 in oral
epithelial cells is significantly enhanced by IFN-c in a time-
dependentmanner.
Production of CXCL9 and CXCL10 mRNA transcripts
in an oral epithelial cell line in response to LPS
CXCL10 mRNA was expressed in control cells (no
exposure to LPS), but was enhanced by stimulation
with LPS, 2, 4, and 6 h after exposure. This expression
subsequently decreased after 8 h of stimulation (Fig. 3).
In contrast, CXCL9 mRNA was not expressed in either
control or LPS-stimulated cells at any of the time-
points tested.
Antimicrobial effect of CXCL9, CXCL10, CCL27, or
CCL28 on S. sanguinis and E. coli
CCL27 and CCL28 were used as positive controls. The
clear zones of bacterial growth depletion as a result of
the antimicrobial activity of the chemokines are indi-
cated in Fig. 4 and Fig. 5. All chemokines investigated
demonstrated a level of antimicrobial activity at the
tested concentration (Table 1). It was found that
CXCL9 was the most eﬀective chemokine against both
S. sanguinis and E. coli; CCL27 and CXCL10 had a
Fig. 1. Expression of 18S, chemokine CXCL9, and chemokine
(C-X-C motif) ligand 10 (CXCL10) mRNAs in the H357 cell
line, either treated with interferon-c for 48 h (IFN) or untreated
for 48 h (CON). The left column ‘m.w.’ indicates the molecular
weight. The molecular weight of CXCL9 expression is located
at 351 bp, CXCL10 expression is at 601 bp.
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less eﬀective antimicrobial action against S. sanguinis
than against E. coli; and CCL28 had more eﬀective
antimicrobial action against S. sanguinis than against
E. coli. These results clearly demonstrate that the
epithelial-derived chemokines CXCL9 and CXCL10
exert antimicrobial activity.
Discussion
Chemokines are known to have antimicrobial eﬀects
but little is known of the action of chemokines derived
from the oral mucosal epithelium. The present study is
the first to examine the expression of CXC ELR-posi-
tive chemokines by oral epithelial cells when stimulated
with bacteria-derived products such as LPS. The pre-
sent study has established that a cell line of oral origin
is capable of expressing CXCL9 and CXCL10 mRNAs
when stimulated with LPS. The production of these
chemokines was also enhanced by inflammatory stimuli
such as IFN-c.
Expression of CXCL10 mRNA was increased in
H357 cells after stimulation with LPS, whereas expres-
sion of CXCL9 mRNA was not induced over the same
time-period. Previously, we have shown that CXCL10
can act as a potent chemoattractant of lymphocytes;
hence, this local production of CXCL10 by oral epithe-
lial cells in response to LPS could have important
eﬀects on oral inflammation, perhaps crucially in the
initial stages of inflammation.
Previous studies have also shown that LPS treatment
alone can induce or enhance expression of CXCL10
mRNA in several diﬀerent cell types (12, 21–23). How-
ever, in contrast to the present findings, LPS stimula-
tion did not induce production of CXCL10 from
cultured skin keratinocytes (24), suggesting perhaps
that oral keratinocytes are more responsive than cuta-
neous keratinocytes to LPS stimulation. This diﬀerence
in expression may reflect the high bacterial load in the
oral cavity.
The rapid expression of CXCL10 mRNA observed in
the present study is in accordance with that of murine
macrophages (17, 25) although LPS stimulation may be
more transient than IFN-c relative to stimulation of
Fig. 2. Expression of chemokine (C-X-C motif) ligand 9
(CXCL9) and chemokine (C-X-C motif) ligand 10 (CXCL10)
mRNAs in three diﬀerent strains of normal human oral ker-
atinocytes (NHOK1, NHOK2, and NHOK3), either treated
with interferon-c for 48 h (IFN-c) or untreated for 48 h
(Con). The values were normalized relative to expression of
18S mRNA, used as a housekeeping mRNA.
Fig. 3. (A) Expression of CXCL9, CXCL10, and 18S mRNAs
by H357 cells, unstimulated (CON) or stimulated with
lipopolysaccharide (LPS) for 2, 4, 6, or 8 h. (B) Densitometric
analysis of CXCL10 mRNA relative to 18S mRNA, with
(grey) and without (blue) LPS treatment.
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CXCL10 (10). This short-term eﬀect may be essential
to avoid over-stimulation of CXCL10 in response to
resident bacteria in proximity to the epithelium. Inter-
leukin-10 is known to be able to down-regulate produc-
tion of LPS-induced CXCL10 in macrophages (22).
This cytokine is present within oral lichen planus
lesions and is increased in serum and saliva from
patients with oral lichen planus (26), and thus may
act to down-regulate expression of CXCL10 in oral
inflammation.
There are few reports of LPS-induced production of
CXCL9. The present study revealed that CXCL9
mRNA was not expressed by H357 cells when stimu-
lated with LPS. In contrast to the present study,
CXCL9 mRNA was found to be expressed in LPS-sti-
mulated murine dendritic cells (12); however, in
another study, this chemokine was not induced in the
same murine cell line by LPS, despite induction of
CXCL9 by IFN-c (25).
It is possible that CXCL9 displays a delayed
response, in comparison with CXCL10, as induction of
CXCL9 mRNA in lung tissue of mice treated intra-
venously with LPS shows a later induction than
CXCL10 mRNA, and is never expressed at the same
levels as CXCL10 (25).
Many studies report that LPS and IFN-c act syner-
gistically to induce the production of high levels of
CXCL10 mRNA, for example, in breast carcinoma
cells (21, 22). It is then possible that CXCL10 levels
could be enhanced in oral inflammation where there is
both LPS and IFN-c, perhaps through the enhance-
ment of specific TLRs (27).
Gram-positive bacteria, such as S. sanguinis, contain
components other than LPS that are known to stimu-
late chemokine release from various cell types and it
would be interesting to determine whether these are
also capable of stimulating production of CXC ELR-
negative chemokines in oral epithelium. Many Gram-
positive bacterial components act on a diﬀerent Toll-
like receptor, TLR-2, which is functionally expressed
on keratinocytes (28). However, TLR-2 agonists do not
induce production of CXCL10 in macrophages (29) or
dendritic cells (30) in vitro. This suggests that TLR-2
agonistic bacterial products would also not induce
CXCL10 in epithelial cells. Therefore, only products
bound by TLR-4 would be influential in up-regulating
CXCL10 production in epithelial cells. In addition, as
LPS-mediated CXCL10 production is TLR-4 depen-
dent, this strongly suggests that oral keratinocytes bear
functional TLR-4, and therefore stimulation of epider-
mal cells with LPS is not caused by TLR-2 agonist con-
taminants in LPS preparations, as previously suggested
(28).
Chemokine modulation in oral cells by bacterial
products is thus complex and many diﬀerent factors,
including T-cell contact, may play a factor in chemo-
kine induction during an immune response.
The present studies suggest that in certain circum-
stances, bacterial products could stimulate oral
Fig. 4. Radial diﬀusion gels demonstrating the antimicrobial
activity of 100 lg ml!1 of human recombinant chemokine
CXCL9, CXCL10, chemokine (C-C motif) ligand (CCL)27,
and CCL28 on Streptococcus sanguinis (A) and Escherichia
coli (B). The negative control (-ve) contains 0.01% acetic acid
only. The diameter of the cleared zone around the well con-
taining chemokine represents the antimicrobial properties of
the chemokine.
Fig. 5. Antimicrobial activity of 50, 10, and 1 lM concentra-
tions of CXCL9 on Escherichia coli JM22; 0 lM contains
0.01% acetic acid only.
Table 1
Antimicrobial activity of 100 lg ml!1 of human recombinant chemokine CXCL9, CXCL10, chemokine CCL27 and CCL28 on
Streptococcus sanguinis and Escherichia coli
Bacterial species CXCL9 CXCL10 CCL27 CCL28
E. coli 34.6 " 6.80 14.9 " 5.65 20.6 " 0.90 15.4 " 6.04
S. sanguis 44.4 " 14.05 8.4 " 3.52 10.0 " 5.45 21.0 " 5.70
Values are mean " SD of three experiments and represent the diameter of bacterial clearance (minus the well diameter) multiplied by 10
to convert to units. The negative control had no eﬀect on the microbial growth in any of the experiments tested.
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epithelial cells to produce an inflammatory response
through TLR-4 agonists (perhaps after continuous
stimulation with TLR-2) and this may induce epithe-
lially derived CXCL10-mediated inflammation. This
inflammation would presumably be characterized by
activated memory T-cell infiltration localized under the
basal epithelium, reminiscent of the pathology of oral
lichen planus.
The chemokine CXCL9 was shown to be a potent
antimicrobial agent against both S. sanguinis and
E. coli, as was CXCL10, but to a lesser degree than
CXCL9, confirming the results of the study by COLE
et al. (6). Although only one oral bacterial species was
tested in the present study, the results hint that the
antimicrobial properties of these chemokines may assist
in countering bacterial growth in the oral cavity.
The choice of using S. sanguinis as a model has been
driven by the delicate role played by this bacterium in
maintaining the balance of the oral flora. Streptococcus
sanguinis is commonly found in healthy tissues as a pio-
neer colonizer, and it is implicated in modulating the
virulence of bacterial biofilms (31). Furthermore, signif-
icant inhibitory eﬀects of the intracellular proteins pro-
duced by S. sanguinis on the growth and the
morphology of many other components of the oral
flora, such as Prevotella intermedia, Porphyromonas gin-
givalis, C. albicans, and Candida tropicalis, and their
biofilms, have been demonstrated (32, 33). This allows
us to conjecture and expect that a series of chain eﬀects
of the antimicrobial activity of CXCL9 and CXCL10
would occur in vivo. As previously shown for the two
chemokines, CCL27 and CCL28, for which a wide
spectrum of antimicrobial activity is well established,
the action of CXCL9 and CXCL10 expected against
other microorganisms of the oral cavity should follow a
similar pattern (7).
The low production of CXCL9 by oral epithelial cells
following stimulation with IFN-c or LPS could poten-
tially be a means of avoiding an overactive antimicro-
bial response as a result of the potent antimicrobial
activity of CXCL9.
In our study, both CCL27 and CCL28 exerted an-
timicrobial properties against E. coli and S. sanguinis.
The chemokine CCL28 has been shown to have micro-
bicidal activity against a wide range of bacteria (both
Gram-negative and Gram-positive) and yeasts (7, 34),
and our findings confirmed that this chemokine was
also eﬀective against the oral commensal, S. sanguinis.
This is only the second report of the antimicrobial
eﬀect of CCL28 upon enterobacterial E. coli after the
study reported by BERRI et al. in 2014 (34).
The production of CXCL10 by oral epithelial cells,
in inflammatory conditions, such as oral lichen planus,
may be induced by resident bacteria that contain TLR-
4 agonists. If this inflammation resulted from constant
TLR-2 stimulation, this may cause a CXCL10-based
inflammation and a resultant influx of memory T-
helper 1 CD4+ cells. Furthermore, CXCL10 is antimi-
crobial at high concentrations. It may be up-regulated
by the presence of bacteria, thus playing a role in the
defense of oral epithelial cells. The antimicrobial
activity of the chemokines tested is likely to be an
important mechanism in the homeostasis of oral bacte-
rial colonization. Any IFN-c in the oral epithelial area
(which could presumably be produced by the infiltrat-
ing T-helper 1 cells) may synergize with TLR-4 agonists
to cause an increased inflammatory state. Further stud-
ies are still warranted to confirm these novel findings.
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Oral erythema multiforme: trends and clinical ﬁndings of a
large retrospective European case series
Antonio Celentano, DDS,a,b Serban Tovaru, MD,c Tami Yap, BDSc, FRACDS,d Daniela Adamo, DDS,e
Massimo Aria, PhD,f and Michele Davide Mignogna, MD, DMDe
Objective. Erythema multiforme (EM) continues to be an underestimated disease with a lack of strict classification and
diagnostic criteria. We present the analysis of a case series of 60 oral EM patients from 2 centers and illustrate the range of oral
clinical presentations.
Study Design. Clinical data from 60 EM patients with oral involvement, diagnosed and treated between 1982 and 2014, were
retrospectively collected from the archives of 2 independent hospitals. Statistical analyses of the data were performed using the
Pearson c-squared test and the Mann-Whitney U test.
Result. Thirty-one patients (51.7%) were male and 29 (48.3%) were female, with a mean (!SD) age of 37.9 years (!18.1). The
frequency of previous occurrences ranged from 0 to 10 (mean ! SD: 1.4 ! 2.0). Twenty-nine patients (48%) had no previous
occurrence. Medications (particularly antipyretics, food additives, and antibiotics) were the suspected precipitants in 28
patients (46.7%), whereas herpes simplex virus infection was suspected in 18 (30.0%). All but 1 patient had involvement of
multiple oral sites, with the buccal mucosa being the most commonly involved oral site (75%), followed by the vermillion
border (71.7%).
Conclusions. Patients with EM may present initially to oral health care workers. Medications and herpes simplex virus
continue to be the most typically involved precipitating factors. Our data highlight the additional role of food-derived antigens.
Although laboratory tests can provide support diagnostically, EM diagnosis continues to be based on clinical features. A
medication and food diary should be encouraged particularly in patients with recurrent forms. (Oral Surg Oral Med Oral
Pathol Oral Radiol 2015;120:707-716)
Erythema multiforme (EM) is a group of acute immune-
mediated disorders that can affect the skin and mucous
membranes. It has previously been classiﬁed into 4
major variants: erythema multiforme minor (EMm),
erythema multiforme major (EMM), Stevens-Johnson
syndrome (SJS), and toxic epidermal necrolysis (TEN,
also known as Lyell disease).1-3
Many authors still consider EMm, EMM, SJS, and
TEN to be a single disease continuum, varying on a
spectrum of clinical severity. Others consider EM a
separate entity to SJS and TEN, particularly due to its
strong association with infections, such as herpes sim-
plex virus (HSV).3 This is in contrast to the majority of
cases of SJS and TEN, which are commonly medication
induced. Additionally, cutaneous ﬁndings may be
distinct, although clinical overlap does exist.3-9
The development of EM has been linked to a type 4
cytotoxic reaction, mediated by T lymphocytes and
triggered by numerous factors. These include infections
(particularly HSV-1 and HSV-2), medication use, ma-
lignancy, autoimmune diseases, radiation therapy, and
immunizations.10
Many pathogens have been associated with EM,
including Mycoplasma pneumoniae, Chlamydophila
pneumoniae, hepatitis viruses, Epstein-Barr virus, Orf
virus, human immunodeﬁciency virus, cytomegalovirus,
Mycobaterium leprae, and varicella zoster virus, as well as
several vaccination agents (small pox, rabies, and human
papillomavirus).11-31 Additionally, endocrine triggers have
been implicated in the occurrence of EM.32,33
The differential diagnosis of EM encompasses a
wide range of diseases, including urticaria, ﬁxed drug
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Statement of Clinical Relevance
Prompt recognition of erythema multiforme by all
oral health clinicians is important to prevent diag-
nostic delay as oral mucosal involvement may pre-
cede extension of the disease. Identiﬁcation of
trigger factors and diagnostic features is pertinent as
illustrated by this case series.
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eruption, bullous pemphigoid, paraneoplastic pem-
phigus, Sweet syndrome, Rowell syndrome, poly-
morphous light eruption, and cutaneous small vessel
vasculitis. To improve the diagnostic accuracy, histo-
pathologic analyses and others laboratory tests can be
used.14 Cutaneous involvement is variable, ranging
from isolated symmetric targetoid lesions, which are
commonly distributed on the extensor surfaces of the
extremities; on the hands; around the elbows and
knees with extensive involvement of the arms, legs,
and trunk; and with or without oral or other mucous
membrane involvement.1,14 Both SJS and TEN can be
fatal, with a reported mortality rate of 1% to 5% and
25% to 35%, respectively.34
EM is usually a self-limiting disease, resolving within
weeks without signiﬁcant sequelae. However, in a minority
of cases, the disease may recur frequently, establishing a
well-deﬁned variant known as “recurrent EM.”35,36
Most patients with EM can be managed with symp-
tomatic therapy along with identiﬁcation and modiﬁ-
cation of all the suspected initiating factors. However,
patients with severe EM may require hospitalization for
hydration, analgesia, antiviral therapy, and systemic
therapy with corticosteroids, immunosuppressants, and/
or antiviral suppressive therapy.14,35 Daily antiviral
therapy has been used successfully to control the dis-
ease in patients with recurrent EM.37
Knowledge about EM is full of conﬂict. Diagnostic
criteria are not universally accepted, and the diagnosis
continues to be one of exclusion, based on clinical his-
tory. Epidemiologic data and case series in the literature
are dated. Additionally, there is a lack of extensive EM
case series demonstrating the range of oral presentations.
Here, we present the analysis of a series of 60 patients
affected by EM with oral involvement. The range of
clinical presentation is illustrated.
MATERIAL AND METHODS
Data were collected from clinical records of 60 EM
patients, diagnosed and treated between 1982 and 2014
in 2 centers: the Oral Medicine Unit, Federico II Uni-
versity of Naples in Naples, Italy (Center 1), and the
Oral Medicine-Oral Pathology Department, University
of Medicine and Pharmacy in Bucharest, Romania
(Center 2).
The study was approved by the Ethics Committee of
the University “Federico II” of Naples in June 2014. Data
were collected by 2 blinded researchers and conﬁrmed by
1 supervisor, the heads of the respective Oral Medicine
departments. A digital template, developed at Center 1,
was utilized at both centers. Data collected included age,
gender, habits, number and duration of outbreaks, previ-
ous or concomitant infections, antecedent drugs or other
precipitants, presence of mucosal and cutaneous lesions,
oral sites involved, histopathologic ﬁndings, and details of
hospitalization.
Inclusion criteria of the ﬁrst phase of the study
required a deﬁnitive diagnosis of EM and/or SJS in the
clinical discharge summary. Acknowledging the
absence of unique validated diagnostic methods for
EM,3,7 this study included only those cases in which
other diseases were clearly excluded from the differ-
ential diagnosis. Cases were only included in the study
if the following data were clearly recorded: patient
medical history, medication history, outbreaks details,
course of the illness (self-limiting and well-responder to
symptomatic therapy), evidence of mucocutaneous le-
sions (ﬁxed targetoid lesions, raised atypical papules,
mucosal involvement, or a combination of these) with
clinical and/or photographic morphology descriptions
and/or information on the extent of mucocutaneous
involvement, signs, and symptoms. The clinical-based
approach described by Al-Johani et al (2007) was
used to classify the clinical forms of our cases.3 The
analysis of site distribution was performed with the
Pearson c-squared test. The dependence analysis
between lesion site and age and signiﬁcant difference
between medians was determined using a Mann-
Whitney U test.
RESULTS
Initially, 67 EM medical records were included; how-
ever, 7 cases were inadequate in description or did not
satisfy the diagnostic criteria and were excluded from
the study, thus leaving 60 patients. Fifteen EM patients
were obtained from Center 1 and 45 patients from
Center 2.
Thirty-one patients (51.7%) were male, and 29 (48.3%)
were female, with a mean (!SD) age of 37.9 years
(!18.1) at the time of diagnosis. Seventeen patients were
smokers, and 1 case of alcohol abuse was reported.
Fifty-one (85.0%) patients were classiﬁed as EMm,
and 9 (15%) were classiﬁed as EMM.
The mean duration of the EM outbreaks was
7 ! 6 days (ranging from 2 to 42 days). The number of
previous outbreaks ranged from 0 to 10 (mean-
! SD ¼ 1.4 ! 2.0). Twenty-nine patients (48%) had
not experienced a previous outbreak, 9 patients (15%)
had a single previous outbreak, and 22 patients (37%)
had 2 or more outbreaks. Sixteen cases had accompa-
nying histopathology with predominant ﬁndings of
necrosis, intraepithelial exocytosis, necrotic keratino-
cytes, Civatte bodies, edematous corium hyperemic
vessels, lymphohistiocytic inﬂammatory inﬁltrate with
rare eosinophils, and subepidermal clefts. No deeper
extension of the inﬁltrate or prominent melanin incon-
tinence was observed, which allowed us to exclude
cases of ﬁxed drug eruptions. Drugs were suspected as
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precipitants in 28 patients (46.7%), the most implicated
being antipyretics, food allergens, and antibiotics.
HSV infection was suggested to be a triggering factor in
18 patients (30.0%), 10 of whom had supportive serologic
HSV testing (8 enzyme-linked immunosorbent assay test
and 2 polymerase chain reaction [PCR]). In 13 patients
(21.6%), a medical history of previous infections was re-
ported, 11 of which were concomitant to the EM outbreak.
These infections included pneumonia (3 cases), urinary
infection (2 cases), and M. pneumoniae (1 case). Two
patients were found to be positive for hepatitis C. A
concomitant history of candidiasis was reported in 3 cases
(2 oral and 1 genital). Hospitalization of the patient was
required in 7 cases (11.6%). Table I presents the summary
of clinical data from case series. All infections reported in
the clinical record within 30 days from the diagnosis of
EM were recorded under consideration as “concomitant”
infections. The infections described in Table I thus
occurred within 30 days before the EM presentations,
unless otherwise speciﬁed.
Exclusive oral involvement was observed in 29 pa-
tients (46.66%). All but 1 patient had involvement of
Table III. Dependence analysis between drug ante-
cedents and precipitators
Precipitators MedianeIQR P value*
No. of drug
antecedents
Herpes .002y
Yes 0.0e1.0
No 1.0e1.0
Infection .418
Yes 0.0e2.0
No 1.0e1.0
Classiﬁcation .929
EM minor 1.0e2.0
EM major 1.0e1.0
IQR is the interquartile range. The signiﬁcance difference between
medians was measured by Mann-Whitney U test.
*Signiﬁcant .01 < P # .05.
ySigniﬁcant P # .01.
Table IV. Dependence analysis between demographic
characteristics and precipitators
Precipitators
Gender
P value*Female Male
Herpes simplex
virus
Yes 34.52% Yes 25.8% 0.464
No 65.5% No 74.2%
Other Infections Yes 17.2% Yes 29.0% 0.281
No 82.8% No 71.0%
Classiﬁcation EM major 24.1% EM major 6.5% .045y
EM minor 75.9% EM minor 93.5%
Age MedianeIQR
HSV Yes 29e17 .628
No 30e33
Other Infections Yes 29e34 .993
No 29e27
Classiﬁcation EM major 39e40 .045y
EM minor 29e27
IQR is the inter-quartile range. The signiﬁcance difference between
conditional distributions was measured by the Pearson c-squared test.
The signiﬁcance difference between medians was measured by the
Mann-Whitney U test.
*Signiﬁcant P < .01 to # .05.
ySigniﬁcant P # .01.
Table II. Distribution of site of lesions by gender
Site
Gender
Total P value*Female Male
B Yes 79.3% Yes 71.0% Yes 75.0% .556
No 20.7% No 29.0% No 25.0%
L Yes 72.4% Yes 51.6% Yes 61.7% .098
No 27.6% No 48.4% No 38.3%
V Yes 79.3% Yes 64.5% Yes 71.7% .204
No 20.7% No 35.5% No 28.3%
T Yes 62.1% Yes 51.6% Yes 56.7% .414
No 37.9% No 48.4% No 43.3%
A Yes 27.6% Yes 25.8% Yes 26.7% .876
No 72.4% No 74.2% No 73.3%
F Yes 37.9% Yes 6.5% Yes 21.7% .003y
No 62.1% No 93.5% No 78.3%
P Yes 34.5% Yes 38.7% Yes 36.7% .734
No 65.5% No 61.3% No 63.3%
TP Yes 13.8% Yes 9.7% Yes 11.7% .620
No 86.2% No 90.3% No 88.3%
Number of sites with lesions MedianeIQR 4.03.0 MedianeIQR 3.0 2.0 MedianeIQR 3.5e3.0 .095
IQR, Interquartile range. The signiﬁcance difference between conditional distributions was measured by the Pearson c-squared test. The signiﬁ-
cance difference between medians was measured by the Mann-Whitney U test.
*Signiﬁcant P < .01 to # .05.
ySigniﬁcant P # .01.
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multiple oral sites. The buccal mucosa was the most
commonly involved oral site (75%) followed by the
vermillion border (71.7%) and labial mucosa (61.7%).
Twenty-four of 60 patients (40.0%) had concomitant
involvement of all of these sites, and 44 (73.3%) pa-
tients had involvement of at least 2 of 3 sites. Details of
sites involved for each case are described in Table I.
The ﬂoor of mouth was signiﬁcantly more commonly
involved in females (37.9%) than in males (6.5%)
(P ¼ .003) (Table II). Involvement of the tongue was
signiﬁcantly related to age (median interquartile range:
Yes ¼ 32-33 years; no ¼ 25-21 years; P ¼ .013).
Clinical forms were signiﬁcantly associated with
gender (female: EMM ¼ 24.1%; EMm ¼ 75.9%;
male: EMM ¼ 6.5%; EMm ¼ 93.5%; P ¼ .045).
Other signiﬁcant results of the dependence analysis are
shown in Tables III and IV.
DISCUSSION
Current literature regarding the epidemiology of EM
remains scarce and controversial. This is reﬂective of
the lack of universally accepted classiﬁcation criteria.
Additionally, there may be a component of under-
reporting, particularly of cases of short duration when
hospitalization is not required. This study presents the
largest oral EM case series in last 2 decades,38,39
describing the multiple clinical features that charac-
terize this group of diseases, and the dependence
analysis of associated variables.
The consensus is that EM and related disorders occur
predominantly in young adults, with majority of cases
occurring between the second and ﬁfth decades of
life.3,39 There is no a clear predilection for gender or
race. However, variation in age at presentation should
not be underestimated, as several cases of pediatric
patients have been reported, including neonates.20,40-45
In our case series, the mean age was 37.9 years (range
7-78 years), with no signiﬁcant difference between
males and females. Interestingly, there was a signiﬁcant
gender predilection for the clinical forms with EMM
being more frequent in the females and EMm being
more frequent in males. Clinical forms were addition-
ally signiﬁcantly related to age (see Table IV).
The most commonly reported triggers are infections
agents and medications, with HSV-1 and HSV-2 being
the most commonly reported precipitators of EMm and
EMM. Medications and HSV, taken together, were
implicated in approximately 67% of cases in our series.
Typically, the onset of EMm and EMM lesions begins
10 to 14 days after the clinical manifestation of an HSV
infection.3 Unfortunately, the number of studies using
conﬁrmatory PCR to assess for the presence of HSV-
DNA is low, with conclusion of infection based pre-
dominantly on clinical history. The reported association
of HSV with the recurrent variant of EM is between 61%
and 100%.14 The percentage of patients affected solely
by HSV without a history of medication use in our
series was 21.6% (13 cases), which is similar to the
23% reported by Wetter and Davis in 2010, but
dissimilar from the 70% to 100% values reported by
Schoﬁeld in 1993 and Huff in 1983.2,35,46
Five more cases were also potentially associated with
HSV, but the patients were using medications simul-
taneously. It is not uncommon for patients affected by
EM, in association with a concomitant or previous
infection, to have started drug therapies (e.g., antibi-
otics, antivirals, or anti-inﬂammatory drugs). Of the
total of 18 patients (30.0%), 10 patients (16.7%) were
screened for HSV exposure by using serologic tests.
Some authors have suggested the use of a Tzanck smear
test, which is an easy and inexpensive test to identify
viral balloon cells.47 However, PCR assays are much
more sensitive and target a wide range of infectious
agents. Thus, PCR should form part of the mandatory
criteria to clearly identify the trigger and to support
the use of antivirals in particular patients.
Currently, the literature consistently supports medi-
cations as precipitants in more than 50% of EM epi-
sodes.1-3,48 Some authors have reported ﬁgures as low
as 10% of cases, although this has not been our expe-
rience.49,50 Moreover, the list of the medications asso-
ciated with the induction of EM continues to expand
and include new categories of drugs, such as tyrosine-
kinase inhibitors; biologic agents, such as tumor ne-
crosis factor-a inhibitors, phosphoinositide 3-kinase
inhibitor, retinoids.51-59 In our experience, medication
use has a marked role as a triggering factor in 28 pa-
tients (46.7%). The most commonly implicated medi-
cations were nonsteroidal anti-inﬂammatory drugs,
antibiotics, antifungals, and antivirals. In 1 case, the
oral contraceptive pill was also considered to be asso-
ciated. Alcohol consumption has been reported as a risk
factor in drug-induced EM, particularly if it is associ-
ated with antiepileptic therapies.60,61 Our case series
included 1 case of alcohol abuse with unknown
signiﬁcance.
Food-borne antigens, triggers ﬁrst suggested by
Lozada in 1978, were supported by evidence as
playing an important role in 7 cases of our series.62
Another suggested trigger is radiotherapy, although
concomitant medication use is an expectant common
confounder.63-65 There was no history of radio-
therapy present in our case series.
In a previous case series, M. pneumoniae infection
was reported to be responsible for almost two-thirds of
SJS cases, particularly in childhood cases, although it
was never associated with a typical EM eruption.66 In
contrast, the role of this infection in EM has recently
been challenged and re-evaluated, suggesting that
the M. pneumoniae-induced rash and mucositis may
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represent a distinct syndrome from EM and SJS.67 An
established association with M. pneumoniae was
clearly reported in only 1 of our 3 pneumonia case, a
73-year-old female. Positive culture tests for Candida
were only found in only 3 (5%) of our cases (2 oral and
1 genital), a lower rate than the 20% reported by
Lozada-Nur in 1989.38 Cases of “persistent EM,” a rare
variant of the disease characterized by uninterrupted
lesion eruptions often linked with Epstein-Barr virus
infection, were not present in our series.14,15
The character of presenting clinical features of EM
potentially can change during the course of the disease,
leading to an overlap of the variants. Oral involvement
in EM is reported in 60% to 70% of cases.1,2 In our
series, exclusive oral involvement was observed in 29
patients (46.6%). Lesions were predominantly erosive
or bullous with the buccal mucosa, vermilion border,
and labial mucosa being the most commonly affected
sites. Figure 1 presents typical crusting of the vermilion
border seen in exclusively oral EM. This site may
Fig. 1. The presenting labial clinical features were dominated by an erosive/bullous pattern and crusting. The number found in the
lower right corner corresponds to the patient number as reported in Table I.
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predisposed to by its particular epithelial and connective
tissue structures and the immunologic composition. In
these cases of exclusive oral involvement, clinicians
should consider the differential diagnosis with focus on
the timing of the outbreak, history of drug
consumption, the course of the illness, atypical sites
involved, and symmetric distribution of the lesions.
Eight cases (13.3%) of our series presented with at
least 1 additional site of mucosal involvement, genital
in 4 cases (6.7%), ocular in 2 cases (3.3%), nasal in 1
case (1.7%) and genital and ocular in 1 case (1.7%).
Cutaneous involvement was found in 25 cases (41.7%),
particularly perioral lesions in 10 cases (16.7%),
followed by acral in 5 cases (8.4%) and arm lesions.
According to the current classiﬁcation criteria,
different clinical forms are broadly categorized on the
basis of the presence, morphology, and extension of the
mucocutaneous disease. Some authors accept a diagnosis
of EM in patients with less than 10% of body surface
area (BSA) involvement, deﬁning the disease beyond
this as SJS/TEN.3 All the cases described in our case
series had no more than 10% of BSA involvement.
EM is further subdivided into EMm and EMM and
variably deﬁned by either the presence or absence of
mucous membrane involvement or the extent or
number of mucosal sites involved.3,14,46,68 In our study,
we utilized the classiﬁcation system described by Al-
Johani et al (2007), which distinguishes EMm and
EMM as involvement of 1 or more than 1 mucosal sites,
respectively.3 Fifty-one (85.0%) of our patients were
classiﬁed as EMm, and 9 (15%) were classiﬁed as EMM.
The most accepted criteria to differentiate the diagnoses
of EMM and SJS, regardless of BSA involvement, are
centered on the basis of the presence of systemic symp-
toms and a positive Nikolsky sign.3 Utilizing such criteria,
3 of our EMM cases that required hospitalization could be
reclassiﬁed as mild forms of SJS.
More than half of the patients had experienced at
least 1 previous outbreak, which supports the com-
monality of recurrence. Seven of our cases (11.6%)
could be considered the recurrent variant of EM, which
is lower than the rate reported by Cretu et al (20%).69
The limitations of this retrospective study include
acceptance of the variations in the use of clinical tests
and the limited use of HSV PCR and dietary records
across the 30 years during which these patients were
observed. Furthermore, the difﬁculty in collecting
recent data on the same patients through recall affected
our ability to better deﬁne the clinical behavior of the
disease and patient responses to previous exposures to
triggers, and therefore the outcome of our cohort.
CONCLUSIONS
EM may present initially with oral mucosal involve-
ment before an increase in disease severity. Prompt
recognition, particularly of bilateral bullous and ulcer-
ative involvement of the buccal mucosa, the labial
mucosa, or the vermilion border, is important to avoid
any delay in diagnosis. Although approximately half of
those presenting with EM report no previous episodes,
it remains unclear which of these patients will progress
to recurrence, so all patients should be informed and
encouraged to have an awareness of their exposures to
drug and food antigens. With the lack of universally
accepted classiﬁcation criteria and the absence of spe-
ciﬁc diagnostic tests, EM, especially in its mild forms,
continues to be an underestimated disease.
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LETTERS TO THE EDITOR
Oral erythema multiforme:
trends and clinical ﬁndings
of a large retrospective: European
case series
To the Editor:
Celentano et al.1 are to be congratulated on their recent
publication. This excellent addition to the literature
reports a retrospective case series of 60 oral erythema
multiforme (EM) patients. However, presently,
diagnostic criteria that distinguish between EM major
(EMM), EM minor (EMm), Stevens-Johnson syndrome
(SJS), and toxic epidermal necrolysis (TEN) are avail-
able. Celentano et al.1 have combined all of these
diagnostic entities within the category of EM. This
grouping is certainly appropriate, since the study
patient population was initiated in 1982, when all such
diagnoses would have been described within the
category of EM. The authors commented that
diagnostic criteria between EMM, EMm, SJS, and TEN
presently are not universally accepted. However, a case
can be made that such diagnostic criteria are presently
relatively well established, although not universally
accepted.1-7
In 2005, Williams and Conklin2 summarized the
dermatologic diagnostic standards for EM, SJS, and
TEN, as reported by Bastuji-Garin et al.,3 Assier et al.,4
and Auquier-Dunant et al.,5 and Cote et al.6 These
standards describe EM, SJS, and TEN as separate
diagnostic entities with relatively well-deﬁned diag-
nostic characteristics. Furthermore, Ayangco and
Rogers7 deﬁned the similarities and differences between
EMm and EMM.
Hopefully in the near future, the oral medicine and
oral and maxillofacial pathology communities will
undertake conﬁrmation of universally accepted diag-
nostic standards for EMM, EMm, SJS, and TEN,
possibly at the next World Workshop of Oral
Medicine.
Ronald S. Brown, DDS, MS
Professor
Department of Comprehensive Dentistry
Howard University College of Dentistry
Washington
DC, USA
Associate Clinical Professor
Department of Otolaryngology
Georgetown University Medical Center
Washington
DC, USA
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In reply: Oral erythema
multiforme: trends and
clinical ﬁndings of a large
retrospective: European case
series
In reply:
The authors are very appreciative of comments pre-
sented by Professor Brown regarding our recent pub-
lication,1 which highlighted the applicability of
diagnostic criteria proposed by several authors in the
last two decades.2-7
We agree that future studies should consider the use
of these presently well-established diagnostic criteria
differentiating between erythema multiforme minor
(EMm), erythema multiforme major (EMM), Stevens-
Johnson syndrome (SJS), and toxic epidermal necrol-
ysis (TEN). This may allow the clinical community to
achieve more accurate epidemiologic data that can
contribute to a better understanding and management of
the disease.
Antonio Celentano, DDS, PhD
Student at University Federico II of Naples
Department of Neurosciences, Reproductive and
Odontostomatological Sciences
Naples, Italy
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Simultaneous removal of
third molars and
completion of a sagittal split
osteotomy: effects of age and
presence of third molarsda
commentary
To the Editor:
This was a new research hypothesis, and the authors
tried to address the same with a retrospective cohort
study design.1 We congratulate the authors on their
approach and effort to address the same. We could
not draw any conclusions from the article and request
the authors to provide clariﬁcations in the some areas
as described below.
The authors have stated in the results section: “When
correlating the occurrence of adverse fractures by the
number of patients, slight evidence of a difference was
noted for presence or absence of third molar or degree
of impaction and no statistical differences were noted
for sex (P ¼ .073; P ¼ .069; and P ¼ .336, respec-
tively) (Table 4)” and later in the results section again
stated: “As shown above, there was no relation between
presence of third molar and adverse fracture when the
occurrence per patient was considered.” These two
statements contradict each other. Can statistical differ-
ence be considered in this comparison?
Another instance was in the results section: “How-
ever, when evaluating the occurrence of adverse frac-
ture correlated to the presence of third molar with the
number of osteotomies performed, there was a signiﬁ-
cance association between the bad splits with presence
of third molar in the site of the osteotomy (P ¼ .05)”
but later below Table 5, the authors stated, “The asso-
ciation between rows (groups) and columns (outcomes)
is considered to be not quite statistically signiﬁcant.”
Can statistical difference be considered in this com-
parison? Can we compute the odds ratio and conﬁdence
intervals to quantify the association?
In Table 4, the authors have compared the mean age
between “yes” and “no” of a bad split variable using the
analysis of variance F test. Can this comparison be done
with the help of independent sample t test or Student t
test? The mean ages in the tables and the text did not
match. We request the authors to address the above
queries so that readers can have a deﬁnitive conclusion
from this manuscript.
Kalyana Chakravarthy Pentapati, MDS*
Associate Professor
Department of Public Health Dentistry
Manipal College of Dental Sciences
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Abstract
Background Lichen planus of the lips (LPL) is not frequently described in the literature.
The objective of this study is to investigate the clinical outline, behavior, and prognosis of
LPL.
Methods Clinical data of patients with true oral lichen planus (LP) involving the lips,
diagnosed and treated at our Oral Medicine Unit (University Federico II of Naples, Italy),
have been collected and analyzed. Concurrently, a PubMed search was carried out from
1950 to March 2014 to assess epidemiological and clinical data about LPL.
Results Our case series revealed 13 patients (female/male ratio 0.4) with a mean (! SD)
age of 71.85 years (! 6.72). The lower/upper lip involvement ratio was 9, mainly with
mixed clinical patterns (76.9%), generally including erosion and mild keratosis. In most
cases, the lips were involved with other oral sites but displayed a better evolution of the
lesions. The literature review showed 21 reports of LPL (35 patients, female/male ratio 0.4)
with a mean (! SD) age of 45.35 years (! 16.19).
Conclusions In the literature, erosive (28.57%) lower lip lesions showed a clear
predominance (lower/upper lip ratio 6.5). One case of malignant transformation was also
reported. The prevalence of isolated LPL was clearly reported only in two studies, ranging
from 0.51% to 8.9%. In our patients, lesions were mostly found at the inner border of the
lower vermillion and presented a tendency for self-limitation, or to regression after
treatment, like cutaneous lesions. The lip lesions were small and easy to overlook, and
therefore the prevalence of these lesions may have been underestimated.
Introduction
Lichen planus (LP) is a chronic T-cell-mediated muco-
cutaneous inflammatory disease with an etiology and
pathogenesis that is not completely understood.1 It affects
1–2% of the general adult population, with the highest
frequency in women over 40.2
Histological characters pathognomonic for LP are the
liquefactive degeneration of the basal cell layer, a juxtaep-
ithelial band-like zone of cellular infiltration, predomi-
nantly lymphocytic, and the absence of epithelial
dysplasia. An interruption of the basement membrane,
appearance of eosinophilic Civatte bodies, parakeratosis,
acanthosis, and histological cleft formation may also be
present.2,3
The clinical presentation is complex, with white, red,
or mixed lesions. Six variants for oral LP (OLP) have
been described: reticular, papular, plaque-like, erosive,
atrophic, and bullous. The reticular form, with white stri-
ations (Wickham’s striae) is the most typical.4 These vari-
ants can also coexist and change during the course of the
disease.5
Oral involvement is quite common and is often the
only site of manifestation of the disease. OLP typically
affects the buccal mucosa, tongue, and gingiva, with sym-
metrical and bilateral lesions, and less frequently the lips
and the palate.1
Coincident cutaneous lesions appear in approximately
15% of the patients,4 presenting as purple, polygonal,
pruritic papules on the wrists, ankles, and genitalia.
Other dermatological features are nail pitting, pterygium
formation, nail loss, and scarring alopecia.2
The diagnosis results from integration of the histologi-
cal and clinical data, as well as the medical history, which
ª 2016 The International Society of Dermatology International Journal of Dermatology 2016, 55, e473–e481
e473
is necessary to exclude lichenoid reactions to drugs, den-
tal materials, or graft-versus-host disease.5
Lip involvement, particularly if isolated, is not com-
mon, and few case reports are described. Lip lesions are
probably subject to a variety of injuries, such as biting,
application of makeup, or sun exposure, which can
change the clinical features and mimic lesions of a differ-
ent nature. Therefore, LP of the lips (LPL) is difficult to
detect, and it is often misdiagnosed.
On the other hand, it has been suggested that injuries
acting on lip lesions in OLP could increase the risk of
malignant transformation,6 so that the diagnosis and
management of such lesions are mandatory.
In this paper, we present a retrospective study of
patients affected by LPL, who were diagnosed and treated
at the Oral Medicine Unit of the University Federico II of
Naples, Italy.
Contextually, a review of the literature about lip
involvement in the course of OLP has been performed to
integrate the clinical data discussed. The purpose of this
paper is to identify distinct features of LPL relating to its
clinical presentation, evolution, and response to treat-
ment, and concurrent oral or skin lesions.
Materials and methods
All the clinical records of OLP treated at the Oral Medicine
Unit of the University Federico II were scanned, and all the
cases in which lips (upper, lower, or both) were
involved were selected for a retrospective analysis. Cases of
allergic mucositis, associations with dental fillings/amalgams,
lichenoid lesions, and graft-versus-host disease were
excluded.
All the patients were diagnosed and treated by teams
experienced in oral medicine and dermatology from the
University of Naples Federico II for oral, and skin and genital
exams, respectively.
The diagnostic pattern for LP at our unit includes medical
history, thorough skin and oral exam, and the realization of a
biopsy for histomorphologic confirmation; no direct
immunofluorescence is usually performed. If the case is
consistent with a diagnosis of LP and oral lesions are present,
a diagnosis of OLP is realized. Exclusion of allergic or lichenoid
lesions is possible through confrontation of medical history and
absence of local irritating factors (i.e., drugs, dental fillings);
differential diagnosis with discoid lupus is done through the
integration of clinical and histological data. Within the group of
cases of OLP, if lesions on the lips were present, the case was
considered as LPL.
For each file selected, these variables have been considered:
age and sex, presence of any concurrent oral lesions, clinical
form of LP, the symptoms, any skin involvement, systemic
pathologies, hepatitis C virus (HCV) infection, drug therapy,
realization of a biopsy specimen of the lip lesion, treatment, and
outcome.
Concurrently, a review of the literature has been realized
using the MEDLINE database via PubMed for articles about
LPL published from inception (1950) to March 2014. The key
words we have used are association, OLP and cutaneous LP,
lip, involvement, and clinical feature, in various combinations.
The inclusion criteria were the English language and the
relevance of the title or the abstract to the field of research,
including lip lesions in OLP/LP, both as sole manifestations of
the disease and with concurrent lesions in other sites, in
patients of either sex, and of any age and nationality.
The exclusion criteria were papers describing oral lichenoid
lesions, graft-versus-host-disease, or other forms of LP different
from OLP.
For each article reporting a case of LPL, these variables have
been considered: year and country of publication, number of
cases described, sex and age of the patient, presence of any
concurrent oral lesions, clinical form of LP, symptoms, any skin
involvement, systemic pathologies and HCV infection, a
confirmatory biopsy, treatment, and outcome.
Epidemiological data about isolated lip lesions or concurrent
lip lesions in OLP have also been investigated, and the related
articles have been classified according to the year and country
of publication, and number of patients involved in the study.
Articles producing only narrative data were excluded.
Two reviewers selected the studies then extracted and
classified the data. Another independent reviewer checked the
selection and the data classification.
Results
Of the 388 OLP files recorded from 2002, 63 were
excluded for incomplete information about the clinical
data considered in this study. Thirteen clinical records of
patients affected by true OLP involving the lips were
found and reviewed, representing 4% of the remaining
325 OLP files, which had been considered elective for the
selection, with a mean follow-up of 5.15 years (Figs. 1
and 2; Table 1). The patient’s mean age at the last follow-
up was 71.85 years, and the female/male ratio was 0.4. In
all but two cases, the lips were not the only site of oral
involvement, i.e., tongue, buccal mucosa, gingiva, and
mucobuccal fold; the other localizations of the lesions, in
order of frequency (69.23% of cases for both tongue and
buccal mucosa; 53.85%, the gingiva; 23.08%, mucobuc-
cal fold). The lower lip was more frequently affected than
the upper lip, with a ratio of 9 : 1. With the exception of
two erosive forms and one keratotic form, all the other
patients showed mixed clinical patterns, generally includ-
ing erosion and mild keratosis. Nine patients complained
of pain and burning (one also complained of xerostomia),
while four of them were reported to be asymptomatic.
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Only two patients showed concurrent skin lesions or
lesions in other mucous epithelia. Two other patients
reported a previous skin involvement, which had sponta-
neously disappeared.
HCV infection was detected in six patients. Moreover,
all but three patients showed some systemic pathologies
and had followed some chronic, often multidrug therapy.
Three patients were former smokers, but none reported
smoking at the time of examination.
No history of lichenoid lesions in near family members
was recorded except for one doubtful case.
Biopsies were made on the lip lesions to exclude actinic
cheilitis in some cases with medical history of prolonged
ultraviolet exposition.
Most of the patients were treated with nystatin and cor-
tisone ointments. One patient with OLP and cutaneous LP
also reported a previous therapy with cyclosporine.
One asymptomatic patient was given no treatment and
only scheduled for a regular follow-up. One patient with a
solitary lesion on the upper lip was treated with surgical
excision due to the suspicion of malignancy, which proved
positive.
Most of the lesions remained constant during the
course of time, while four of them showed signs of regres-
sion or complete remission. Interestingly, the lip lesions in
a few cases showed a different and more favorable course
than other lesions of the mouth in the same patient,
appearing later on in the development of the disease, or
regressing earlier.
In the review of the literature, the data of 17 case
reports and four case series of LPL that met the inclusion
criteria were analyzed, for a total of 35 patients
Figure 1 (a) Mild plaque keratosis
with multiple micro-erosions of the
vermillion. (b) White keratotic striae
on labial mucosa with perilesional
erythema–exfoliative features of the
vermillion with skin inflammation. (c)
Ulceration of the vermillion with
peripheral keratotic striae. The rest of
the lip shows erythema and mild
keratosis with exfoliation of the
vermillion border that appears
undefined. (d) Multiple ulcerations of
the mucosal border of the vermillion
associated with keratotic isolated
papules and striae
Figure 2 (a) Reticular keratotic lesions
of the labial mucosa with keratotic
plaques and exfoliation of the
vermillion. (b) Squamous cell
carcinoma of the lip. (c) Erythema,
papules, annular keratotic striae, and
erosions of the vermillion interesting
also the mucosal side. (d) Linear
keratotic lesion with mild plaque.
Keratosis of the upper vermillion
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(Table 2). All the cases were presented as true LP, but in
three cases, the lesions were diagnosed as concurrent LP
and fungal infection,7 morphea,8 and systemic lupus ery-
thematosus.9 A histological specimen was provided in 17
articles.7–23
The age of the patients ranged from 7 to 75 years
(mean ! SD 45.35 ! 16.19), and the female/male ratio
was 0.4. As for the geographical distribution, nine reports
were from Europe,8,15,19,21–23,25–27 seven from
Asia,7,9–12,16,20 and five from America.13,14,17,18,24
Of the 21 case reports and series, 17 described an
isolated lip involvement.7–12,14,17–22,24–27 The lower/upper
lip involvement ratio was 6.5, while in two cases both
the lower and upper lip presented lesions.11,25
Table 1 Case series: LP of the lip
Case
no.
Year of
diagnosis Patient
Age/
sex
Isolated
(oral mucosa) Symptoms Clinical form
Skin
involvement Systemic pathologies HCV Drugs
1 2002 G G 72/M Yes (upper) Burning Erosive No Liver insufficiency Yes No
2 2003 C C 80/F No (lower).
Buccal, tongue
Burning Erosive,
keratosic
No Osteoarthritis Yes ASA,
bisp
3 2004 S G 78/M No (lower). Buccal,
fold, tongue
No Atrophic,
plaque, reticular
Previously
legs and wrists
COPD,
former smoker +
alcohol, hiatal hernia,
ischemic cardiopathy,
kidney insufficiency,
prostatic hypertrophy
No Antihy
anti-
ASA
stati
4 2006 B G 77/M No (lower + upper).
Buccal, gingiva,
tongue.
No Erosive, plaque,
reticular
No Former smoker,
hypertension,
ischemic cardiopathy,
prostatic hypertrophy
No Antihy
ASA
stati
silod
5 2007 N C 63/M No (lower). Buccal,
gingva
No Plaque, reticular Previously
lichen ruber
Former smoker +
alcohol. celiac
disease, rheumatoid
arthritis
No No
6 2007 D C 61/F No (lower). Diffused Pain,
xerostomia
Annular, bullous,
LSA
Hands, feet,
vagina, nails
Osteoarthritis,
osteoporosis
No No
7 2007 S A 77/M No (lower). Gingiva Burning Erosive, keratosic No No Yes No
8 2007 R A 76/M No (lower). Buccal,
fold, tongue
Burning Atrophic, erosive,
reticular
No Prostatic
hypertrophy
No Alfuzo
9 2008 P C 78/F No (lower). Buccal,
gingiva, tongue
Burning Plaque, reticular Axillas, wrists Aortic mechanic
valve
Yes Allopu
biso
10 2013 G C 62/M No (lower). Buccal,
tongue
Burning Erosive, reticular No No No No
11 2014 F A 74/M Yes (upper + lower) Burning Erosive No No No No
12 2014 G V 67/M No (upper + lower).
Gingiva, palate,
buccal, tongue
Burning Reticular,
ulcerative
No Liver insufficiency Yes Immu
13 2014 A A 69/F No (lower). Gingiva,
tongue
No Keratosic No Hypertension Yes Amilo
hydr
ASA, aminosalicylic acid; COPD, chronic obstructive pulmonary disease; HCV, hepatitis C virus; K lip, OSSC (oral squamous
cell carcinoma) of the lip; LP, lichen planus; LSA, lichen sclerosis et atrophicus.
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Discussion
In the literature, the most frequently reported clinical
form of LPL is the erosive (10 cases),7,14,16–20,22,24,25 fol-
lowed by the reticular/annular (three),10,11,21 nodular
(one),23 and bullous (one).15 Accordingly, symptoms such
as pain, burning, bleeding, and crusting were reported in
13 cases,7,14–22,27 while only two cases were completely
asymptomatic.10,11 Only four cases of concurrent skin
lesions have been described.15,20,23,24
It is worth noting that for two reports it was
impossible to determine if a confirmatory biopsy had
been made for the diagnosis,25,26 while two other
papers describe cases in which the diagnosis was only
clinical.24,27
gies HCV Drugs Biopsy Diagnosis Familial Treatment Outcome Notes
Yes No Yes K lip,
lichenoid
infiltrate
No Surgical
excision
Remission Died in 2004
of liver
insufficiency
Yes ASA,
bisphosphonates
No LP No Cortisone +
nystatin
Stable
rnia,
athy,
cy,
phy
No Antihypertensives,
anti-H2, allopurinol,
ASA, beta blockers,
statins
Yes LP Yes? Cortisone +
nystatin
Stable Skin involvement
appeared and
disappeared
spontaneously
several times
athy,
phy
No Antihypertensives,
ASA, beta blockers,
statins, nitroglycerin,
silodosin
No LP No Nystatin Regression
oid
No No Yes LP No Nystatin Stable Spontaneous
remission
of skin lesions.
Koebner +
(buccal lesions)
No No Yes LP No Cortisone,
nystatin,
cyclosporine
Worsening
in the mouth,
Stable on
the lip
Keratosis on the
lip only.
Skin lesions
appeared after
oral lesions
Yes No Yes LP No Cortisone +
nystatin
Remission LP lasted 10 years,
then disappeared
No Alfuzosin, ASA No LP No Cortisone +
nystatin
Stable Koebner +
Yes Allopurinol,
bisoprolol, warfarin
No LP No Nystatin Stable in the
mouth,
regression
on the lips
Skin lesions
appeared after
oral lesions
No No No LP No Cortisone +
nystatin
Stable Lip lesions
appeared after
oral lesions
No No No LP No Cortisone +
nystatin
Stable
Yes Immunosuppressors No No Cortisone +
nystatin
Stable
Yes Amiloride +
hydrochlorothiazide
No LP No None Stable
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Most of the patients are reported to have no systemic
pathology, and only in six cases, a serological positivity
for HCV infection was reported.17,25
As for the treatment, tacrolimus was used in five
cases,10,11,14,16,17 and the reported outcome was regres-
sion in two cases,11,16 remission in one,17 and the persis-
tence of the lesion in one14 (in one there was no reported
outcome); corticosteroids, alone or in association with
other drugs, were reported to have been used in 10 arti-
cles,7,13,15,18,19,21–25 causing remission of the lesion in
most cases.7,13,15,18,19,21–24 However, in one article, recur-
rence and malignant transformation was described.25 Imi-
quimod and chloroquine phosphate were also reported to
have been used.12,26 In the first reported uncertain case of
LPL, Whittle described the use of mercury, arsenic, and
x-rays in its treatment.27
Few data about the prevalence of lip involvement in LP
can be found in the literature (Table 3). The prevalence
of isolated LPL was assessed only in two studies, with
very different results: Aminzadeh et al. in 200928 reported
a prevalence of 0.51% in a total of 186 Iranian patients,
while Xue et al. in 200529 reported a prevalence of 8.9%
in a total of 674 Chinese patients. Lip involvement, con-
currently with other oral sites, is reported to have a
prevalence between 32.3% and 6.3%,28–32 being the third
most common site of involvement according to Xue
et al.’s epidemiological study, or the fourth according to
Eisen and Carrozzo’s reviews.33,34 LPL is unanimously
considered to affect the lower lip far more frequently
than the upper lip.
In accordance to these data, in the case series
described, the lesions were almost always erosive, or ero-
sive and keratotic, and consequently, symptomatic.
The particular predilection for the male gender and
lower lip, as well as the clinical features of the lesions,
seem to suggest some environmental and behavioral influ-
ence on the development of these lesions, such as solar
radiation, wind exposure, air pollution, and the habit of
smoking. For this reason, attention has been focused on
detecting the cancerization of LPL, reported, in fact, in a
23-year-old former smoker by Harland et al.23 as well as
in one of our patients.
LPL seems to be rare but still somewhat underesti-
mated. In our case series, the lesions appeared as small
areas of mild keratosis and/or moderate erosion, often
associated with atrophy, erythema, and exfoliation, and
were mainly located at the limit between the vermillion
and the labial mucosa. This is a very rough area due to
the exposure of the inner part of the vermillion to oral
irritants, such as saliva, food, and tooth margins. Clinical
features could be a combination of dystrophia and inflam-
matory conditions overcoming the lichenoid aspects.
Additionally, the lip involvement in more than one case
resembled the course of cutaneous LP, disappearing or
regressing spontaneously after some years, or appearing
after the other oral lesions, even though skin involvement
affected only a small percentage of patients. In accor-
dance with this finding, the isolated lip lesions described
in the literature underwent remission or regression.
The transitional mucosa of the lip, with its distinct
antigenic structure, might be responsible both for the
mildness of the lesions and for their cutaneous-like
progression.
Another possibility, supported by more evidence, is that
the difference in the clinical behavior of cutaneous LP
and OLP, between which LPL might stand, is to be found
Table 3 Prevalence of lip involvement in oral LP
Year
First author/
reference Country
No. of
patients Age range
Female/
male
Isolated
lip Lip involvement
Cutaneous
involvement
(% of patients)
2010 Bajaj30 India 95 17–62 (34–36
mean value)
55/40 NA 29.4%. Upper 7.4% (reticular).
Lower 22.1% (reticular, erosive)
NA
2009 Carrozzo34 Italy Review NA NA NA Lower lip 4th most involved site 15
2009 Aminzadeh2 Iran 187 46 (mean value) 72%/28% 0.51% 6.3% 1.25
2005 Xue29 China 674 10–78 (49–52
mean value)
66%/34% 8.9% Upper 1.91% (erosive). Lower 32.3%
(reticular). Third most common site of
involvement
11
2005 Eisen33 USA Review NA NA NA 4th most common site of involvement 15
2002 Eisen31 USA 723 13–82 (57–47
mean value)
75%/25% NA Upper 2%. Lower 14% NA
2001 Romero32 Spain 62 63 (mean value) 52%/48% NA 28.6% LP HCV+ vs. 7.3% LP HCV- NA
1992 Bagan-
Sebastian
Spain 205 NA NA NA NA NA
HCV, hepatitis C virus; LP, lichen planus; NA, not applicable.
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in the immunological composition and molecular expres-
sion of the two epithelia. T-helper 22 cell-produced inter-
leukin-22 and -23 have been proven to be more expressed
in oral lesions,35 probably because of the massive pres-
ence of T-helper 22 cells in the oral mucosa. In the same
way, the cytotoxic molecules interleukin-17 and Foxp3,36
perforin, and granzyme B,37 and finally caspase 3, Bax,
and Bcl-2 associated with apoptosis38 have been found to
be highly expressed only in oral lesions. In addition, a
concentration of CD4-positive cells in the oral mucosa
has been related to the entity of these lesions.37 Possibly,
the turning point between these different molecular pat-
terns, which can be related to the different clinical behav-
ior of the skin and oral lesions, might be at the interface
of the skin and oral mucosa, namely the vermillion.
On the other hand, the milder presence of microbiota
and environmental factors might act on lip lesions, with a
beneficial effect: ultraviolet B radiation is known to
reduce the lesions in LP, and phototherapy is also used to
treat skin lesions.39 It is possible that such factors act in
multiple ways, on the one hand controlling the immuno-
logical response of the epithelia but also, on the other
hand, acting as a chronic irritating stimulus on the
lesions.
Given all these considerations, lip lesions in LP, show-
ing transitional characteristics between the oral and cuta-
neous forms, might need independent categorization and
could be the starting point for a better understanding of
the immunopathogenesis, prognosis, and treatment of this
disease. They should be detected very carefully by the
clinician because they are insidious and easily overlooked
and might undergo malignant transformation.
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Clinical techniques and technology
The GOCCLES® medical device is effective  
in detecting oral cancer and dysplasia in dental 
clinical setting. Results from a multicentre clinical trial
Il dispositivo medico GOCCLES® è in grado di individuare displasie e cancro orale 
se impiegato nel setting odontoiatrico. Risultati da uno studio multicentrico
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SUMMARY
The purpose of this study is to demonstrate that the GOCCLES® medical device allows proper autofluorescence examination of the oral 
mucosa in a dental care setting. This is a non-randomised multicentre clinical trial on consecutive patients at risk for oral cancer. Patients 
underwent a classical naked eye inspection of the oral cavity followed by autofluorescence examination wearing the GOCCLES® spectacles 
while the light from a dental curing light irradiated the oral mucosa. Lesions were defined as visible potentially malignant lesions and/or 
fluorescence loss areas. All persisting lesions underwent excisional or incisional biopsy. Sixty-one patients were enrolled. Data from 64 
biopsies were analysed. Of the 62 lesions identified by the device, 31 were true positives. The device identified 31 of 32 true positive le-
sions. One lesion (an invasive carcinoma) was not visible to the naked eye. The device identified all lesions classified as moderate dysplasia 
to invasive cancer. In 56.7% of cases, true positive lesions showed greater extension when observed through the device. The GOCCLES® 
medical device allowed the direct visualisation of fluorescence loss in patients suffering from mild to severe dysplasia and in situ to invasive 
oral cancer. It allowed autofluorescence examination with each source of light used during the study. These results suggest that the role of 
the autofluorescence visualisation is that of a complementary inspection following naked eye examination when dealing with patients at 
risk for oral cancer. The device allows detection of otherwise invisible lesions and otherwise impossible complete resections.
KEY WORDS:0SBMDBODFSr&BSMZ%FUFDUJPOPG$BODFSr%FOUJTUSZr'MVPSFTDFODFr$VSJOH-JHIUTr%FOUBM
RIASSUNTO 
Scopo di questo studio è dimostrare che il dispositivo medico GOCCLES® permette di condurre l’esame dell’autofluorescenza del cavo 
orale nel setting odontoiatrico. Si tratta di uno studio multicentrico non randomizzato su pazienti consecutivi a rischio di cancro orale. I 
pazienti sono stati sottoposti ad ispezione del cavo orale ad occhio nudo seguita dall’esame dell’autofluorescenza condotto indossando gli 
occhiali GOCCLES® mentre una lampada fotopolimerizzante illuminava la mucosa orale. Le lesioni sono state definite come qualunque 
lesione precancerosa del cavo orale visibile ad occhio nudo o area di perdita di fluorescenza visibile con GOCCLES®. Tutte le lesioni 
persistenti sono state sottoposte a biopsia escissionale o incisionale. Sono stati reclutati 61 pazienti e analizzati i dati da 64 lesioni. Delle 
62 lesioni identificate dal dispositivo, 31 erano veramente positive. Il dispositivo ha identificato 31 delle 32 lesioni veramente positive. 
Una lesione (un carcinoma invasivo) non era visibile ad occhio nudo. Tutte le lesioni classificate come displasia tra moderata e severa e 
ogni carcinoma sono stati correttamente identificati dal dispositivo. Nel Il 56,7% delle lesioni identificate dal dispositivo mostrava margini 
più ampi rispetto a quelli visibili ad occhio nudo. Il dispositivo medico GOCCLES® permette di osservare il fenomeno della perdita di 
fluorescenza in pazienti affetti da displasia o cancro del cavo orale. Ha permesso di effettuare l’esame dell’autofluorescenza con ciascuna 
lampada fotopolimerizzante testata. I risultati suggeriscono di impiegare GOCCLES® come esame complementare rispetto all’ispezione 
ad occhio nudo del cavo orale su pazienti a rischio per cancro orale. Il dispositivo permette di identificare lesioni altrimenti visibili o i cui 
margini sono sottostimati dall’ispezione ad occhio nudo. 
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Introduction
No oral cancer screening test on large populations is cur-
rently recommended for oral cancer. However, studies on 
low-cost oral cancer diagnostic techniques are currently 
ongoing  1. The autofluorescence examination is among 
these techniques.
Autofluorescence of the oral mucosa consists of a dim 
light coming from oxidised flavin adenine dinucleotide 
	'"%
BOEPUIFSáVPSPQIPSFTXIFOFYDJUFECZCMVFWJ-
olet and ultra-violet (UV) light  2. Healthy tissues pro-
duce a 515 nm (green) light. Conversely, tissues with 
disorders of cell metabolism (such as dysplastic muco-
sa) appear as dark spots on a green background  2. The 
disruption of the extracellular matrix, hyperemia and 
neo-angiogenesis also contribute to reduce fluorescence 
emission 2.
Persistent areas of decreased fluorescence can therefore 
be a sign of dysplasia or cancer and should be treated ac-
cordingly. Today, it is commonly accepted that potentially 
malignant lesions of the oral cavity must be treated if they 
persist for more than 2 weeks, and many researchers are 
trying to find a role for autofluorescence not only in the 
early detection, but also in the complete surgical resection 
of cancerous or pre-cancerous lesions 3.
The GOCCLES® (Glasses for Oral Cancer – Curing Light 
Exposed – Screening) medical device was created in or-
der to provide comfortable, easy and low cost direct vi-
sualisation of abnormalities of the oral cavity tissue fluo-
rescence.
This device has already been tested in a clinical trial, with 
promising results  4. However, that study suffered from 
several limitations, and was a pilot study on just 32 pa-
tients. Two-thirds of enrolled patients were in follow-up 
after the surgical resection of an oral cancer, and therefore 
at high risk of showing dysplastic tissues at histological 
examination regardless of the results of autofluorescence 
examination because of disease relapse or incomplete re-
section. Moreover, during this trial only a prototype of the 
device was studied, and it was tested with only one dental 
DVSJOHMJHIU	BO&MJQBS.&41&
'VSUIFSNPSFUIF
study was conducted only by the research team respon-
sible for the creation of the device, with obvious conflicts 
of interest.
In order to demonstrate the capability of the GOCCLES® 
medical device to allow proper autofluorescence exami-
nation of the oral mucosa, which is the aim of this multi-
centre trial, it is therefore necessary to involve more pa-
tients, multiple research groups and curing lights, and to 
test the final model of the device.
Materials and methods
The GOCCLES® device (Pierrel S.p.A, Italy) consists of a 
QBJSPGHMBTTFTFRVJQQFEXJUIàMUFST	'JHŇ
UIBUIJHIMJHIU
autofluorescence when the oral mucosa is illuminated by 
the light emitted by any dental curing light.
The device was studied in a non-randomised multicentre 
clinical trial in which eligible consecutive patients under-
went oral examination with GOCCLES®.
Subjects above the age of 17 years were eligible for the 
study if showing potentially malignant lesions of the oral 
mucosa or if they were in follow-up after surgical resec-
tion for oral cancer. Patients who underwent radiotherapy 
for oral or head and neck cancer in the previous three 
months were excluded from the study.
All eligible subjects were informed in detail on the study 
protocol and participants joined the study voluntarily 
after signing an informed consent form. All eligible 
subjects showing lesions at naked eye oral inspection or 
on autofluorescence analysis were asked to participate 
JO UIF TUVEZ 'PS FUIJDBM SFBTPOT TVCKFDUTXJUI UPUBMMZ
negative naked eye and autofluorescence examinations 
did not undergo biopsy of the oral mucosa and were 
excluded.
Enrollment took place at the following six Centers: Unit 
of Maxillofacial Surgery, C.I. Columbus, Università Cat-
tolica del Sacro Cuore (Rome); Department of Recon-
structive and Diagnostic Surgical Sciences, Unit of Oral 
Pathology and Medicine and Complex Unit of Maxil-
MPGBDJBM4VSHFSZ'POEB[JPOF*3$$4$B(SBOEB0TQFE-
ale Maggiore Policlinico, University of Milan (Milan); 
Department of Integrated Activities Head-Neck, Unit of 
Maxillofacial Surgery and Unit of Oral Medicine, Uni-
WFSTJUÆ EJ/BQPMJ 'FEFSJDP ** 	/BQMFT
6OJU PG.BYJM-
lofacial Surgery, Nuovo Ospedale San Giovanni Battista 
	'PMJHOP
&OSPMMNFOUMBTUFEPOFZFBSBOETUBSUFEJO4FQ-
tember 2013.
Patients underwent a naked eye classical inspection of 
the oral cavity followed by the autofluorescence exami-
nation wearing the GOCCLES® medical device while 
the light from a dental curing light irradiated the oral 
mucosa. All examinations were performed by skilled 
physicians and surgeons with patients lying in a dental 
chair in a setting similar to that of the dental practice. 
All operators were asked to hold the light at 20-40 cm 
Fig. 1. The GOCCLES (Glasses for Oral Cancer – Curing Light 
Exposed – Screening) medical device.
GOCCLES® is effective in detecting oral cancer in a dental clinical setting
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distance from the oral mucosa and to direct the light 
perpendicularly to the inspected area. The naked eye in-
spection and the autofluorescence examination had to be 
performed by the same operator. All fluorescence loss 
areas were regarded as potentially malignant lesions of 
the oral mucosa. The following dental curing lights were 
used during the study: Elipar S10 3M ESPE (used by the 
Units of Milan); Led.B Carlo de Giorgi (Units of Rome 
BOE 'PMJHOP
 0QUJMVY ,FSS $PSQPSBUJPO 	6OJUT PG
Naples). After examinations, all lesions persisting for at 
least two weeks (detected by at least one between the 
naked eye inspection and the autofluorescence exami-
nation) underwent excisional biopsy. If the excisional 
biopsy was not feasible, patients underwent incisional 
biopsy. All biopsies were properly oriented and showed 
the margins detected by both examinations. If an inci-
sional biopsy including both identified margins was not 
feasible, two incisional biopsies of the same lesion on 
different margins were allowed. Different incisional bi-
opsies of the same lesion were considered as a single bi-
opsy. All biopsies underwent histological examination. 
No blinding on pathologist assessment or data analysts 
was planned.
'PSFBDIMFTJPOUIFGPMMPXJOHEBUBXFSFSFDPSEFEJGWJT-
ible to the naked eye and/or on autofluorescence analysis; 
which examination showed the greater extension if results 
were non-overlapping; which margins identified by the 
two techniques were infiltrated; the histological report. 
True positive lesions were defined as any dysplasia or 
DBODFSPGUIFPSBMDBWJUZ'BMTFQPTJUJWFMFTJPOTJODMVEFE
negative histological findings and any other disorder of 
the oral mucosa not related to cancer.
Primary outcomes of the study were: proportion of vis-
ible lesions; proportion of infiltrated margins; propor-
tion of true positive, false positive and false negative 
lesions. Given the study design, it was not possible to 
assess true negative lesions (no proper follow-up was 
planned).
The study protocol was approved by the respective ethics 
committees of the Institutions involved in the study.
Statistical analysis
Differences in terms of diagnostic performance between 
the autofluorescence analysis and naked eye inspection 
of the oral mucosa were assessed using the two-tailed 
McNemar test. Data analysis was performed with the 
IBM SPSS 22 Statistics Software for Windows. Statistical 
significance was set at p = 0.05.
4BNQMF TJ[FDBMDVMBUJPOXBTCBTFEPO UIF SFTVMUTPG UIF
previous study 4. Assuming that the examination of auto-
fluorescence showed larger margins compared to the na-
ked eye in 25% of the lesions and that the opposite occurs 
in about 5% of cases, a sample of 100 patients was set 
in order to observe a significant difference between the 
two examinations with a probability of 95% (accepting a 
probability of type I error of 5%).
An interim analysis was planned at one year. After analy-
sis of the first results the study was discontinued given the 
low probability of achieving more conclusive results with 
the preset sample of 100 patients.
Results
Sixty-one patients were enrolled and all underwent both 
naked eye inspection and autofluorescence examination 
of oral cavity mucosa. Data from all 61 patients entered 
the analysis. Main characteristics of the patients are sum-
marised in Table I.
Autofluorescence of the oral mucosa was analysed using 
a Led.B curing light on 29 patients (47.6% of the sample), 
an Elipar S10 on 21 patients (34.4%) and an Optilux 501 
on 11 patients (18.0%).
Naked eye inspection of the oral cavity detected 60 sus-
pect lesions, while autofluorescence examination with the 
GOCCLES® device detected 62 suspect lesions. A total of 
65 lesions were detected: in 59 cases (90.8% of observed 
suspected lesions) they were visible to both naked eye and 
autofluorescence, while 2 suspected lesions (3.1%) were 
only visible during the naked eye inspection and 4 (6.2%) 
were only visible on the autofluorescence examination. 
No significant differences in terms of detected suspect 
lesions were observed between the naked eye inspection 
Table I. Main demographic and clinical characteristics of the patients enrolled in the GOCCLES study, by center
Rome Milan Naples Foligno TOTAL
Patients [N] 14 21 11 15 61
Age [mean, (SD)] 67 (14) 66 (16) 66 (13) 63 (11) 66 (14)
Gender [N, (%)] Female 8 (57.1) 15 (71.4) 8 (72.7) 7 (46.7) 39 (63.9)
Group [N, (%)] A*
B†
11 (78.6)
3 (21.4)
16 (76.2)
5 (23.8)
11 (100)
0 (0)
14 (93.3)
1 (6.7)
52 (85.2)
9 (14.8)
Biopsies/patient
[N, (%)]
1
2
3
14 (100)
0 (0)
0 (0)
21 (100)
0 (0)
0 (0)
10 (90.9)
1 (9.1)
0 (0)
13 (86.6)
1 (6.7) 
1 (6.7)
58 (95.1)
2 (3.3)
1 (1.6)
* Patients suffering from suspected dysplastic lesions of the oral mucosa.
† Patients in follow-up after surgical resection of oral cancer.
A. Moro et al.
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and autofluorescence examination of oral mucosa (McNe-
mar test p = 0.687).
Sixty-five biopsies of the oral mucosa were thus tak-
FO'JGUZFJHIUQBUJFOUTVOEFSXFOUPOFPSBMNVDPTBCJ-
opsy, while two underwent two biopsies and another 
patient underwent three biopsies because of multiple 
lesions. An invalid sample was excluded from statisti-
cal analyses and data from 64 of 65 biopsies (98.5% 
of all biopsies) were analysed. Thirty-two of 64 sam-
ples (50.0% of the valid samples) were classified as 
false positives. Of the 32 truly positive samples, 11 
(17.2% of the valid samples) were classified as mild 
dysplasia, 4 (6.3%) as moderate dysplasia, 3 (4.7%) 
as severe dysplasia, 2 (3.1%) as carcinoma in situ and 
12 (18.8%) as invasive cancer.
Of the 60 suspected lesions detected by naked eye in-
spection of the oral cavity, 31 were true positive lesions 
(51.6%), while of the 62 lesions identified on autofluo-
rescence examination, 31 (50.0%) were true positives. 
In particular, autofluorescence examination identified all 
the lesions classified as moderate to severe dysplasia and 
all lesions classified as cancer. Main results of the study 
are summarised in Table II. Both techniques identified 31 
of 32 (96.9%) actual lesions. One lesion (a carcinoma) 
was not visible to the naked eye, while one lesion (a mild 
dysplasia) was not visible on the autofluorescence exami-
nation. No significant differences in terms of diagnostic 
performance were observed between the two techniques 
(McNemar test p = 1.000).
Thirty true positive lesions were visible by both classi-
cal inspection and autofluorescence analysis. In 17 cases 
(56.7% of the 30 true positive lesions), extension of the 
lesion detected on the autofluorescence examination was 
greater than that observed at naked eye inspection, while 
in two cases (6.7%) the margins overlapped and in nine 
cases (30.0%) autofluorescence examination showed a 
smaller lesion. In two cases (6.7%), the operator was un-
sure whether the margins were overlapping or not.
The resection margins identified during the naked eye 
inspection were infiltrated in 21 cases (67.7% of the 31 
lesions identified). Of the 31 true positive lesions identi-
fied by autofluorescence examination, 24 (77.4%) showed 
infiltrated margins. No significant differences were ob-
served between the two techniques in terms of free resec-
tion margins (McNemar test p = 0.754, see Tab. III).
No statistically significant differences were observed in 
the performance of the autofluorescence test using differ-
ent curing lights (Tab. IV).
Discussion
The GOCCLES® medical device allowed visualisation of 
fluorescence loss in patients suffering from mild to severe 
EZTQMBTJB BOE PSBM DBODFS 	'JH 
 5IF EFWJDF XPSLFE
Table II. Autofluorescence examination. 
Lesion description Detected by naked 
eye inspection only
Detected by both 
techniques
Detected by
AF examination only
TOTAL*
False positive† [N (%)] 1 (3.1) 28 (87.5) 3 (9.4) 32 (50.0)
True positive [N (%)] 1 (3.1) 30 (93.8) 1 (3.1) 32 (50.0)
Of which:
Mild dysplasia [N (%)] 1 (9.1) 10 (90.9) 0 (0) 11 (17.2)
Moderate dysplasia [N (%)] 0 (0) 4 (100) 0 (0) 4 (6.3)
Severe dysplasia [N (%)] 0 (0) 3 (100) 0 (0) 3 (4.7)
Carcinoma in situ [N (%)] 0 (0) 2 (100) 0 (0) 2 (3.1)
Invasive cancer [N (%)] 0 (0) 11 (91.7) 1 (8.3) 12 (18.8)
TOTAL [N (%)] 2 (3.1) 58 (90.6) 4 (6.3) 64 (100)
* The percentages under the “total” column relate to the whole sample. † Includes other non-precancerous and non-cancerous disorders of the oral mucosa.
Definitive diagnoses are based on histological findings. No patients were negative for both naked eye and autofluorescence analysis because no subject with totally negative 
physical examination underwent biopsy of the oral mucosa.
Table III. Proportions of free and infiltrated margins of the lesions identified during naked eye inspection of the oral cavity and on autofluorescence exami-
nation. 
Not visible
to AF
AF margins
not infiltrated
AF margins
infiltrated
TOTAL
Not visible to the NE - 0 (0%) 1 (3.1%) 1 (3.1%)
NE margins not infiltrated 1 (3.1%) 3 (9.4%) 6 (18.8%) 10 (31.3%)
NE margins infiltrated 0 (0%) 4 (12.5%) 17 (53.1%) 21 (65.6%)
TOTAL 1 (3.1%) 7 (21.9) 24 (75.0%) 32 (100%)
NE: naked eye inspection; AF: auto fluorescence examination.
No patients showed lesions invisible to both techniques because no subject with totally negative physical examination underwent the biopsy of the oral mucosa.
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properly with each source of light used in this study, 
which have different technical characteristics reproducing 
the variety of available dental curing lights. The Led.B 
is a LED lamp with a wavelength of 440-490 nm and an 
intensity of 1,000-1,200 mW/cm2; the Elipar S10 LED 
lamp has a 430-480 nm wavelength and an intensity of 
1,000 mW/cm2; the Optilux 501 is a halogen lamp with a 
wavelength of 400-505 nm and an intensity of 850-1,000 
mW/cm2. The GOCCLES® device was also previously 
successfully tested with another halogen lamp with dif-
ferent characteristics (400-500 nm wavelength and 600 
mW/cm2 intensity).
The study was performed with patients lying in dental 
chairs in order to reproduce the settings of common den-
tal practice. The intended purpose of the device was to 
allow any dentist equipped with a curing light to perform 
low-cost autofluorescence examination. According to the 
scientific literature, autofluorescence examination shows 
otherwise invisible characteristics of the oral mucosa that 
are associated with oral cancer  2 4. However, the current 
evidence suggests that the role of the autofluorescence 
examination is that of a complementary inspection fol-
lowing the naked eye examination, which should not be 
replaced by any screening test. Moreover, given the high 
risk of false positive findings (50% in this study), it is rec-
ommended that every dentist equipped with the device 
is properly trained before using it and that only patients 
at risk for oral cancer or showing potentially malignant 
lesions undergo examination with GOCCLES®. Remark-
ably, however, in one case GOCCLES® allowed the detec-
tion of an otherwise invisible lesion, and in four cases it 
allowed otherwise impossible complete resections of le-
sions with infiltrated margins.
We hope that the availability of additional low cost 
screening techniques encourages more careful and more 
frequent inspections of the oral cavity among dentists, 
and further promotes a much needed culture of oral can-
cer prevention: naked eye inspection of the oral cavity 
alone could, in fact, save about 37,000 lives worldwide 
each year 5.
'VSUIFSNPSF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Table IV. Comparison of the performance of the GOCCLES device with different curing lights.
Auto fluorescence examination results Lesion margin detection
TP lesion FP lesion Not detected p value* Free margins Infiltrated 
margins
p value*
Led.B [N (%)] 15 (46.9) 16 (50.0) 1 (3.1) 0.488 4 (26.7) 11 (73.3) 0.174
Elipar S10 [N (%)] 8 (38.1) 13 (61.9) 0 (0) 0 (0) 8 (100)
Optilux 501 [N (%)] 8 (72.7) 3 (27.3) 0 (0) 3 (37.5) 5 (62.5)
TP: true positive; FP: false positive. * Chi square test.
Fig. 2. Oral cancer in an edentulous patient in follow-up after surgical resection of a malignant lesion. Autofluorescence 
examination (on the left) vs. conventional visual examination (on the right). The lesion is barely visible if the oral examination 
is performed with superficiality. Loss of fluorescence increased contrast making it easier to see the tumour. Also visible in 
this figure is a clear difference in the extension of the margins of the lesion: fluorescence loss extended beyond the margins, 
which were visible to the naked eye. The arrow points to the main lesion. The margins of the lesion (as visible on the auto-
fluorescence examination) are also highlighted. 
A. Moro et al.
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sign (it was impossible to assess the proportion of false 
negatives in this study as no follow-up of negative pa-
UJFOUT XBT QMBOOFE
 'VSUIFS TUVEJFT PO NVDI MBSHFS
samples (possibly randomised clinical trials comparing 
the device with other techniques) are needed to define 
its diagnostic performance. The previous pilot study 
(in which patients underwent a follow-up of one year) 
showed 100% sensitivity, 95% specificity, 93% positive 
predictive value and 100% negative predictive value. 
However, the device was studied on patients at very high 
risk, and most had a history of oral cancer. It is likely 
that the diagnostic performance is heavily affected by 
the population tested, being poorer in the general popu-
lation and improving greatly when dealing (as appropri-
ate) with subjects at risk.
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Abstract
Objective. To compare sociodemographic and clini-
cal characteristics in patients with burning mouth
syndrome (BMS) and their relationship with pain.
Design. Cross-sectional clinical study.
Setting. University-Hospital.
Subjects. 75 BMS patients were enrolled.
Methods. The study was conducted between Sep-
tember 2011 and March 2012 at the “Federico II”
University of Naples. Demographic characteristics
and clinical information including age, sex, educa-
tional level, marital status, job status, age at disease
onset, oral symptoms, and triggers were collected
via questionnaire interviews. To assess pain inten-
sity the visual analogue scale (VAS) was adminis-
tered. Descriptive statistics were collected, and
Pearson Chi-square tests, Kruskal–Wallis nonpara-
metric tests and the Spearman bivariate correlation
were performed.
Results. The mean age was 61.17 (611.75, female/
male ratio5 3:1). The mean age at disease onset was
56.75 (612.01). A low educational level (8.5764.95)
and 80% of unemployment were found. Job status
and age at disease onset correlated with the VAS
scale (P50.019 and P5 0.015, respectively). Tongue
morphology changes, taste disturbances, and intra-
oral foreign body sensation have a significant
dependence on gender (P5 0.049, 0.001, and 0.045,
respectively); intraoral foreign body sensation has a
significant dependence on marital status (P5 0.033);
taste disturbances have a significant dependence on
job status. (P5 0.049); xerostomia has a significant
dependence on age (P5 0.039); and tongue color
changes and a bitter taste have a significant depend-
ence on educational level (P5 0.040 and 0.022,
respectively). Marital status and educational level
have a significant dependence on the triggers
(P5 0.036 and 0.049, respectively).
Conclusions. The prevalence of BMS is higher in
women, and in married, unemployed, and less
highly educated patients. Burning is the most fre-
quent symptom while stressful life events are the
most frequent trigger reported.
Key Words. Burning Mouth Syndrome; Sociodemo-
graphic Factors; Oral Burning; Educational Level;
Gender; Oral Pain
Introduction
Burning Mouth Syndrome (BMS) is a complex chronic
orofacial pain disorder characterized by an intraoral
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burning sensation for which no medical or dental cause
can be found, unremitting for at least 4 to 6 months
[1,2]. It is identified by three diagnostic criteria: pain in
the mouth present daily and persisting constantly or for
most of the day, oral mucosa of a normal appearance,
and the absence of local and systemic diseases [3,4].
It occurs more commonly in middle-aged and elderly
women, and rarely affects individuals under the age of
30 years. The prevalence may vary but ranges from
0.7% to 3.6% in men and 0.6 to 12.2% in women [5,6].
Other studies have reported a higher prevalence ranging
from 0.6% to 15%[7–12].
The main symptom is a burning sensation in the oral
mucosa and perioral regions that usually has a bilateral
and symmetric distribution. Sometimes the pain is
described as scalding, tingling, or numbing [13]. Other
oral symptoms, such as dysgeusia, a bitter/metallic
taste, subjective xerostomia, and foreign body sensation
have been reported [14]. Pungent or hot food or bever-
ages, stress, and tiredness have been reported to wor-
sen pain. The corresponding pain alleviating factors are
eating, sucking pastilles, drinking cold beverages, and
relaxation [15].
The onset is generally spontaneous, and without any
recognizable precipitating factors. However, some BMS
patients report antecedent dental procedures, the initia-
tion of medications, or stressful life events [16]. Sponta-
neous remission is rare [17].
The pain has precise physical, anatomical, and patho-
logical dimensions [18], but is also characterized by cul-
tural or universal components in its expression and
manifestation, with different interpretations from the
social or cultural perspective [19]. This is due to the
psychological, social, and cultural dimensions of noci-
ception. In this context, the pain is conditioned by per-
sonal and particular elements affecting the individual
suffering from the condition, and also by the social ele-
ments that identify the individual, such as his or her
sociodemographic characteristics [20].
Although BMS has been extensively studied, little is
known about the relationships between sociodemo-
graphic characteristics, symptoms, and triggers in the
onset of disease. Therefore, this study aims to explore
1) the sociodemographic profiles in a sample of BMS
patients; 2) the patients’ perceived pain intensity, the
oral symptoms reported, the triggers in the onset of the
disease and the relationships with sociodemographic
variables such as gender, age, educational level, marital
status, and employment status and; 3) the diagnostic
delay comparing the age of the patients with their age
at the onset of the disease.
To the best of our knowledge, this is the first study that
analyzes the relationships between clinical outcomes
and sociodemographic variables.
Materials and Methods
This was a cross-sectional single-assessment clinical
study performed at the oral medicine unit of the
“Federico II University of Naples.”
One hundred and ten BMS cases were screened for
possible participation between September 2011 and
March 2012. Seventy-five cases were included in the
trial in accordance with the inclusion/exclusion criteria.
All patients received written information and provided
their written informed consent for the management of
personal data before their participation.
The study was approved by the Ethics Committee of
the Federico II University (approval number 177/08).
The inclusion criteria for BMS were 1) either sex, aged
18 or older; 2) the presence of chronic pain in the oral
mucosa in the absence of hard and soft tissue lesions of
any kind; 3) pain lasting more than 4 months, continuous
throughout the day, with no paroxysm and not following
any unilateral nerve trajectory; and 4) the absence of any
abnormalities from the following laboratory investigations:
salivary flow rates, laboratory tests, and tests for the
detection of candidiasis. The exclusion criteria encom-
passed patients presenting with organic conditions that
could be considered a causative factor, such as diabe-
tes, anemia, thyroid disease, hyposcialia-related systemic
disorders (e.g., Sjogren’s syndrome), contact allergies,
psychotic illness, organic brain syndrome, or neurological
disease; subjects with signs of parafunctional habits; or
patients regularly treated with anxiolytic, antidepressant,
anticonvulsant, or psychotropic drugs. Even in the
absence of mucosal lesions, a local effect of dental
materials related to contact hypersensitivity was
excluded by means of patch tests when the symptoms
had started after any dental rehabilitation. A final diagno-
sis of BMS was established only after all other possible
causes of the oral complaints had been ruled out.
At admission, each subject underwent a medical anam-
nesis (including history, clinical features, and age at dis-
ease onset), a general medical examination, an intraoral
examination and extraoral examination, and laboratory
tests (e.g., a full blood cell count, and analyses of serum
levels of iron, ferritin, folate, vitamin B12, and glucose).
The data were obtained using face-to-face question-
naire interviews addressing sociodemographic variables,
age at disease onset, oral symptoms, and triggers at
disease onset. To assess the pain intensity the visual
analogue scale (VAS) was administered. The VAS is
usually presented as a 10-cm horizontal line, with each
point clearly marked. The patient marks on a line the
point that they feel represents their perception of their
current state. It is a test which is widely used in psycho-
social measurements to assess subjective phenomena.
It is easy to administer, fast to complete, and with a
high response rate [21].
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The demographics of the patients such as gender, age,
educational level, marital status, and employment status
were compared with data relating to South Italy from
the recent ISTAT (Italian National Institute of Statistics)
census (2011) [22].
Regarding the symptoms, we requested the patients to
report the presence of: any change of tongue morphol-
ogy, change of tongue color, bitter taste, scalding, burn-
ing, pain, taste disturbances, xerostomia, sialorrhea, or
intraoral foreign body sensation. The patients could indi-
cate one or more symptoms. Furthermore, regarding
the triggers, patients were asked to report any precipi-
tating factors such as the starting of any new medica-
tions, dental procedures or stressful life events [23]
occurring in the time frame of 1–12 weeks before the
onset of BMS. In such a case, we suggested that the
patients should indicate preferentially one trigger.
Finally, we analyzed the diagnostic delay comparing the
age of the patients at their first medical appointment
with their age at the onset of the disease.
An oral medicine specialist was responsible for deter-
mining the diagnosis of BMS, and for collecting all the
demographic and medical data from the patients.
Statistical Analysis
Descriptive statistics, including means, standard devia-
tions, medians, and interquartile range, were used to
summarize all the variables. The Pearson Chi-square
test was used to verify the significance of any depend-
ence between qualitative variables. Because numerical
variables do not have a normal distribution we chose to
use nonparametric tests. To verify the significance differ-
ence between medians, we performed the Kruskal–
Wallis nonparametric test while to measure the degree
of correlation we used the Spearman bivariate correla-
tion index.
Results
Table 1 summarizes the demographic and clinical
parameters. The demographics of the patient group
were compared with data relating to South Italy from
the ISTAT 2011 census Website [22].
The number of study years of the patients was
8.5764.95 (8.1264.83 for the females and
9.8965.20 for the males). These data were similar to
those of South Italy.
Some differences were detected in marital status and in
job status. We found that 6.7% of our patient group
were single compared with 29.6% in South Italy, 5.3%
were divorced compared with 1.3%, and 12.1% were
widowed compared with 7.1%.
There was a higher level of unemployment (60 patients,
80%) compared with the data relating to South Italy
(45%; P< 0.001). The percentage of male unemployed
patients was 84% compared with 28% in South Italy.
The percentage of unemployed women was 80% com-
pared with 60%.
Comparing the age of the patient group with the age at
disease onset we found a diagnostic delay of
4.426 0.26 years.
Dependence Analysis of Age at Disease Onset
As shown in Table 2, job status and educational level
correlated (P <0.001 and P = 0.006, respectively) with
age at disease onset.
Dependence Analysis of VAS Scale
Table 3 shows the dependence analysis of the VAS
scale in relation to gender, job status, and marital
Table 1 Sociodemographic and clinical
characteristics of BMS patients
Patient
Characteristics
Frequencies
(Percentages)
Gender Male 19 (25.3)
Female 56 (74.7)
Education level
(in years)
0–4 8 (10.7)
5–7 27 (36.0)
8–10 15 (20.0)
11–13 15 (20.0)
14–18 10 (13.3)
Mean6SD 8.576 4.95
Age (in years) 20–29 1 (1.3)
30–39 2 (2.7)
40–49 9 (12.0)
50–59 22 (29.3)
60–69 19 (25.3)
70–79 19 (25.3)
>79 3 (4.0)
Mean6SD 61.176 11.75
Marital status Single 5 (6.7)
Married 57 (76.0)
Divorced 4 (5.3)
Widowed 9 (12.0)
Job status Employed 15 (20.0)
Unemployed 60 (80.0)
Age at disease onset
(in years)
20–29 2 (2.7)
30–39 4 (5.3)
40–49 13 (17.3)
50–59 21 (28.0)
60–69 24 (32.0)
70–79 11 (14.7)
Mean6SD 56.756 12.01
VAS scale 1–4 18(24)
5–7 29(38.7)
8–10 28(37.3)
Sociodemographic Characteristics and Burning Mouth Syndrome
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status. Only job status correlated with the VAS scale (P
= 0.019). Furthermore, the table shows the dependence
analysis of the VAS scale in relation to age, educational
level, and age at disease onset. Only age at disease
onset correlated with the VAS scale (P = 0.015).
Analysis of Symptoms and Dependence
Table 4 shows the dependence analysis of the symp-
toms in relation to gender, marital status, job status,
age, educational level, and age at disease onset.
Changes of the tongue morphology, taste disturbances,
and intraoral foreign body sensation have a significant
dependence on gender (P = 0.049, P = 0.001, and P =
0.045, respectively); intraoral foreign body sensation has
a significant dependence on marital status (P = 0.033);
taste disturbances have a significant dependence on
job status. (P = 0.049); xerostomia has a significant
dependence on age (P = 0.039); and changes of
tongue color and a bitter taste have a significant
dependence on educational level (P = 0.040 and P =
0.022, respectively).
No symptom correlated positively with age at disease
onset.
Analysis of Triggers and Dependence
Table 5 shows the dependence analysis of the triggers
in relation to gender, marital status, job status, age,
educational level, and age at disease onset. Marital sta-
tus and educational level have a significant dependence
on the triggers (P = 0.036 and P = 0.049, respectively).
Initiation of drugs and stressful life events were the most
common triggers reported by single BMS patients
(40%), stressful life events was the most common trig-
ger reported by married patients (46%) and by widowed
BMS patients (44%), and antecedent dental procedures
and stressful life events were the most common triggers
in divorced BMS patients with the same percentage
(50%).
In terms of educational level, the trigger most commonly
reported by patients with the lowest level of education
(0–4 years) was antecedent dental procedures (50%).
The patients with study periods from 5 to 13 frequently
reported as a trigger stressful life events while the
patients with the highest educational level (14–18) did
not identify any specific cause of their disease (50%).
Discussion
Several pain conditions show a remarkable gender-
related difference in their prevalence [24]. Men and
women do not suffer from the same illnesses or do so
with a different intensity and risk [25]. Epidemiological
studies have shown that the female gender is itself a
risk factor for chronic pain, although these findings
appear to be pain site dependent. Gender differences
are more consistently found in relation to abdominal
pain and headache while instead for orofacial pain
Table 2 Dependence analysis of age at disease
onset in relation to gender, job status, marital
status, and educational level
Age at Disease
Onset P Value
Gender
Male 60.746 14.06 0.094
Female 55.396 11.05
Job status
Employed 46.336 10.66 <0.001**
Unemployed 59.356 10.96
Marital status
Single 49.806 23.08 0.193
Married 57.826 10.45
Divorced 47.256 10.05
Widowed 58.006 13.45
Educational level Spearman q 20.314 0.006**
The significance difference between the means was meas-
ured by the Anova test procedure.
* Significant 0.01!P!0.05.
** Significant P!0.01.
Table 3 Dependence analysis of VAS in relation
to gender, job status, marital status, age,
educational level, and age at disease onset
VAS
Patient
Characteristics
Median–
IQR P Value
Gender Male 6.0-3.0 0.597
Female 6.5-6.0
Marital status Single 5.8-4.0 0.495
Married 6.0-4.0
Divorced 7.0-6.0
Widowed 4.0-3.0
Job Status Employed 5.0-3.0 0.019*
Unemployed 7.0-4.0
Educational level
(in years) vs VAS
20.124 0.288
Age (in years) vs VAS 0.223 0.055
Age at disease onset
(in years) vs VAS
0.279 0.015*
IQR5 interquartile range. The significance difference between
the medians was measured by the Kruskal–Wallis nonpara-
metric Anova. The correlation was measured by the Spear-
man correlation coefficient.
* Significant 0.01<P!0.05.
** Significant P!0.01.
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consistent gender differences in prevalence have not
been established [26].
The true prevalence of BMS is difficult to establish due
to the lack of rigorous diagnostic criteria in many studies
which do not make any distinction between the second-
ary symptoms of oral burning and the syndrome itself.
For this reason, estimates of the prevalence of BMS
range from 0.7% to 7% of the general population and
increase to 12–18% for postmenopausal women
[27–29]. BMS occurs at a 90% higher rate in women
than in men [30,31] and usually presents from 3 years
before to 12 years after menopause [5]. The reported
gender ratio of the affected patients (females to males)
has ranged from 3:1 to 16:1. [32,33]. In our study, the
male/female ratio was 1:3.
Multiple biopsychosocial mechanisms contribute to gen-
der differences in BMS conditions, including sex hor-
mones, endogenous opioid function, genetic factors, pain
coping, and catastrophisizing, and gender roles [28].
BMS occurs in middle aged and elderly subjects with
an age range from 27 to 87 but rarely affects individuals
under the age of 30 years, never having been described
in children or adolescents. It usually occurs in the fifth to
seventh decade of life [6].
The mean age of our patients was 61 years with a peak
between 50 and 59 (22 patients); we had only one
patient of 29 years. Furthermore, BMS occurs later in
men than in women (65 compared with 60 years).
In this study, we found the same educational level in
BMS patients as in the general South Italy population,
revealing a higher percentage of BMS patients with a
low educational level (less than 8 years, 35 patients,
46%).
Table 5 Gender, age, educational level, job status, marital status, and age at disease onset differences
in relation to triggers of BMS
Trigger Undefined
Initiation of
Medications
Antecedent
Dental
Procedures
Antecedent
Dental Proce-
dures/Stressful
Life Events
Stressful
Life Events P Value
Gender Male 47.4% 5.3% 10.5% 5.3% 31.6% 0.089
Female 23.2% 3.6% 23.2% 0.0% 50.0%
Marital status Single 20.0% 40.0% 0.0% 0.0% 40.0% 0.036*
Married 31.6% 1.8% 19.3% 1.8% 45.6%
Divorced 0.0% 0.0% 50.0% 0.0% 50.0%
Widowed 33.3% 0.0% 22.2% 0.0% 44.4%
Job status Unemployed 30.0% 3.3% 25.0% 1.7% 40.0% 0.180
Employed 26.7% 6.7% 0.0% 0.0% 66.7%
Age (in years) 20–29 100.0% 0.0% 0.0% 0.0% 0.0% 0.137
30–39 0.0% 50.0% 50.0% 0.0% 0.0%
40–49 22.2% 0.0% 22.2% 0.0% 55.6%
50–59 22.7% 4.5% 18.2% 0.0% 54.5%
60–69 15.8% 0.0% 21.1% 5.3% 57.9%
70–79 42.1% 5.3% 21.1% 0.0% 31.6%
>79 100.0% 0.0% 0.0% 0.0% 0.0%
Educational level 0–4 12.5% 0.0% 50.0% 0.0% 37.5% 0.049*
5–7 29.6% 0.0% 22.2% 0.0% 48.1%
8 210 40.0% 0.0% 13.3% 0.0% 46.7%
11–13 13.3% 13.3% 0.0% 6.7% 66.7%
14–18 50.0% 10.0% 30.0% 0.0% 10.0%
Age of disease
onset
20–29 50.0% 50.0% 0.0% 0.0% 0.0% 0.383
30–39 25.0% 0.0% 25.0% 0.0% 50.0%
40–49 23.1% 0.0% 30.8% 0.0% 46.2%
50–59 19.0% 4.8% 14.3% 0.0% 61.9%
60–69 33.3% 4.2% 16.7% 4.2% 41.7%
70–79 45.5% 0.0% 27.3% 0.0% 27.3%
The significance difference between the conditional distributions was measured by the Pearson Chi-square test.
* Significant 0.01<P!0.05.
** Significant P!0.01.
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On the contrary, in terms of marital status and job sta-
tus, the data of the sample were different from those
reported for South Italy. We found a higher percentage
of married patients and widowed patients, and a lower
percentage of single patients. Moreover, we found a
higher percentage of unemployment (80%). Unemploy-
ment seems to be the most important stressful life event
in our patients.
Through a comparison of the age at BMS onset and the
age of the patients, we evaluated the professional diag-
nostic delay. Mignogna et al. in 2005, found that it usually
takes 34 months to arrive at a definitive diagnosis (range,
1–348 months; median, 13 months). The average num-
ber of medical and dental practitioners consulted by each
patient over this period and who initially misdiagnosed
BMS was 3.1 (range, 0–12; median, 3) [34].
In this study, the diagnostic delay was 4.426 0.26 years
(median 53 months). Therefore, we can argue that the
health care providers’ awareness of BMS, in 9 years,
has not improved.
Gender and marital status did not influence age at dis-
ease onset. Conversely, educational level and job status
were correlated with this factor (P< 0.001 and P = 0.006,
respectively). In fact, BMS is recognized earlier in patients
who have a higher educational level and are employed. A
higher level of education seems to lead to a more
informed patient with a better understanding of the rela-
tionship between stressful events and somatic disorders.
Furthermore, stress in the workplace could predispose
some people to somatic symptoms [35].
In literature, oral mucosal burning pain represents the
principal symptom of BMS. Pain levels may vary from
mild to severe [36,37]. The mean severity of BMS pain
has been assessed at about 5–8 cm (or 50–80 mm) on
a 10-cm (100 mm) VAS scale [38,39].
Our data were in line with the current literature, because
oral burning was present in 59 patients (79%); the
Median-IQR of VAS in men was 6.0–3.0 and in women
6.5–6.0.
Consistently, the literature suggests that females may
rate their pain as being more intense than males [40].
However, we did not observe any statistically significant
difference in pain intensity in relation to gender. The
pain intensity is equally high in men and women, being
independent of gender (P = 0.597).
Hungria et al., in relation to temporomandibolar disor-
ders (TMD) found that patients with a lower educational
level suffer more from pain than people with a higher
educational level. However, in our patients pain was not
related to educational level (P=0.288) [41].
In other chronic pain conditions, Goulet et al. found that
age influences the intensity of pain. In that study, the
authors found that individuals in the elderly group (551)
were three times more likely to rate jaw pain as severe
than the younger age group (18–34) [42]. In contrast, in
our study, the age of the patients was not related to the
pain intensity (q = 0.223, P = 0.055).
Job status and age at disease onset were correlated
with the VAS scale in this study (P = 0.019 and 0.015,
respectively). Generally, pain intensity in orofacial pain
syndromes (such as temporomandibular disorders) will
increase with the duration of the illness [43]. This tend-
ency was observed in our sample of BMS patients; it is
conceivable that the prolonged time for diagnosis
(median 53 months), and the absence of any treatment
could contribute to increasing the psychological stress
of the patients and consequently the pain intensity.
Unemployed patients showed higher values on the VAS
scale compared with employed patients. Unemployment
could contribute to the psychological stress of patients
and, consequently, could influence directly the pain
intensity.
Clinical presentations of BMS may vary as some
patients can be monosymptomatic (burning or pain only)
or oligosymptomatic [29]. Generally, in BMS, oral burn-
ing alone is rare, it being more frequently associated
with one or more other oral symptoms, such as xerosto-
mia, paresthesia, and altered taste [3].
Other authors have reported xerostomia in approxi-
mately 46–67% of BMS patients [2,33]; in our study,
xerostomia was the most frequent symptom after oral
burning (45 patients, 60%).
In contrast with the current literature that has reported
dysgeusia in almost 70% of BMS patients [1,38,44], in
our study taste disturbances was ranked in eighth place
(22 patients, 30%). A bitter taste, a very specific oral
sensation, was in third place (32 patients, 43%). We
found that taste disturbances were frequent in women
(34% compared with 16%) and in the unemployed (33%
compared with 13%).
Another factor to consider is that our patients show an
excessive concern about their health and are focused
on inspecting their mouth many times during the day,
noting any changes of the tongue morphology and
tongue color. They evaluate mainly the tongue probably
because this is the site most affected by symptoms. A
changing of the tongue morphology was noted princi-
pally by men (52% compared with 36%) A changing of
the tongue color was observed frequently in patients
with a lower educational level (5–7 years; 55%).
The age at disease onset did not modify the quality of
the symptoms reported by our patients.
The onset of BMS is spontaneous although some
patients report antecedent dental procedures, the initia-
tion of medications, or other illnesses [16,29,44].
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In this study, the most frequent trigger reported was
stressful life events (34 patients, 45%); in contrast with
the current literature, antecedent dental procedures
were in third place (15 patients, 20%).
Through the analysis of dependence, we can see that
gender, job status, and age at disease onset did not
influence the triggers in BMS. On the contrary, marital
status and educational level were associated.
The surprising dependence on marital status needs to
be addressed by further studies: at the moment no
hypothesis seems to be appropriate.
Antecedent dental procedures was the most common
trigger in patients with the lowest educational level
(50%) while patients with the highest level of education
fail to find a cause for their BMS (50%).
In conclusion, BMS remains an important medical con-
dition which often places a significant burden on both
the patient and the health care system.
This article reports that BMS occurs more frequently in
women than men. Nevertheless, gender does not influence
pain intensity perception, which is equally high in women
and in men. Pain intensity is higher in the unemployed and
is related to diagnostic delay. A longer time in reaching a
diagnosis is connected with higher pain intensity.
Burning is the most frequent symptom while stressful
life events is the most frequent trigger reported in
patients with BMS.
Within the limitations of the study, it can be concluded
that the sociodemographic characteristics of patients
could play a role in determining the clinical features of
BMS. However, further investigations and multicentric
studies are needed to support our hypothesis.
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ABSTRACT: Background. Nodular fasciitis is a non-neoplastic prolifera-
tion within the subcutaneous tissue and the deep fascia of the fibro-
blasts, probably of a reactive nature characterized by apparent
infiltration of the connective tissues by a mitotically active spindle cell
lesion. Nodular fasciitis in the head/neck region is rarely found and only
2 previous cases affecting the tongue have been reported.
Methods and Results. The purpose of this study was for us to report a
very rare case of a 67-year-old man with a history of a 3-month subepi-
thelial asymptomatic nodule of the tongue tip with an ulcerated surface.
An excisional biopsy of the mass was performed with 0.5-mm surgical
margins.
Conclusion. The clinical and histological features of nodular fasciitis may
mimic a head and neck malignancy, but it is often misdiagnosed as a
malignant mesenchymal neoplasm. Even if it is a rare entity, nodular fas-
ciitis should be considered in cases of rapidly growing masses of the
head and neck region. VC 2015 Wiley Periodicals, Inc. Head Neck 38:
E29–E31, 2016
KEY WORDS: nodular fasciitis, tongue, lingual fasciitis, mesenchy-
mal neoplasm, pseudosarcomatous fibromatosis
INTRODUCTION
Nodular fasciitis is a non-neoplastic proliferation within
the subcutaneous tissue and the deep fascia of the fibro-
blasts. It is probably of a reactive nature and occurs typi-
cally in the third to fifth decades of life with no sex
predilection.1,2 The clinical and macroscopic appearance
is nonspecific and microscopic examination shows an
apparent infiltration of the connective tissues by a mitoti-
cally active spindle cell lesion.
It can develop in almost any site, except the viscera,
and is most commonly encountered in the upper extrem-
ities.1,3 Nodular fasciitis in the head and neck region is
rarely found, but is more common in children. In the oral
mucosa, it has also rarely been reported, with the most
common involvement being in the buccal mucosa. Only 2
previous cases of nodular fasciitis of the tongue have
been described in literature by Takagi and Ishikawa4 in
1982 and by Mart!ınez–Blanco et al5 in 2002.
CASE REPORT
In July 2014, a 67-year-old white man was referred to
our Oral Medicine Unit, Department of Head and Neck
Diseases, Federico II University of Naples, presenting
with an asymptomatic lesion of the tongue tip that had
been growing rapidly for 3 months and with no history of
trauma.
Clinically, the lesion appeared as a firm subepithelial
myxoid nodule of approximately 2 cm, with an ulcerated
surface and hard consistency upon palpation (Figure 1A).
His medical history included hypercholesterolemia.
Routine hematologic tests revealed a phosphorus level of
2.9 mg/dL (normal range, 3–4.5), a total cholesterol level
of 206 mg/dL (normal value, up to 190), and an immuno-
globulin G4 subclass deficiency with a level of 0.004 g/L
(normal range, 0.08–1.40).
Because of the anatomic position of the lesion and
of its volume, it occupied the entire thickness of the
muscle.
An excisional biopsy of the mass was performed with
0.5-mm surgical margins of excision. Histology revealed
a proliferation of plump spindle cells arranged in irregular
fascicles with a focal storiform pattern and no characteris-
tic vascular pattern. The cells had vesicular and hyper-
chromatic nuclei and small to medium sized nucleoli.
Brisk mitotic activity was observed with no sign of necro-
sis (Figure 1B–1D). Immunohistochemistry showed posi-
tivity for vimentin and smooth muscle actin (Figure 1E).
Based on its morphological features and immunohisto-
chemical profile, it was diagnosed as a fasciitis-like myo-
fibroblastic proliferation.
This study was approved by the Ethics Committee of
University “Federico II” of Naples on October 2014 with
the protocol number 173/14. Appropriate written informed
consent and permission were obtained from the patient
described in this article.
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DISCUSSION
The pathogenesis of nodular fasciitis remains unknown,
but it seems that it is a self-limiting lesion, reactive or
inflammatory in nature, rather than a true neoplasm, often
triggered by trauma. The clinical and histological features
of nodular fasciitis may mimic a malignancy because of
its acute onset, rapid growth, rich cellularity, and mitotic
activity, thus leading to it often being misdiagnosed as a
malignant mesenchymal neoplasm.
As a result, the diagnosis is often a challenge for many
clinicians as well as for the pathologists.
Differential diagnosis encompassed reactive prolifera-
tions, such as pyogenic granuloma, inflammatory myofi-
broblastic tumors (historically known as “pseudotumors”),
several soft tissue sarcoma-like leiomyosarcoma, rhabdo-
myosarcoma, fibrosarcoma, myxoid neurofibroma, myx-
oid hematologic malignancies like myeloid sarcomas,
non-Hodgkin lymphomas and multiple myeloma, and sar-
comatoid variant of squamous cell carcinoma.5,6
The usefulness of the fine-needle aspiration cytology in
nodular fasciitis diagnosis is supported by many authors,
but is not shared by several other authors because it can
easily lead to misdiagnoses of malignant neoplasms of
spindle cells or salivary glands or cutaneous tumors, so
this aspect remains to this day discordant.7
Conservative surgical excision remains the standard treat-
ment of these lesions. Self-resolution has widely been
reported in literature, spontaneous or after partial resection.8
A rational clinical algorithm to manage these kind of
patients could be the following: after a mandatory incisional
biopsy, a 4 to 6-week period of follow-up should be consid-
ered because of the possibility of spontaneous regression of
the tumor. If resolution does not occur after this period, com-
plete conservative surgical therapy should be performed.
After the first surgery, our patient has until today a
5-month negative follow-up.
Even if it is a rare entity, nodular fasciitis should be con-
sidered in cases of rapidly growing masses of the head and
FIGURE 1. (A) A nodular subepithelial mass with ulcerated surface is visible on the tongue tip. (B) A panoramic view of the tumor (hematoxylin-
eosin stain, original magnification 3100). The spindle cells showed vesicular nuclei with nucleoli (C) hematoxylin-eosin stain, original magnifica-
tion 3150 and (D) hematoxylin-eosin stain, original magnification 3200. (E) The tumor cells show a widespread immunoreactivity for smooth
muscle actin (SMA; immunoperoxidase stain for SMA, original magnification 3200).
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neck region. The comprehensive knowledge of this entity is
indispensable to correctly plan the appropriate therapy and to
avoid a misdiagnosis of malignant mesenchymal neoplasms
for which more aggressive treatment options are needed.
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Abstract
Primary mucosal leishmaniasis is a rare infectious disease, particularly in immunocompetent patients. We present a 50-year-old patient with
a 6-week history of a painful lesion of the left buccal mucosa that mimicked cancer. The exophytic lesion looked invasive, and we took an
incisional biopsy specimen to exclude cancer. The diagnosis of leishmaniasis was unexpected, and the patient was successfully treated with
amphotericin B for five weeks. After five months the patient had a visceral recurrence. Chronic exophytic and ulcerated mucosal lesions that
do not heal within 3–4 weeks should be regarded as the first signs of oral cancer, but primary oral leishmaniasis can easily mimic it.
© 2015 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
Keywords: Exophytic lesion; Infectious diseases; Mucosal leishmaniasis; Oral cancer; Oral leishmaniasis
Leishmaniases are neglected tropical parasitic diseases that
are classified clinically into three forms, visceral, cuta-
neous, and mucosal leishmaniasis.1,2 They can all affect the
head and neck region with primary mucosal lesions that
can imitate a wide range of oral infectious diseases and
neoplasms.1–3
We present the case of a 50-year-old, immunocompetent,
white man who was referred to us in January 2014 with a
six-week history of a symptomatic lesion of the left buccal
mucosa, which looked malignant (Fig. 1) He was a heavy
smoker and had no contributory history. He was from an area
of Naples, Southern Italy, where leishmaniasis is endemic,
and had no history of recent travels abroad. He complained
of pain, spasm of the jaw, and weight loss of 6 kg. His
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Pansini n.5, Naples, 80131, Italy. Tel.: +39 0817462181.
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Fig. 1. Clinical features of our case: a widespread exophytic mass of the left
buccal mucosa extending to the upper and lower fornix, and the retromolar
area. The surface showed erythema, multiple erosions, and mild keratosis
that was speckled anteriorly and had a deep ulcer posteriorly.
dental history included poor oral hygiene and the presence of
a crown fracture of 28.
Routine haematological tests showed no abnormality
except for increased activity of lactate dehydrogenase
(650 U/L).
http://dx.doi.org/10.1016/j.bjoms.2015.01.021
0266-4356/© 2015 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
A. Celentano et  al. /  British Journal of  Oral and Maxillofacial Surgery 53 (2015) 396–398 397
Fig. 2. Histopathological examination of the buccal lesion showing dis-
ruption of the epithelial layer, which was partially ulcerated and partially
dyskeratotic and hyperplastic (haematoxylin and eosin, original magnifica-
tion ×10).
Fig. 3. Further magnification showed a wide number of intracellular and
extracellular Leishmania spp. amastigotes (haematoxylin and eosin, original
magnification ×63).
There was a widespread exophytic mass of the left buccal
mucosa that extended to the upper and lower fornix, and to the
retromolar area. The lesion was hard, and the surface charac-
terised by erythema, erosions, and keratosis, partly speckled
and ulcerated.
Clinical features were consistent with malignancy. Exam-
ination of an incisional biopsy specimen showed a large
number of Leishmania  spp. amastigotes (Figs. 2 and 3).
Dermatological examination and abdominal computed
tomography excluded systemic involvement and confirmed
a diagnosis of primary oral leishmaniasis.
Leishmaniases are a worldwide threat with about 58,000
cases of visceral and 220,000 cases of cutaneous disease
reported annually, high rates of mortality and morbidity,3–5
and (according to the WHO) an estimated 350 million people
at risk of contracting the infection.4
The female sand fly (genus Phlebotomus  or Lutzomyia)
transmits the parasite.2 People that have to stay in endemic
areas (such as inhabitants, migrant workers, soldiers, and
refugees) are considered at risk.6
Systemic spread of the disease is common, and may
involve the liver, spleen, abdominal lymphatic system, lymph
nodes, and bone marrow. Oral involvement with mucosal dis-
ease, and any mucosal leishmaniasis of the head and neck, is
rare in immunocompetent patients, at least as the only mani-
festation. Differential diagnoses encompass a range of other
diseases including oral squamous cell carcinoma (SCC).7
The standard treatment of mucosal forms of the disease is
based on pentavalent antimonial drugs.8
Oral SCC is among the 10 most common cancers world-
wide, and affects about 700,000 people. Alcohol, smoking,
and HPV are risk factors.9 Any indurated, heterogeneous
lesion of the oral mucosa, particularly one that presents with
white patches mixed with erythematous, erosive, or ulcer-
ated areas, should lead to a suspicion of malignancy and in
particular oral SCC.
Examination of a biopsy specimen is an essential first step.
However, this will not always be sufficient to diagnose an
infectious disease, and in all uncertain cases procedures such
as an ELISA or polymerase chain reaction will be necessary.
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Oral manifestations of phosphatase 
and tensin homolog hamartoma tumor 
syndrome
A report of three cases
Antonio Celentano, DDS; Daniela Adamo, DDS; Stefania 
Leuci, DDS, PhD; Michele Davide Mignogna, MD, DMD
Germline mutations in the phosphatase and tensin homolog (PTEN) gene are linked to a spectrum of disorders known as “PTEN hamartoma tumor syndrome” (PHTS). These 
disorders are Cowden disease (CD), Bannayan-Riley-
Ruvalcaba syndrome (BRRS), adult Lhermitte-Duclos 
disease (LDD) and autism spectrum disorders associated 
with macrocephaly. The bulk of the clinical data regard-
ing these disorders comes from studies of patients with 
CD and, less commonly, with BRRS.1
Here, we present a case series of three patients: a 
26-year-old man affected by CD and a 60-year-old man 
and his 33-year-old daughter, both affected by BRRS and 
having the complaint of multiple oral papillomatous 
lesions and cutaneous trichilemmomas. The purpose of 
this study is to add new data to the current literature on 
the clinical findings of these rare diseases, considering 
that oral manifestations are identified as major diagnos-
tic criteria of PHTS. 
CASE DESCRIPTIONS
All three cases described here involve patients treated in 
the Oral Medicine Unit, Department of Head and Neck 
Diseases, University of Naples Federico II, Italy. The 
internal institutional review board at the University at 
Naples Federico II approved this study, and we obtained 
written informed consent from all participants before 
completing study assessments.
Case 1. In October 2013, a 26-year-old white man was 
referred to the oral medicine unit with the main com-
plaint of asymptomatic keratotic lesions of the maxillary 
and mandibular gingiva (Figure 1). His medical history 
included a mild form of celiac disease, as well as multiple 
papillomatous lesions of the penis, hands and plantar 
skin. His dental history was negative for oral disease. He 
had never undergone endoscopy or colonoscopy.
ABSTRACT
Background. Phosphatase and tensin homolog 
(PTEN) hamartoma tumor syndrome (PHTS) encom-
passes several rare disorders linked to mutations of 
the PTEN gene, including Cowden disease (CD) and 
Bannayan-Riley-Ruvalcaba syndrome (BRRS). Th e 
authors present a case series involving patients with 
characteristic periodontal features.
Case Descriptions. Th e authors assessed three 
patients, two of whom already had been diagnosed 
with BRRS: a 60-year-old man and his 33-year-old 
daughter, both of whom had pathognomonic oral 
and cutaneous manifestations, and a 26-year-old man 
aff ected by multiple micropapillomatous and keratotic 
periodontal lesions, through which the diagnosis of 
CD was made. All three patients were referred to the 
oral medicine unit of the authors’ institution because 
of asymptomatic lesions of the oral mucosa, and two of 
them underwent incisional biopsy.
Conclusions. Th is series of cases emphasizes that 
oral health care workers always should perform a more 
careful visual inspection of the oral cavity without 
neglecting a macroscopic analysis of the gingival pat-
tern. Th e knowledge of these diseases and their clinical 
features, associated with a multidisciplinary approach, 
allows clinicians to achieve remarkable diagnostic 
success.
Practical Implications. Gingival manifestations 
may represent one of the primary clinically detect-
able manifestations of these rare systemic diseases, in 
respect of which an early diagnosis could decrease the 
associated mortality and morbidity.
Key Words. Oral medicine; genetics; neoplasms; 
phosphatase and tensin homolog; PTEN hamartoma 
tumor syndrome.
JADA 2014;145(9):950-954.
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The patient, after providing his written informed 
consent, was hospitalized and examined by three of 
the authors (A.C., D.A., M.D.M.) by means of routine 
hematologic tests, including glucose, sodium, potassium, 
chlorine, calcium, creatinine, albumin, hemoglobin, 
alanine aminotransferase, alkaline phosphates, aspartate 
aminotransferase, lactate dehydrogenase, creatine phos-
phokinase, hematocrit, red blood cell (RBC) count, mean 
corpuscular hemoglobin, mean corpuscular volume, 
platelet count, mean platelet volume, RBC distribution 
width, white blood cell count and differential, human 
immunodeficiency virus, and hepatitis B and C viruses. 
All laboratory test values were normal.
The physical examination showed a widespread 
whitish papillomatosis of the maxillary and mandibular 
gingiva with a micropapillary, at times cobblestonelike, 
pattern and a mild keratosis. The same three clinicians 
performed an incisional biopsy of the maxillary gin-
giva, and the histopathological examination revealed a 
proliferation of multiple benign fibromas with overlying 
hyperkeratosis. This histopathological result, together 
with the widespread aspect of lesions in the mouth, the 
presence of multiple dermatologic lesions and the ab-
sence of risk factors or inflammatory processes, led us to 
conjecture a different diagnosis than keratotic lesions.
Because we suspected CD, we conducted further 
investigations. A gastrointestinal endoscopy showed 
two gastric polypoid lesions, and, four weeks later, a 
gene study by means of direct sequencing established 
the diagnosis of CD caused by a germline mutation in 
exon 8. A close surveillance was established and, at press 
time, the patient continues to be monitored closely for 
manifestations of CD.
Case 2. In November 2013, a 33-year-old white woman 
was referred to the oral medicine unit with the main 
complaint of a one-year history of bilateral hamartoma-
tous lesions of the buccal mucosa. Her medical history 
included moderate obesity (body weight, 103 kilograms; 
height, 1.75 meters; body mass index, 33.6), secondary 
amenorrhea (treated by means of ethinyl estradiol and 
drospirenone), diffuse gastric polyposis, osteoporosis 
and Hashimoto thyroiditis (treated by means of levothy-
roxin 125 micrograms per day). The patient has BRRS, 
diagnosed through genetic tests at the age of 25 years 
after the discovery of this disease in her father.
After providing her written informed consent, the pa-
tient was hospitalized and examined by means of routine 
hematologic tests. All laboratory test values were normal.
Physical examination of the patient revealed bilateral 
exophytic lesions of the buccal mucosa (Figure 2) (maxi-
mum diameter, about 1 centimeter) resulting from the 
confluence of multiple papillomas, widespread papillo-
matous lesions of the maxillary and mandibular gingiva 
(Figure 3) and micropapillomatosis of the tongue with a 
cobblestonelike pattern.
The three clinicians (A.C., D.A., M.D.M.) performed 
an incisional biopsy of the left buccal mucosa, and the 
histopathological examination revealed multiple fibro-
papillomas, with well-differentiated cells and parakerato-
sis, and an absence of inflammatory cells.
The skin inspection revealed a trichilemmoma 
localized on the left nasolabial fold, multiple cutaneous 
papillomas of the left hemithorax and the homolateral 
abdominal skin, skin-colored scars on the site of an 
inframammary incision on the right side (results of a 
surgical procedure performed four months previously) 
and a hemangioma on the elbow. A yearly follow-up 
protocol has been established. 
Case 3. In November 2013, a 60-year-old white man 
visited the oral medicine unit, initially not as a patient 
but rather to accompany the woman described in case 2, 
who was his daughter, on her visit.
His medical history included hypertension, colon 
cancer (in 2005) and a series of surgical removals of 
multiple cutaneous trichilemmomas. Physical exami-
nation revealed widespread papillomatous lesions of the 
ABBREVIATION KEY. BRRS: Bannayan-Riley-Ruvalcaba 
syndrome. CD: Cowden disease. LDD: Lhermitte-Duclos 
disease. PHTS: PTEN hamartoma tumor syndrome. PTEN: 
Phosphate and tensin homolog. RBC: Red blood cell.
Figure 1. Clinical features of case 1: widespread keratotic 
lesions and micropapillomatosis of the maxillary gingiva. Figure 2. Clinical features of case 2: exophytic lesions of the left 
buccal mucosa with spongiotic aspect.
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maxillary and mandibular gingiva with the same clinical 
periodontal pattern as in case 2, as well as multiple 
papillomas of the dorsum of the tongue, all of which had 
a cobblestonelike pattern (Figure 4). Skin inspection 
revealed multiple papillomas of the abdomen and some 
macular pigmentations of the glans penis.
Follow-up for all three patients. Three of the authors 
(A.C., D.A., M.D.M.) properly informed the patients 
about the need to undergo a regular follow-up for 
gastric and colon polyps, thyroid nodules, and breast 
and cutaneous diseases because these conditions usually 
are symptomatic of PHTS and also are associated with 
higher cancer risk.
DISCUSSION
CD is a rare, multisystem disease that causes an in-
creased risk of malignancies (breast, thyroid and endo-
metrial) as well as a benign hamartomatous overgrowth 
of tissues (such as skin, colon and thyroid). CD was 
first described in one family in 1963,2 a description then 
extended by Weary and colleagues3 in 1972, who added 
an additional set of five patients and expanded the spec-
trum of component features. Germline PTEN mutations 
first were reported in people with CD in 1997.4,5
BRRS is a rare congenital disorder whose primary 
clinical features include macrocephaly, hamartomatous 
intestinal polyps, lipomas and pigmented macules on the 
penis. Other features include developmental delay, vas-
cular anomalies, large birth weight and joint hyperexten-
sibility.6 Diagnoses are based on the presence of several 
of the primary clinical features. BRRS has been shown 
to be allelic to CD, with approximately 60 percent of 
patients with a clinical diagnosis of BRRS having PTEN 
mutations.7,8 There are relatively few data regarding 
the clinical features of BRRS patients with documented 
PTEN mutations, however; only 30 published cases have 
been identified (in a 2003 review9).
The National Comprehensive Cancer Network, Fort 
Washington, Pa., has established testing criteria denot-
ing when PTEN testing is indicated; these criteria are 
based on the clinical features present in a patient.10 It 
also has established management and screening recom-
mendations for people who have been found to have a 
PTEN mutation. However, in clinical practice, it often is 
necessary to provide treatment for patients on the basis 
of their clinical diagnosis alone, either because testing is 
not possible or because it has been done but no muta-
tion has been found. Thus, accurate clinical diagnostic 
criteria are a necessary adjunct to genetic testing.
Box 1 presents a summary of the diagnostic criteria 
for PHTS proposed by Pilarski and colleagues.1
Patients affected by PHTS require lifelong follow-up, 
and family members should be screened for the disease. 
For example, mammography at regular intervals and 
monthly breast self-examination are of great importance 
for the early diagnosis of breast cancer. Some authors 
even suggest bilateral prophylactic mastectomy for pa-
tients with PHTS.11
Thyroid function tests, thyroid ultrasonography, 
complete blood count, complete urine analysis, Papani-
colau (Pap) test and abdominopelvic ultrasonography 
should be performed with all patients at the first stage 
and repeated at regular intervals. If thyroid nodules are 
present, fine-needle biopsy or surgical biopsy should be 
performed.12
Box 210 presents a brief summary of the management 
of CD. 
As is well known from the literature and confirmed by 
our experience, alterations in the oral mucosa and skin 
usually are present in patients with PHTS.1 Starink and col-
leagues13 reported that 100 percent of patients with PHTS 
developed oral papillomatosis by the second decade of life, 
and, for this reason, in the majority of cases such features 
may precede malignancy in other sites.
A differential diagnosis of oral papillomatous lesions 
includes multiple traumatic fibromas, oral fibromas in 
tuberous sclerosis, Darier-White disease, Heck disease, 
lymphangioma, pyogenic granuloma, fibroepithelial 
polyps, lipoid proteinosis, oral florid papillomatosis, oral 
papillomas in Goltz syndrome, mucosal neuromas of 
Figure 4. Clinical features of case 3: widespread papillomatosis of 
the maxillary gingiva. 
Figure 3. Clinical features of case 2: widespread papillomatous 
lesions of the maxillary gingiva.
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multiple endocrine adenomatosis, acanthosis nigricans, 
pseudoepitheliomatous hyperplasia and squamous cell 
carcinoma.14
CLINICAL IMPLICATIONS
The purpose of this article is to stimulate general dental 
practitioners to perform an accurate oral examination 
focusing mainly on the periodontal mucosa and to 
investigate the differential diagnosis of widespread oral 
papillomatous lesions carefully. These can represent one 
of the primary clinical features of this diagnostic chal-
lenge, even in young people.
Early diagnosis is the most important element in the 
management of PHTS: affected people have a lifetime 
risk of up to 50 percent for breast cancer, 10 percent for 
thyroid cancer and 5 to 10 percent for endometrial can-
cer. More than 90 percent of affected people will show 
some clinical manifestations by their 20s.15-19
Dental practitioners who suspect the presence of a 
PTEN-related syndrome, or more generally of a multiple 
hamartoma syndrome, should request from specialists a 
better screening of their patients to meet major and mi-
nor diagnostic criteria before resorting to genetic inves-
tigation, which is expensive. The important diagnostic 
steps after the oral examination are an accurate anam-
nestic evaluation, an accurate total-body dermatologic 
examination, breast and thyroid sonographic imaging, a 
genitourinary screening, gastroscopy and colonoscopy.
Establishing a clear diagnosis means giving these 
patients the opportunity to undertake an earlier self-
surveillance, thereby decreasing the mortality and 
morbidity associated with these conditions. Once again, 
dentists may play an important role in the diagnosis and 
management of rare systemic diseases. 
BOX 2
Management of Cowden disease.*
WOMEN
dBreast self-examination starting at age 18 years
dClinical breast examination starting at age 25 or fi ve to 10 years 
before the earliest breast cancer in the family occurred, whichever 
comes fi rst
dPatient education about endometrial cancer symptoms and 
clinical screening
dDiscussion of prophylactic mastectomy and hysterectomy
MEN AND WOMEN
dAnnual physical examination starting at age 18 years or fi ve years 
before the youngest age at which cancer occurred in family history, 
whichever comes fi rst
dThyroid sonogram at age 18, then once per year
dColonoscopy, starting at the age of 35 years, then every fi ve to 10 
years
dAnnual dermatologic examination
RISK TO RELATIVES
dExplanation of possible inherited cancer risks to relatives, as well 
as of options for risk assessment and management (the parents of 
an affected proband must be examined clinically and genetically; if a 
parent is affected, his or her family members are at risk)
dGenetic counseling
* Source: National Comprehensive Cancer Network.10
BOX 1
Revised clinical diagnostic criteria for 
PTEN* hamartoma tumor syndrome.†
MAJOR CRITERIA
Breast cancer
Endometrial cancer (epithelial)
Thyroid cancer (follicular)
Gastrointestinal hamartomas (including ganglioneuromas, but 
excluding hyperplastic polyps; three or more gastrointestinal 
hamartomas total)
Lhermitte-Duclos disease (adult)
Macrocephaly (an occipital-frontal head circumference in the 97th 
percentile or higher): 58 centimeters for females, 60 cm for males)
Macular pigmentation of the glans penis
Multiple mucocutaneous lesions (any of the following), proven by 
means of a biopsy or diagnosed by a dermatologist:
dMultiple trichilemmomas (three or more, at least one of them  
proven by means of a biopsy)
dAcral keratoses (three or more palmoplantar keratotic pits, acral 
hyperkeratotic papules or a combination of the two)
dMucocutaneous neuromas (three or more)
dOral papillomas (particularly on tongue and gingiva), multiple 
(three or more)
MINOR CRITERIA
Autism spectrum disorder
Colon cancer
Esophageal glycogenic acanthosis (three or more lesions)
Lipomas (three or more)
Intellectual disability (that is, an intelligence quotient test score of 
75 or lower)
Renal cell carcinoma
Testicular lipomatosis
Thyroid cancer (papillary or follicular variant of papillary)
Thyroid structural lesions (for example, adenoma, multinodular 
goiter)
Vascular anomalies (including multiple intracranial developmental 
venous anomalies)
OPERATIONAL DIAGNOSIS IN AN INDIVIDUAL: 
EITHER OF THE FOLLOWING
Three or more major criteria, but one must be macrocephaly, 
Lhermitte-Duclos disease or gastrointestinal hamartomas
OR
Two major and three minor criteria
OPERATIONAL DIAGNOSIS IN A FAMILY IN WHICH ONE PERSON 
MEETS REVISED CLINICAL DIAGNOSTIC CRITERIA FOR PTEN 
HAMARTOMA TUMOR SYNDROME OR HAS A PTEN MUTATION
Any two major criteria with or without minor criteria
OR
One major criterion and two minor criteria
OR
Three minor criteria
* PTEN: Phosphatase and tensin homolog.
† According to the diagnostic criteria for PTEN hamartoma tumor 
syndrome proposed by Pilarski and colleagues.1
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CONCLUSIONS
Our experience highlights that oral health care workers 
could represent the first line of defense in early diagnosis 
of rare disorders. In the patients in our three cases, gin-
gival clinical features and a widespread oral papilloma-
tosis led us to suspect PHTS or, in the already diagnosed 
patients, PHTS-related lesions.
Three cases of PHTS, two of them in patients of rela-
tively young ages, are not a small number to be seen in a 
single center, and this aspect stresses the importance of 
intercepting disease early.
Nowadays, the visual inspection of the oral cavity 
requires higher standards, commensurately greater time, 
and a wider knowledge of these diseases and their main 
clinical features. A multidisciplinary approach is key 
in these diagnostic challenges and allows clinicians to 
achieve a remarkable diagnostic success. If physicians are 
able to provide an early diagnosis, people with rare disor-
ders can achieve an adequate quality of life, reducing the 
systemic complications of their conditions. ■
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Mucosal leishmaniasis with primary oral involvement: a
case series and a review of the literature
MD Mignogna1, A Celentano1, S Leuci1, M Cascone1, D Adamo1, E Ruoppo1, G Favia2
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OBJECTIVE: To analyze retrospectively a case series of
primary oral leishmaniasis and to review the literature
on head–neck primary mucosal leishmaniasis (ML) in
immunocompetent patients.
SUBJECTS AND METHODS: A PUBMED search was
carried out from 1950 to 2013. Clinical records of
patients with primary head–neck mucosal manifesta-
tions of leishmaniasis were analyzed. In addition, clinical
records between 2001 and 2012 of patients with pri-
mary oral manifestations were collected in two indepen-
dent hospitals.
RESULTS: Our multicenter case series revealed seven
patients with oral leishmaniasis. The most commonly
affected site was the tongue (four patients, 57%), and
the most common clinical presentation was an exophy-
tic lesion (six patients, 85%). The literature review
showed 11 reports published between 2005 and 2013,
describing 13 patients (100% male) affected by head–
neck primary ML (54% laryngeal, 31% oral, 23% pharyn-
geal, and 15% endonasal). The most common clinical
presentation was an exophytic lesion (69%).
CONCLUSIONS: The literature analysis revealed that
in immunocompetent patients, the oral mucosa is the
second most frequently affected site of the head and
neck region. In the oral cavity, the tongue is the most
affected site. Diagnosis of oral leishmaniasis represents
a challenge but must be considered in any differential
diagnosis of exophytic lesions of oral mucosa.
Oral Diseases (2015) 21, e70–e78
Keywords: primary oral leishmaniasis; mucosal; immunocompetent;
head–neck leishmaniasis
Introduction
Leishmaniasis is a parasitic disease caused by several pro-
tozoan species of the genus Leishmania, belonging to the
family Trypanosomatidae. After malaria and African try-
panosomiasis (‘sleeping sickness’), the leishmaniases are
the third most important group of vectorborne diseases
and are ranked ninth in terms of the global burden of dis-
ease of all infectious and parasitic diseases (Prabhu et al,
1992; Stockdale and Newton, 2013).
The leishmaniases are widely dispersed, with transmis-
sion to humans on ﬁve continents, and are endemic in 98
countries. However, the human disease burden is concen-
trated mainly in a few major foci. The epidemiological
data on leishmaniasis are very complex, with intra- and
interspeciﬁc variations in transmission cycles, reservoir
hosts, sand ﬂy vectors, and clinical forms (World Health
Organization, 2010).
Travelers and soldiers who have to stay in endemic
areas, foreign citizens, migrant workers, asylum seekers,
refugees from endemic areas, migrants, and immunosup-
pressed patients are considered as risk groups (Grimaldi
and Schottelius, 2001).
In humans, the clinical forms of the leishmaniases are
broadly categorized into three groups: visceral leishmania-
sis (VL), cutaneous leishmaniasis (CL), and mucosal leish-
maniasis (ML). However, a more complete classiﬁcation
encompasses 11 different clinical forms (World Health
Organization, 2010). Among these, mucocutaneous leish-
maniasis (MCL) or ML pure forms can occur with a
latency of months, even years, after exposure in endemic
areas and because of this huge latency, the diagnosis is
often seriously delayed. All the clinical forms of leishman-
iasis can start with primary mucosal lesions in the head–
neck region, sometimes affecting the oral cavity, or certain
signiﬁcant symptoms detectable by the dental practitioner.
Such symptoms include swallowing difﬁculties, dyspho-
nia, and dyspnea. Therefore, dentists play an important
role in the early diagnosis of oral leishmaniasis, to avoid
the systemic spread of the disease (Pellicioli et al, 2012).
In any such systemic spread, the sites most commonly
involved are the liver, spleen, abdominal lymphatic sys-
tem, lymph nodes, and bone marrow.
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Management of leishmaniasis still represents a big
challenge. Presently, the main target of any drugs used is
to ﬁght the parasite in its different physiological and
biochemical aspects and to promote the immune response
of the host. The therapeutic strategies currently available
include pentavalent antimony derivatives, systemically or
intralesionally administered, pentamidine, metronidazole,
amphotericin B, azoles, and miltefosine (Masmoudi et al,
2013).
The primary objective of this study is to present a retro-
spective multicenter case series describing seven cases of
primary oral leishmaniasis. The secondary objective is to
review the literature on head and neck primary ML in
immunocompetent/otherwise healthy patients, as no simi-
lar data are currently available in the literature, and to
update the current literature with our seven new cases.
Patients and methods
Multicenter case series assessment
We retrospectively selected and analyzed the clinical data
of leishmaniasis patients from the archives of two inde-
pendent hospitals, the outpatient clinic of the Oral Medi-
cine Unit, Department of Head and Neck Diseases,
Federico II University of Naples and the Department of
Dental Sciences and Surgery, University of Bari, reporting
seven new cases with a history of ML with exclusive and
primary oral involvement, diagnosed and treated between
2001 and 2012.
The study was approved by the Ethics Committee of
University of Naples ‘Federico II’.
All patients, after providing their written informed con-
sent, were hospitalized and examined by routine hemato-
logical testing, HIV, HBV, HCV, and oral biopsies with
histopathological evaluation. Abdominal CT and bone
marrow biopsies were made in some cases to exclude any
suspected visceral forms. The study was performed in
accordance with the Declaration of Helsinki.
Literature review
Subsequently, we retrospectively reviewed all articles from
1950 to 2013 focused on cases of ML in immunocompe-
tent/otherwise healthy patients, by searching in the
PubMed database on each of the following keywords:
‘mucosal’, ‘oral’, ‘buccal’, ‘nose’, ‘nasal’, ‘pharynx’, ‘pha-
ryngeal’, ‘esophagus’, ‘esophageal’, ‘larynx’, ‘laryngeal’
in association with ‘leishmaniasis’, and alternatively with
‘healthy’ and ‘immunocompetent’.
The inclusion criteria of this review encompass (i) arti-
cles published in the English language reporting primary
ML for all patients described; (ii) healthy or immunocom-
petent patients who contracted an infection of leishmania-
sis between 1950 and 2013; (iii) mucosal lesions that
presented in the regions of the nasal mucosa, oral mucosa,
nasopharynx, oropharynx, hypopharynx, esophageal, and
laryngeal mucosa; (iv) the absence of any visceral or cuta-
neous manifestations; and 5) documentation on the leish-
mania infection.
A ﬂow chart is shown in Figure 1.
In relation to the reviewed articles, we collected, tabu-
lated, and depicted the following information: country and
year of publication, age, sex, underlying or past diseases,
predisposing risk factors, local conditions, involved sites,
symptoms, lesion description, diagnostic procedures, treat-
ment, follow-up period, and outcomes.
Results
The case series from our database shows seven patients,
three of whom were treated at our institution.
All the patients underwent incisional or excisional
biopsy (cases 2, 4, and 7), and in all cases, the biopsy
showed inﬂammatory lesions, with the presence of para-
sites belonging to Leishmania spp., allowing the diagnosis
of leishmaniasis. Subsequently, all patients underwent rou-
tine laboratory examinations, CT scanning, and bone mar-
row biopsy, revealing no signiﬁcant ﬁndings or evidence
of leishmaniasis elsewhere except for splenomegaly in
case 5 (Figures 2–6).
Case reports
Case 1 – A 55-year-old Caucasian man with a history of a
4-week painful swelling affecting the left side of the ton-
gue. The patient had lived in Senegal for 20 years and
was a smoker (25 cigarettes daily for 30 years).
Physical examination showed a nodular, whitish, and
ulcerated lesion on the left edge of the tongue, 1.7 cm of
maximum diameter, with some mild perilesional ﬁssura-
tions.
The patient was treated with 28 intramuscular injections
of meglumine antimoniate at a daily dose of 5 mg kg!1
body weight.
After 1 month, the patient had a complete remission of
the tongue lesion, but after 8 months, the disease recurred
with the onset of a cutaneous form of leishmaniasis. The
patient was referred to the Infectious Diseases Department
for treatment.
Case 2 – A 48-year-old Caucasian man with a history
of a 7-week painful lesion of the tongue. The patient was
Figure 1 Flow chart
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a former smoker (40 cigarettes daily for 25 years), and
2 years before, he had been treated with polychemothera-
py for B-cell lymphoblastic NHL.
Physical examination revealed a nodular and erythema-
tous lesion, with a hard consistency and a mild bleeding
upon palpation, affecting the left lateral border of the ton-
gue, near the tongue tip.
Surgical treatment with an excisional biopsy was per-
formed. The patient refused the recommended pharmaco-
logical treatment.
After the clinical healing, the patient had a 7-month fol-
low-up period but subsequently developed a visceral form
of leishmaniasis characterized at onset by fever, diarrhea,
hepatosplenomegaly, and lymphadenopathy. The patient
was referred to the Infectious Diseases Department for
treatment.
Case 3 – A 33-year-old man from Pakistan with a his-
tory of a 7-week swelling and soreness of the tongue with
a difﬁculty in swallowing and 4-kg weight loss.
Physical examination revealed an ulcerated, soft-to-ﬁrm,
and dome-shaped mass of the dorsum of the tongue. The
largest diameter was approximately 3.5 cm.
No skin lesions were observed. The patient was treated
with 20 intramuscular injections of meglumine antimoniate
at a daily dose of 5 mg kg!1 body weight.
After 1 month, the patient had a complete remission of
the tongue lesion; after 13 months, the disease recurred
Figure 2 Clinical aspect of the Case n. 1
Figure 3 Clinical aspect of the Case n. 2
Figure 4 Clinical aspect of the Case n. 5
Figure 5 Clinical aspect of the Case n. 7
Figure 6 (Case n. 1) Histopathological examination (Hematoxylin-Eosin,
X400) of the lingual lesion showed disruption of the basal-intermediate
epithelial layers due to inﬂammatory inﬁltration (lymphocytes, macro-
phages and focal plasma cells), intra- and extra-cellular Leishmania spp.
amastigotes and endothelial damage
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with the onset of a cutaneous form of leishmaniasis. The
patient was referred to the Dermatological Department for
treatment.
Case 4 – A 41-year-old Caucasian man with a history
of an 8-week asymptomatic lesion affecting the dorsum of
the tongue.
The man was a farmer, and 4 weeks before the appear-
ance of the lesion, he had undergone two courses of anti-
biotics for a prostatitis.
Physical examination showed a multinodular lesion
affecting the posterior dorsum of the tongue, just anterior
to the circumvallate papillae, with an increased consis-
tency and a maximum diameter of 2 cm.
After excisional surgical treatment, the patient was trea-
ted with stibogluconate 20 mg kg!1 day!1 for 20 days
and had a complete healing with a negative 12-month fol-
low-up.
Case 5 – A 61-year-old Caucasian woman with a history
of a 5-week diffuse and sore swelling of the upper lip.
The woman was from Ischia, a well-known endemic
area of leishmaniasis in Italy. She was in good health
except for a reported splenomegaly, conﬁrmed by abdomi-
nal CT scan.
Physical examination showed a diffuse swelling of the
upper lip measuring approximately 4 9 1.5 cm with
ulcers and erosions extending to the anterior maxillary
vestibule.
Two previous biopsies, performed in others hospitals,
had been negative.
We performed a third biopsy that showed an inﬂamma-
tory reaction and some parasites in the cytoplasm of the
histiocytes, allowing us to establish the diagnosis.
Subsequently, the patient was treated with meglumine
antimoniate at a daily dose of 5 mg kg!1 body weight.
After 10 days, clinical improvement was present, and after
40 days, the patient had a complete healing.
After 2 years, she was referred to the Internal Medicine
Department because of a para-ovarian abdominal mass:
histopathology revealed a visceral form of leishmaniasis.
The patient was referred to the Infectious Diseases Depart-
ment for treatment.
Case 6 – A 66-year-old Caucasian man with a history
of painful and tender lesion affecting the hard and soft
palatal mucosa for several weeks. About 20 years before,
he had been referred to the Department of Respiratory
Diseases, Cotugno Hospital, Naples, Italy, because of a
not speciﬁed pulmonary disease.
Physical examination showed a widespread, irregular,
and granular plaque involving the hard palatal mucosa and
extending to the soft palate, left maxillary gingiva, and
alveolar mucosa. The lesion was also characterized by ery-
thema, and multiple ulcerations mainly localized on the
hard palatal mucosa.
The patient was treated with meglumine antimoniate at
a daily dose of 5 mg kg!1 body weight for 6 weeks, and
subsequently, the lesions healed. The follow-up period
was 30 months, and the result was negative.
Case 7 – A 31-year-old Caucasian man with a history
of a 4-week painful lesion affecting the buccal mucosa.
Physical examination revealed an exophytic and well-
deﬁned lesion of the left buccal mucosa.
This mucosal-colored plaque bled easily and had an
increased consistency and a largest diameter of approxi-
mately 2.2 9 1.5 cm.
The patient was treated with meglumine antimoniate at
a daily dose of 5 mg kg!1 body weight for 20 days. The
follow-up period was 8 months, and the result was nega-
tive.
The case series from our retrospective study revealed
seven patients with oral leishmaniasis, six of whom (85%)
were men and one a woman with a mean ("SD) age at
the time of diagnosis of the disease of 48 ("14) years.
The most commonly affected site was the tongue (four
patients, 57%), followed by one case each on the lip, pala-
tal mucosa, and buccal mucosa.
The clinical aspects presented were exophytic lesions in
six patients (85%) and an ulcerated lesion in one patient
(14%).
The analysis of the literature review revealed eleven
articles published between 2005 and 2013, from ﬁve dif-
ferent countries, with a total of thirteen patients described.
All the patients were male (100%), and their mean ("SD)
age at the time of diagnosis of the disease was 56 ("14)
years.
The largest number of cases was from Italy (six
patients, 46%). Other patients came from Iran (three cases,
23%) and Brazil (two cases, 15%). The other two cases
were from England and India. All the clinical results from
the review are summarized in Tables 1–3.
The treatment was speciﬁed in only eleven of the thir-
teen cases. The most common treatment was amphotericin
B (ﬁve cases, 45%), followed by meglumine antimoniate
(three cases, 27%). One case each (9%) was treated with
stibogluconate, miltefosine, and surgery. The healing times
of the lesions were not available in detail, but the data on
the outcomes, as well as the diagnostic criteria and fol-
low-up, are summarized in Table 4.
Including our case series, the total number of Italian
cases in literature has increased to 13.
No signiﬁcant differences were found between our six
cases (exclude Case 3 from Pakistan) and other cases from
Italy found in the literature review in terms of gender,
age, and response to treatment, except in relation to the
affected sites.
In fact, in the review, there were no Italian cases of pri-
mary oral ML.
Discussion
The leishmaniases are a group of infectious diseases
caused by obligate intracellular protozoan parasites of the
genus Leishmania that continue to be an increasing world-
wide threat. Approximately 58 000 cases of VL and
220 000 cases of CL are ofﬁcially reported each year.
Based on assessments of under-reporting, 0.2–0.4 million
new cases of VL and 0.7–1.2 million new cases of CL are
estimated to occur every year (Desjeux, 1996; Alvar et al,
2012). The WHO estimates that 350 million people are at
risk of contracting leishmaniasis (World Health Organiza-
tion, 2010). These data are troubling considering that the
disease causes signiﬁcant morbidity and mortality account-
ing for more than 57 000 deaths per year and an estimated
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2–2.4 million disability-adjusted life years lost (World
Health Organization, 2000; Hotez et al, 2004).
The parasite resides intracellularly and is transmitted
between hosts by the bite of the female sand ﬂy (genus
Phlebotomus in the Old World localities of Europe,
Africa, and Asia, and Lutzomyia in the New World, the
Americas, and Oceania). The primary hosts are vertebrates
such as humans, domestic dogs and cats, opossums, the
crab-eating fox, and the common black rat. Human infec-
tion is caused by more than 20 different species that infect
mammals (Balasegaram et al, 2012; Montalvo et al, 2012;
Stockdale and Newton, 2013).
Leishmania have a digenetic life cycle consisting of the
morphologically distinct promastigote and amastigote
stages. Promastigotes are the ﬂagellated, motile stage that
reside extracellularly in sand ﬂy vectors of the genera
Phlebotomus or Lutzomyia. Virulent metacyclic promastig-
otes are inoculated into the dermis of mammalian hosts
during sand ﬂy blood meals. Macrophages rapidly inter-
nalize the promastigotes forming a parasitophorous vacu-
ole that then fuses with the lysosomes to generate an
acidic compartment containing hydrolytic enzymes, where
they further differentiate into amastigotes (Sacks et al,
1994; Murray et al, 2010).
Human VL is mainly caused by two species of Leish-
mania parasites, each having a characteristic regional dis-
tribution: L. infantum is the causative agent in the
Mediterranean, Middle-east, Central Asia, China, and
Central and South America; L. donovani in India and East
Africa. VL may also be caused by L. tropica in the Old
World and L. amazonesis in the New World and is fatal
in 85–90% of untreated cases and up to 50% of treated
cases (Gill and Beeching, 2009).
Visceral leishmaniasis is characterized by weight loss,
fever, cytopenia, and hepatosplenomegaly (Carranza-
Tamayo et al, 2010).
Approximately 90% of CL occurs in Afghanistan, Paki-
stan, Syria, Saudi Arabia, Algeria, the Islamic Republic of
Iran, Brazil, and Peru (Kassi et al, 2008), with an incuba-
tion period ranging from 2 weeks up to several months
(Grimaldi and Schottelius, 2001) and a wide spectrum of
clinical presentations ranging from cutaneous ulceration to
various degrees of mucosal involvement.
The symptoms and the extent and localization of the
lesions depend both on the characteristics of the parasite
and on the host immune response.
Cutaneous leishmaniasis is the most prevalent and is
characterized by the presence of ulcers with a well-deﬁned
erythematous border and a central crust that is often hem-
orrhagic, located in exposed areas of the body and ranging
in number from one to ten (Nogueira et al, 2008; Goto
and Lindoso, 2010). MCL is the most severe form and
presents clinically a few years after the manifestation of
the cutaneous form, affecting the upper aerodigestive tract,
with lesions mainly in the oral and nasal mucosa and
occasionally in the laryngeal and pharyngeal mucosa
(Palmeiro et al, 2007; Nogueira et al, 2008). These
lesions are generally associated with pain, edema, halito-
sis, bleeding, and sialorrhea (Palmeiro et al, 2007).
Mucosal leishmaniasis of the upper respiratory tract is
usually associated with the VL form or is found in immu-
nosuppressed individuals like those with HIV infection or
Table 1 Data of 13 patients from pubmed search: epidemiology and predisposing factors
Reference Country Age Sex Underlying or past diseases
Predisposing
risk factors Local impairment
Palmeiro
et al (2007)
Brazil 75 M None Endemic area
Farmer
Deﬁcient oral hygiene,
poor tooth conservation
Pellicioli et al (2012) Brazil 71 M Hypertension (atenolol and
hydrochlorothiazide treated)
Farmer –
Cocuzza et al (2013) Italy 64 M (COPD) since 20 years.
Hypersensitivity to non-steroidal treatment
Anti-inﬂammatory
Endemic area Former smoker
(25 cig day!1)
Oryan (2013) Iran 42 M None Endemic area –
Oryan (2013) Iran 32 M None Endemic area –
Pau et al (2009) Italy 52 M Hypertension (by ACE inhibitors treated) Endemic area,
Shepherd
None
Pau et al (2009) Italy 71 M Ischemic cardiopathy (coronary
by-pass surgery 2002)
Endemic area,
Farmer
None
Habibzadeh
et al (2005)
Iran 40 M None Endemic area None
Guddo et al (2005) Italy 59 M COPD, Low level of IgM (28.8 mg 100 ml!1) Endemic area Smoker
Casolari (2005) Italy 53 M None Endemic area –
Tiseo et al (2008) Italy 64 M Well-compensated type 2 diabetes mellitus Endemic area Until 8 years previously, he had
been a heavy smoker (50 cig day!1)
Mathur et al (2006) India 45 M Hemoglobin = 11.2 G%
Leukocyte tot. count: 12 000 mm!3
Endemic area –
Kassam
et al (2013)
England 66 M COPD (diagnosed in 2002) raised
ESR (34 mm h!1)
– Former smoker (20 cig day!1) for
40 years, recently had three courses
of antibiotics and got salbutamol,
steroid inhalers and an antihistamine
for the COPD
–, Not reported/unknown; ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; ESR, erythrocyte sedimentation rate.
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a solid organ transplant. In these clinical settings, leish-
maniasis shows the most severe signs and symptoms,
characterized by fever, chills, hepatosplenomegaly, pancy-
topenia, gastrointestinal involvement, and/or ascites.
In immunocompetent patients, the primary and exclu-
sive mucosal involvement of the head–neck region is very
uncommon and the exclusive and localized oral mucosa
leishmaniasis is an even more rare event.
Most of the cases reported in literature, and excluded
from our study, describe a mixed form of leishmaniasis, in
which the mucosal lesions are contemporary with or sec-
ondary to the visceral or cutaneous forms.
Diagnosis is very often a challenge with several reports
in the literature of a signiﬁcantly delayed diagnosis or
even an erroneous clinical diagnosis of malignancy (Caso-
lari et al, 2005; Mathur et al, 2006; Tiseo et al, 2008;
Pellicioli et al, 2012; Cocuzza et al, 2013; Oryan et al,
2013). Differential diagnosis encompasses other infectious
or non-infectious diseases such as fungal infections (blas-
tomycosis), tertiary syphilis, sarcoidosis, paracoccidioid-
omycosis, histoplasmosis, tuberculosis, leprosy, lethal
midline granuloma, pemphigus vulgaris, pemphigoid, plas-
macytic gingivitis, (deﬁciencies) anemia, leukemia, anti-
neutrophilic cytoplasmic antibody (ANCA)-associated
(Wegener) granulomatosis, and squamous cell carcinoma
(Casolari et al, 2005; Palmeiro et al, 2007; Pellicioli et al,
2012).
Table 2 Data of 13 patients from pubmed search: Clinical features
Reference Involved sites Symptoms Lesion description
Palmeiro
et al (2007)
Palatal mucosa (hard and
soft palate)
Uvula
Swallowing difﬁculties Granular area with presence of coarse
granulation
gingiva Fine granulation
Pellicioli et al (2012) Palatal mucosa (hard and
soft palate)
oropharynx
Weight loss (approximately 8 kg).
Slight pain and no bleeding upon palpation
Largest diameters measuring
approximately 5 9 4 cm.
Multiple ulcerated nodules, with
granulomatous appearance and ﬁbro-elastic
consistency
Cocuzza et al (2013) True vocal cords 8 months history of hoarseness and discomfort Two focal hard and whitish lesions
Oryan (2013) Laryngeal mucosa Several months history of dysphonia, dyspnea,
hoarseness, and odynophagia
Single lesion
Oryan (2013) Epiglottis, cricoarytenoid muscle,
laryngeal mucosa
Several months history of: dysphonia, dyspnea,
hoarseness, odynophagia.
Vocal cords paralysis; swelling, erythema and
edema of the epiglottis and aryepiglottic folds
Deep mucosal damaging processes
Pau et al (2009) Endonasal mucosa (anterior part
of left cartilaginous septum)
Epistaxis Bright red, 1 cm nodule bled easily,
moderately inﬁltrated, covered by
serohematic crusts
Pau et al (2009) Endonasal mucosa
(left nasal vestibule)
Epistaxis, rhinorrhea, sense of obstruction,
and respiratory difﬁculty.
Moderate labial edema
Hard erythematosus, polypoid, non-ulcerated
and painless, 1.5 cm diameter nodule
Habibzadeh
et al (2005)
Right side of the tongue (against
the ﬁrst molar tooth)
None Fleshy mass, measuring 5 9 7 9 5 mm
Guddo et al (2005) Larynx (subglottic mucosa) Cough, exertional dyspnea, mucus
production, bronchiectases
3 mm mucosal polypoid-like lesion
Casolari (2005) Right epiglottis region
Inﬁltrating the
pharyngo-laryngeal wall
Dyspnea,
Dysphonia
Odynophagia
Whitish, fungating, swelling
Lesion
Tiseo et al (2008) Left wall of the pharynx,
vocal cords
Dysphonia –
Mathur et al (2006) Hemilarynx (bilaterally)
Epiglottis, involving
posterior commissure
Hoarseness, cough and a history of
fever for 18 months
Fixed ulcerative growth,
With edematous surrounding areas
Kassam
et al (2013)
Tongue (left mid-dorsum) 3-month history of swelling and
soreness of the dorsum of the tongue
because of painful ulceration,
and some difﬁculty in swallowing
Lymphoid-like tissue swelling
–, Not reported/unknown.
Table 3 Comparative data on age, gender and sites of involvement
Our cases
(n = 7)
Review cases
(n = 13)
Total
(n = 20)
Overall age
range (years)
31–66 32–75 31–75
Men 6 13 19
Women 1 0 1
Mean ("SD) age 48 ("14)
years
56 ("14)
years
53 ("14)
years
Larynx 0 7 7
Tongue 4 2 6
Pharynx 0 4 4
Palate 1 2 3
Nasal mucosa 0 2 2
Buccal mucosa 1 0 1
Gingiva 0 1 1
Lip 1 0 1
SD, Standard deviation.
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One further important aspect to be discussed is the difﬁ-
culty of establishing the diagnosis of infectious diseases
with a biopsy. Two cases from this literature review, and
one in our case series, had previously been submitted to
several earlier biopsy procedures, with inconclusive histo-
pathological diagnoses. This is probably due to the simi-
larity of all the granulomatous lesions in the
histopathological analysis, the morphological differentia-
tion of the parasites being the only way to make a histo-
pathological diagnosis. This aspect highlights the need to
complete the examination in all uncertain cases with a
more speciﬁc diagnostic procedure like ELISA or PCR.
The literature shows a wide spectrum of diagnostic cri-
teria which encompasses clinical signs, culture of smears
of samples, and PCR. Serological testing has also been
reported, such as the direct agglutination test, conventional
ELISA test, and rk39 rapid diagnostic ELISA test (World
Health Organization, 2010; Pellicioli et al, 2012; Masmo-
udi et al, 2013; Stockdale and Newton, 2013). Serology
can be helpful when other diseases have to be considered
in a differential diagnosis or if there are uncertain clinical
or histopathological data. PCR can be used on skin
mucosa biopsy samples or slit-skin specimens. The sensi-
tivity of this test varies depending on the PCR methods
Table 4 Data of 13 patients from pubmed search: diagnosis and treatment
Reference Diagnostic tests Treatment
Follow-up
(months) Outcome
Palmeiro et al (2007) Montenegro skin test
Serology (IIF)
Histopathological (hematoxylin–eosin,
Ziehl-Neelsen, Silver), Culture
Meglumine antimoniate
(5 mg kg!1 day!1)
i.m. for 20 days
30 Healing
Pellicioli et al (2012) Montenegro skin test
4 Biopsies (inconclusive diagnoses)
Histopathological (hematoxylin–eosin,
Ziehl-Neelsen, Silver, Pas)
Immunohistochemistry
Liposomal amphotericin B for
5 weeks
– Healing with residual
ﬁbrosis
Cocuzza et al (2013) 12-2009
Fibroscopy and laryngeal biopsy
(inﬂammation and hyperplasia)
Amoxicillin Lack of clinical
improvement
07-2010
Second laryngeal biopsy
PCR
Liposomal amphotericin B
(3 mg kg!1 day!1)
for 7 days, then (3 mg kg!1 per
once a week) for 5 weeks
Achieved complete
recovery
05-2011
Third laryngeal biopsy
Liposomal amphotericin B
(3 mg kg!1 day!1) for 7 days,
then (3 mg kg!1 per once a week)
for 5 weeks
20 Resolution of
symptoms and good
health
Oryan (2013) Laryngoscopy
Cytologic (Wright and Papanicolaou)
Nested PCR
– – –
Oryan (2013) Laryngoscopy
Cytologic (Wright and Papanicolaou)
Immunocytochemistry, Nested PCR
– – –
Pau et al (2009) Endoscopy
Facial X-ray
Histopathological (Giemsa)
Meglumine antimoniate
300 mg ml!1: intralesional
inﬁltration (1 ml per weekly) for
4–5 weeks
36 Full resolution
Pau et al (2009) Rhinoscopy
Cytological and histopathological (Giemsa)
Isoenzymatic characterization
Meglumine antimoniate
300 mg ml!1: intrales. inﬁltr.
(1 ml per weekly) for 4 weeks
12 Healing
Habibzadeh
et al (2005)
Histopathological
Indirect immunoﬂuorescence
Surgical 48 Healing
Guddo et al (2005) Bronchoscopy
Histopathological (hematoxylin–eosin,
Ziehl-Neelsen, Gram, Grocott, Giemsa)
PCR, ELISA test on serum
Microbiological
Ciproﬂoxacin (without clinical
improvement) then Amphotericin
B: (0.5 mg kg!1 day!1)
- Clinical improvement
Casolari et al (2005) Laryngoscopy
Multiple Histological (Giemsa), Culture
Nested PCR
Liposomal amphotericin B 2
courses, 10 days apart,
(3 mg kg!1 day!1) for 5 days
12 Healing
Tiseo et al (2008) CT scan
Direct laryngoscopy
Histological (Giemsa)
Antibody title (weakly positive)
Liposomal amphotericin B: starting
with 0.5 mg kg!1 day!1, Overall
dosage: 950 mg
2 Healing Lesion
decrease
Mathur et al (2006) Direct laryngoscopy, Histopathological
(hematoxylin–eosin, Pas, Giemsa), Serology
Stibogluconate (20 mg kg!1 day!1)
For 2–3 weeks
3 Signiﬁcant symptom
improvement
Kassam et al (2013) Histopathological (hematoxylin–eosin, Giemsa) PCR Miltefosine: 150 mg BD for 28 days 10 Healing
–, Not reported/unknown; IIF, indirect immunoﬂuorescence; PCR, polymerase chain reaction; CT, computed tomography.
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and the clinical features of the lesions (World Health
Organization, 2010; Oryan et al, 2013). For this reason,
the identiﬁcation of amastigotes in biopsy specimens from
the skin or mucosa is the most common diagnostic tool
(World Health Organization, 2010).
The cases described from our database conﬁrm that the
most common clinical presentation of primary ML in the
head and neck region is an exophytic lesion found in 85%
of our cases as compared to 69% in the literature review.
The most commonly involved oral site is the tongue,
followed by the palatal mucosa.
Comparing our results with the data from the literature,
we found an 8 year difference in the mean age of the
patients, with the same standard deviation of 14 years.
Our data conﬁrm a near-exclusive dominance of the male
gender.
Predisposing local conditions have to be highlighted:
As reported in the review and in our case series, more
than 50% of the patients had a local impairment, such as
a smoking habit or inﬂammatory conditions such as
chronic obstructive pulmonary disease, and recurrent respi-
ratory tract infections (Ferlito et al, 1986; Ben!ıtez et al,
2001; Aliaga et al, 2003; Guddo et al, 2005; Tiseo et al,
2008; Teemul et al, 2013).
It is important to emphasize that, in our experience,
localized ML can be considered in some cases as an
aspect of a not yet detectable systemic infection. In fact,
in our case series, during follow-up, two patients showed
cutaneous forms of the disease and two patients a visceral
form.
The relapse in some cases is probably due to under-
treatment. We suppose that in these patients, there may
remain a hidden reservoir of parasites in a quiescent state.
A limited number of drugs are available for the treat-
ment of leishmaniasis, and these face challenges including
the development of drug resistance, the limited efﬁcacy
for different strains and species, and the cost.
The treatment depends on the causative Leishmania;
however, species identiﬁcation is fastidious, time-consum-
ing, and not always available. In such cases, the choice of
the drug should be inferred from the geographical setting
of the patient, and the epidemiological data of Leishmania
distribution as well as the clinical symptoms.
The treatment of choice for mucosal forms of leishman-
iasis is based on the administration of pentavalent antimo-
nial drugs, such as meglumine antimoniate, or
stibogluconate (Masmoudi et al, 2013).
To conclude, leishmaniasis of the mucous membranes
of the head–neck region must be considered in the differ-
ential diagnosis of mucosal lesions. It is becoming an
emerging infectious disease not only in immunocompro-
mised patients but also in those geographical settings
where the parasite is endemic, because of the increasing
modern habit of people to travel often abroad.
The diagnosis remains a challenge because of the varying
clinical presentation and its ability to emulate different dis-
eases. The dentist plays an important role in the early diag-
nosis of leishmaniasis which has systemic repercussions.
Any patient affected by leishmaniasis should be man-
aged by a professional with expertise in this disease, pref-
erably an infectious disease specialist. Furthermore, after a
complete healing and a long follow-up period without
signs or symptoms, the possibility of relapses has to be
considered.
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 A 5-year-old male presented with an asymptomatic grooved and atrophic right side of the tongue 
(Fig. 1A), noticed 8 months before by his pediatrician as “right mild lingual deviation”. At the time of birth, the child was in good health except for right-sided congenital muscular torticollis (CMT) without plagiocephaly and clinically evident facial asymmetry. Neurologic, radiologic (including cervical-spine 3D-CT-Scan), cardiologic, hematologic, ophthalmologic, and otorhinolaryngologic tests were negative, and the patient received only 8 months of physiotherapy started at the age of 18 months. With the suspicion of an ipsilateral CMT sequela a differential diagnostic algorithm was started excluding a hypoglossus central dysfunction through Magnetic Resonance Imaging. Ultrasonography of the head and neck region showed the presence of a 5 mm median cyst in submental area (Fig. 1B) and asymmetry between the genioglossus muscles (right=2.8 mm; left=5.8 mm) (Fig. 1C).  Current treatment options for CMT encompass physiotherapy, surgery or other treatments like botulinum toxin. Conservative therapy includes stretching of the shortened SCM and is considered the first line of treatment. Early diagnosis and treatment are mandatory to prevent sequelae affecting the cervical range of motion and secondary musculoskeletal deformities (Jung et al., 2015; Lee et al., 2015; Nilesh and Mukherji, 2013).  In our patient we assumed that compressions of the neck anatomical structures due to CMT and to the right-sided head position could have impaired the normal growth of the genioglossus muscle acting directly or indirectly on mechanoreceptors or on the hypoglossus pre-lingual portion. In addition, the initiation of physiotherapy was delayed, and the monitoring of the suprahyoid region muscles was insufficient.  
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Therefore, it is likely that the soft-tissue compression has led to abnormalities of soft-tissue differentiation causing edema, degeneration of muscle fibers and fibrosis within the involved muscles (Nilesh and Mukherji 2013). Oral Medicine specialists should regularly monitor the appearance of any supra/infra-hyoid region asymmetry through Ultrasonography. 
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